include,title,abstract,first_author,year,journal,doi,pubmed_id,authors,pubmed_type,publication_types,mesh,webofscience_id,central_id,openalex_id,title_length,title_word_count,title_sentence_count,abstract_length,abstract_word_count,abstract_sentence_count,language_title,language_abstract
false,comparison bedtime insulin regimen patient type diabetes mellitus,background compare insulin regimen combination therapy oral hypoglycemic agent bedtime insulin produce similar improvement glycemic control induces less weight gain objective determine whether bedtime insulin regimen differ respect effect weight gain patient type diabetes design randomize control trial setting four outpatient clinic central hospital patient patient mean age year mean body mass index kg whose type diabetes poorly control sulfonylurea therapy mean glycosylated hemoglobin value mean fast plasma glucose level mmol l mg dl intervention random assignment year treatment bedtime intermediate acting insulin plus glyburide mg placebo metformin g placebo glyburide metformin second injection intermediate acting insulin morning patient teach adjust bedtime insulin dose basis fast glucose measurement measurement body weight biochemical symptomatic hypoglycemia index glycemic control result year body weight remain unchanged patient receive bedtime insulin plus metformin mean change kg p compare group increase kg kg kg patient receive bedtime insulin plus glyburide receive bedtime insulin plus oral drug receive bedtime morning insulin respectively great decrease glycosylated hemoglobin value observe bedtime insulin metformin group difference percentage point year p compare month p compare group group also significantly symptomatic biochemical case hypoglycemia p group conclusion combination therapy bedtime insulin plus metformin prevents weight gain regimen also seem superior bedtime insulin regimens respect improvement glycemic control frequency hypoglycemia,Yki-Järvinen H,1999,Ann Intern Med,https://doi.org/10.7326/0003-4819-130-5-199903020-00002,10068412,Yki-Järvinen H; Ryysy L; Nikkilä K; Tulokas T; Vanamo R; Heikkilä M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000419: Albuminuria; D001786: Blood Glucose; D001794: Blood Pressure; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005500: Follow-Up Studies; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008055: Lipids; D008687: Metformin; D008875: Middle Aged; D015430: Weight Gain",,,https://openalex.org/W1981978041,80,12,1,2215,407,13,en,en
true,effect katpchannel blockade glibenclamide warm phenomenon,increase tolerance myocardial ischaemia observe second two sequential exercise test e warm phenomenon propose clinical model ischaemic preconditioning atp sensitive k channel appear mediator ischaemic preconditioning experimental clinical study aim study investigate role k atp channel warm phenomenon twenty six patient coronary artery disease randomize receive mg oral glibenclamide selective atp sensitive k channel blocker placebo sixty minute glibenclamide placebo administration patient give infusion dextrose ml x min correct glucose plasma level respectively infusion saline infusion rate thirty minute beginning infusion patient group underwent two consecutive treadmill exercise test recovery period min establish baseline condition exercise test blood glucose level similar placebo glibenclamide group vs mg x ml p ns placebo administration rate pressure product mm st segment depression significantly increase second exercise test compare first vs beat x min x mmhg x p change glibenclamide vs beat x min x mmhg x p ns significant drug test interaction p two way anova glibenclamide dose previously show abolish ischaemic preconditioning coronary angioplasty prevent increase ischaemic threshold observe second two sequential exercise test finding confirm ischaemic preconditioning play key role warm phenomenon setting least partially mediate activation atp sensitive k channel,Tomai F,1999,Eur Heart J,https://doi.org/10.1053/euhj.1998.1311,10082152,Tomai F; Danesi A; Ghini AS; Crea F; Perino M; Gaspardone A; Ruggeri G; Chiariello L; Gioffrè PA,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000255: Adenosine Triphosphate; D000284: Administration, Oral; D000328: Adult; D000368: Aged; D003327: Coronary Disease; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D005500: Follow-Up Studies; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D019157: Ischemic Preconditioning, Myocardial; D008297: Male; D008875: Middle Aged; D026902: Potassium Channel Blockers; D016037: Single-Blind Method; D016896: Treatment Outcome",,,https://openalex.org/W1990802756,74,10,1,1967,362,8,en,en
false,short term intensive insulin therapy method overcome secondary failure sulfonylurea patient type diabetes non insulin dependent,study group comprise patient male female type diabetes secondary failure sulphonylurea derivates su develop patient submit day therapy injection insulin per day total dose insulin permit decrease mean daily glycaemia mmol l mg dl termination intensive insulin therapy iit patient insulin requirement u daily alternatively qualify treatment su glybenclamide alone su plus biguanide derivate bg phenformin need u daily continue conventional therapy insulin alone insulin plus su glybenclamide marked reduction fasting postprandial blood glucose iit subsequent month follow mean glycaemia initially fast state mmol l mg dl hour breakfast mmol l mg dl decrease significantly four group mmol l mg dl mmol l mg dl fast state mg dl mmol l mg dl breakfast least hypoglycaemic effect find patient iit treat exclusively insulin mean daily dose iu decrease glycaemia evident patient treat su give single drug combination bg insulin mean daily dose iu studied patient basal stimulate mg glucagon v c peptide secretion markedly decrease iit greatly increase termination increase persist follow month observation correlate initial values short term iit patient niddm secondary failure su effective reduce hyperglycaemia make possible continue oral antidiabetic treatment su secretion endogenous insulin seem limited influence metabolic control patient treat four different pharmacological regiment iit,Jedynasty K,1998,Pol Arch Med Wewn,,10085698,Jedynasty K; Kasperska-Czyzykowa T; Stepień K; Nowaczyk R,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article,"D000368: Aged; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D004351: Drug Resistance; D004359: Drug Therapy, Combination; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D010629: Phenformin; D013453: Sulfonylurea Compounds; D017211: Treatment Failure",,,https://openalex.org/W2467368005,157,25,1,2237,415,9,en,en
true,year multicenter randomize double blind comparison repaglinide glyburide treatment type diabetes dutch german repaglinide study group,objective repaglinide newly develop oral blood glucose lowering agent exert effect stimulate insulin secretion multicenter study design compare efficacy safety drug glyburide year randomized double blind study outpatient type diabetes research design method total subject woman men participate following characteristic age year duration diabetes year range bmi kg hba c fast plasma glucose mmol l majority subject previously treat sulfonylurea alone combination metformin patient randomize ratio repaglinide mg glyburide mg daily treatment study protocol include screen visit assess patient eligibility titration period week dosage repaglinide glyburide optimize subsequent month treatment period fixed optimal dosage result trial complete subject repaglinide glyburide group hba c initially decrease group increase second half year maintenance period similar extent repaglinide glyburide subject vs screening respectively small group subject previously control condition diet n sustained improvement metabolic control could observe drug slightly good glyburide repaglinide theta hba c vs p lt trend see fast plasma glucose change serum lipid course study repaglinide treated glyburide treated subject withdraw due adverse event mostly hyperglycemia difference adverse event drug report difference incidence hypoglycemia conclusion repaglinide safe efficacious oral blood glucose lowering agent potency similar glyburide rapid onset action hepatic clearance allow meal related administration include subject impaired kidney function,Wolffenbuttel BH,1999,Diabetes Care,https://doi.org/10.2337/diacare.22.3.463,10097930,Wolffenbuttel BH; Landgraf R,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D001786: Blood Glucose; D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005215: Fasting; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D010880: Piperidines",,,https://openalex.org/W2127119840,164,25,2,2359,438,18,en,en
false,short term cost effectiveness model oral antidiabetic medicine europe,short term month cost effectiveness model develop simulate current medical practice disease progression patient type non insulin dependent diabetes mellitus uncontrolled diet exercise model base decision analytical technique include probability switch treatment reason switch common switch option effectiveness economic measure main outcome order assess effectiveness use symptom free day acceptable control sfdacs represent day treatment without adverse event symptom acceptable control glucose lipid economic evaluation incremental cost incur directly health insurance system consider model prove useful evaluation new oral antidiabetic agent since short term aim antidiabetic therapy provide adequate control absence adverse effect symptom prerequisite successful long term treatment furthermore short term analysis provide data compare initial investment drug therapy potential saving longer treatment period,Hood SC,1998,Pharmacoeconomics,10.2165/00019053-199813030-00006,10178657,Hood SC; Annemans L; Rutten-van Mölken M,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D003362: Cost-Benefit Analysis; D003924: Diabetes Mellitus, Type 2; D005060: Europe; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008687: Metformin; D018803: Models, Economic",,,,80,12,1,1210,196,7,en,en
false,evaluation potential clinical economic effect bodyweight stabilisation acarbose patient type diabetes mellitus,bodyweight acknowledged independent risk factor coronary heart disease chd present model analysis undertake investigate clinical economic impact bodyweight gain patient type non insulin dependent diabetes mellitus effect development chd base retrospective evaluation data diabetes intervention study dis patient type diabetes mellitus stable bodyweight group significantly low rate combine chd event patient show bodyweight gain group b year prevention bodyweight gain therefore appear meaningful strategy management diabetes mellitus addition clinical advantage prevention chd also result economic saving associate avoided treatment coronary event base clinical outcome dis calculated per patient net saving patient type diabetes mellitus stable bodyweight amount deutschmark dm compare patient experience bodyweight increase step situation project current type diabetes mellitus practice oral first line treatment type diabetes mellitus usually initiate glibenclamide glyburide know increase bodyweight reflect group b novel alpha glucosidase inhibitor acarbose contrast appear effective glibenclamide advantage bodyweight neutral reflect group clinical viewpoint acarbose thus consider alternative glibenclamide viewpoint drug cost monotherapy acarbose time expensive glibenclamide germany result per patient incremental cost dm acarbose year balance potential year cost saving dm result potential acarbose prevent chd around one third incremental cost acarbose may recoup single effect however far possible benefit acarbose include avoidance hypoglycaemia deferral costly insulin therapy may improve economic value novel antidiabetic agent give indirect approach evaluation many limitation finding need critical appraisal comparative trial urgently require substantiate preliminary result,Banz K,1998,Pharmacoeconomics,https://doi.org/10.2165/00019053-199813040-00007,10178668,Banz K; Dinkel R; Hanefeld M; Schwanebeck U,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D020909: Acarbose; D000328: Adult; D001835: Body Weight; D003661: Decision Support Techniques; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D014312: Trisaccharides",,,https://openalex.org/W2040971139,141,20,1,2461,418,14,en,en
false,troglitazone,unlabelled troglitazone first new group oral antidiabetic drug thiazolidinediones indicate treatment patient type non insulin dependent diabetes mellitus troglitazone act enhance effect insulin peripheral target site unlike sulphonylurea drug associate hypoglycaemia administer monotherapy clinical trial troglitazone usually mg day patient type diabetes mellitus consistently show marked improvement glycaemic control well reduction fast serum insulin c peptide triglyceride level comparative study either glibenclamide glyburide metformin indicated similar glycaemic control troglitazone agent serum insulin level low troglitazone glibenclamide clinical trial approximately year duration show glycaemic control maintain troglitazone long term basis general troglitazone well tolerate majority patient however discontinuation troglitazone elevated liver enzyme level occur approximately patient receive drug frequent monitoring liver enzyme require e g least time first year therapy among patient start troglitazone therapy incorporation boxed warning increase monitoring requirement product labelling estimate risk liver related death approximately conclusion troglitazone improve ability target cell respond insulin drug show improve glycaemic control patient type diabetes mellitus use monotherapy combination oral antidiabetic drug insulin efficacy similar glibenclamide metformin although troglitazone generally well tolerate close monitoring liver enzyme function require minimise rare occurrence serious hepatic dysfunction drug acquisition liver function monitoring cost well potential adverse effect important factor may ultimately determine precise place troglitazone management type diabetes mellitus nevertheless first member new class oral antidiabetic agent thiazolidinediones troglitazone offer effective treatment option patient type diabetes mellitus action improve insulin sensitivity,Plosker GL,1999,Drugs,https://doi.org/10.2165/00003495-199957030-00014,10193691,Plosker GL; Faulds D,article,D016428: Journal Article; D016454: Review,"D000328: Adult; D000368: Aged; D000818: Animals; D019540: Area Under Curve; D002839: Chromans; D003924: Diabetes Mellitus, Type 2; D004347: Drug Interactions; D005947: Glucose; D005905: Glyburide; D006207: Half-Life; D006801: Humans; D007004: Hypoglycemic Agents; D016032: Randomized Controlled Trials as Topic; D013844: Thiazoles; D045162: Thiazolidinediones; D000077288: Troglitazone",,,https://openalex.org/W2051006205,12,1,1,2543,412,15,en,en
true,relationship fast plasma glucose glycosylated hemoglobin,contextnew criterion diagnosis type diabetes mellitus recently introduce lower diagnostic fasting plasma glucose fpg concentration mmol l mg dl objectiveto determine individual diabetes diagnose new fpg concentration criterion would excessive glycosylation elevate hemoglobin hba c level definitionswe determine distribution hba c level individual use classification normal new criterion fpg concentration mmol l mg dl impair fast glucose new criterion fpg concentration mmol l mg dl diabetes diagnose solely new fpg concentration criterion mmol l mg dl diabetes diagnose previous fpg concentration criterion mmol l mg dl higher designcross sectional analysis large data set nhanes iii meta analysis research group mrg diagnosis diabetes use glycated hemoglobin contain individual fpg concentration hour glucose concentration use oral glucose tolerance test hba c level simultaneously measure cross tabulated fpg concentration mmol l mg dl mmol l mg dl mmol l mg dl mmol l mg dl hba c level separate interval normal less upper limit normal uln slightly elevate uln uln plus high high uln plus resultsamong subject normal fpg concentration hba clevels nhanes iii mrg data set normal slightly elevate high among individual impaired fast glucose hba c concentration normal slightly elevate high among diabetic patient diagnose new fpg criterion hba c level normal slightly elevate high diabetic patient diagnose former fpg criterion hba c level normal slightly elevate high conclusionsabout new cohort diabetic patient data set normal hba c level believe diabetes diagnose fpg concentration less mmol l mg dl unless excessive glycosylation evident individual without excessive glycosylation moderate elevation fpg concentration mmol l mg dl diagnose impaired fast glucose treat appropriate diet exercise diagnostic labeling achieve goal early intervention without subject person potentially negative insurance employment social psychological consequence diagnosis diabetes mellitus,Davidson MB,1999,JAMA,https://doi.org/10.1001/jama.281.13.1203,10199430,Davidson MB; Schriger DL; Peters AL; Lorber B,article,D016428: Journal Article,"D000328: Adult; D001786: Blood Glucose; D003430: Cross-Sectional Studies; D003924: Diabetes Mellitus, Type 2; D005189: False Positive Reactions; D005215: Fasting; D005951: Glucose Tolerance Test; D006442: Glycated Hemoglobin; D006801: Humans",,,https://openalex.org/W2113628803,71,8,1,2955,576,8,en,en
false,sulfonylurea ischaemic preconditioning double blind placebo controlled evaluation glimepiride glibenclamide,glimepiride new sulfonylurea diabetes treatment suppose impact less extra pancreatic atp dependent k channel conventional drug glibenclamide study perform evaluate whether result good maintenance atp dependent k channel mediate ischaemic myocardial preconditioning double blind placebo controlled study period total coronary occlusion balloon angioplasty high grade coronary artery stenosis use model compare effect drug quantification myocardial ischaemia achieve record intracoronary ecg time occurrence angina vessel occlusion patient underwent three dilatation first dilatation dilatation serve determine severity ischaemia vessel occlusion dilatation baseline value record thereafter glimepiride patient mg glibenclamide patient mg placebo patient intravenously administer min dilatation start min beginning drug administration mean st segment shift placebo group decrease dilatation dilatation mv ci mv p similar reduction also occur glimepiride group repetitive balloon occlusion lead reduction dilatation dilatation mv ci mv p little influence however mean st segment shift glibenclamide group dilatation dilatation mv ci mv p accordingly time angina balloon occlusion slightly increase placebo group dilatation dilatation ci p increase glimepiride group dilatation dilatation ci p remain unchanged glibenclamide group dilatation dilatation ci p result show glimepiride maintain myocardial preconditioning glibenclamide might able prevent,Klepzig H,1999,Eur Heart J,https://doi.org/10.1053/euhj.1998.1242,10213347,Klepzig H; Kober G; Matter C; Luus H; Schneider H; Boedeker KH; Kiowski W; Amann FW; Gruber D; Harris S; Burger W,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D015906: Angioplasty, Balloon, Coronary; D003327: Coronary Disease; D004311: Double-Blind Method; D004562: Electrocardiography; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007275: Injections, Intravenous; D019194: Ischemic Preconditioning; D008297: Male; D008875: Middle Aged; D013453: Sulfonylurea Compounds; D016896: Treatment Outcome",,,https://openalex.org/W2162891101,123,14,1,2133,400,12,en,en
false,effect gliclazide plasma insulin intact split proinsulin south asian subject type diabetes mellitus,diabetic medicinevolume issue p effect gliclazide plasma insulin intact split proinsulin south asian subject type diabetes mellitus first publish december http doi org j xcitations aboutpdf toolsrequest permissionexport citationadd favoritestrack citation shareshare give accessshare full text accessshare full text accessplease review term condition use check box share full text version article read accept wiley online library term condition useshareable linkuse link share full text version article friend colleague learn copy url share linkshare onfacebooktwitterlinked inredditwechat cite literature volume issue february pages relatedinformation,Ammari F,1999,Diabet Med,https://doi.org/10.1046/j.1464-5491.1999.00025.x,10229308,Ammari F; Davies MJ; Koppiker N; Gregory R; Burden AC,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001210: Asia, Southeastern; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005907: Gliclazide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D007515: Islets of Langerhans; D008297: Male; D008875: Middle Aged; D011384: Proinsulin; D011498: Protein Precursors; D006113: United Kingdom",,,https://openalex.org/W2467311283,131,22,1,864,119,2,en,en
true,double blind randomized comparison meal related glycemic control repaglinide glyburide well controlled type diabetic patient,objective study design compare diurnal blood glucose excursion effect accidental dietary noncompliance type diabetic patient well controlled either repaglinide glyburide treatment research design method single center double blind randomize study comprise type diabetic patient whose mean fast blood glucose value repaglinide glyburide titration stabilization range mg dl study consist initial screening day titration period week week stabilization period study period end study day day study period half patient group receive two meal first day three meal next day half sequence reverse repaglinide administer preprandially meal glyburide administer recommend current labeling e either one two daily dos breakfast dinner regardless whether lunch omit diurnal blood glucose excursion day three meal eat compare two group minimum blood glucose concentration bgmin measurement compare lunch dinner day three two meal result randomized patient enter day study period complete trial result show significant difference repaglinide glyburide group average blood glucose excursion fast blood glucose p influence mean bgmin omit meal differ significantly repaglinide glyburide group p latter group bgmin decrease mg dl result omit lunch whereas repaglinide group bgmin unchanged two meal day mg dl three meal day mg dl hypoglycemic event n occur glyburide group two meal day connection omit lunch hypoglycemic event record repaglinide group conclusion result suggest treatment repaglinide well controlled type diabetic patient miss delay meal superior treatment longer acting sulfonylurea drug glyburide respect risk hypoglycemic episode,Damsbo P,1999,Diabetes Care,https://doi.org/10.2337/diacare.22.5.789,10332683,Damsbo P; Clauson P; Marbury TC; Windfeld K,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001786: Blood Glucose; D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004435: Eating; D002149: Energy Intake; D005215: Fasting; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008875: Middle Aged; D010880: Piperidines",,,https://openalex.org/W1988474859,143,19,1,2363,414,13,en,en
true,effect repaglinide addition metformin monotherapy glycemic control patient type diabetes,objective compare effect repaglinide combination metformin monotherapy drug glycemic control patient type diabetes research design method total patient type diabetes inadequate glycemic control hba c gt receive antidiabetic agent metformin enrol multicenter double blind trial subject randomize continue prestudy dose metformin n continue prestudy dose metformin addition repaglinide n receive repaglinide alone n patient receive repaglinide optimal dose determine week titration continue month maintenance period result subject receive combined therapy hba c reduce p fast plasma glucose mmol l p significant change observe subject treat either repaglinide metformin monotherapy hba c decrease respectively fast plasma glucose mmol l increase mmol l decrease respectively subject receive repaglinide either alone combination metformin increase fast level insulin baseline end trial mu l respectively p lt gastrointestinal adverse event common metformin group increase body weight occur repaglinide combine therapy group kg respectively p lt conclusion combine metformin repaglinide therapy result superior glycemic control compare repaglinide metformin monotherapy patient type diabetes whose glycemia well control metformin alone repaglinide monotherapy effective metformin monotherapy,Moses R,1999,Diabetes Care,https://doi.org/10.2337/diacare.22.1.119,10333912,Moses R; Slobodniuk R; Boyages S; Colagiuri S; Kidson W; Carter J; Donnelly T; Moffitt P; Hopkins H,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001315: Australia; D001786: Blood Glucose; D002096: C-Peptide; D002219: Carbamates; D002784: Cholesterol; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005215: Fasting; D005230: Fatty Acids, Nonesterified; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D008875: Middle Aged; D010880: Piperidines; D014280: Triglycerides",,,https://openalex.org/W2043316108,109,17,1,1934,358,11,en,en
false,relationship glucose incident cardiovascular event metaregression analysis publish data study individual follow year,assess relationship nondiabetic glucose level cardio vascular risk three independent search use medline follow manual search reference retrieve article conduct two physician one medical librarian data report least three quantiles interval nature relationship glucose cardiovascular event e linear nonlinear could explore ensure incremental cardiovascular risk consistent across quantiles intervals analyzed study comprise people male cardiovascular event year person years study report fast glucose level n h glucose level n h glucose level n casual glucose level n include glucose load use vary g high glucose interval study include glucose value diabetic range relationship glucose level risk cardiovascular event model study beta coefficients combine compare glucose level mmol l mg dl fasting h glucose level mmol dl mg dl mmol l mg dl associate relative cardiovascular event risk ci ci respectively progressive relationship glucose level cardiovascular risk extends diabetic threshold,Coutinho M,1999,Diabetes Care,https://doi.org/10.2337/diacare.22.2.233,10333939,Coutinho M; Gerstein HC; Wang Y; Yusuf S,article,"D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D001786: Blood Glucose; D002318: Cardiovascular Diseases; D048909: Diabetes Complications; D003920: Diabetes Mellitus; D005260: Female; D018149: Glucose Intolerance; D005951: Glucose Tolerance Test; D006801: Humans; D015994: Incidence; D008297: Male; D008875: Middle Aged; D012044: Regression Analysis,,,https://openalex.org/W2090824142,175,26,2,1522,276,6,en,en
false,american diabetes association annual meeting treatment type diabetes,,Bloomgarden ZT,1999,Diabetes Care,https://doi.org/10.2337/diacare.22.2.357,10333958,Bloomgarden ZT,article,D016423: Congress; D016433: News,"D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D006801: Humans; D007004: Hypoglycemic Agents",,,https://openalex.org/W2045656363,92,16,2,0,0,0,en,
false,effect oral antidiabetic agent plasma amylin level patient non insulin dependent diabetes mellitus type,purpose study comparison effect oral therapy non insulin dependent diabetes mellitus niddm either sulphonylurea biguanide derivative plasma amylin level healthy individual fasting plasma amylin level pmol l mean sem min v injection mg glucagon fourfold increase observe patient niddm receive glibenclamide cas fast plasma amylin level twofold high healthy control pmol l p follow glucagon administration increase twofold patient treat metformin cas fast plasma amylin level similar healthy individual pmol l glucagon stimulation increment plasma amylin minimal relevant mean value significantly low compare healthy individual niddm patient treat glibenclamide untreated obese patient newly diagnose niddm administration glibenclamide day result increase basal pmol l p glucagon stimulate p plasma amylin concentration whereas patient receive metformin show decrease fast plasma level peptide pmol l p glucagon injection pmol l p respect trophic effect amyloid deposit pancreatic islet hypothetic effect amylin increase insulin resistance present result emphasize particular usefulness metformin pharmacological treatment niddm contraindication side effect metformin take account drug administration,Zapecka-Dubno B,1999,Arzneimittelforschung,https://doi.org/10.1055/s-0031-1300423,10337452,Zapecka-Dubno B; Czyzyk A; Dworak A; Bak MI,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000682: Amyloid; D001786: Blood Glucose; D002096: C-Peptide; D003430: Cross-Sectional Studies; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D058228: Islet Amyloid Polypeptide; D008297: Male; D008687: Metformin",,,https://openalex.org/W2037854924,123,19,1,1906,341,8,en,en
true,glycemic control diet sulfonylurea metformin insulin patient type diabetes mellitus subtitle progressive requirement multiple therapy ukpds subtitle,contexttreatment diet alone insulin sulfonylurea metformin know improve glycemia patient type diabetes mellitus treatment frequently attain target fast plasma glucose fpg concentration less mmol l mg dl glycosylated hemoglobin c hba c unknown objectiveto assess often therapy achieve glycemic control target level set american diabetes association designrandomized control trial conduct patient recruit follow every month year enrollment settingoutpatient diabetes clinic uk hospitals patientsa total patient newly diagnose type diabetes range age year median interquartile range fpg concentration mmol l mg dl hba c level mean sd body mass index kg interventionsafter month low fat high carbohydrate high fiber diet patient randomize therapy diet alone insulin sulfonylurea metformin main outcome measuresfasting plasma glucose hba c level proportion patient achieve target level hba c less mmol l mg dl fpg year follow diagnosis resultsthe proportion patient maintain target glycemic level decline markedly year follow year monotherapy diet insulin sulfonylurea respectively achieve fpg level less mmol l mg dl achieve hba c level obese patient randomize metformin attain fpg level less mmol l mg dl attain hba c level patient less likely achieve target level young obese hyperglycemic patients conclusionseach therapeutic agent monotherapy increase fold proportion patient attain hba c compare diet alone however progressive deterioration diabetes control year approximately patient could attain goal monotherapy year decline approximately majority patient need multiple therapy attain glycemic target level long term,Turner RC,1999,JAMA,https://doi.org/10.1001/jama.281.21.2005,10359389,Turner RC; Cull CA; Frighi V; Holman RR,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D001786: Blood Glucose; D003131: Combined Modality Therapy; D003924: Diabetes Mellitus, Type 2; D018752: Diet, Fat-Restricted; D004040: Dietary Carbohydrates; D004043: Dietary Fiber; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D016015: Logistic Models; D008297: Male; D008687: Metformin; D008875: Middle Aged; D015999: Multivariate Analysis; D011446: Prospective Studies; D013453: Sulfonylurea Compounds",,,https://openalex.org/W1975588287,195,41,1,2438,452,7,en,en
false,morning blood glucose determination monitoring metabolic control type elderly diabetic case treat oral hypoglycemic agent,daily blood glucose profile measure type elderly diabetic case evaluate whether fasting breakfast post prandial breakfast blood glucose concentration able predict blood glucose value throughout day diet treated alone group n percentage daily blood glucose profile plasma glucose value less hour breakfast value follow supper hour respectively group treat oral hypoglycemic agent oha n follow respectively oha group mean plasma glucose value hour significantly high patient low plasma glucose level mg dl patient level mg dl vs mg dl p hour similar two group vs mg dl patient low plasma glucose level mg dl hour value correlate positively r r hour value r correlation observe hour value hand hour value associate time points value result reveal breakfast plasma glucose value predictive low blood glucose value night sleep breakfast blood glucose value predict low blood glucose value supper patient oha,Ohba K,1999,Nihon Ronen Igakkai Zasshi,https://doi.org/10.3143/geriatrics.36.122,10363530,Ohba K; Koibuchi H; Matsuura Y; Okazaki K; Ajiro Y; Satoh S; Sasai K; Suzuki T; Nnakano H; Mmetori S,article,"D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000368: Aged; D015190: Blood Glucose Self-Monitoring; D002940: Circadian Rhythm; D003924: Diabetes Mellitus, Type 2; D005215: Fasting; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2035261592,144,22,1,1639,333,7,en,en
false,effect troglitazone body fat distribution type diabetic patient,troglitazone recently report specifically promote differentiation pre adipocytes adipocytes vitro subcutaneous fat indicate relation insulin resistance improving action troglitazone expand finding investigate clinical level long term administration troglitazone influence body fat distribution type diabetic patients troglitazone mg day administer month type diabetic patient whose glycemic control poor total patient receive diet therapy alone single treatment group bmi hba c patient concomitantly receive glibenclamide mg day concomitant sulfonylurea group bmi hba c bmi hba c serum lipid level body fat distribution determine compute tomography ct scan umbilical level measure compare troglitazone treatment month troglitazone treatment hba c level decrease bmi increase group body fat distribution single treatment group visceral fat area vfa decrease cm p subcutaneous fat area sfa increase cm p result decrease visceral subcutaneous v ratio p concomitant sulfonylurea group vfa unchanged cm sfa increase cm p thereby decrease v ratio p serum triglyceride level area glucose curve g oral glucose tolerance test decrease significantly single treatment group according data troglitazone appear promote fat accumulation subcutaneous adipose tissue rather visceral adipose tissue mildly obese japanese people type diabetes shift energy accumulation visceral subcutaneous adipose tissue may greatly contribute troglitazone mediated amelioration insulin resistance,Mori Y,1999,Diabetes Care,https://doi.org/10.2337/diacare.22.6.908,10372240,Mori Y; Murakawa Y; Okada K; Horikoshi H; Yokoyama J; Tajima N; Ikeda Y,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000005: Abdomen; D000273: Adipose Tissue; D001786: Blood Glucose; D001794: Blood Pressure; D015992: Body Mass Index; D002839: Chromans; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005260: Female; D005951: Glucose Tolerance Test; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008055: Lipids; D008297: Male; D008875: Middle Aged; D012867: Skin; D013844: Thiazoles; D045162: Thiazolidinediones; D014057: Tomography, X-Ray Computed; D000077288: Troglitazone; D014781: Viscera",,,https://openalex.org/W1999236387,76,13,1,2252,405,8,en,en
true,comparison repaglinide glibenclamide treatment type diabetic patient previously treat sulphonylureas,objective compare efficacy safety repaglinide novel oral prandial glucose regulator glibenclamide oral hypoglycaemic agent treatment patient type diabetes method week double blind parallel group trail total type diabetic patient treat oral hypoglycaemic agent randomize receive either repaglinide administer preprandially three time daily glibenclamide give preprandially twice daily per manufacturer recommendation result end study h postprandial blood glucose value low repaglinide group glibenclamide group difference approach statistical significance repaglinide mol x l v glibenclamide mmol x l p statistically significant difference mean blood glucose level end study two group repaglinide mmol x l v glibenclamide mmol x l p baseline hba c value decrease degree repaglinide glibenclamide group significant difference repaglinide glibenclamide treatment group level fast blood glucose fructosamine fast c peptide insulin proinsulin neither treatment group show clinically significant change blood lipid profile repaglinide glibenclamide well tolerate significant difference observe two treatment group respect adverse event include hypoglycaemic episode weight change accumulation repaglinide apparent maintenance period conclusion repaglinide well tolerate glibenclamide equally effective management type diabetes repaglinide may however offer improvement postprandial blood glucose control compare glibenclamide thereby help reduce relative long term risk diabetic complication,Landgraf R,1999,Eur J Clin Pharmacol,https://doi.org/10.1007/s002280050613,10379630,Landgraf R; Bilo HJ; Müller PG,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D010880: Piperidines; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2040754013,129,18,1,2126,392,11,en,en
true,quality life type diabetic patient affect complication intensive policy improve blood glucose blood pressure control ukpds u k prospective diabetes study group,determine patient type diabetes effect quality life qol therapy improve blood glucose control improve blood pressure bp control diabetic complication hypoglycemic episodes perform two cross sectional study patient enrol randomize controlled trial intensive blood glucose control policy compare conventional blood glucose control policy tight bp control policy compare less tight bp control policy also undertaken longitudinal study patient randomized control trial intensive blood glucose control policy compare conventional blood glucose control policy subject qol assess time randomization month year randomization two cross sectional sample type diabetic patient randomize therapy blood glucose control patient mean age duration randomization year complete specific questionnaire cover four aspect qol patient mean age duration randomization year complete generic qol measure sample patient respectively also randomize therapy bp control sample non diabetic control subject average age also give specific questionnaire longitudinal sample type diabetic patient randomize either intensive conventional blood glucose policy mean age randomization give specific questionnaire sample sizes month year randomization respectively specific questionnaire assess specific domain qol include mood disturbance profile mood state cognitive mistake cognitive failure questionnaire symptom work satisfaction generic questionnaire eq assess general health questionnaire self administered cross sectional study show allocated therapy neutral effect neither improvement deterioration qol score mood cognitive mistake symptom work satisfaction general health longitudinal study also show difference qol score specific domain assess show marginally symptom patient allocate conventional intensive policy cross sectional study patient macrovascular complication last year bad general health measure generic questionnaire without complication scale score median respectively p tariff score median respectively p problem mobility respectively p problem usual activity respectively p measure specific questionnaire also show reduce vigor p patient microvascular complication last year report tension p total mood disturbance p measure specific questionnaire patient without complication patient treat insulin two hypoglycemic episode previous year report tension p overall mood disturbance p less work satisfaction p measure specific questionnaire hypoglycemic attack adjust age duration randomization systolic bp hba c sex multivariate polychotomous regression patient type diabetes complication disease affect qol whereas therapeutic policy show reduce risk complication effect qol discern whether frequent hypoglycemic episode affect qol whether patient certain p,,1999,Diabetes Care,https://doi.org/10.2337/diacare.22.7.1125,10388978,,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000339: Affect; D000368: Aged; D001786: Blood Glucose; D015190: Blood Glucose Self-Monitoring; D001794: Blood Pressure; D003071: Cognition; D003430: Cross-Sectional Studies; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006304: Health Status; D006801: Humans; D007588: Job Satisfaction; D008137: Longitudinal Studies; D008297: Male; D008875: Middle Aged; D011788: Quality of Life; D011795: Surveys and Questionnaires; D014481: United States",,,https://openalex.org/W4253271202,204,37,3,3935,707,16,en,en
false,rosiglitazone,rosiglitazone thiazolidinedione antidiabetic agent improve insulin resistance key underlying metabolic abnormality patient type non insulin dependent diabetes mellitus animal model insulin resistance rosiglitazone decrease plasma glucose insulin triglyceride level also attenuate prevent diabetic nephropathy pancreatic islet cell degeneration contrast troglitazone rosiglitazone induce cytochrome p metabolism interact significantly nifedipine oral contraceptive metformin digoxin ranitidine acarbose clinical trial patient type diabetes mellitus rosiglitazone mg day single daily dose divided daily dos improve glycaemic control show decrease fast plasma glucose glycosylated haemoglobin hba c addition rosiglitazone mg day exist sulphonylurea metformin insulin therapy achieve reduction fast plasma glucose hba c oral combination improve insulin sensitivity beta cell function accord homeostasis model assessment consistent mechanism action rosiglitazone appear associate low risk hypoglycaemia patient receive monotherapy evidence date rosiglitazone share hepatotoxicity troglitazone,Balfour JA,1999,Drugs,https://doi.org/10.2165/00003495-199957060-00007,10400405,Balfour JA; Plosker GL,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D001786: Blood Glucose; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D004347: Drug Interactions; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007515: Islets of Langerhans; D019338: Polypharmacy; D000077154: Rosiglitazone; D013844: Thiazoles; D045162: Thiazolidinediones",,,https://openalex.org/W3190844582,13,1,1,1385,218,9,es,en
false,vasodilatory effect troglitazone improve blood pressure rest mental stress type diabetes mellitus,present study examine hemodynamic mechanism blood pressure bp lowering troglitazone patient type diabetes mellitus dm rest mental arithmetic test mat twenty two patient dm normal high normal bp control match age gender glucose tolerance bp study dm subject show significantly high systolic bp response mat control versus mm hg p dm patient control systolic bp mm hg mat heart rate diastolic bp significantly different group dm group randomize receive troglitazone n mg glyburide n mg mat repeat month treatment treatment reduce glucose equally mmol l troglitazone mmol l glyburide troglitazone reduce insulin microu ml p c peptide ng ml p level troglitazone significantly reduce bp baseline p systolic bp response mat p whereas glyburide affect bp baseline mat stroke volume cardiac output change either drug troglitazone decrease peripheral vascular resistance dyne cm p improve insulin resistance rather improved glycemic control associate low resting stress bp value patient dm reduction vascular resistance may primary hemodynamic mechanism manner troglitazone lower bp insulin sensitizer may offer potential therapeutic advantage subject dm elevated bp,Sung BH,1999,Hypertension,https://doi.org/10.1161/01.hyp.34.1.83,10406828,Sung BH; Izzo JL; Dandona P; Wilson MF,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D001794: Blood Pressure; D002839: Chromans; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006439: Hemodynamics; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D012016: Reference Values; D012146: Rest; D013315: Stress, Psychological; D013844: Thiazoles; D045162: Thiazolidinediones; D000077288: Troglitazone; D014664: Vasodilation",,,https://openalex.org/W2114510502,120,18,1,1661,322,14,en,en
false,high dose biotin inducer glucokinase expression may synergize chromium picolinate enable definitive nutritional therapy type ii diabetes,glucokinase gk express hepatocyte pancreatic beta cell central regulatory role glucose metabolism efficient gk activity require normal glucose stimulated insulin secretion postprandial hepatic glucose uptake appropriate suppression hepatic glucose output gluconeogenesis elevated plasma glucose hepatic gk activity subnormal diabetes gk may also decrease beta cell type ii diabetic supraphysiological concentration biotin promote transcription translation gk gene hepatocytes effect appear mediate activation soluble guanylate cyclase recent evidence indicate biotin likewise increase gk activity islet cell hand high dose biotin suppresses hepatocyte transcription phosphoenolpyruvate carboxykinase rate limiting enzyme gluconeogenesis administration high dose biotin improve glycemic control several diabetic animal model recent japanese clinical study conclude biotin mg orally substantially lower fast glucose type ii diabetic without side effects recently demonstrate utility chromium picolinate type ii diabetes appear reflect improved peripheral insulin sensitivity parameter unlikely directly influence biotin thus joint administration supranutritional dos biotin chromium picolinate likely combat insulin resistance improve beta cell function enhance postprandial glucose uptake liver skeletal muscle inhibit excessive hepatic glucose production conceivably safe convenient nutritional regimen constitute definitive therapy many type ii diabetic may likewise useful prevention management gestational diabetes biotin also aid glycemic control type patient,McCarty MF,1999,Med Hypotheses,https://doi.org/10.1054/mehy.1997.0682,10416947,McCarty MF,article,D016428: Journal Article,"D001710: Biotin; D003924: Diabetes Mellitus, Type 2; D004357: Drug Synergism; D004790: Enzyme Induction; D015971: Gene Expression Regulation, Enzymologic; D005941: Glucokinase; D007502: Iron Chelating Agents; D010848: Picolinic Acids",,,https://openalex.org/W2079348671,158,24,1,1921,301,12,en,en
false,late recovery ventricular function child idiopathic dilate cardiomyopathy,background prognosis child idiopathic dilate cardiomyopathy idc variable patient fail exhibit improvement left ventricular lv function high year mortality rate whereas improvement lv fractional shortening lvfs associate good survival however complete recovery lv performance normal examine method result clinical feature echocardiogram child idc review sixteen patient group identify demonstrate progressive improvement lvfs ultimately recover within normal range compare patient group lvfs remain depressed group lvfs first examination z improve within normal range z p group initial lvfs z change significantly z lv dilate initial examination patient z recovery group associate decrease lv dimension within normal range z p whereas lv dimension group patient remain increased z mean follow time lv function note normal year range year total duration follow year range year conclusion complete recovery lv function possible child idc recovery may occur within first year initial examination patient long period need majority patient lv function ultimately return normal heart j,Lewis AB,1999,Am Heart J,https://doi.org/10.1016/s0002-8703(99)70121-3,10426848,Lewis AB,article,D016428: Journal Article,"D002311: Cardiomyopathy, Dilated; D002648: Child; D002675: Child, Preschool; D006801: Humans; D007223: Infant; D007231: Infant, Newborn; D011379: Prognosis; D012189: Retrospective Studies; D016277: Ventricular Function, Left",,,https://openalex.org/W1973454713,88,11,1,1740,364,15,en,en
false,clinical pharmacokinetics pharmacodynamics bromfenac,bromfenac nonsteroidal anti inflammatory drug whose peak plasma concentration reach hour oral administration bromfenac bind extensively plasma albumin area plasma concentration time curve linearly proportional dose oral dos mg relationship total plasma analgesic effect establish small amount bromfenac eliminate unchanged remain drug biotransformed glucuronide metabolite excrete urine bile rapid elimination occur healthy individual half life h renal disease hepatic disease age alter disposition kinetics bromfenac dosage adjustment may advisable bromfenac modestly decrease free phenytoin concentration bromfenac cause idiosyncratic hepatic toxicity withdraw manufacturer pending investigation case report,Skjodt NM,1999,Clin Pharmacokinet,https://doi.org/10.2165/00003088-199936060-00002,10427465,Skjodt NM; Davies NM,article,D016428: Journal Article; D016454: Review,"D000700: Analgesics; D000894: Anti-Inflammatory Agents, Non-Steroidal; D001577: Benzophenones; D001969: Bromobenzenes; D004347: Drug Interactions; D006801: Humans",,,https://openalex.org/W2071342642,59,6,1,956,148,9,en,en
false,type diabetes overview,type diabetes heterogeneous disorder clinical expression disorder require genetic environmental factor one theory concern etiology result evolution thrifty genotype survival benefit past detrimental current environment oppose theory represent adult metabolic response fetal malnutrition hyperglycemia type diabetes result absolute relative insulin deficiency often relative insulin deficiency attributable inability adequately compensate insulin resistance insulin resistance may cause variety genetic metabolic factor common etiological factor insulin resistance central obesity insulin resistance associate cluster metabolic abnormality include glucose intolerance hypertension unique dyslipidemia procoagulant state increase macrovascular disease clinical intervention study demonstrate reduction chronic microvascular macrovascular complication type diabetes require treatment hyperglycemia achieve hemoglobin c blood pressure mmhg plasma ldl cholesterol mmol l mg dl oral antihyperglycemic agent increase endogenous insulin secretion decrease insulin resistance low postprandial plasma glucose rise delay absorption complex carbohydrate long term glycemic control type diabetes require progressive stepwise combination treatment oral agent eventually combination treatment oral agent insulin,Lebovitz HE,1999,Clin Chem,https://doi.org/10.1093/clinchem/45.8.1339,10430816,Lebovitz HE,article,D016428: Journal Article; D016454: Review,"D002318: Cardiovascular Diseases; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D007333: Insulin Resistance; D009765: Obesity; D012307: Risk Factors",,,https://openalex.org/W2121202645,28,6,1,1652,256,12,en,en
true,comparison preconstituted fixed combination low dose glyburide plus metformin versus high dose glyburide alone treatment type diabetic patient,present study assess compare effectiveness safety preconstituted fix combination low dose glyburide plus metformin higher dose glyburide monotherapy patient type diabetes randomized double blind cross study comprise patient day run period dietary treatment patient receive combined glyburide mg day metformin mg day preconstitued fixed combination glyburide alone mg day dose increase stepwise month treatment give regimen month total week washout group cross period body weight fast plasma glucose hba c blood lactate total cholesterol hdl cholesterol triglyceride measure beginning end end postprandial plasma glucose fast postprandial plasma insulin c peptide evaluate beginning end latter time point additional assessment include routine clinical chemistry measurement ecg ophthalmoscopic examination statistical analysis perform paired student test analysis variance cross study thirty three patient complete study fast plasma glucose postprandial plasma glucose hba c level improve significantly combine treatment glyburide low dos plus metformin effect achieve without major change insulin c peptide concentration circulate lactate concentration increase regimen include metformin remain well within reference value normal subject plasma total cholesterol triglyceride level remain substantielly unchanged throughout study whereas hdl cholesterol concentration increase slightly significantly glyburide plus metformin therapy routine clinical chemistry measurement ecg ophthalmoscopic examination change study result demonstrate improved metabolic control achieve preconstituted fixed combination low dose glyburide plus metformin patient type diabetes compare high dos sulphonylurea alone,Erle G,1999,Acta Diabetol,https://doi.org/10.1007/s005920050146,10436254,Erle G; Lovise S; Stocchiero C; Lora L; Coppini A; Marchetti P; Merante D,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D001835: Body Weight; D002096: C-Peptide; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004338: Drug Combinations; D005215: Fasting; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D019518: Postprandial Period; D013997: Time Factors",,,https://openalex.org/W2090001313,165,24,1,2382,413,15,en,en
false,effect combination insulin acarbose compare insulin gliclazide type diabetic patient,prospective study aim compare insulin plus acarbose insulin plus gliclazide respect effect insulin requirement lipid profile body mass index bmi achieve good glycemic control forty patient type diabetes mellitus conventional insulin therapy subcutaneous insulin therapy consisting regular nph insulin two time day include study randomize double blind treatment insulin combination gliclazide acarbose month group acceptable glycemic control achieve end study period mean hba c level decrease acarbose group gliclazide group difference group significant p acarbose group total cholesterol ldl concentration decrease significantly parameter change gliclazide group hdl level decrease significantly mg dl mg dl p bmi increase significantly kg kg p total daily insulin dose change acarbose group significantly increase u day significant gliclazide group p acarbose group significant difference responder nonresponders respect fasting stimulate c peptide hba c level baseline bmi value gliclazide group baseline bmi value significantly high nonresponding group compare responder p conclusion combination insulin acarbose good alternative type diabetic patient insulin therapy seem beneficial combination gliclazide may advantage achieve good glycemic control without increase insulin dose bmi also may advantage provide decrease ldl level important prevent atherosclerosis,Güvener N,1999,Acta Diabetol,https://doi.org/10.1007/s005920050151,10436259,Güvener N; Gedik O,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D020909: Acarbose; D001786: Blood Glucose; D002096: C-Peptide; D002784: Cholesterol; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005907: Gliclazide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D011446: Prospective Studies; D014280: Triglycerides",,,https://openalex.org/W2042182322,111,17,1,2070,362,13,en,en
true,high incidence severe hypoglycaemia lead hospital admission type diabetic patient treat long acting versus short acting sulphonylureas,summary aim comparison frequency severe hypoglycaemia lead hospital admission people type diabetes mellitus dm treat long vs short acting sulphonylureas method community base study year period population city basle switzerland number diabetic patient treat oral hypoglycaemic agent establish basis tablet consumption defined daily dose e g mg glibenclamide mg glibornuride result twenty eight type diabetic patient admit severe hypo glycaemia median age year death sixteen admission patient treat long acting sulphonylureas patient treat short acting form population type dm basle treat long acting sulphonylureas person years observation incidence severe hypoglycaemia per person years long acting sulphonylureas vs per person year short acting form odds ratio confidence interval decrease food intake nine patient major contribute factor conclusion severe hypoglycaemia lead hospital admission common elderly type diabetic patient treat long acting compare short acting sulphonylureas long acting sulphonylureas avoid,Stahl M,1999,Diabet Med,https://doi.org/10.1046/j.1464-5491.1999.00110.x,10445835,Stahl M; Berger W,article,D003160: Comparative Study; D016428: Journal Article,"D000368: Aged; D000369: Aged, 80 and over; D016022: Case-Control Studies; D016001: Confidence Intervals; D003924: Diabetes Mellitus, Type 2; D004630: Emergencies; D005260: Female; D005905: Glyburide; D006785: Hospitals, University; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D015994: Incidence; D007297: Inpatients; D008297: Male; D008875: Middle Aged; D016017: Odds Ratio; D012189: Retrospective Studies; D013453: Sulfonylurea Compounds; D013557: Switzerland",,,https://openalex.org/W2035926403,158,20,1,1432,235,12,en,en
true,pharmacologic therapy type diabetes mellitus,type diabetes mellitus chronic metabolic disorder result defect insulin secretion insulin action elevated rate basal hepatic glucose production presence hyperinsulinemia primary cause fast hyperglycemia meal impaired suppression hepatic glucose production insulin decrease insulin mediated glucose uptake muscle contribute almost equally postprandial hyperglycemia united state five class oral agent work different mechanism action currently available improve glycemic control patient type diabetes recently complete united kingdom prospective diabetes study ukpds show type diabetes mellitus progressive disorder treat initially oral agent monotherapy eventually require addition oral agent many patient insulin therapy need achieve target glycemic level ukpds improved glycemic control irrespective agent use sulfonylureas metformin insulin decrease incidence microvascular complication retinopathy neuropathy nephropathy review examine goal antihyperglycemic therapy review mechanism action efficacy nonglycemic benefit cost safety profile five approved class oral agent rationale use oral agent monotherapy combination combination insulin provide,DeFronzo RA,1999,Ann Intern Med,10.7326/0003-4819-131-4-199908170-00008,10454950,DeFronzo RA,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review","D020909: Acarbose; D000284: Administration, Oral; D000465: Algorithms; D002219: Carbamates; D002839: Chromans; D003924: Diabetes Mellitus, Type 2; D019317: Evidence-Based Medicine; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008687: Metformin; D010880: Piperidines; D013453: Sulfonylurea Compounds; D013844: Thiazoles; D045162: Thiazolidinediones; D014312: Trisaccharides; D000077288: Troglitazone",,,,51,8,1,1562,262,7,en,en
false,hypoglycemia associate high dos sertraline sulphonylurea compound noninsulin dependent diabetes mellitus patient,unlike selective serotonin reuptake inhibitor ssri sertraline linear pharmacokinetics increase dose lead proportional increase drug concentration half life sertraline h reach steady state one week accord product monograph hypoglycemia associate sertraline coadministration oral hypoglycemics belong sulphonylurea derivative rarely report patient schizoaffective disorder non insulin dependent diabetes mellitus niddm treat sertraline risperidone glyburide develop hypoglycemia present article highlight inhibition p enzyme affect several different factor interaction possible whenever patient concomitantly receive two drug bind p system great inhibition likely induce dos high recommend process reverse within day discontinue sertraline good glycemic control follow discontinuation psychotropic drug oral hypoglycemic agent knowledge individual p enzyme important metabolism individual drug together understanding patient drug metabolizing ability factor may lead appropriate prescribing research specific p enzymes responsible metabolism particular drug remain unclear,Takhar J,1999,Can J Clin Pharmacol,,10465860,Takhar J; Williamson P,article,D002363: Case Reports; D016428: Journal Article,"D000328: Adult; D018687: Antidepressive Agents, Second-Generation; D003924: Diabetes Mellitus, Type 2; D004347: Drug Interactions; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D008297: Male; D011618: Psychotic Disorders; D020280: Sertraline; D013453: Sulfonylurea Compounds",,,https://openalex.org/W188838531,133,17,1,1451,220,10,en,en
false,glucose tolerance mortality comparison american diabetes association diagnostic criterion decode study group european diabetes epidemiology group diabetes epidemiology collaborative analysis diagnostic criterion europe,american diabetes association ada recommend fast glucose alone oral glucose tolerance test use diagnose diabetes mellitus assess mortality associate ada fasting glucose criterion compare h post challenge glucose criteria assess baseline data glucose concentration fasting h g oral glucose tolerance test prospective european cohort study include men woman age year old mean follow year assess risk death accord different diagnostic glucose categories compared men normal fast glucose mmol l men newly diagnose diabetes mellitus ada fast criterion mmol l hazard ratio death ci woman hazard ratio impaired fasting glucose mmol l hazard ratio criteria mmol l ratio newly diagnose diabetes men woman impaired glucose tolerance mmol l within fasting glucose classification mortality increase increase h glucose however h glucose classification impaired glucose tolerance diabetes trend increase fast glucose concentrations fasting glucose concentration alone identify individual increase risk death associate hyperglycaemia oral glucose tolerance test provide additional prognostic information enable detection individual impaired glucose tolerance great attributable risk death,,1999,Lancet,,10466661,,article,"D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001786: Blood Glucose; D003920: Diabetes Mellitus; D005215: Fasting; D005260: Female; D005500: Follow-Up Studies; D005951: Glucose Tolerance Test; D006801: Humans; D006943: Hyperglycemia; D008297: Male; D017410: Practice Guidelines as Topic; D016016: Proportional Hazards Models; D012307: Risk Factors; D012955: Societies, Medical; D014481: United States; D014944: World Health Organization",,,https://openalex.org/W4300535524,247,36,4,1803,315,9,en,en
false,reduce glucose effectiveness feature glucose intolerance evidence elderly type diabetic subject,one factor determine glucose tolerance glucose disappearance independent dynamic insulin glucose effectiveness debate role development type diabetes still open aim present study evaluate insulin delivery insulin sensitivity si glucose effectiveness sg group elderly type diabetic patient f age year kg bmi kg compare young control c f year kg kg elderly control e f year kg kg perform oral ogtt intravenous fsigt glucose tolerance test ogtt show c e normotolerant markedly reduce glucose tolerance also confirm fsigt glucose tolerance index kg min v c e p total insulin area overall insulin delivery different control group early phase area instead significantly reduce mu min ml vs c e p give reduction dynamic first phase insulin delivery min microu ml mg dl vs c p p e si min microu ml different c e study show marked difference sg control group min v p c p e mostly due zero insulin component gezi v c e p elderly group take together sg exhibit positive correlation area insulin concentration early phase kg r p r p respectively demonstrate importance first phase insulin delivery modulate glucose effectiveness glucose tolerance,Viviani GL,1999,Aging (Milano),https://doi.org/10.1007/bf03399659,10476312,Viviani GL; Pacini G,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000367: Age Factors; D000368: Aged; D000375: Aging; D001786: Blood Glucose; D001835: Body Weight; D003924: Diabetes Mellitus, Type 2; D005215: Fasting; D005260: Female; D018149: Glucose Intolerance; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007333: Insulin Resistance; D008297: Male; D014044: Tolbutamide",,,https://openalex.org/W2406857988,111,16,1,2155,487,10,en,en
false,glucose intolerance year risk coronary heart disease total mortality honolulu heart program,association glucose intolerance measure study entry date year incidence coronary heart disease chd chd mortality total mortality examine honolulu heart program prospective study follow cohort japanese american men year old living island oahu hi baseline glucose measure nonfasting state h g glucose load history use medication diabetes obtain interview cohort divide four category glucose tolerance low normal high normal asymptomatic hyperglycemia know diabetes year follow incident case chd death chd total death occur relative risk rrs obtain use cox proportional hazard model low normal category reference rrs adjust age well age bmi hypertension cholesterol triglyceride smoking alcohol japanese diet index age adjusted risk factor adjusted rrs outcome significant asymptomatic hyperglycemic know diabetes group p age adjusted rrs chd incidence total mortality marginally significant high normal group rrs significant adjust risk factors result suggest dose response relation glucose intolerance baseline chd incidence chd mortality total mortality independent risk factor cohort middle aged old japanese american men,Rodriguez BL,1999,Diabetes Care,https://doi.org/10.2337/diacare.22.8.1262,10480768,Rodriguez BL; Lau N; Burchfiel CM; Abbott RD; Sharp DS; Yano K; Curb JD,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000368: Aged; D003327: Coronary Disease; D003920: Diabetes Mellitus; D005260: Female; D005500: Follow-Up Studies; D018149: Glucose Intolerance; D006254: Hawaii; D006801: Humans; D015994: Incidence; D008297: Male; D008875: Middle Aged; D016016: Proportional Hazards Models; D018570: Risk Assessment,,,https://openalex.org/W2043852083,111,18,1,1609,280,8,en,en
false,controversial aspect regard metformin type diabetic patient reduction late complication early single drug administration increase risk death late administration combination sulfonylurea compound,,Ritzmann P,1999,Praxis (Bern 1994),,10483287,Ritzmann P,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D001786: Blood Glucose; D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D006801: Humans; D008687: Metformin; D008875: Middle Aged; D009765: Obesity; D012307: Risk Factors; D013453: Sulfonylurea Compounds; D015996: Survival Rate",,,https://openalex.org/W2417538082,233,36,1,0,0,0,en,
false,carnitine transport inhibition sulfonylurea human kidney proximal tubular epithelial cell,kidney play important role homeostasis carnitine ability reabsorb carnitine almost completely glomerular filtrate transport process responsible reabsorption investigate thus far laboratory animal report characteristic carnitine uptake proximal tubular epithelial cell line derive human kidney uptake process find obligatorily dependent na involvement anion process saturable michaelis menten constant microm na carnitine stoichiometry process also find responsible uptake acetylcarnitine propionylcarnitine two acyl ester carnitine potential therapeutic use human uptake process specific carnitine acyl ester betaine structural analog carnitine interact uptake process significant extent present study also show sulfonylurea oral hypoglycemic agent currently use management type diabetes inhibit carnitine uptake system among sulfonylurea test glibenclamide potent inhibitor inhibition competitive glibenclamide inhibit uptake carnitine also acetylcarnitine propionylcarnitine inhibition likely result direct interaction compound carnitine transporter inhibition could demonstrate purified rat kidney brush border membrane vesicle,Huang W,1999,Biochem Pharmacol,https://doi.org/10.1016/s0006-2952(99)00219-1,10487540,Huang W; Shaikh SN; Ganapathy ME; Hopfer U; Leibach FH; Carter AL; Ganapathy V,article,D016428: Journal Article,"D000284: Administration, Oral; D000818: Animals; D001692: Biological Transport; D002331: Carnitine; D002460: Cell Line; D002462: Cell Membrane; D004847: Epithelial Cells; D006801: Humans; D007004: Hypoglycemic Agents; D007687: Kidney Tubules, Proximal; D008871: Microvilli; D051381: Rats; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2051404033,105,14,1,1562,253,14,en,en
false,natural history insulin secretory dysfunction insulin resistance pathogenesis type diabetes mellitus,pathogenesis type diabetes involves abnormality insulin action insulin secretion endogenous glucose output ego however sequence abnormality develop relative contribution deterioration glucose tolerance remain unclear absence detailed longitudinal study measure insulin action insulin secretion ego longitudinally pima indian glucose tolerance deteriorate normal ngt impair igt diabetic year transition ngt igt associate increase body weight decline insulin stimulated glucose disposal decline acute insulin secretory response air intravenous glucose change ego progression igt diabetes accompany increase body weight decrease insulin stimulated glucose disposal air increase basal ego thirty one subject retain ngt similar period also gain weight air increase decrease insulin stimulated glucose disposal thus defect insulin secretion insulin action occur early pathogenesis diabetes intervention prevent diabetes target abnormality,Weyer C,1999,J Clin Invest,https://doi.org/10.1172/jci7231,10491414,Weyer C; Bogardus C; Mott DM; Pratley RE,article,D016428: Journal Article,"D000328: Adult; D000886: Anthropometry; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005947: Glucose; D005951: Glucose Tolerance Test; D006801: Humans; D007328: Insulin; D007333: Insulin Resistance; D000078790: Insulin Secretion; D008297: Male; D009765: Obesity; D012737: Sex Factors",,,https://openalex.org/W2077149049,123,18,1,1270,215,8,en,en
false,clinical pharmacokinetics troglitazone,troglitazone new thiazolidinedione oral antidiabetic agent approve use improve glycaemic control patient type diabetes rapidly absorb absolute bioavailability food increase absorption pharmacokinetics troglitazone linear clinical dosage range mg daily mean elimination half life range hour facilitate daily administration regimen pharmacokinetics troglitazone similar patient type diabetes healthy individual human troglitazone undergoes metabolism sulfation glucuronidation oxidation form sulfate conjugate glucuronide conjugate quinone metabolite respectively major metabolite plasma minor metabolite age gender type diabetes renal impairment smoking race appear influence pharmacokinetics troglitazone major metabolite patient hepatic impairment plasma concentration troglitazone increase fold fold respectively cholestyramine decrease absorption troglitazone troglitazone may enhance activity cytochrome p cyp transporter thereby reduce plasma concentration terfenadine cyclosporin atorvastatin fexofenadine also reduce plasma concentration oral contraceptive hormone ethinylestradiol norethindrone levonorgestrel troglitazone alter pharmacokinetics digoxin glibenclamide glyburide paracetamol acetaminophen pharmacodynamic interaction troglitazone warfarin alcohol ethanol pharmacodynamic modelling show improvement fast glucose triglyceride level increase dose mg knowledge systemic troglitazone exposure within dose group improve prediction glucose lower response adverse effect beyond base administer dose,Loi CM,1999,Clin Pharmacokinet,https://doi.org/10.2165/00003088-199937020-00001,10496299,Loi CM; Young M; Randinitis E; Vassos A; Koup JR,article,D016428: Journal Article; D016454: Review,D001682: Biological Availability; D015415: Biomarkers; D002839: Chromans; D002986: Clinical Trials as Topic; D015897: Comorbidity; D004347: Drug Interactions; D006801: Humans; D007004: Hypoglycemic Agents; D013844: Thiazoles; D045162: Thiazolidinediones; D000077288: Troglitazone,,,https://openalex.org/W1963517446,41,4,1,2092,349,17,en,en
false,absorption metabolism excretion single oral dose c repaglinide repaglinide multiple dosing,objective present study design assess disposition c repaglinide whole blood plasma urine faeces measure total recovery drug related material urine faeces single mg oral dose c repaglinide multiple dosing method single centre open label phase trial six healthy male volunteer receive mg prandial glucose regulator repaglinide four time daily day min meal morning day breakfast omit dose give oral solution contain mg c repaglinide result oral dosing mean peak plasma concentration repaglinide ng ml range ng ml observe time peak concentration h approximately repaglinide associate metabolite distribute red blood cell measurable c radioactivity present whole blood sample h dose within h dose c repaglinide administer dose appear faeces excrete urine plasma major compound repaglinide urine major metabolite unidentified polar compound aromatic amine dicarboxylic acid faeces major metabolite administer dose therefore repaglinide excrete predominantly metabolite major vivo metabolite repaglinide human regular dose day morning plasma trough level repaglinide exception almost always low measure indicate absence accumulation dose mg four time daily repaglinide well tolerate episode hypoglycaemia conclusion oral dose repaglinide mean peak plasma concentration rapidly attain thereafter plasma concentration decrease promptly major route excretion via faeces property make repaglinide suitable insulin secretagogue patient type diabetes retain sufficient beta cell function,van Heiningen PN,1999,Eur J Clin Pharmacol,https://doi.org/10.1007/s002280050667,10501822,van Heiningen PN; Hatorp V; Kramer Nielsen K; Hansen KT; van Lier JJ; De Merbel NC; Oosterhuis B; Jonkman JH,article,"D016430: Clinical Trial; D017426: Clinical Trial, Phase I; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000042: Absorption; D000284: Administration, Oral; D000293: Adolescent; D000328: Adult; D019540: Area Under Curve; D002219: Carbamates; D002250: Carbon Radioisotopes; D004305: Dose-Response Relationship, Drug; D004912: Erythrocytes; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008657: Metabolic Clearance Rate; D010880: Piperidines; D013997: Time Factors; D014018: Tissue Distribution",,,https://openalex.org/W2064954514,113,17,1,2186,435,17,en,en
false,characterization cytochrome p enzymes involve vitro metabolism rosiglitazone,identify human cytochrome p enzyme involve vitro metabolism rosiglitazone potential oral antidiabetic agent treatment type diabetes mellitus method specific p enzyme involve metabolism rosiglitazone determine combination three approach multiple regression analysis rate metabolism rosiglitazone human liver microsome selective p substrate effect selective chemical inhibitor rosiglitazone metabolism capability express p enzyme mediate major metabolic route rosiglitazone metabolism result major product metabolism follow incubation rosiglitazone human liver microsome para hydroxy n desmethyl rosiglitazone rate formation vary fold human liver investigate correlate paclitaxel alpha hydroxylation p formation metabolite inhibit significantly cis retinoic acid cyp c inhibitor furafylline quinidine ketoconazole addition metabolite produce microsome derive cell line transfected human cyp c cdna evidence cyp c play minor role metabolism rosiglitazone sulphaphenazole cause limited inhibition pathway human liver microsome microsome cell transfected cyp c cdna able mediate metabolism rosiglitazone particular n demethylation pathway albeit much slow rate cyp c rosiglitazone cause moderate inhibition paclitaxel alpha hydroxylase activity cyp c ic microm weak inhibition tolbutamide hydroxylase activity cyp c ic microm cause marked inhibition cytochrome p activity investigate cyp c c e conclusion cyp c primarily responsible hydroxylation n demethylation rosiglitazone human liver minor contribution cyp c,Baldwin SJ,1999,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.1999.00030.x,10510156,Baldwin SJ; Clarke SE; Chenery RJ,article,D016428: Journal Article,"D001189: Aryl Hydrocarbon Hydroxylases; D019388: Cytochrome P-450 CYP1A2; D065727: Cytochrome P-450 CYP2C8; D065729: Cytochrome P-450 CYP2C9; D003577: Cytochrome P-450 Enzyme System; D018076: DNA, Complementary; D004791: Enzyme Inhibitors; D006801: Humans; D007004: Hypoglycemic Agents; D007700: Kinetics; D008862: Microsomes, Liver; D000077154: Rosiglitazone; D039181: Steroid 16-alpha-Hydroxylase; D013250: Steroid Hydroxylases; D013844: Thiazoles; D045162: Thiazolidinediones; D014162: Transfection; D014407: Tumor Cells, Cultured",,,https://openalex.org/W1586241840,107,20,1,2065,335,10,en,en
false,recent advance pharmacological treatment type diabetes mellitus,several new pharmacological agent attempt correct abnormality pathogenesis type diabetes mellitus availability agent different mechanism action side effect profile permit design individualized regimen address various pathophysiologic abnormality,Parulkar AA,1999,Compr Ther,https://doi.org/10.1007/bf02944293,10520444,Parulkar AA; Fonseca VA,article,D016428: Journal Article; D016454: Review,"D001786: Blood Glucose; D003131: Combined Modality Therapy; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D015444: Exercise; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D011379: Prognosis; D015431: Weight Loss",,,https://openalex.org/W2048292889,72,10,1,307,42,2,en,en
false,interaction sulfonylurea exercise glucose homeostasis type diabetic patient,determine whether plasma glucose lowering effect sulfonylurea acute submaximal exercise additive accordingly determine whether may increase risk hypoglycemia combine fast patients eight postabsorptive type diabetic patient examine three occasion oral sulfonylurea mg glibenclamide min ergometer cycle exercise vo max exercise glibenclamide heart rate vo lactate response exercise comparable p day without glibenclamide plasma insulin concentration always increase glibenclamide lower identically exercise without glibenclamide however throughout exercise absolute concentration insulin low day without glibenclamide compare day glibenclamide vs pmol l p start exercise glucose concentration similar experiment p rate decrease glucose exercise high p day glibenclamide exercise compare day glibenclamide alone day exercise alone vs mmol l min respectively consequently glucose nadir low day glibenclamide exercise day glibenclamide exercise alone vs mmol l respectively p exercise rate appearance plasma glucose determine h glucose infusion low day glibenclamide day without glibenclamide vs mg min kg p contrast glucose clearance identical p postabsorptive type diabetic patient hypoglycemic action glibenclamide exercise enhance treatment combine interaction reflect increase inhibition glibenclamide enhanced insulin level hepatic glucose production hepatic glucose production accelerate exercise,Larsen JJ,1999,Diabetes Care,https://doi.org/10.2337/diacare.22.10.1647,10526729,Larsen JJ; Dela F; Madsbad S; Vibe-Petersen J; Galbo H,article,D016428: Journal Article,"D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004837: Epinephrine; D015444: Exercise; D005080: Exercise Test; D005934: Glucagon; D005905: Glyburide; D006706: Homeostasis; D019382: Human Growth Hormone; D006801: Humans; D006854: Hydrocortisone; D007004: Hypoglycemic Agents; D007328: Insulin; D008875: Middle Aged; D009638: Norepinephrine; D010101: Oxygen Consumption; D005082: Physical Exertion; D013453: Sulfonylurea Compounds; D013997: Time Factors",,,https://openalex.org/W2158134896,93,14,1,2110,365,9,en,en
false,review metabolic cardiovascular effect oral antidiabetic agent beyond glucose level lowering,become evident cardiovascular disease major cause morbidity mortality type diabetes mellitus raise possibility glucose lower agent nonglucose lowering effect might add benefit review focus metabolic cardiovascular effect oral antidiabetic agent go beyond glucose level lower effect include lipid modifying action antithrombotic profibrinolytic activity direct action level vessel wall improve endothelial function prevent smooth muscle hyperplasia additional activity particularly see new oral antidiabetic agent hold promise reduce cardiovascular complication beyond achievable glucose lower alone,Ginsberg H,1999,J Cardiovasc Risk,https://doi.org/10.1177/204748739900600512,10534139,Ginsberg H; Plutzky J; Sobel BE,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D000975: Antioxidants; D001777: Blood Coagulation; D002318: Cardiovascular Diseases; D002319: Cardiovascular System; D008078: Cholesterol, LDL; D002839: Chromans; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D006949: Hyperlipidemias; D007004: Hypoglycemic Agents; D007333: Insulin Resistance; D008687: Metformin; D013844: Thiazoles; D045162: Thiazolidinediones; D000077288: Troglitazone",,,https://openalex.org/W1873924216,107,15,1,799,122,5,en,en
false,lipoprotein profile differs insulin treatment alone combination therapy insulin sulphonylureas patient type diabetes mellitus,study whether change endogenous insulin secretion glycaemic control affect plasma concentration lipoprotein patient type diabetes mellitus fifteen patient age year mean sem body weight kg body mass index kg treat sulphonylurea insulin combination insulin alone randomized double blind crossover study patient treat multiple daily injection regimen addition glibenclamide mg daily placebo tablets combination therapy dose insulin less p increase plasma c peptide concentration p plasma level free insulin change plasma level sex hormone binding globulin shbg insulin like growth factor binding protein igfbp lower difference h blood glucose profile hba c vs p body weight similar significant decrease plasma ldl cholesterol vs mmol l p apolipoprotein lipoprotein increase vldl triglycerides vs mmol l p combination therapy ratio ldl cholesterol apolipoprotein b concentration significantly low combination therapy p combination therapy insulin sulphonylureas increase portal insulin supply thereby alters liver lipoprotein metabolism compare insulin therapy alone,Lindström T,1999,Diabet Med,https://doi.org/10.1046/j.1464-5491.1999.00170.x,10547208,Lindström T; Nyström FH; Olsson AG; Ottosson AM; Arnqvist HJ,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D002096: C-Peptide; D008078: Cholesterol, LDL; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007328: Insulin; D018970: Insulin-Like Growth Factor Binding Protein 1; D007334: Insulin-Like Growth Factor I; D008074: Lipoproteins; D008079: Lipoproteins, VLDL; D008297: Male; D008875: Middle Aged; D012738: Sex Hormone-Binding Globulin; D013453: Sulfonylurea Compounds; D014280: Triglycerides",,,https://openalex.org/W2130000595,160,22,1,1569,269,8,en,en
false,role sulphonylurea combination therapy assess trial sulphonylurea withdrawal,summary aim evaluate effect add insulin sulphonylurea su effect su withdrawal glycaemic control type diabetic patient fail treatment su alone method one hundred seventy five patient include placebo controlled multicentre study phase month premixed insulin add glibenclamide therapy phase ii month depend response insulin dose fix placebo glibenclamide replace open su therapy insulin sensitivity kitt beta cell function c peptide metabolic control hba c monitor result hba c improve p phase high hba c value p high kitt value p baseline associate beneficial response combination treatment phase ii glycaemic control unchanged control glibenclamide group placebo group su withdrawal fast blood glucose fbg increase within week patient patient fbg increase phase ii define su responder protocol multivariate analysis long duration diabetes associate su response gad antibody positive patient among non responders vs p conclusion poor glycaemic control combination preserved insulin sensitivity lack gad antibody predict beneficial response combination therapy achieve patient su failure,Landstedt-Hallin L,1999,Diabet Med,https://doi.org/10.1046/j.1464-5491.1999.00171.x,10547209,Landstedt-Hallin L; Arner P; Lins PE; Bolinder J; Olsen H; Groop L,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D015999: Multivariate Analysis; D010919: Placebos; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2078984100,96,14,1,1597,311,12,en,en
false,short term cost treatment model type diabetes comparison glipizide gastrointestinal therapeutic system metformin acarbose,compare manage care perspective year cost first line monotherapy strategy type diabetes patient glipizide gastrointestinal therapeutic system git metformin acarbose markov model monte carlo simulation develop compare cost achieve full glycemic control hemoglobin c first line strategy patient population model assume newly diagnose type diabetes patient eligible monotherapy oral agent monotherapy could succeed add treatment model include cost routine medical care supply medication adverse event treatment failures using monte carlo simulation mean year cumulative cost per patient glipizide git metformin acarbose first line strategy respectively main cost driver drug price mean year cost saving first line glipizide git metformin acarbose simulation show cost saving glipizide git compare agents model suggest first line monotherapy glipizide git result desirable short term economic benefit manage care model incorporate recommended glycemic goal perform well sensitivity analysis applicable variety clinical practice useful economic assessment new therapy result model verify prospectively typical care setting,Ramsdell JW,1999,Am J Manag Care,,10558125,Ramsdell JW; Grossman JA; Stephens JM; Botteman MF; Arocho R,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D020909: Acarbose; D003663: Decision Trees; D003924: Diabetes Mellitus, Type 2; D016527: Drug Costs; D005913: Glipizide; D017048: Health Care Costs; D006295: Health Resources; D006801: Humans; D007004: Hypoglycemic Agents; D008329: Managed Care Programs; D008390: Markov Chains; D008687: Metformin; D009010: Monte Carlo Method; D009819: Office Visits; D014312: Trisaccharides; D014481: United States",,,https://openalex.org/W2398443498,143,21,1,1576,268,8,en,en
false,effect octreotide glucose insulin level patient type diabetes glibenclamide,report case year old woman recurrent gastrointestinal bleeding type diabetic patient well control glibenclamide volume resuscitation transfusion packed blood cell infusion octreotide mcg hr start decide start long term octreotide treatment potential effect glycemic control study gram oral glucose tolerance test perform two consecutive day without octreotide infusion octreotide blood glucose high insulin level low clinical indication expand situation arise patient diabetes sulfonylurea may require octreotide conceivable dramatic worsening glycemic control,Lee PE,1999,Diabetes Metab,,10566126,Lee PE; Meneilly GS,article,"D002363: Case Reports; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006490: Hemostatics; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D015282: Octreotide",,,https://openalex.org/W132520489,106,19,1,758,122,6,en,en
false,insulin lispro treatment patient type diabetes mellitus oral agent failure,study assess safety profile efficacy new combination therapy insulin lispro plus sulfonylurea patient type diabetes mellitus experience secondary oral agent failure total patient randomly assign treatment group preprandial insulin lispro plus sulfonylurea l bedtime neutral protamine hagedorn nph insulin plus sulfonylurea n preprandial insulin lispro plus bedtime nph insulin l n mean decrease glycosylated hemoglobin baseline patient receive l receive n receive l n within treatment p l vs n p fast blood glucose level higher patient receive l mg dl l n mg dl receive n mg dl p comparison conversely postprandial blood glucose level low patient receive l mg dl l n mg dl receive n mg dl p comparison overall rate hypoglycemia episode per day statistically significant l n l n therapy compare vs vs respectively rate nocturnal hypoglycemia low l group vs n group vs l n group p l safety profile equal n l n effective treatment patient type diabetes experience oral sulfonylurea agent failure l offer alternative establish combination therapy patient whose type diabetes control sulfonylurea alone,Bastyr EJ,1999,Clin Ther,https://doi.org/10.1016/s0149-2918(99)80049-6,10566566,Bastyr EJ; Johnson ME; Trautmann ME; Anderson JH; Vignati L,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D061268: Insulin Lispro; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2093981439,98,16,1,1825,384,9,en,en
false,strategy good diabetes control u,recent survey u indicate total diabetes care deliver primary care physician current management practice term point initiation pharmacological treatment fall considerably short american diabetes association recommendation part delay initiate treatment due fear provoke hypoglycaemia result general avoidance blood glucose monitoring part patient consequence apparent disregard diabetes care blood glucose concentration adequately control u reflect high incidence chronic complication particularly diabetic neuropathy likely major cost implication future effort improve standard diabetes care number u authority begin produce guideline primary care physician state texas treatment algorithm incorporate recommendation base current u registration trial data develop recommendation adopt state texas form part minimum standard care mandate state department health diabetes council provide guidance selection use oral antidiabetic drug include sulphonylureas metformin troglitazone repaglinide acarbose patient type diabetes glycaemic control prevention cardiovascular complication hop organised implementation treatment algorithm produce good control diabetes complication current ad hoc strategy use individual practitioner,Garber AJ,1999,Drugs,https://doi.org/10.2165/00003495-199958001-00014,10576528,Garber AJ,article,D016428: Journal Article; D016454: Review,"D002318: Cardiovascular Diseases; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D013781: Texas; D014481: United States",,,https://openalex.org/W1985941324,48,8,1,1724,285,7,en,en
false,low dose ethanol predisposes elderly fast patient type diabetes sulfonylurea induced low blood glucose,previously demonstrate risk hypoglycemia low among otherwise healthy elderly fast patient type diabetes take oral sulfonylurea medication nevertheless agent cause hypoglycemia clinical practice suggest accompany factor must typically present hypoglycemia occur ethanol one putative risk factor evaluate mechanism low blood glucose among sulfonylurea user hypothesize low concentration ethanol would reduce blood glucose concentration elderly type diabetic patient receive sulfonylurea short term fast total type diabetic patient age year receive mg glyburide daily participate prospective double blind placebo controlled patient study consist two h fast least week apart hour fasting study subject receive intravenous infusion either mmol kg h ethanol equivalent one two alcoholic beverage saline placebo random order ethanol plasma glucose insulin counterregulatory hormone assess min final h fast blood ethanol level peak mmol l low legal limit intoxication new mexico ethanol study plasma glucose concentration differ baseline placebo vs ethanol mmol l p nadir plasma glucose low ethanol infusion compare placebo vs mmol l p absolute decline plasma glucose also great ethanol study placebo study vs mmol l p counterregulatory hormone level increase ethanol study nonesterified fatty acid concentration suppress compare placebo study low dos ethanol predispose fast elderly type diabetic patient low blood glucose short term fast may one several mechanism sulfonylurea induced hypoglycemia occur elderly patient,Burge MR,1999,Diabetes Care,https://doi.org/10.2337/diacare.22.12.2037,10587839,Burge MR; Zeise TM; Sobhy TA; Rassam AG; Schade DS,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000284: Administration, Oral; D000368: Aged; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004347: Drug Interactions; D000431: Ethanol; D005215: Fasting; D005230: Fatty Acids, Nonesterified; D005260: Female; D005934: Glucagon; D019382: Human Growth Hormone; D006801: Humans; D008297: Male; D013453: Sulfonylurea Compounds; D013997: Time Factors",,,https://openalex.org/W2047948602,116,16,1,2136,360,9,en,en
false,repaglinide new compound treatment patient type diabetes,repaglinide new oral blood glucose lower agent member carbamoylmethyl benzoic acid cmba family mechanism action partly similar sulphonylurea release insulin pancreatic beta cell stimulate closure atp dependent potassium channel however repaglinide regulate channel via different binding site beta cell glibenclamide drug cause insulin release absence glucose voltage clamping oral administration drug rapidly absorbed eliminate therefore use meal related dosing regimen repaglinide take main meal meal related use may give physiological mimick daytime insulin requirement daily twice daily use sulphonylurea patient use repaglinide less likely develop hypoglycaemic symptom miss postpone meal comparison patient glibenclamide treatment long term comparative phase clinical study find repaglinide equally effective maintain glycaemic control exist sulphonylurea give significantly good control postprandial blood glucose level repaglinide use monotherapy obese non obese type diabetic patient also effective combination drug like metformin thiazolidines excretion liver bile also attractive drug diabetic patient diminished kidney function especially elderly diabetic although overall incidence hypoglycaemia similar use repaglinide sulphonylurea serious hypoglycaemic episode observe repaglinide treated patient,Wolffenbuttel BH,1999,Neth J Med,https://doi.org/10.1016/s0300-2977(99)00068-6,10593133,Wolffenbuttel BH,article,D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D001786: Blood Glucose; D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D005247: Feeding Behavior; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007408: Intestinal Absorption; D008657: Metabolic Clearance Rate; D010880: Piperidines",,,https://openalex.org/W2147616425,81,14,1,1770,282,11,en,en
false,lack interaction thioctic acid glibenclamide acarbose,aim thioctic acid ta glibenclamide acarbose widely use either alone concomitantly treat patient suffer noninsulin dependent diabetes niddm study systematically investigate drug drug interaction ta glibenclamide ta acarbose method fourteen male female healthy volunteer participate randomize open three period cross trial treatment c follow fourth period treatment baseline profile plasma insulin glucose concentration variable serve pharmacodynamic measure assess enter trial treatment mg ta orally b mg glibenclamide orally c mg ta mg glibenclamide mg ta mg acarbose time course r ta ta well glibenclamide concentration measure specific analytical method result clinically relevant change ta enantiomer pharmacokinetics glibenclamide acarbose also glibenclamide pharmacokinetics alter ta clinically meaningful extent plasma insulin glucose concentration indicate interaction ta glibenclamide ta acarbose glibenclamide expect effect insulin glucose level independent comedication minor short lasting adverse event majority expect hypoglycaemic symptom occur treatment glibenclamide conclusion coadministration single dos ta glibenclamide ta acarbose appear cause drug drug interaction,Gleiter CH,1999,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.1999.00097.x,10594485,Gleiter CH; Schreeb KH; Freudenthaler S; Thomas M; Elze M; Fieger-Büschges H; Potthast H; Schneider E; Schug BS; Blume HH; Hermann R,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D020909: Acarbose; D000328: Adult; D001786: Blood Glucose; D018592: Cross-Over Studies; D004347: Drug Interactions; D004791: Enzyme Inhibitors; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008063: Thioctic Acid,,,https://openalex.org/W1622416307,69,10,1,1598,259,12,en,en
false,oral pharmacologic management type diabetes,epidemiologic interventional study lead lower treatment target type diabetes formerly know non insulin dependent diabetes include glycosylated hemoglobin level percent less meal blood glucose level mg per dl mmol per l new oral medication make target easy achieve especially patient recently diagnose diabetes acarbose metformin miglitol pioglitazone rosiglitazone troglitazone help patient insulin control glucose level allow early treatment little risk hypoglycemia two new long acting sulfonylurea glimepiride extended release glipizide short acting sulfonylurea like agent repaglinide simply reliably augment patient insulin supply combination agent additive therapeutic effect restore glucose control single agent longer successful oral therapy early type diabetes relatively inexpensive evidence cost effectiveness accumulate,Riddle MC,1999,Am Fam Physician,,10605995,Riddle MC,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D017485: 1-Deoxynojirimycin; D020909: Acarbose; D000284: Administration, Oral; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D004791: Enzyme Inhibitors; D005944: Glucosamine; D065089: Glycoside Hydrolase Inhibitors; D006801: Humans; D007004: Hypoglycemic Agents; D050112: Imino Pyranoses; D008687: Metformin; D013453: Sulfonylurea Compounds; D013844: Thiazoles; D045162: Thiazolidinediones; D014481: United States",,,https://openalex.org/W24538750,49,8,1,1057,171,6,en,en
false,improve management type diabetes mellitus meglitinides,,Quillen DM,1999,Hosp Pract (1995),https://doi.org/10.1080/21548331.1999.11443957,10611897,Quillen DM; Kuritzky L; Samraj GP,article,D016428: Journal Article,"D002219: Carbamates; D000075202: Contraindications; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D010880: Piperidines",,,https://openalex.org/W2315923336,65,11,2,0,0,0,en,
true,repaglinide type diabetes week fixed dose efficacy safety study,week multicenter double blind randomize fixed dose trial patient type diabetes receive daily preprandial treatment placebo n repaglinide mg n repaglinide mg n last observation carried forward calculation repaglinide mg mg treatment decrease mean fasting plasma glucose fpg value mg dl mg dl placebo group increase fpg value mg dl repaglinide treatment group end study change hba c baseline value range percentage point low placebo group event severe hypoglycemia nearly hypoglycemic symptom episode blood glucose level mg dl repaglinide well tolerate preprandial fixed dose regimen mg mg assign without adjustment clinical parameter,Jovanovic L,2000,J Clin Pharmacol,https://doi.org/10.1177/00912700022008694,10631622,Jovanovic L; Dailey G; Huang WC; Strange P; Goldstein BJ,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005215: Fasting; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D010352: Patient Dropouts; D010880: Piperidines; D013997: Time Factors; D016896: Treatment Outcome",,,https://openalex.org/W2158768965,79,14,1,891,168,6,en,en
false,use sulphonylureas elderly,type diabetes mellitus heterogeneous disorder characterise defect insulin secretion well reduce insulin action age glucose intolerance gradually develop manifest primarily increase postprandial blood glucose response fast blood glucose level often less elevated abnormal beta cell secretion insulin main feature treatment elderly patient type diabetes mellitus focus reduction hyperglycaemic complaint prevention development progression secondary complication although regular physical activity dietary measure aim bodyweight normalisation cornerstone therapy pharmacological treatment oral blood glucose lowering agents often prove necessary control hyperglycaemia united kingdom prospective diabetes study ukpds clearly show patient type diabetes mellitus intensively treat oral blood glucose lowering agent insulin develop less microvascular complication question whether achievement strict metabolic control also benefit elderly patient still unanswered sulphonylureas drug stimulate insulin secretion enhance release insulin pancreatic beta cells without effect insulin synthesis frequently use treatment type diabetes mellitus several preparation available general major difference effectiveness various sulphonylureas long term treatment sulphonylureas decrease fasting postprandial plasma glucose level mmol l glycosylated haemoglobin however initial decline plasma glucose level often go slightly following month year sulphonylureas usually well tolerate hypoglycaemia frequently occur adverse effect may serious damaging elderly associate primarily long acting sulphonylureas like chlorpropamide glibenclamide glyburide hypoglycaemic episode may trigger serious event like myocardial infarction stroke therefore shorter acting compound like tolbutamide gliclazide relatively well tolerate appear best choice treat elderly patient advisable start low dose increase dose need small step efficacy sulphonylureas much great take meal fact type diabetes mellitus progressive disease residual beta cell function decrease time insulin therapy may ultimately warrant significant number patient,Graal MB,1999,Drugs Aging,https://doi.org/10.2165/00002512-199915060-00007,10641958,Graal MB; Wolffenbuttel BH,article,D016428: Journal Article; D016454: Review,"D000368: Aged; D000375: Aging; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2022796086,40,7,1,2777,442,20,en,en
false,new direction type diabetes mellitus update current oral antidiabetic therapy,article review relevant literature include publish clinical trial review currently available oral hypoglycemic agent result show benefit glycemic control establish multiple clinical trial long term control blood glucose level type type diabetic patient decrease incidence prolong time progression diabetic retinopathy nephropathy neuropathy increased understanding pathophysiology behind type diabetes lead development many new agent aim treat underlying insulin resistance relative insulinopenia sulfonylurea group use many year act stimulate insulin secretion useful alone combination therapy insulin another oral hypoglycemic agent biguanides act decrease hepatic glucose production increase peripheral insulin sensitivity alpha glucosidase inhibitor act nonsystemically block metabolism digested polysaccharide therefore lower amount carbohydrate absorb meal benzoic acid derivative act manner similar sulfonylurea enhance pancreatic insulin production offer short duration action lower risk hypoglycemia thiazolidinediones increase peripheral insulin sensitivity effective monotherapy combination therapy oral hypoglycemic agent properly administer effective control type diabetes prevent long term complication,Brown DL,1999,J Natl Med Assoc,,10643211,Brown DL; Brillon D,article,D016428: Journal Article; D016454: Review,"D002219: Carbamates; D002839: Chromans; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D008687: Metformin; D010880: Piperidines; D013453: Sulfonylurea Compounds; D013844: Thiazoles; D045162: Thiazolidinediones; D000077288: Troglitazone",,,https://openalex.org/W2196820307,91,16,1,1612,242,12,en,en
true,pharmacodynamics pharmacokinetics intravenous glibenclamide caucasian chinese patient type diabetes,objective analyse kinetics effect glibenclamide gb glucose insulin proinsulin secretion two ethnic group type diabetic patient one caucasian chinese origin background diabetes mellitus type global disease affect ethnic group ethnic difference prevalence metabolic characteristic disease important interethnic pharmacodynamic pharmacokinetic difference report several drug exception detailed study sulphonylurea lack material method patient study two occasion either gb control mg gb administer v immediately administration g oral glucose tolerance test concentration insulin proinsulin determine mean radioimmunoassay without cross reactivities gb concentration determine use high performance liquid chromatography pharmacodynamic result calculated use net area curve basal value set zero p value less consider significant result glucose administer orally without gb chinese patient high plasma glucose increase min mmol l x min v mmol l x min high increase plasma insulin level caucasian min pmol l x min v pmol l x min min pmol l x min v pmol l x min gb administer plasma glucose increase reduce increase serum insulin proinsulin level great ethnic group compare basal value min proinsulin insulin ratio rpi low min follow increase chinese patient high increase serum insulin level min pmol l x min v pmol l x min low rpi min vs min vs relative caucasian serum gb data best fit biexponential v model interethnic difference pharmacokinetic parameter conclusion summary follow oral glucose administration without gb chinese type diabetic patient high plasma insulin level also high plasma glucose level first min might reflect reduce insulin sensitivity rapid glucose absorption gb augment glucose induced release insulin proinsulin ethnic group effect insulin secretion pronounced conclusion minor pharmacodynamic pharmacokinetic difference find two group seem appropriate employ dosage principle use gb caucasian chinese,Jönsson A,2000,Eur J Clin Pharmacol,https://doi.org/10.1007/s002280050004,10663449,Jönsson A; Chan JC; Rydberg T; Vaaler S; Hallengren B; Cockram CS; Critchley JA; Melander A,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D044466: Asian People; D001786: Blood Glucose; D002851: Chromatography, High Pressure Liquid; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005947: Glucose; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007262: Infusions, Intravenous; D007328: Insulin; D008297: Male; D008875: Middle Aged; D011384: Proinsulin; D011863: Radioimmunoassay; D013997: Time Factors; D044465: White People",,,https://openalex.org/W2112036649,121,14,1,2743,490,22,en,en
true,single dose pharmacokinetics repaglinide subject chronic liver disease,repaglinide novel insulin secretagogue develop response need fast acting oral prandial glucose regulator treatment type non insulin dependent diabetes mellitus repaglinide metabolize mainly liver pharmacokinetics may therefore alter hepatic dysfunction open parallel group study compare pharmacokinetics tolerability single mg dose repaglinide healthy subject n patient chronic liver disease cld n value auc cmax significantly high cld patient compare healthy subject mrt prolong cld patient value tmax differ group significantly prolong cld patient compare previously determine value healthy subject auc inversely correlate caffeine clearance cld patient healthy subject blood glucose profile similar group adverse event principally hypoglycemia similar two group none serious repaglinide clearance significantly reduce patient hepatic impairment agent use caution group,Hatorp V,2000,J Clin Pharmacol,https://doi.org/10.1177/00912700022008793,10664920,Hatorp V; Walther KH; Christensen MS; Haug-Pihale G,article,"D016430: Clinical Trial; D017426: Clinical Trial, Phase I; D016428: Journal Article",D000328: Adult; D001786: Blood Glucose; D001798: Blood Proteins; D002110: Caffeine; D002219: Carbamates; D002908: Chronic Disease; D006801: Humans; D007004: Hypoglycemic Agents; D008107: Liver Diseases; D008297: Male; D008875: Middle Aged; D010880: Piperidines; D011485: Protein Binding,,,https://openalex.org/W2038071902,82,10,1,1206,207,9,en,en
false,economic assessment troglitazone adjunct sulfonylurea therapy treatment type diabetes,assess economic efficiency add troglitazone sulfonylurea therapy improve glycemic control despite high prevalence type diabetes exist treatment strategy often fail new oral agent give wider segment population type diabetes hope achieve near normal blood glucose level troglitazone novel chemical entity one promise new agent conduct economic analysis base glycemic control data randomized clinical trial compare troglitazone placebo add glyburide patient simulation model use translate data long term outcome associate diabetes patient poorly control type diabetes mellitus despite glyburide therapy risk function develop progress nephropathy retinopathy neuropathy hypoglycemia macrovascular disease develop diabetes control complication trial large epidemiologic study cost estimate base data state payor database survey literature main outcome model cost consequences number patient develop type complication mean time development complication cost per life year gain lyg cost per quality adjusted life year model predict every patient treat troglitazone improved glycemic control could mean patient would experience one severe diabetic complication eg blindness end stage renal disease amputation may increase life expectancy year benefit obtain additional per lyg undiscounted ratio remain per lyg variation input clinical trial demonstrate troglitazone glyburide improve glycemic control compare glyburide alone base result model estimate diabetic complication cost well accept cost effective threshold,Caro JJ,2000,Clin Ther,https://doi.org/10.1016/s0149-2918(00)87983-7,10688395,Caro JJ; Klittich WS; Raggio G; Kavanagh PL; O'Brien JA; Shomphe LA; Flegel KM; Copley-Merriman C; Sigler C,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D002839: Chromans; D015331: Cohort Studies; D003362: Cost-Benefit Analysis; D003924: Diabetes Mellitus, Type 2; D016527: Drug Costs; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D018803: Models, Economic; D016032: Randomized Controlled Trials as Topic; D013453: Sulfonylurea Compounds; D013844: Thiazoles; D045162: Thiazolidinediones; D000077288: Troglitazone; D014481: United States",,,https://openalex.org/W2105964383,109,17,1,1998,320,11,en,en
false,addition low dose rosiglitazone sulphonylurea therapy improve glycaemic control type diabetic patient,study design test efficacy safety low dose rosiglitazone potent insulin sensitizing thiazolidinedione combination sulphonylurea type diabetic patients intention treat analysis patient male mean age year available randomize receive week twice daily placebo n rosiglitazone mg n rosiglitazone mg n addition exist sulphonylurea treatment gliclazide patient glibenclamide glipizide two patient take carbutamide glimepiride change haemoglobin c hba c fast plasma glucose fpg fructosamine insulin c peptide albumin lipid measure safety evaluated mean baseline hba c fpg mmol l rosiglitazone dos mg b plus sulphonylurea produce significant decrease compare sulphonylurea plus placebo hba c respectively p fpg mmol l mmol l respectively p hdl cholesterol ldl cholesterol increase potentially beneficial decrease non esterified fatty acid gamma glutamyl transpeptidase level see rosiglitazone group overall incidence adverse experience similar three treatment group significant cardiac event hypoglycaemia hepatotoxicity overall combination rosiglitazone sulphonylurea safe well tolerate effective patient type diabetes,Wolffenbuttel BH,2000,Diabet Med,https://doi.org/10.1046/j.1464-5491.2000.00224.x,10691158,Wolffenbuttel BH; Gomis R; Squatrito S; Jones NP; Patwardhan RN,article,"D016430: Clinical Trial; D017428: Clinical Trial, Phase III; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D002096: C-Peptide; D002784: Cholesterol; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005060: Europe; D005260: Female; D019270: Fructosamine; D005907: Gliclazide; D005913: Glipizide; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D000077154: Rosiglitazone; D012449: Safety; D013844: Thiazoles; D045162: Thiazolidinediones; D014280: Triglycerides",,,https://openalex.org/W2169421904,114,15,1,1561,283,6,en,en
true,pharmacokinetics pharmacodynamics gliclazide caucasian australian aborigine type diabetes,aim gliclazide pharmacokinetics pharmacodynamics assess caucasian australian aborigine uncomplicated type diabetes method subject stable dose mg gliclazide twice daily take mg morning study standard breakfast gliclazide give next h regular blood sample draw serum glucose insulin gliclazide assay gliclazide measure use h p l c noncompartmental analysis use describe primary data multicompartment model incorporate entero hepatic recirculation fit group mean serum gliclazide profile result caucasian old aborigine mean age v year p similar diabetes duration body mass index glycated haemoglobin noncompartmental analysis reveal group difference gliclazide kinetics post breakfast serum glucose insulin response also similar apart long time maximum concentration max glucose amongst aborigine v h caucasian p gliclazide max exhibit skewed unimodal distribution associate gliclazide maximum concentration glucose insulin response patient serum gliclazide profile suggestive enterohepatic recirculation biphasic absorption model derived estimate extent putative enterohepatic recirculation dose caucasian aborigine respectively conclusion gliclazide equally effective caucasian aboriginal diabetic patient pharmacokinetics oral gliclazide appear complex previously think gliclazide pharmacodynamics unrelated rate extent absorption consistent threshold concentration hypoglycaemic effect,Davis TM,2000,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.2000.00162.x,10718777,Davis TM; Daly F; Walsh JP; Ilett KF; Beilby JP; Dusci LJ; Barrett PH,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001315: Australia; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005907: Gliclazide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D044468: Native Hawaiian or Other Pacific Islander; D019518: Postprandial Period; D044465: White People",,,https://openalex.org/W1516390496,112,14,1,1874,303,16,en,en
false,repaglinide combination therapy type diabetes,addition dietary lifestyle change stand cornerstone type diabetes care pharmacological treatment whether single multidrug pattern often necessary efficient blood glucose control besides insulin four different oral antidiabetic drug category available act different potentially synergistic way oral antidiabetic drug include biguanides act reduction hepatic glucose production efficient obese patient alpha glucosidase inhibitor delay carbohydrate intestinal absorption thiazolidinediones glitazones act insulin sensitizer insulin secretion enhancer mainly include sulfonylurea increase insulin secretion credit long clinical usage join new generation insulin secretion enhancer lead repaglinide mimic physiological insulin secretion profile specific stimulatory effect beta cells characterize fast onset short half life obviously combination different antidiabetic drug targetting different synergistic additive pathway help improve blood glucose,Moses R,1999,Diabetes Metab,,10746009,Moses R,article,D016428: Journal Article,"D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D007515: Islets of Langerhans; D008687: Metformin; D010880: Piperidines",,,https://openalex.org/W2411187505,56,11,1,1244,198,4,en,en
true,comparative efficacy potency long term therapy glipizide glyburide patient type diabetes mellitus,background long term study comparative efficacy relative potency glipizide glyburide sparse controversial method randomized prospective trial compare effectiveness relative potency glipizide glyburide month period patient type diabetes mellitus dm glyburide glipizide unresponsive diet therapy glycemic control assess use method quarterly fast plasma glucose fpg hour postprandial plasma glucose standard breakfast insulin glucose response sustacal test meal challenge every month quarterly hemoglobin ale intravenous glucose tolerance test every month measure first second phase insulin secretion patient characteristic similar treatment group result similar dos glipizide mglday glyburide mglday result comparable reduction fpg hemoglobin ale increase first phase insulin response intravenous glucose tolerance test great reduction fpg hour postprandial plasma glucose glipizide glyburide month contrary physician desk reference consistent another short term study long term study demonstrate glipizide glyburide equipotent similar dos control hyperglycemia dm conclusion glipizide glyburide effective control hyperglycemia similar dos dm glipizide exhibit great reduction fpg ppg month additional study need validate equipotency drug,Kitabchi AE,2000,Am J Med Sci,https://doi.org/10.1016/s0002-9629(15)40712-8,10746824,Kitabchi AE; Kaminska E; Fisher JN; Sherman A; Pitts K; Bush A; Bryer-Ash M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005913: Glipizide; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D019518: Postprandial Period; D011446: Prospective Studies; D013810: Therapeutic Equivalency; D013997: Time Factors; D016896: Treatment Outcome",,,https://openalex.org/W2014151283,123,18,1,1659,282,10,en,en
false,miglitol,unlabelled miglitol first pseudomonosaccharide alpha glucosidase inhibitor smooths postprandial peak plasma glucose level thus improves glycaemic control reflect reduced glycosylated haemoglobin hba c level oral antihyperglycaemic agent indicate treatment patient type diabetes mellitus miglitol generally well tolerate unlike sulphonylurea agent associate bodyweight gain hypoglycaemia administer monotherapy drug systemically absorb metabolise rapidly excreted via kidney clinical trial miglitol usually mg time daily patient type diabetes mellitus consistently demonstrate significant improvement glycaemic control period month also mark reduction postprandial serum insulin level although miglitol generally effect fast insulin level comparative study miglitol similar efficacy acarbose low therapeutic dos mg time daily respectively addition although sulphonylurea agent provide superior reduction hba c level miglitol provide similar superior reduction fasting postprandial plasma glucose level combination oral antidiabetic agent insulin miglitol improve glycaemic control patient metabolic control suboptimal despite dietary pharmacological intervention adverse event associate miglitol treatment involve disturbance gastrointestinal tract common effect flatulence abdominal pain diarrhoea symptom usually dose dependent mild moderate severity occur onset treatment decline time resolve promptly discontinuation drug dosage adjustment monotherapy miglitol associate hypoglycaemia concomitant use oral antidiabetic agent may necessitate dosage adjustment agent miglitol significant effect renal cardiovascular respiratory haematological parameter long term study dosage adjustment require elderly patient hepatic impairment mild moderate renal insufficiency conclusion long term well design trial miglitol reduces fast postprandial plasma glucose level thus improve glycaemic control reflect reduced hba c level patient type diabetes mellitus adverse event associate miglitol involve disturbance gastrointestinal tract agent useful first line therapy patient type diabetes mellitus insufficiently control diet alone second line adjuvant therapy insufficiently control diet sulphonylurea agent miglitol may prove particularly beneficial elderly patient hepatic impairment mild moderate renal impairment oral antidiabetic agent contraindicate need use caution,Scott LJ,2000,Drugs,https://doi.org/10.2165/00003495-200059030-00012,10776834,Scott LJ; Spencer CM,article,D016428: Journal Article; D016454: Review,"D017485: 1-Deoxynojirimycin; D001682: Biological Availability; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D005944: Glucosamine; D005959: Glucosidases; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D050112: Imino Pyranoses; D007408: Intestinal Absorption; D008099: Liver; D019518: Postprandial Period; D016032: Randomized Controlled Trials as Topic; D014018: Tissue Distribution",,,https://openalex.org/W2067338816,8,1,1,3113,491,18,it,en
true,effect new oral hypoglycaemic agent nateglinide insulin secretion type diabetes mellitus,new non sulphonylurea oral hypoglycaemic agent nateglinide show enhance insulin secretion animal healthy human volunteer thus offer potential advance treatment type diabetes mellitus study examine whether nateglinide enhance insulin secretion particularly first phase insulin response patient type diabetes double blind placebo controlled trial examine effect single oral dose mg nateglinide give min prior intravenous glucose tolerance test igtt insulin secretion otherwise healthy caucasian men recently diagnose type diabetes duration since diagnosis month insulin secretion overall first phase significantly increase nateglinide p c peptide p proinsulin p secretion overall glucose concentration follow glucose challenge low nateglinide placebo p nateglinide significantly increase insulin secretion type diabetic patient particular restore first phase insulin response study necessary determine effect chronic administration insulin secretion blood glucose concentration,Whitelaw DC,2000,Diabet Med,https://doi.org/10.1046/j.1464-5491.2000.00256.x,10784228,Whitelaw DC; Clark PM; Smith JM; Nattrass M,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D002096: C-Peptide; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D007700: Kinetics; D008297: Male; D008875: Middle Aged; D000077715: Nateglinide; D010649: Phenylalanine; D010919: Placebos; D011384: Proinsulin",,,https://openalex.org/W1979628859,104,16,1,1264,208,4,en,en
true,lack interaction tolcapone tolbutamide healthy volunteer,assess effect tolcapone inhibitor cytochrome p cyp c vitro pharmacokinetics hypoglycemic effect cyp c substrate tolbutamide healthy male volunteer randomize receive single dose tolbutamide mg plus either placebo tolcapone mg overnight fast minute start hour glucose infusion ml h participant cross receive alternative regimen washout period least day tolcapone effect pharmacokinetics tolbutamide metabolite influence effect tolbutamide plasma glucose concentration serious adverse event abnormal laboratory result vital sign report conclusion clinically relevant drug drug interaction tolcapone tolbutamide give together clinical practice appear unlikely,Jorga KM,2000,J Clin Pharmacol,https://doi.org/10.1177/00912700022009161,10806608,Jorga KM; Fotteler B; Gasser R; Banken L; Birnboeck H,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D019540: Area Under Curve; D001189: Aryl Hydrocarbon Hydroxylases; D001577: Benzophenones; D001786: Blood Glucose; D018592: Cross-Over Studies; D065607: Cytochrome P-450 Enzyme Inhibitors; D003577: Cytochrome P-450 Enzyme System; D004347: Drug Interactions; D004791: Enzyme Inhibitors; D005947: Glucose; D006261: Headache; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007262: Infusions, Intravenous; D008297: Male; D009596: Nitrophenols; D016037: Single-Blind Method; D039181: Steroid 16-alpha-Hydroxylase; D013250: Steroid Hydroxylases; D014044: Tolbutamide; D000077867: Tolcapone",,,https://openalex.org/W2043184075,75,10,1,912,154,5,en,en
false,efficacy safety cerivastatin type diabetes hypercholesterolemia,prevalence coronary heart disease chd markedly increase diabetic patient compare non diabetic individual prognosis less good serum total low density lipoprotein ldl cholesterol concentration show powerful predictor chd morbidity mortality patient type diabetes available data suggest target cholesterol concentration patient diabetes similar non diabetic individual previous myocardial infarction lead u investigate efficacy tolerability safety new highly potent statin cerivastatin diabetic hyperlipidaemia multinational multicentre double blind randomize study type diabetic patient hypercholesterolaemia ldl cholesterol mmol l triglyceride mmol l eligible patient randomly assign group receive cerivastatin mg mg placebo ratio week monitor clinic every weeks patient screen allocate study group fifty one receive placebo patient assign active treatment group mg mg cerivastatin close study total cholesterol decrease ldl cholesterol decrease triglyceride concentration decrease cerivastatin mg mg group respectively significant difference group haemoglobin c adverse event increase liver muscle enzyme study period hypercholesterolaemic patient type diabetes significant reduction ldl cholesterol total cholesterol concentration cerivastatin treatment daily dose mg cerivastatin effective diabetic hypercholesterolaemia co reduction triglyceride concentration effect cerivastatin coronary morbidity mortality currently investigate clinical trial,Rubinstein A,1999,J Cardiovasc Risk,https://doi.org/10.1177/204748739900600607,10817086,Rubinstein A; Maritz FJ; Soule SG; Markel A; Chajek-Shaul T; Maislos M; Tal S; Stolero D,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D016009: Chi-Square Distribution; D003327: Coronary Disease; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D019161: Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006937: Hypercholesterolemia; D015228: Hypertriglyceridemia; D008297: Male; D008875: Middle Aged; D011725: Pyridines; D012307: Risk Factors",,,https://openalex.org/W2282216811,80,11,1,2053,339,11,en,en
true,cost effectiveness intensive blood glucose control policy patient type diabetes economic analysis alongside randomise control trial ukpds,estimate cost effectiveness conventional versus intensive blood glucose control patient type diabetes incremental cost effectiveness analysis alongside randomise control trial uk hospital clinic base study centres patient newly diagnose type diabetes mean age year conventional primarily diet glucose control policy versus intensive control policy sulphonylurea insulin incremental cost per event free year gain within trial period intensive glucose control increase trial treatment cost pound confidence interval pound pound per patient reduce cost complication pound pound pound compare conventional management standard practice visit pattern assume rather trial condition incremental cost intensive management pound pound pound per patient within trial event free time gain intensive group year lifetime gain year incremental cost per event free year gain pound cost effect discount year pound cost discount year effect discount intensive blood glucose control patient type diabetes significantly increase treatment cost substantially reduce cost complication increase time free complication,Gray A,2000,BMJ,https://doi.org/10.1136/bmj.320.7246.1373,10818026,Gray A; Raikou M; McGuire A; Fenn P; Stevens R; Cull C; Stratton I; Adler A; Holman R; Turner R,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D015190: Blood Glucose Self-Monitoring; D003362: Cost-Benefit Analysis; D003365: Costs and Cost Analysis; D003924: Diabetes Mellitus, Type 2; D003928: Diabetic Nephropathies; D003930: Diabetic Retinopathy; D018572: Disease-Free Survival; D005500: Follow-Up Studies; D006760: Hospitalization; D006801: Humans; D008875: Middle Aged",,,https://openalex.org/W1976787772,164,26,1,1449,240,4,en,en
false,erythromycin improve glycaemic control patient type ii diabetes mellitus,erythromycin mimic effect gastrointestinal hormone motilin bind receptor act motilin agonist recently find motilin stimulates insulin secretion low dos dos require stimulate gastric contractile activity study effect erythromycin insulin secretion glycaemic control patient diabetes mellitus inpatients n type ii non insulin dependent diabetes mellitus randomly assign receive either erythromycin mg orally three time day n placebo n week first study another outpatient type ii diabetes also treat erythromycin mg orally three time day n placebo n week second study finally nine inpatient type ii diabetes eight normal control subject receive intravenous erythromycin mg x kg x h saline infusion insulin secretion examine third study erythromycin lower fast blood glucose fructosamine concentration p increased basal well glucose stimulated insulin secretion p first study low dos erythromycin treatment week also significantly improve glycaemic control type ii diabetic patient second study erythromycin infusion significantly increase plasma insulin decrease glucose concentration type ii diabetic control subject greatly potentiate glucose induced insulin secretion latter third study result indicate erythromycin give orally antidiabetogenic effect therefore erythromycin derivative lack antibacterial activity could therapeutic value type ii diabetic patient,Ueno N,2000,Diabetologia,https://doi.org/10.1007/s001250051323,10819233,Ueno N; Inui A; Asakawa A; Takao F; Tani S; Komatsu Y; Itoh Z; Kasuga M,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004917: Erythromycin; D005260: Female; D005765: Gastrointestinal Agents; D006801: Humans; D008297: Male; D008875: Middle Aged; D010919: Placebos",,,https://openalex.org/W2031704968,82,11,1,1755,306,7,en,en
false,recent development emerge therapy type diabetes mellitus,patient type non insulin dependent diabetes mellitus require pharmacotherapy initially monotherapy subsequently combination adjunct diet exercise exogenous insulin ultimately require substantial proportion reflect progressive natural history disease sulphonylureas biguanides employ decade oral antidiabetic agent limited capacity provide long term glycaemic control cause serious adverse effect thus efficacious tolerable antidiabetic agent require recent year witness introduction agent novel mode action alpha glucosidase inhibitor acarbose miglitol reduce postprandial hyperglycaemia first thiazolidinedione insulinsensitising drug troglitazone rosiglitazone although former withdraw country due adverse effect another glitazone pioglitazone expect approve near future recently introduce drug include glimepiride meglitinide insulin secretagogue repaglinide attention also focus increasingly combination therapy use insulin together sulphonylureas metformin troglitazone rapid acting insulin analogue use alternative conventional insulin role management type diabetes mellitus presently uncertain report reduced frequency hypoglycaemia encourage development new drug aim counter principal metabolic defect disorder respectively relative insulin deficiency insulin resistance novel class rapid acting secretagogues evaluation include morphilinoguanide bts meglitinides mitiglinide kad senaglinide succinate ester derivative represent potential novel approach improve beta cell function enhancement insulin biosynthesis secretion enhancement nutrient induced insulin secretion mechanism several putative target within beta cell potentiators insulin secretion include glucagon like peptide analogue phosphodiesterase inhibitor imidazoline derivative pm amylin agonist pramlintide slow gastric emptying suppression glucagon secretion non thiazolidinedione insulin sensitising agent include gamma receptor agonist g x gg chiro inositol insulin analogue prolonged action inhaled insulin preparation also investigation insulin mimetic agent include organic vanadium compound whether new agent offer clinically relevant efficacy tolerability advantage exist therapy remain determine,Evans AJ,1999,Drugs R D,https://doi.org/10.2165/00126839-199902020-00001,10820647,Evans AJ; Krentz AJ,article,D016428: Journal Article; D016454: Review,"D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents",,,https://openalex.org/W2046056662,71,10,1,2810,411,18,en,en
false,pharma clinics medication month glimepiride amarylle,glimepiride commercialize belgium trade name amarylle aventis new sulphonylurea compound indicate treatment type diabetes diet exercise failure available mg tablet initial dos mg progressively increase mg per day necessary maximal daily dose mg recommend take glimepiride day first main meal particular binding sulphonylurea b cell langerhans pancreatic islet perhaps presence extrapancreatic effect hypoglycaemic risk circulate plasma insulin level low glimepiride glibenclamide reference sulphonylurea agent use comparative clinical trial,Scheen AJ,2000,Rev Med Liege,,10823010,Scheen AJ,article,D004740: English Abstract; D016428: Journal Article,"D000284: Administration, Oral; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D006801: Humans; D007004: Hypoglycemic Agents; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2413453284,66,14,3,788,144,5,en,en
true,repaglinide acutely amplify pulsatile insulin secretion augmentation burst mass effect burst frequency,repaglinide new oral hypoglycemic agent act prandial glucose regulator propose treatment type diabetes stimulate insulin secretion aim study explore action repaglinide rapid pulsatile insulin release high frequency insulin sampling analysis insulin concentration time series examine healthy lean male subject single dose double blind placebo controlled crossover design subject undergo overnight fast blood sampling initiate continue every minute min min single dose mg repaglinide placebo give serum insulin concentration time series assess deconvolution analysis regularity statistic approximate entropy apen average insulin concentration increase repaglinide administration basal vs stimulated period p value placebo vs repaglinide vs pmol l p insulin secretory burst mass vs pmol x l x pulse p amplitude vs pmol x l x min p augment repaglinide administration concomitant trend toward increase basal insulin secretion observe vs pmol x l x min p interpulse interval unaltered vs min pulse p apen increase significantly repaglinide administration vs p suggest less orderly oscillatory pattern insulin release conclusion single dose repaglinide amplifies insulin secretory burst mass basal secretion change burst frequency possible importance mechanism treatment type diabetes characterize disrupt pulsatile insulin secretion remain clarify,Juhl CB,2000,Diabetes Care,https://doi.org/10.2337/diacare.23.5.675,10834429,Juhl CB; Pørksen N; Hollingdal M; Sturis J; Pincus S; Veldhuis JD; Dejgaard A; Schmitz O,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D001786: Blood Glucose; D002096: C-Peptide; D002219: Carbamates; D018592: Cross-Over Studies; D004311: Double-Blind Method; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D007700: Kinetics; D008297: Male; D010880: Piperidines; D010919: Placebos,,,https://openalex.org/W2138283946,122,18,1,1920,355,9,en,en
true,increase prandial insulin secretion administration single preprandial oral dose repaglinide patient type diabetes,examine dose related pharmacodynamics pharmacokinetics single preprandial oral dose repaglinide patient type diabetes total caucasian men type diabetes participate two placebo controlled double blind randomize cross study patient randomize receive single oral dose repaglinide mg study mg study placebo study administer min first two sequential identical standard meal breakfast lunch h apart study day week apart blood sample take frequent interval period approximately h measurement plasma glucose insulin c peptide repaglinide concentrations first meal period min administration repaglinide reduce significantly area curve auc glucose concentration significantly increase auc insulin level c peptide level insulin secretion rate result compare administer placebo dose dependent log linear effect repaglinide administration insulin secretion pronounced early prandial period within min cause relative increase insulin secretion second meal period min difference repaglinide placebo administration auc glucose concentration c peptide concentration estimate insulin secretion rate single dose repaglinide mg breakfast improves insulin secretion reduce prandial hyperglycemia dose dependently administration repaglinide effect insulin secretion second meal consume h breakfast,Owens DR,2000,Diabetes Care,https://doi.org/10.2337/diacare.23.4.518,10857945,Owens DR; Luzio SD; Ismail I; Bayer T,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D019540: Area Under Curve; D001786: Blood Glucose; D002096: C-Peptide; D002219: Carbamates; D015331: Cohort Studies; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004435: Eating; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D008297: Male; D008875: Middle Aged; D010880: Piperidines",,,https://openalex.org/W1964418709,140,21,1,1810,307,7,en,en
true,effect oral hypoglycemic agent diet protein metabolism type diabetes,test whether oral hypoglycemic agent oha gliclazide without metformin isoenergetic iso low energy diet lead improve altered kinetics whole body protein metabolism type diabetes total type diabetic patient age year weight kg bmi kg fast glucose fsg mmol l means sem obese control subject year kg kg fsg mmol l consume iso g x kg x day protein body weight correspond bmi bmi formula diet day obese control subject day diabetic patient day lead energy iso protein intake g day ohas give iso day lead day diabetic subject iso lead h oral n glycine method use obtain nitrogen flux q synthesis breakdown b muscle protein catabolism estimate n tau methylhistidine mh excretion iso hyperglycemia q b adjust fat free mass sex age high nitrogen balance net endogenous protein synthesis b low control subject p oha decrease fsg mmol l mh increase plasma insulin glucose ratio nitrogen retention b level control subject change b correlate fsg r p fast plasma c peptide r p led oha weight decrease kg glycemia reach near normal level nitrogen equilibrium maintain q decrease b p value find control subjects oha iso correct protein turnover relation glycemia plasma c peptide led maintain protein homeostasis obese control subject diabetes patient oha normalized protein metabolism finding implication diet oha prescription,Gougeon R,2000,Diabetes Care,https://doi.org/10.2337/diacare.23.1.1,10857959,Gougeon R; Styhler K; Morais JA; Jones PJ; Marliss EB,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D004359: Drug Therapy, Combination; D005230: Fatty Acids, Nonesterified; D005260: Female; D005907: Gliclazide; D006029: Glycosuria; D006801: Humans; D007004: Hypoglycemic Agents; D007700: Kinetics; D008297: Male; D008687: Metformin; D008875: Middle Aged; D009765: Obesity; D011506: Proteins; D014508: Urea; D015431: Weight Loss",,,https://openalex.org/W1981107426,86,15,1,2023,422,9,en,en
true,rapid short acting mealtime insulin secretion nateglinide control prandial mean glycemia,objective study assess efficacy safety four fixed dos nateglinide compare placebo treatment patient type diabetes focus prandial state randomize double blind placebo controlled multicenter study conduct patient receive either nateglinide dos mg n mg n mg n mg n placebo n three main meal week level hba c fast plasma glucose fpg fructosamine plasma lipid measure predetermined interval effect nateglinide prandial glucose insulin c peptide triglyceride level measure liquid standard meal sustacal mead johnson evansville adverse event hypoglycemic episode recorded liquid meal challenge nateglinide rapidly increase mealtime insulin level within min drug intake reduced mealtime glucose excursion without affect triglyceride level study end point reduction hba c level statistically significantly great nateglinide dos mg placebo respectively p mean level fpg significantly reduce versus placebo nateglinide mg group mmol l p overall nateglinide well tolerated study demonstrate nateglinide improves mealtime mean glycemic control dose dependent manner restore early insulin secretion phase nateglinide well tolerate suitable treatment patient type diabetes,Hanefeld M,2000,Diabetes Care,https://doi.org/10.2337/diacare.23.2.202,10868832,Hanefeld M; Bouter KP; Dickinson S; Guitard C,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D019540: Area Under Curve; D001786: Blood Glucose; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004435: Eating; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D008297: Male; D008875: Middle Aged; D000077715: Nateglinide; D010649: Phenylalanine; D010919: Placebos; D012449: Safety",,,https://openalex.org/W2170502600,108,15,1,1635,300,7,en,en
true,improve control mealtime glucose excursion coadministration nateglinide metformin,objective nateglinide new short acting phenylalanine derivative treat type diabetes reduces mealtime blood glucose excursion physiologic regulation insulin secretion study evaluate pharmacokinetic pharmacodynamic interaction nateglinide metformin subject type diabetes research design method total type diabetic subject following baseline characteristic enrol age year bmi kg hba c fast plasma glucose mmol l subject previously treat glyburide switch metformin monotherapy week study start subject randomly receive combination mg metformin either mg nateglinide placebo meal day follow alternate treatment day later week washout drug subject receive day open label nateglinide treatment plasma concentration glucose insulin nateglinide metformin assess frequently inpatient period result postmeal plasma glucose level significantly low subject treat nateglinide plus metformin treat either drug alone p lt especially lunch dinner coadministration nateglinide metformin affect pharmacokinetics either drug treatment safe well tolerate conclusion combination therapy nateglinide metformin effective either treatment alone result pharmacokinetic interaction coadministration nateglinide metformin appear excellent option treat patient type diabetes control monotherapy,Hirschberg Y,2000,Diabetes Care,https://doi.org/10.2337/diacare.23.3.349,10868864,Hirschberg Y; Karara AH; Pietri AO; McLeod JF,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001786: Blood Glucose; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D004435: Eating; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D000077715: Nateglinide; D010649: Phenylalanine; D019518: Postprandial Period",,,https://openalex.org/W2027016841,99,13,1,1786,296,12,en,en
true,mealtime glucose regulation nateglinide type diabetes mellitus,objective pharmacodynamic effect nateglinide novel antidiabetic agent investigate patient type diabetes mellitus method ten patient participate single center double blind crossover study plasma glucose insulin level measure h follow five day treatment period nateglinide mg placebo give three time daily breakfast lunch dinner fifth treatment consist mg nateglinide four time daily fourth dose give evening snack result take min meal dos mg nateglinide cause dose dependent increase plasma insulin level significantly great placebo high dos effective longer duration action low dos nateglinide also significantly good placebo lower plasma glucose level mg mg dos similarly effective superior mg nateglinide treatment follow fourth mg dose glucose lowering effect treatment maintain night serious adverse event occur study event hypoglycemia clinically meaningful change safety parameter conclusion nateglinide produce rapid short lived dose related increase plasma insulin significantly lower mealtime glucose excursion compare placebo incidence hypoglycemia decrease mealtime glucose level produce significant improvement overall h glycemia,Walter YH,2000,Eur J Clin Pharmacol,https://doi.org/10.1007/s002280050730,10877006,Walter YH; Spratt DI; Garreffa S; McLeod JF,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D018592: Cross-Over Studies; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D000077715: Nateglinide; D010649: Phenylalanine; D010919: Placebos",,,https://openalex.org/W2033646716,70,9,1,1579,254,12,en,en
true,effect glibenclamide katpchannel blocker warm phenomenon type diabetic patient chronic stable angina pectoris,warm phenomenon one clinical model ischemic preconditioning refers increase tolerance myocardial ischemia second two consecutive exercise tests blockers k atp channel sulfonylurea drug induce loss ischemic preconditioning study aim investigate effect glibenclamide sulfonylurea high affinity myocardial k atp channel result two consecutive exercise test diabetic patient coronary artery disease eighteen type ii diabetic patient chronic stable angina pectoris participate study patient underwent two consecutive treadmill exercise test recovery period min fast state day exercise test mg oral glibenclamide give patient min later ml glucose solution give orally half hour later time peak plasma level glibenclamide two exercise test repeat consecutively min recovery period difference blood glucose level exercise test day p without glibenclamide heart rate rate pressure product mm st depression peak exercise increase significantly p time mm st segment depression onset pain well duration exercise also increase st segment depression st recovery time significantly decrease p contrast value significantly change glibenclamide p significant drug test interaction p two way anova glibenclamide oral hypoglycemic agent k atp channel blocker activity mg oral dose abolish warm phenomenon clinical finding ischemic precondition two consecutive exercise test therefore glibenclamide use carefully patient coronary heart disease diabetes mellitus since agent lead decrease ischemic threshold exercise capacity,Ovünç K,2000,Clin Cardiol,https://doi.org/10.1002/clc.4960230713,10894443,Ovünç K,article,D003160: Comparative Study; D016428: Journal Article,"D000251: Adenosine Triphosphatases; D000255: Adenosine Triphosphate; D000284: Administration, Oral; D000328: Adult; D000787: Angina Pectoris; D001794: Blood Pressure; D027682: Cation Transport Proteins; D002908: Chronic Disease; D017023: Coronary Angiography; D003924: Diabetes Mellitus, Type 2; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D005905: Glyburide; D006339: Heart Rate; D006801: Humans; D007004: Hypoglycemic Agents; D019157: Ischemic Preconditioning, Myocardial; D008297: Male; D008875: Middle Aged; D015221: Potassium Channels",,,https://openalex.org/W2054079638,146,29,1,2054,362,9,en,en
false,repaglinide troglitazone combination therapy improved glycemic control type diabetes,multicenter open label clinical trial compare efficacy safety repaglinide troglitazone combination therapy repaglinide monotherapy troglitazone monotherapy type diabetes inadequately control sulfonylurea acarbose metformin alone patients type diabetes n inadequate glycemic control hba c previous monotherapy randomly assign receive repaglinide mg meal troglitazone mg daily combination repaglinide mg meal troglitazone mg daily week washout period trial assess week treatment week week force titration week fixed dose treatment week week week titration maximum dose change hba c fast plasma glucose fpg value measured combination therapy show significant reduction mean hba c value great either type monotherapy repaglinide monotherapy result reduction hba c value significantly great troglitazone vs p combination therapy effective reduce fpg value mg dl either repaglinide mg dl troglitazone mg dl monotherapies adverse event similar groups combination therapy repaglinide troglitazone lead better glycemic control monotherapy either agent alone repaglinide monotherapy effective lower hba c level troglitazone monotherapy repaglinide troglitazone combination therapy effective show unexpected adverse event,Raskin P,2000,Diabetes Care,https://doi.org/10.2337/diacare.23.7.979,10895850,Raskin P; Jovanovic L; Berger S; Schwartz S; Woo V; Ratner R,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D015415: Biomarkers; D001786: Blood Glucose; D002219: Carbamates; D002839: Chromans; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D010880: Piperidines; D013844: Thiazoles; D045162: Thiazolidinediones; D000077288: Troglitazone",,,https://openalex.org/W1993034883,91,12,1,1699,291,6,en,en
false,response pancreatic beta cells improve insulin sensitivity woman high risk type diabetes,purpose study examine response pancreatic beta cells change insulin sensitivity woman high risk type diabetes oral glucose tolerance test ogtts frequently sample intravenous glucose tolerance test fsigts conduct latino woman impaired glucose tolerance history gestational diabetes week treatment mg day troglitazone n placebo n insulin sensitivity assess minimal model analysis beta cell insulin release assess acute insulin response glucose airg tolbutamide airt fsigts min incremental insulin response min din ogtts beta cell compensation insulin resistance assess product disposition index minimal model insulin sensitivity measure beta cell insulin release placebo group significant change insulin sensitivity measure insulin release beta cell compensation insulin resistance glucose tolerance troglitazone treatment result significant increase insulin sensitivity report previously response airg change significantly disposition index airg increase significantly baseline p compare placebo p airt p min din p fell improved insulin sensitivity troglitazone treatment disposition index measure beta cell function change significantly baseline p compare placebo p minimal model analysis reveal change baseline insulin sensitivity troglitazone treatment account lowered plasma insulin concentration neither oral intravenous glucose tolerance change significantly baseline compare placebo troglitazone treatment predominant response beta cells improve insulin sensitivity woman high risk type diabetes reduction insulin release maintain nearly constant glucose tolerance,Buchanan TA,2000,Diabetes,https://doi.org/10.2337/diabetes.49.5.782,10905487,Buchanan TA; Xiang AH; Peters RK; Kjos SL; Berkowitz K; Marroquin A; Goico J; Ochoa C; Azen SP,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D002839: Chromans; D003924: Diabetes Mellitus, Type 2; D016640: Diabetes, Gestational; D005260: Female; D005947: Glucose; D018149: Glucose Intolerance; D005951: Glucose Tolerance Test; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D007515: Islets of Langerhans; D011247: Pregnancy; D012307: Risk Factors; D013844: Thiazoles; D045162: Thiazolidinediones; D014044: Tolbutamide; D000077288: Troglitazone",,,https://openalex.org/W2031885427,108,18,1,2171,373,11,en,en
false,troglitazone metformin combination sulfonylurea patient type diabetes,combination oral therapy often use control hyperglycemia patient type diabetes compare effectiveness metformin troglitazone add sulfonylurea therapy patient type diabetes suboptimal blood glucose control use randomized group design compare efficacy safety tolerability troglitazone metformin patient type diabetes mellitus inadequately control diet oral sulfonylurea thirty two subject randomize receive either troglitazone metformin week include week drug titration period primary outcome variable mean change level glycosylated hemoglobin hb c baseline secondary outcome include mean change baseline fast plasma glucose c peptide level renal metabolic side effect symptomatic tolerability addition either troglitazone metformin oral sulfonylurea therapy significantly decrease hb c level treatment regimens also significantly reduce fast plasma glucose c peptide level find significant difference treatment arm efficacy metabolic side effect tolerability result demonstrate troglitazone metformin significantly improve hb c fast plasma glucose c peptide level add oral sulfonylurea therapy patient type diabetes inadequate glucose control,Kirk JK,1999,J Fam Pract,,10907625,Kirk JK; Pearce KA; Michielutte R; Summerson JH,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D002839: Chromans; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005260: Female; D005913: Glipizide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D008875: Middle Aged; D013453: Sulfonylurea Compounds; D013844: Thiazoles; D045162: Thiazolidinediones; D000077288: Troglitazone",,,https://openalex.org/W2401881665,94,14,1,1483,225,7,en,en
true,rational approach drug therapy type diabetes mellitus,several new pharmacological agent recently develop optimise management type non insulin dependent diabetes mellitus aim article briefly review various therapeutic agent available management patient type diabetes mellitus suggest potential approach drug selection three general therapeutic modality relevant diabetes care first modality lifestyle adjustment aim improve endogenous insulin sensitivity insulin effect achieve increased physical activity bodyweight reduction diet behavioural modification use pharmacological agent surgery first modality discuss depth article second modality involve increase insulin availability administration exogenous insulin insulin analogue sulphonylureas new insulin secretagogue repaglinide frequently encountered adverse effect agent hypoglycaemia bodyweight gain also concern especially patient obese association hyperinsulinaemia premature atherosclerosis still debatable question third modality consist agent biguanides thiazolidinediones enhance insulin sensitivity agent decrease insulin requirement like alpha glucosidase inhibitor type diabetes mellitus heterogeneous disease multiple underlie pathophysiological process therapy individualise base degree hyperglycaemia hyperinsulinaemia insulin deficiency addition several factor consider prescribe specific therapeutic agent factor include efficacy safety affordability ease administration,Chehade JM,2000,Drugs,https://doi.org/10.2165/00003495-200060010-00006,10929931,Chehade JM; Mooradian AD,article,D016428: Journal Article; D016454: Review,"D003924: Diabetes Mellitus, Type 2; D005544: Forecasting; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin",,,https://openalex.org/W2018194304,63,11,1,1804,271,15,en,en
false,bioequivalence study two brand glipizide tablet,open randomize two way crossover bioequivalence study two mg tablet preparation glipizide glipizyd tabl mg tarchomi skie zak ady farmaceutyczne polfa glibenese tabl mg pfizer compare healthy male volunteer pharmacokinetic variable mean maximum plasma concentration mean time reach maximum plasma concentration mean area plasma concentration time curve statistically significantly different two formulation conclude two tablet preparation glipizide likely bioequivalent,Kobylińska M,2000,Acta Pol Pharm,,10934787,Kobylińska M; Bukowska-Kiliszek M; Barlińska M; Sobik B; Kobylińska K,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D019540: Area Under Curve; D002851: Chromatography, High Pressure Liquid; D005913: Glipizide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D015203: Reproducibility of Results; D013607: Tablets; D013810: Therapeutic Equivalency",,,,58,10,1,602,104,5,en,en
false,less nocturnal hypoglycemia good post dinner glucose control bedtime insulin glargine compare bedtime nph insulin insulin combination therapy type diabetes hoe study group,available basal insulin formulation provide constant reliable h insulin supply compare efficacy safety glargine long acting insulin analog nph insulin insulin naive type diabetic patient treat oral antidiabetic agents type diabetic patient age year bmi kg mean sd poor glycemic control oral antidiabetic agent randomize treatment year bedtime insulin glargine bedtime nph insulin oral agent continue unchanged fast blood glucose fbg target mmol l mg dl average glycemic control improve similarly insulin hba c reference range vs year glargine vs nph mean sem p vs baseline however less nocturnal hypoglycemia vs patient glargine vs nph p low post dinner glucose concentration vs mmol l p insulin glargine nph insulin dos weight gain comparable patient reach target fbg hba c average glargine nph group year use insulin glargine compare nph associate less nocturnal hypoglycemia low post dinner glucose level data consistent peakless long duration action insulin glargine compare nph achievement acceptable average glucose control require titration insulin dose fbg target mmol l data support use insulin glargine instead nph insulin combination regimens type diabetes,Yki-Järvinen H,2000,Diabetes Care,https://doi.org/10.2337/diacare.23.8.1130,10937510,Yki-Järvinen H; Dressler A; Ziemen M; HOE 901/300s Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D001794: Blood Pressure; D002096: C-Peptide; D002784: Cholesterol; D008076: Cholesterol, HDL; D002940: Circadian Rhythm; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D007330: Insulin Antibodies; D000069036: Insulin Glargine; D007336: Insulin, Isophane; D049528: Insulin, Long-Acting; D008297: Male; D008875: Middle Aged; D019518: Postprandial Period; D014280: Triglycerides",,,https://openalex.org/W2013339698,211,31,2,1680,318,10,en,en
false,response training blood glucose awareness relate absence previous hypoglycemic coma,,ter Braak EW,2000,Diabetes Care,https://doi.org/10.2337/diacare.23.8.1199,10937524,ter Braak EW; de Valk HW; de la Bije YF; van der Laak MF; van Haeften TW; Erkelens DW,article,"D016430: Clinical Trial; D016420: Comment; D018848: Controlled Clinical Trial; D016422: Letter; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001007: Anxiety; D001364: Awareness; D003922: Diabetes Mellitus, Type 1; D003926: Diabetic Coma; D005239: Fear; D005260: Female; D006801: Humans; D007003: Hypoglycemia; D008297: Male; D010353: Patient Education as Topic; D010465: Perception",,,https://openalex.org/W2004387358,100,16,1,0,0,0,en,
false,k q variant human pc gene associate insulin resistance type diabetes among danish caucasian,human plasma cell membrane differentiation antigen pc show inhibit insulin receptor tyrosine kinase activity recently k q polymorphism human pc gene find sicilian population show strongly associate insulin resistance objective present investigation examine danish caucasian population whether k q variant associate type diabetes glucose tolerant subject impaired whole body insulin sensitivity genotyped danish type diabetic patient find allele frequency variant ci whereas allele frequency ci among match glucose tolerant control subject p control subject significant difference among wild type heterozygous homozygous subject regard serum insulin plasma glucose level fasting min min oral glucose tolerance test ogtt estimate insulin resistance obtain homeostasis model assessment homa furthermore investigate impact variant danish population sample comprise young healthy subject glucose tolerant offspring type diabetic probands respectively study population polymorphism associate altered insulin sensitivity index estimate intravenous glucose tolerance test combination intravenous injection tolbutamide addition among offspring variation serum insulin serum c peptide response measure ogtt relate pc genotype conclusion k q polymorphism human pc gene associate type diabetes insulin resistance among danish caucasian,Rasmussen SK,2000,Diabetes,https://doi.org/10.2337/diabetes.49.9.1608,10969849,Rasmussen SK; Urhammer SA; Pizzuti A; Echwald SM; Ekstrøm CT; Hansen L; Hansen T; Borch-Johnsen K; Frittitta L; Trischitta V; Pedersen O,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D019943: Amino Acid Substitution; D001786: Blood Glucose; D003718: Denmark; D003924: Diabetes Mellitus, Type 2; D005260: Female; D014644: Genetic Variation; D006579: Heterozygote; D006720: Homozygote; D006801: Humans; D007328: Insulin; D007333: Insulin Resistance; D008297: Male; D008562: Membrane Glycoproteins; D008875: Middle Aged; D010727: Phosphoric Diester Hydrolases; D011755: Pyrophosphatases; D044465: White People",,,https://openalex.org/W2097739553,126,22,1,1868,320,9,en,en
true,oral hypoglycaemic agent diabetic pregnancy,summary aim assess maternal neonatal complication pregnancy diabetic woman treat oral hypoglycaemic agent pregnancy method cohort study include consecutively register orally treat pregnant diabetic patient set diabetic obstetrical service university hospital woman treat metformin woman treat sulphonylurea pregnancy reference group diabetic woman treat insulin pregnancy result prevalence pre eclampsia significantly increase group woman treat metformin compare woman treat sulphonylurea insulin vs vs p difference neonatal morbidity observe orally treat insulin treated group case severe hypoglycaemia jaundice see orally treated group however group woman treat metformin third trimester perinatal mortality significantly increase compare woman treat metformin vs p conclusion treatment metformin pregnancy associate increased prevalence pre eclampsia high perinatal mortality,Hellmuth E,2000,Diabet Med,https://doi.org/10.1046/j.1464-5491.2000.00314.x,10972579,Hellmuth E; Damm P; Mølsted-Pedersen L,article,D003160: Comparative Study; D016428: Journal Article,"D000037: Abruptio Placentae; D000328: Adult; D001724: Birth Weight; D002585: Cesarean Section; D015331: Cohort Studies; D003924: Diabetes Mellitus, Type 2; D016640: Diabetes, Gestational; D005260: Female; D005313: Fetal Death; D006801: Humans; D007004: Hypoglycemic Agents; D007231: Infant, Newborn; D007232: Infant, Newborn, Diseases; D007328: Insulin; D008687: Metformin; D009017: Morbidity; D011225: Pre-Eclampsia; D011247: Pregnancy; D011256: Pregnancy Outcome; D011254: Pregnancy in Diabetics; D014044: Tolbutamide",,,https://openalex.org/W2150312049,53,7,1,1224,202,6,en,en
false,pharmacological treatment postprandial hyperglycemia,every diabetes treatment contribute control postprandial blood glucose yet agent specifically target goal alpha glucosidase inhibitor lead acarbose mainly address postprandial glucose control agent inhibit intestinal disaccharidase competitive effect use either sole treatment combination antidiabetic drug agent improve insulin secretion kinetics case repaglinide et nateglinide efficient control postprandial blood glucose less degree fast blood glucose agent shortly quickly stimulate insulin secretion available soon oral therapy secondary failure trial currently conduct clarify role fast acting insulin analog monotherapy combination finally insulin sensitizing agent investigate way improve postprandial glucose efflux potentiate insulin effect optimal strategy use different therapeutic agent remain establish well long term effect diabetic complication,Blickle JF,2000,Diabetes Metab,,10975046,Blickle JF,article,D016428: Journal Article; D016454: Review,"D003924: Diabetes Mellitus, Type 2; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D019518: Postprandial Period",,,https://openalex.org/W161548532,58,8,1,1155,182,9,en,en
true,therapy focus lower postprandial glucose fast glucose may superior lower hba c ioez study group,compare overall efficacy combination therapy focus fasting postprandial blood glucose patient type diabetes adequately control oral sulfonylurea agent alone total patient randomly assign month combination regimen glyburide g address postprandial blood glucose insulin lispro l g premeal blood glucose metformin g fast blood glucose fbg bedtime nph insulin nph g end point hba c significantly low therapy p significantly low l g compare either nph g p g p fbg end point significantly low nph g mmol l compare either l g mmol l p g mmol l p mean h postprandial glucose test meal significantly low l g mmol l versus nph g mmol p versus g mmol l p overall rate hypoglycemia episode per day low statistically significant group p adding second antihyperglycemic agent regardless timing action lower hba c glucose value however insulin lispro use focus postprandial blood glucose great impact overall metabolic control data support importance lower postprandial blood glucose optimize overall glycemic control thus improve long term outcome,Bastyr EJ,2000,Diabetes Care,https://doi.org/10.2337/diacare.23.9.1236,10977012,Bastyr EJ; Stuart CA; Brodows RG; Schwartz S; Graf CJ; Zagar A; Robertson KE,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005215: Fasting; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D061268: Insulin Lispro; D007336: Insulin, Isophane; D008297: Male; D008875: Middle Aged; D019518: Postprandial Period",,,https://openalex.org/W2023604660,124,22,2,1586,298,6,en,en
false,pioglitazone,pioglitazone orally administer insulin sensitise thiazolidinedione agent develop treatment type diabetes mellitus pioglitazone activate nuclear peroxisome proliferator activate receptor gamma ppar gamma lead increase transcription various protein regulate glucose lipid metabolism protein amplify post receptor action insulin liver peripheral tissue lead improve glycaemic control increase endogenous secretion insulin placebo controlled clinical trial monotherapy pioglitazone mg day show decrease blood glycosylated haemoglobin hba c level patient type diabetes mellitus addition pioglitazone mg day preexist therapy metformin pioglitazone mg day sulphonylurea insulin voglibose therapy show decrease hba c fast blood glucose level significantly patient poorly control type diabetes mellitus pioglitazone also associate improvement serum lipid profile randomised placebo controlled clinical study drug well tolerate adult patient age clinical study oedema report monotherapy pool data show hypoglycaemia patient addition pioglitazone sulphonylurea insulin treatment report hepatotoxicity,Gillies PS,2000,Drugs,https://doi.org/10.2165/00003495-200060020-00009,10983737,Gillies PS; Dunn CJ,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D002986: Clinical Trials as Topic; D004359: Drug Therapy, Combination; D005947: Glucose; D006801: Humans; D007004: Hypoglycemic Agents; D050356: Lipid Metabolism; D000077205: Pioglitazone; D013844: Thiazoles; D045162: Thiazolidinediones",,,https://openalex.org/W3192686273,12,1,1,1497,233,9,ca,en
false,holiday hypoglycaemia exist,determine whether excessive prolonged unusual physical exertion could associate episode mild hypoglycaemia non insulin dependent diabetes mellitus niddm patient treat glibenclamide month observation retrospective analysis patient personal diary determine hypoglycaemic risk diabetic unit department medicine aging chieti university school medicine enrol niddm outpatient adjust sex age body mass index alcohol intake oral treatment regimen glibenclamide patient test monthly circadian blood glucose profile glycosylated hemoglobin mild hypoglycaemia define basis blood glucose value mmol l associate mild autonomic symptom without require external assistance diabetic patient fill personal diary indicate therapy regimen characteristic eventual hypoglycaemic episode occur observation period niddm patient experience one two episode mild hypoglycaemia observation period analysis patient diary show hypoglycaemic episode associate excessive prolonged unexpected physical exertion within group episode occur holiday holiday hypoglycaemia analyze socio demographic clinical characteristic diabetic patient report hypoglycaemic event find high risk holiday hypoglycaemia patient low educational level sedentary occupation among ex farmers result present study unexpected physical exertion may represent relevant cause mild hypoglycaemia diabetic patient receive oral antidiabetic therapy however hypoglycaemic cause may underestimate literature educational program conduct general practitioner diabetologists could useful patient reduce number mild hypoglycaemic episode,Guagnano MT,2000,Panminerva Med,,11019600,Guagnano MT; Pace-Palitti V; Formisano S; Della Loggia F; D'Anchino M; Della Vecchia R; Merlitti D; Sensi S,article,D016428: Journal Article,"D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D005082: Physical Exertion; D012189: Retrospective Studies",,,https://openalex.org/W2398719108,33,5,1,2053,307,9,en,en
false,long term dietary treatment increased amount fiber rich low glycemic index natural food improve blood glucose control reduce number hypoglycemic event type diabetic patient,evaluate type diabetic patient long term feasibility high fiber hf diet compose exclusively natural foodstuff efficacy diet relation blood glucose control incidence hypoglycemic episodes study randomize parallel group participant part large multicenter study effect acarbose glucose control diabetes total type diabetic patient age year bmi kg week run period habitual diet randomize either hf n low fiber lf diet n week two diet compose exclusively natural foodstuff weight maintaining aside fiber content similar nutrient end run period dietary treatment fast blood sample measurement plasma cholesterol hdl cholesterol triglyceride hba c collect daily glycemic profile perform day participant consume standard menu representative treatment diet hf lf study subject hf group lf group complete study compare lf diet hf diet week decrease mean daily blood glucose concentration p number hypoglycemic event p compliance diet take account subject hf diet lf diet compliant subgroup compare lf diet hf diet significantly reduce mean daily blood glucose concentration p hba c p number hypoglycemic event p type diabetic patient hf diet feasible long term compare lf diet improve glycemic control reduce number hypoglycemic event,Giacco R,2000,Diabetes Care,https://doi.org/10.2337/diacare.23.10.1461,11023137,Giacco R; Parillo M; Rivellese AA; Lasorella G; Giacco A; D'Episcopo L; Riccardi G,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001786: Blood Glucose; D002784: Cholesterol; D008076: Cholesterol, HDL; D015331: Cohort Studies; D003922: Diabetes Mellitus, Type 1; D003927: Diet, Diabetic; D004040: Dietary Carbohydrates; D004043: Dietary Fiber; D002149: Energy Intake; D005260: Female; D006801: Humans; D007003: Hypoglycemia; D007328: Insulin; D008297: Male; D010349: Patient Compliance; D014280: Triglycerides",,,https://openalex.org/W1967887315,203,29,1,1875,387,8,en,en
true,nateglinide,nateglinide novel phenylalanine derivative inhibit atp sensitive k channel pancreatic beta cells presence glucose thereby stimulate prandial release insulin nateglinide reduces fast mealtime blood glucose level animal healthy volunteer patient type non insulin dependent diabetes mellitus produce prompt prandial insulin response return baseline insulin level meal randomised double blind week study patient type diabetes oral nateglinide mg time daily meal improve glycaemic control significantly relative placebo nateglinide mg plus metformin mg time daily confer great glycaemic improvement either drug give alone nateglinide mg time daily plus metformin g twice daily superior metformin plus placebo nateglinide mg time daily significantly reduce hyperglycaemia relative placebo week double blind study patient type diabetes mellitus combination therapy troglitazone mg daily produce significantly well glycaemic control either drug give monotherapy mild hypoglycaemia frequently report adverse event patient treatment nateglinide mg time daily week clinical study clinically significant abnormality laboratory result ecg vital sign physical examination finding note patient take drug,Dunn CJ,2000,Drugs,https://doi.org/10.2165/00003495-200060030-00007,11030470,Dunn CJ; Faulds D,article,D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D002986: Clinical Trials as Topic; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D006934: Hypercalcemia; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D000077715: Nateglinide; D010179: Pancreas; D010649: Phenylalanine",,,https://openalex.org/W3190644818,11,1,1,1527,242,8,it,en
false,pharmacological property nateglinide rapid onset short duration insulinotropic agent treatment type diabetes,early defect type diabetes loss acute insulin release food intake cause prolonged elevation postprandial glucose level suppress postprandial hyperglycemia consider important prevent diabetic complication sulfonylurea well known insulin secretagogues widely use treatment type diabetes agent however appear able ameliorate impairment first phase insulin secretion postprandial hyperglycemia nateglinide derivative phenylalanine non sulfonylurea insulin secretagogue although vitro insulin releasing effect nateglinide similar sulfonylurea hypoglycemic effect rapid short lasting vivo unique pharmacodynamic profile nateglinide likely result rapid absorption elimination novel antidiabetic agent make possible compensate impaired first phase insulin response thus suppress postprandial hyperglycemia clinical trial nateglinide reduce prandial glucose excursion improve early phase insulin release dose dependently week treatment nateglinide highly physiologic mealtime glucose regulator rapidly increase insulin secretion take meal mimic early phase insulin release lose patient type diabetes,Ikenoue T,2000,Nihon Yakurigaku Zasshi,https://doi.org/10.1254/fpj.116.171,11031747,Ikenoue T; Kondo N,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D000077715: Nateglinide; D010649: Phenylalanine",,,https://openalex.org/W2015992806,128,17,1,1424,219,10,en,en
true,comparison glyburide insulin woman gestational diabetes mellitus,woman gestational diabetes mellitus rarely treat sulfonylurea drug concern teratogenicity neonatal hypoglycemia little information efficacy drug group women study woman singleton pregnancy gestational diabetes require treatment woman randomly assign week gestation receive glyburide insulin accord intensified treatment protocol primary end point achievement desired level glycemic control secondary end point include maternal neonatal complications mean sd pretreatment blood glucose concentration measure home one week mg per deciliter mmol per liter glyburide group mg per deciliter mmol per liter insulin group p mean concentration treatment mg per deciliter mmol per liter glyburide group mg per deciliter mmol per liter insulin group p eight woman glyburide group percent require insulin therapy significant difference glyburide insulin group percentage infant large gestational age percent percent respectively macrosomia define birth weight g percent percent lung complication percent percent hypoglycemia percent percent admit neonatal intensive care unit percent percent fetal anomaly percent percent cord serum insulin concentration similar two group glyburide detect cord serum infant glyburide group woman gestational diabetes glyburide clinically effective alternative insulin therapy,Langer O,2000,N Engl J Med,https://doi.org/10.1056/nejm200010193431601,11036118,Langer O; Conway DL; Berkus MD; Xenakis EM; Gonzales O,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D001786: Blood Glucose; D000013: Congenital Abnormalities; D016640: Diabetes, Gestational; D005260: Female; D005312: Fetal Blood; D005320: Fetal Macrosomia; D005905: Glyburide; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007231: Infant, Newborn; D007328: Insulin; D011247: Pregnancy; D011256: Pregnancy Outcome",,,https://openalex.org/W2326851691,81,12,1,1945,347,9,en,en
true,oral hypoglycemic drug gestational diabetes,gestational diabetes mellitus contentious subject since first describe global perspective author question existence burden morbidity cause whether make diagnosis simply increase expense complexity perinatal care argument rag test gestational diabetes pregnancy testing result define disorder affected woman treat willing acknowledge moderate abnormality carbohydrate metabolism pregnancy require attention one point agreement diet,Greene MF,2000,N Engl J Med,https://doi.org/10.1056/nejm200010193431608,11036125,Greene MF,article,D016420: Comment; D016421: Editorial,"D001786: Blood Glucose; D000013: Congenital Abnormalities; D016640: Diabetes, Gestational; D005260: Female; D005312: Fetal Blood; D005320: Fetal Macrosomia; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007231: Infant, Newborn; D007328: Insulin; D011247: Pregnancy; D011256: Pregnancy Outcome; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2034108829,48,6,1,677,114,6,en,en
true,pharmacology clinical experience repaglinide,repaglinide novonorm r novel oral antidiabetic agent first new class insulin secretagogues know prandial glucose regulator approve use patient type diabetes prandial glucose regulation aim restore first phase insulin response follow consumption meal miss patient type diabetes repaglinide administration result insulin profile reflect healthy individual closely provide tight glycaemic control reduce risk hypoglycaemic event repaglinide quickly absorb rapidly eliminate biliary excretion make suitable use patient renal impairment appear bloodstream within min dosing stimulate short term insulin release pancreatic beta cells bind unique site beta cell membrane rapid elimination ensure postprandial insulin level quickly return preprandial level high prandial glucose level subsides repaglinide give one meal one tablet meal tablet basis particularly effective patient previously treat oral antidiabetic agent significantly reduce glycosylated haemoglobin hba c level also offer increase mealtime flexibility safety compare oral antidiabetic agent result short plasma half life lack accumulation repaglinide repeated dosing risk meal nocturnal hypoglycaemia substantially reduce compare oral antidiabetic agent repaglinide act synergistically metformin consistently improve glycaemic control patient insufficiently control metformin alone result recent study show similar synergistic effect neutral protamine hagedorn nph insulin troglitazone,Massi-Benedetti M,2000,Expert Opin Investig Drugs,https://doi.org/10.1517/13543784.9.4.885,11060717,Massi-Benedetti M; Damsbo P,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D002219: Carbamates; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D004435: Eating; D006801: Humans; D007004: Hypoglycemic Agents; D010880: Piperidines",,,https://openalex.org/W2138804577,53,6,1,1930,316,12,en,en
false,insulin sensitiser drug,insulin resistance predominant early pathological defect type diabetes well risk factor development type diabetes insulin resistance also associate increased cardiovascular risk metabolic disturbance include visceral adiposity hyperinsulinaemia impair glucose tolerance hypertension dyslipidaemia new approach oral antidiabetic therapy target improvement insulin sensitivity muscle adipose tissue hepatic level result improvement glycaemic control feature insulin resistance syndrome potential long term benefit preventing delaying onset diabetic complication macrovascular disease,Murphy E,2000,Expert Opin Investig Drugs,https://doi.org/10.1517/13543784.9.6.1347,11060747,Murphy E; Nolan JJ,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007333: Insulin Resistance; D013844: Thiazoles",,,https://openalex.org/W2061146365,24,3,1,743,112,4,en,en
false,effect oral hypoglycaemic agent dyslipidaemia nigerian patient newly diagnose non insulin dependent diabetes mellitus prospective study,thirty five patient non insulin dependent diabetes niddm treat follow week six manage diet metformin nine receive glibenclamide twelve combination metformin glibenclamide remain eight patient receive metformin type sulphonylurea chlorpropamide glipizide analysis variance different drug regime show equivalent glycaemic controlling effect influence dyslipidaemia variable within treatment group change insignificant group thus conclude commonly use oral hypoglycaemic agent adversely affect plasma lipid level nigerian patient niddm,Agboola-Abu CF,2000,West Afr J Med,,11070748,Agboola-Abu CF; Ohwovoriole AE; Akinlade KS,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000704: Analysis of Variance; D044383: Black People; D002747: Chlorpropamide; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005913: Glipizide; D005905: Glyburide; D006801: Humans; D006949: Hyperlipidemias; D007004: Hypoglycemic Agents; D008055: Lipids; D008297: Male; D008687: Metformin; D009549: Nigeria; D011446: Prospective Studies",,,https://openalex.org/W2403610518,160,23,1,754,120,4,en,en
true,nateglinide alone combination metformin improves glycemic control reduce mealtime glucose level type diabetes,objective evaluate efficacy tolerability nateglinide metformin alone combination type diabetic patient inadequately control diet focus change hba c fast plasma glucose fpg mealtime glucose excursion research design method randomized double blind study patient hba c level week placebo run receive week treatment mg nateglinide meal n mg metformin three time day n combination therapy n placebo n hba c fpg evaluate regularly plasma glucose level determine sustacal challenge week hypoglycemia adverse event record result study end point hba c reduce baseline nateglinide metformin increase placebo respectively p lt change fpg follow pattern mmol l p lt combination therapy additive hba c fpg mmol l p lt vs monotherapy sustacal challenge great reduction mealtime glucose nateglinide monotherapy compare metformin monotherapy placebo adjust area curve auc min mmol x h x l p lt even great effect observe combination therapy auc min mmol x h x l p lt vs metformin placebo regimen well tolerate conclusion nateglinide metformin monotherapy improve overall glycemic control different mechanism nateglinide decrease mealtime glucose excursion whereas metformin primarily affect fpg combination nateglinide metformin complementary effect improve hba c fpg postprandial hyperglycemia,Horton ES,2000,Diabetes Care,https://doi.org/10.2337/diacare.23.11.1660,11092289,Horton ES; Clinkingbeard C; Gatlin M; Foley J; Mallows S; Shen S,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001786: Blood Glucose; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004435: Eating; D005006: Ethnicity; D005215: Fasting; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D008875: Middle Aged; D000077715: Nateglinide; D010649: Phenylalanine; D011446: Prospective Studies; D014481: United States",,,https://openalex.org/W2036731511,133,20,1,1946,399,13,en,en
false,hypoglycemic diuretic hypocholesterolemic effect winter cherry withania somnifera dunal root,hypoglycemic diuretic hypocholesterolemic effect root w somnifera ashvagandha assess human subject six mild niddm subject six mild hypercholesterolemic subject treat powder root w somnifera day suitable parameter study blood urine sample subject along dietary pattern end treatment period decrease blood glucose comparable oral hypoglycemic drug significant increase urine sodium urine volume significant decrease serum cholesterol triglyceride ldl low density lipoprotein vldl low density lipoprotein cholesterol observe indicate root w somnifera potential source hypoglycemic diuretic hypocholesterolemic agent clinical observation reveal adverse effect,Andallu B,2000,Indian J Exp Biol,,11116534,Andallu B; Radhika B,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000328: Adult; D000924: Anticholesteremic Agents; D001786: Blood Glucose; D002214: Capsules; D003924: Diabetes Mellitus, Type 2; D004231: Diuresis; D004232: Diuretics; D006801: Humans; D006937: Hypercholesterolemia; D007004: Hypoglycemic Agents; D008055: Lipids; D008875: Middle Aged; D009318: Natriuresis; D010936: Plant Extracts; D018517: Plant Roots; D010946: Plants, Medicinal; D011188: Potassium; D011208: Powders; D012964: Sodium; D019657: Solanaceae",,,https://openalex.org/W2245981351,104,17,1,865,142,6,en,en
true,management type diabetes mellitus cardiovascular risk,although diagnosis type noninsulin dependent diabetes mellitus make blood glucose level exceed value increase risk microvascular complication macrovascular disease major complication type diabetes mellitus epidemiological prospective data demonstrate treatment hyperglycaemia markedly effective reduce risk microvascular disease less potent reduce myocardial infarction stroke peripheral vascular disease treatment cardiovascular risk factor although definition less prevalent hyperglycaemia appear effective prevent macrovascular disease treatment hyperglycaemia recent year data intervention trial suggest great benefit respect prevention macrovascular disease achieve effective treatment hypertension hypercholesterolaemia use small dos aspirin acetylsalicylic acid treat hyperglycaemia alone hand uk prospective diabetes study ukpds examine impact intensive glucose blood pressure bp control micro macrovascular complication intervention trial include patient type diabetes mellitus ukpds data epidemic increase number patient type diabetes mellitus high cardiovascular risk however initiate several new trial address particular possible benefit treatment common form dyslipidaemia high serum triglyceride low high density lipoprotein cholesterol level patient type diabetes mellitus thus disease associate high vascular risk majority patient need likely benefit pharmacological treatment several cardiovascular risk factor provide treatment target achieve life style modification,Yki-Järvinen H,2000,Drugs,https://doi.org/10.2165/00003495-200060050-00001,11129129,Yki-Järvinen H,article,D016428: Journal Article; D016454: Review,"D000959: Antihypertensive Agents; D002318: Cardiovascular Diseases; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D006949: Hyperlipidemias; D006973: Hypertension; D007004: Hypoglycemic Agents; D008019: Life Style; D010975: Platelet Aggregation Inhibitors; D018570: Risk Assessment",,,https://openalex.org/W78898943,62,9,1,1985,316,7,en,en
true,recent advance pharmacologic management diabetes mellitus,importance glucose control reduce complication diabetes mellitus clearly demonstrate emergency physician routinely expect treat wide range problem relate disease include make initial diagnosis type occasionally type diabetes also common patient poorly control diabetes recent introduction new class agent lower blood glucose especially type diabetes improve control category patient reduce complication rate agent troglitazone potentially fatal complication require careful monitoring emergency physician aware common complication drug patient present ed hypoglycemia common cause call emergency visit side effect either metformin acarbose insulin lispro improve postprandial glycemic control type insulin requiring type diabetic hypoglycemia less risk insulin lispro quality life well rapidly act insulin new method insulin delivery continuous subcutaneous infusion greatly improve glucose control give great freedom patient reduce risk hypoglycemia,Carlton FB,2000,Emerg Med Clin North Am,https://doi.org/10.1016/s0733-8627(05)70156-5,11130936,Carlton FB,article,D016428: Journal Article; D016454: Review,"D020909: Acarbose; D000284: Administration, Oral; D002219: Carbamates; D002839: Chromans; D003920: Diabetes Mellitus; D062787: Drug Overdose; D004630: Emergencies; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D061268: Insulin Lispro; D008687: Metformin; D010880: Piperidines; D013453: Sulfonylurea Compounds; D013844: Thiazoles; D045162: Thiazolidinediones; D000077288: Troglitazone",,,https://openalex.org/W1965420891,68,9,1,1335,225,10,en,en
true,effect rifampicin pharmacokinetics pharmacodynamics glimepiride,study effect rifampicin pharmacokinetics pharmaco dynamics glimepiride new sulphonylurea antidiabetic drug randomise two phase cross study healthy volunteer treat day mg rifampicin placebo daily day single oral dose mg glimepiride administer plasma glimepiride blood glucose concentration measure h rifampicin decrease mean area plasma concentration time curve glimepiride p mean elimination half life p significant difference blood glucose response glimepiride observe placebo rifampicin phase however symptomatic hypoglycaemia occur placebo phase effect rifampicin pharmacokinetics glimepiride suggest rifampicin induce cyp c mediated metabolism glimepiride thereby slightly increase systemic clearance interaction modest significantly alter glucose lowering effect glimepiride healthy volunteer probably limited clinical significance however patient hypoglycaemic effect glimepiride may reduce concomitant treatment rifampicin,Niemi M,2000,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.2000.00295.x,11136298,Niemi M; Kivistö KT; Backman JT; Neuvonen PJ,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000904: Antibiotics, Antitubercular; D001786: Blood Glucose; D018592: Cross-Over Studies; D004347: Drug Interactions; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D012293: Rifampin; D013453: Sulfonylurea Compounds",,,https://openalex.org/W1597998832,80,10,1,1293,203,7,en,en
true,near normoglycaemic remission african americans type diabetes mellitus associate recovery beta cell function,summary aim prospectively determine frequency remission possible mechanism beta cell recovery non whites type diabetes mellitus setting intensive glycaemic regulation use pharmacological agent method twenty six consecutive newly diagnose african american type diabetic patient present primarily severe hyperglycaemia mmol l follow least year initial hospitalization include treatment insulin fluid electrolyte outpatient intensive glycaemic regulation include insulin glibenclamide diabetes education diet alter nutrient content plasma glucose c peptide response oral glucose tolerance test hba c measure day presentation remission define hba c fasting plasma glucose mmol l month discontinue pharmacological agent result eleven patient develop remission mean day pharmacological treatment remain remission follow day one relapse day fifteen patient develop remission follow day require continue pharmacological therapy well controlled mean hba c significant difference age sex plasma glucose presentation initial glycaemic regulation final body mass index magnitude weight change pharmacological agent use treatment two group plasma c peptide response oral glucose initially day suppress subject subsequently increase increase significantly great undergo remission neither significant weight loss severe hypoglycaemia observe either group intensive treatment conclusion forty two per cent newly diagnose unselected african americans type diabetes treat intensively use pharmacological agent education diet developed near normoglycaemic remission remission associate great recovery glucose stimulated insulin secretion suggest therapy direct promote beta cell recovery preservation potentially useful approach treatment type diabetes mellitus,McFarlane SI,2001,Diabet Med,https://doi.org/10.1046/j.1464-5491.2001.00395.x,11168335,McFarlane SI; Chaiken RL; Hirsch S; Harrington P; Lebovitz HE; Banerji MA,article,D016428: Journal Article,"D001741: Black or African American; D000368: Aged; D015415: Biomarkers; D044383: Black People; D001786: Blood Glucose; D002096: C-Peptide; D003131: Combined Modality Therapy; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D005260: Female; D005500: Follow-Up Studies; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D007515: Islets of Langerhans; D008297: Male; D008875: Middle Aged; D009519: New York City; D010353: Patient Education as Topic; D011446: Prospective Studies; D013997: Time Factors",,,https://openalex.org/W2146975696,130,17,1,2348,377,15,en,en
false,pharmacokinetics bioavailability metformin glyburide tablet administer alone food,two randomize crossover study conduct evaluate pharmacokinetics include food effect fixed combination metformin glyburide tablet pharmacokinetics bioavailability two strength mg mg mg mg metformin glyburide tablet assess relative coadministered metformin glyburide tablet study effect high fat meal bioavailability metformin glyburide mg mg tablet assess relative fast condition study fix combination metformin glyburide tablet show bioequivalence metformin component reference metformin tablet comparable bioavailability glyburide component reference glyburide tablet food appear affect bioavailability either component appreciable extent,Marathe PH,2000,J Clin Pharmacol,https://doi.org/10.1177/009127000004001222,11185672,Marathe PH; Arnold ME; Meeker J; Greene DS; Barbhaiya RH,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000293: Adolescent; D000328: Adult; D001682: Biological Availability; D018592: Cross-Over Studies; D005260: Female; D018565: Food-Drug Interactions; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D013607: Tablets,,,https://openalex.org/W2122289372,101,12,1,842,125,5,en,en
true,flexible meal related dosing repaglinide facilitates glycemic control therapy naive type diabetes,double blind randomized placebo controlled parallel group study assess efficacy safety particular regard body weight hypoglycemia repaglinide use flexible mealtime dose regimen situation close everyday clinical practice total patient type diabetes consider poorly control diet without history previous antidiabetic medication randomize receive mg repaglinide mealtime increase mg week depend blood glucose response placebo week patient free choose flexible meal pattern adjust dose schedule two four preprandial dos per day accordance one meal one dose meal dose principle additional snack requirement treatment schedule treatment repaglinide significantly improve glycemic control respect baseline placebo reduce hba c baseline fast plasma glucose mmol l improvement glycemic control independent meal pattern adopt patient include commonly take two four meal daily correlation meal pattern risk hypoglycemia improvement glycemic control also independent degree obesity age year significant body weight increase repaglinide group mealtime dose repaglinide effective improve overall glycemic control type diabetic patient control suboptimal use diet alone patient able vary meal pattern conventional regimen three meal daily without compromise control increase risk adverse event,Moses RG,2001,Diabetes Care,https://doi.org/10.2337/diacare.24.1.11,11194214,Moses RG; Gomis R; Frandsen KB; Schlienger JL; Dedov I,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001786: Blood Glucose; D001835: Body Weight; D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D004032: Diet; D004311: Double-Blind Method; D005215: Fasting; D005260: Female; D005502: Food; D006442: Glycated Hemoglobin; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D010880: Piperidines; D010919: Placebos",,,https://openalex.org/W2118629010,107,13,1,1743,291,7,en,en
false,diastolic dysfunction normotensive men well controlled type diabetes,pseudonormal pattern ventricular filling never consider study report prevalence left ventricular diastolic dysfunction lvdd aim completely evaluate prevalence lvdd subject diabetes study men type diabetes age year without evidence diabetic complication hypertension coronary artery disease congestive heart failure thyroid overt renal disease maximal treadmill exercise test show ischemia lvdd evaluate doppler echocardiography include use valsalva maneuver pulmonary venous recording unmask pseudonormal pattern left ventricular filling lvdd find subject pseudonormal pattern ventricular filling impair relaxation systolic function normal subject correlation lvdd index metabolic control lvdd much common previously report subject well controlled type diabetes free clinically detectable heart disease high prevalence phenomenon high risk population suggest screen lvdd type diabetes include procedure valsalva maneuver pulmonary venous recording unmask pseudonormal pattern ventricular filling,Poirier P,2001,Diabetes Care,https://doi.org/10.2337/diacare.24.1.5,11194240,Poirier P; Bogaty P; Garneau C; Marois L; Dumesnil JG,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D003924: Diabetes Mellitus, Type 2; D003971: Diastole; D004452: Echocardiography; D005080: Exercise Test; D006801: Humans; D017078: Laser-Doppler Flowmetry; D008297: Male; D008875: Middle Aged; D011667: Pulmonary Veins; D014636: Valsalva Maneuver; D018487: Ventricular Dysfunction, Left",,,https://openalex.org/W2086170960,78,10,1,1418,238,4,en,en
true,mealtime glucose regulation nateglinide healthy volunteer,objective study design compare pharmacodynamic effect single dos nateglinide repaglinide placebo mealtime insulin secretion glycemic control healthy subject research design methods fifteen healthy volunteer participate open label five period crossover study receive single min preprandial dos mg nateglinide mg repaglinide placebo min preprandially mg repaglinide subject receive dose h apart pharmacodynamic pharmacokinetic assessment perform h postdose results nateglinide induced insulin secretion rapidly mg repaglinide placebo min preprandial mean rate insulin rise u ml min respectively min postmeal interval peak insulin concentration decrease rapidly nateglinide treated group similar placebo within h postdose mg repaglinide peak insulin concentration delay return baseline slowly nateglinide treatment nateglinide treatment produce low average plasma glucose concentration h postdose interval either dose repaglinide placebo p lt vs mg repaglinide placebo plasma glucose concentration return rapidly predose level nateglinide treatment either dose repaglinide treatment repaglinide produce sustained hypoglycemic effect h postdose conclusions single dose study nondiabetic volunteer nateglinide provide rapid shorter lived stimulation insulin secretion repaglinide result low meal related glucose excursion similar result observe diabetes nateglinide may produce physiological insulin secretory response potential reduced risk postabsorptive hypoglycemia,Kalbag JB,2001,Diabetes Care,https://doi.org/10.2337/diacare.24.1.73,11194245,Kalbag JB; Walter YH; Nedelman JR; McLeod JF,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000293: Adolescent; D000328: Adult; D001786: Blood Glucose; D015992: Body Mass Index; D001835: Body Weight; D002219: Carbamates; D018592: Cross-Over Studies; D003510: Cyclohexanes; D005260: Female; D005502: Food; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D007700: Kinetics; D008297: Male; D008875: Middle Aged; D000077715: Nateglinide; D010649: Phenylalanine; D010880: Piperidines; D010919: Placebos; D013997: Time Factors,,,https://openalex.org/W2159654541,66,8,1,1983,323,13,en,en
true,beneficial detrimental effect intensive glycaemic control emphasis type diabetes mellitus,diabetes mellitus major health problem world several clinical trial show major complication diabetes mellitus partially prevent delay intensive glycaemic control however benefit risk aim near normal blood glucose level intensive glycaemic control delay onset progression retinopathy nephropathy neuropathy epidemiological observational study show cardiovascular event may correlate severity duration diabetes mellitus major randomise trial show weak nonsignificant benefit intensive glycaemic management decrease event rate modest improvement lipid profile result blood glucose control although majority case enough reach current target detrimental effect intensive glycaemic control include bodyweight gain hypoglycaemia controversial issue management patient diabetes mellitus include unproven increase cardiovascular morbidity sulphonylureas hyperinsulinaemia still unknown long term effect new oral antihyperglycaemic agent alone combination traditional therapy sulphonylureas metformin important individualise management set glycaemic goal control cardiovascular risk factor blood pressure lipid control treatment aspirin acetylsalicylic acid ace inhibitor consistently show benefit prevention macro microvascular complication patient diabetes mellitus measure deserve priority,Camacho P,2000,Drugs Aging,https://doi.org/10.2165/00002512-200017060-00004,11200307,Camacho P; Pitale S; Abraira C,article,D016428: Journal Article; D016454: Review,"D001766: Blindness; D001786: Blood Glucose; D002318: Cardiovascular Diseases; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006801: Humans; D006946: Hyperinsulinism; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D007676: Kidney Failure, Chronic; D008297: Male; D012306: Risk; D015430: Weight Gain",,,https://openalex.org/W1993071511,108,16,1,1674,252,10,en,en
true,impairment early insulin response glucose load rather insulin resistance responsible postprandial hyperglycemia see obese type diabetes assessment use nateglinide new insulin secretagogue,insulin secretory pattern phenotype type diabetes impairment rapid pulsatile secretion insulin response rise blood glucose meal intake restoration endogenous rapid insulin secretion oral glucose load establish first time use nateglinide newly develop insulin secretagogue obese patient type diabetes mellitus clearly demonstrate nateglinide serum insulin level quickly raise glycemic response curve almost normalize amount insulin secretion min therefore lack rapid pulsatile secretion insulin response glycemic rise oral glucose load rather insulin resistance responsible postprandial glycemic response obese type diabetes patient,Uchino H,2000,Endocr J,https://doi.org/10.1507/endocrj.47.639,11200947,Uchino H; Niwa M; Shimizu T; Nishiyama K; Kawamori R,article,D016430: Clinical Trial; D016428: Journal Article,"D000328: Adult; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005947: Glucose; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D007333: Insulin Resistance; D000078790: Insulin Secretion; D008297: Male; D008875: Middle Aged; D000077715: Nateglinide; D009765: Obesity; D010649: Phenylalanine; D019518: Postprandial Period",,,https://openalex.org/W1988864220,223,35,2,851,143,4,en,en
true,effect pharmacokinetics oral glibenclamide glipizide caucasian chinese patient type diabetes,effect kinetics oral glibenclamide gb glipizide gz study caucasian chinese patient ten group type diabetes randomised order mg gb mg gz placebo give orally administration g oral glucose concentration insulin proinsulin determine use radioimmunoassay ria without cross reactivities sulphonylurea concentration determine use high performance liquid chromatography hplc significant interethnic difference gb gz effect whether glucose insulin proinsulin insulin ratio time point follow gz however chinese patient great increment serum proinsulin min compare caucasian apart maximum plasma concentration cmax area plasma concentration time curve auc gz high among chinese significant interethnic difference pharmacokinetics find appear dosage principle could use caucasian chinese patient type diabetes gb gz prescribe,Jönsson A,2000,Eur J Clin Pharmacol,https://doi.org/10.1007/s002280000214,11214781,Jönsson A; Chan JC; Rydberg T; Vaaler S; Hallengren B; Cockram CS; Critchley JA; Melander A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D044466: Asian People; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005913: Glipizide; D005951: Glucose Tolerance Test; D005905: Glyburide; D006442: Glycated Hemoglobin; D006207: Half-Life; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D011384: Proinsulin; D044465: White People",,,https://openalex.org/W2070344632,119,16,1,1120,190,7,en,en
false,use dose response characteristic therapeutic agent treatment decision type diabetes,diabetes obesity metabolismvolume issue p use dose response characteristic therapeutic agent treatment decision type diabetes alan j garber alan j garber baylor college medicine methodist hospital houston tx usasearch paper author alan j garber alan j garber baylor college medicine methodist hospital houston tx usasearch paper author first publish december http doi org j xcitations alan j garber md phd fannin street suite houston tx usa read full textaboutpdf toolsrequest permissionexport citationadd favoritestrack citation shareshare give accessshare full text accessshare full text accessplease review term condition use check box share full text version article read accept wiley online library term condition useshareable linkuse link share full text version article friend colleague learn copy url share linkshare onemailfacebooktwitterlinkedinredditwechat reference joint national committee prevention detection evaluation treatment high blood pressure sixth report joint national committee prevention detection evaluation treatment high blood pressure arch intern med anonymous national cholesterol education program second report expert panel detection evaluation treatment high blood cholesterol adult adult treatment panel ii circulation american diabetes association standard medical care patient diabetes mellitus diabetes care suppl american diabetes association management dyslipidemia adult diabetes diabetes care suppl uk prospective diabetes study group intensive blood glucose control sulphonylureas insulin compare conventional treatment risk complication patient type diabetes ukpds lancet uk prospective diabetes study group effect intensive blood glucose control metformin complication overweight patient type diabetes ukpds lancet anonymous diabinese chlorpropamide product information physician desk reference rd edn montvale nj medical economics company orinase tolbutamide tablet package insert kalamazoo mi pharmacia upjohn company tolinase tolzamide tablet package insert kalamazoo mi pharmacia upjohn company anonymous micronase glyburide product information physician desk reference rd edn montvale nj medical economics company anonymous diamicron gliclazide product information compendium pharmaceutical specialty cps edn ontario canadian pharmacist association anonymous glucotrol glipizide product information physician desk reference rd edn montvale nj medical economics company anonymous amaryl glimepiride product information physician desk reference rd edn montvale nj medical economics company glucophage metformin hydrochloride package insert princeton nj bristol meyers squibb company precose acarbose tablet package insert west ct bayer corporation rezulin troglitazone package insert parsippany nj parke davis pharmaceuticals prandin repaglinide package insert princeton nj novo nordisk pharmaceuticals groop lc sulfonylurea niddm diabetes care kikuchi modulation insulin secretion non insulin dependent diabetes mellitus two novel oral hypoglycaemic agent nn diabetic med lebovitz kahn cr weir gc ed oral antidiabetic agent joslin diabetes th edn philadelphia lea febiger turner r cull c holman r united kingdom prospective diabetes study year update randomize control trial effect improved metabolic control complication non insulin dependent diabetes mellitus ann intern med groop lc ratheiser k luzi l et al effect sulphonylurea glucose stimulated insulin secretion healthy non insulin dependent diabetic subject dose response study acta diabetol united kingdom prospective diabetes study group united kingdom prospective diabetes study ukpds relative efficacy randomly allocate diet sulphonylurea insulin metformin patient newly diagnose non insulin dependent diabetes follow three year br med j ferner antsiferov ml kelman aw alberti kg rawlins md relationship dose concentration tolbutamide insulin glucose response patient non insulin dependent diabetes eur j clin pharmacol goldberg rb holvey sm schneider j dose response study glimepiride patient niddm previously receive sulfonylurea agent diabetes care simonson dc kourides ia feinglos shamoon h fischette ct efficacy safety dose response characteristic glipizide gastrointestinal therapeutic system glycemic control insulin secretion niddm result two multicenter randomize placebo controlled clinical trial diabetes care wahlin boll e sartor g melander schersten b impaired effect sulfonylurea follow increased dosage eur j clin pharmacol stenman melander groop ph groop lc benefit increase sulfonylurea dose ann intern med karam jh sanz n salamon e nolte ms selective unresponsiveness pancreatic cells acute sulfonylurea stimulation sulfonylurea therapy niddm diabetes davidson mb peter al overview metformin treatment type diabetes mellitus j med bloomgarden zt insulin resistance current concept clin ther bailey cj hypoglycemic antihyperglycemic antidiabetic drug diabetic med garber aj duncan tg goodman mill dj rohlf jl efficacy metformin type ii diabetes result double blind placebo controlled dose response trial j med nagi dk yudkin j effect metformin insulin resistance risk factor cardiovascular disease plasminogen activator inhibitor niddm subject study two ethnic group diabetes care defronzo ra goodman multicenter metformin study group efficacy metformin patient non insulin dependent diabetes mellitus n engl j med mcintyre hd bird dm paterson ca ravenscroft pj cameron dp metformin increase insulin sensitivity basal glucose clearance type non insulin dependent diabetes mellitus aust nz j med hermann l schersten b bitzen po kjellstrom lindgarde f melander therapeutic comparison metformin sulfonylurea alone various combination double blind control study diabetes care hermann l schersten b melander antihyperglycaemic efficacy response prediction dose response relation treatment metformin sulphonylurea alone primary combination diabetic med grant pj effect high medium dose metformin therapy cardiovascular risk factor patient type ii diabetes diabetes care pugh j metformin monotherapy type ii diabetes adv ther wildasin em skaar dj kirchain wr hulse metformin promising oral anithyperglycemic treatment noninsulin dependent diabetes mellitus pharmacotherapy garber aj metformin mechanism antihyperglycemic action pharmacodynamic property safety perspective endocr pract brown jb pedula k barzilay j herson mk latare p lactic acidosis rate type diabetes diabetes care stacpoole pw metformin lactic acidosis guilt association diabetes care lalau jd mourlhon c bergeret lacroix c consequence metformin intoxication diabetes care reaven gm johnston p hollenbeck cb et al combine metformin sulfonylurea treatment patient noninsulin dependent diabetes fair poor glycemic control j clin endocrinol metab haupt e knick b koschinsky liebermeister h schneider j hirche h oral antidiabetic combination therapy sulphonylureas metformin diabetic metab yee h fong nt review safety efficacy acarbose diabetes mellitus pharmacotherapy coniff rf shapiro ja robbins et al reduction glycosylated hemoglobin postprandial hyperglycemia acarbose patient niddm placebo controlled dose comparison study diabetes care coniff rf shapiro ja seaton tb long term efficacy safety acarbose treatment obese subject non insulin dependent diabetes mellitus arch intern med spencer cm markham troglitazone drug fonseca va valiquett tr huang sm ghazzi mn whitcomb rw troglitazone monotherapy improve glycemic control patient type diabetes mellitus randomized control study troglitazone study group j clin endocrinol metab schwartz raskin p fonseca v graveline jf effect troglitazone insulin treated patient type ii diabetes mellitus n engl j med maggs dg buchanan ta burant cf et al metabolic effect troglitazone monotherapy type diabetes mellitus randomized double blind placebo control trial ann intern med kumar prange schulze j lettis barnett ah troglitazone insulin action enhancer improve glycaemic control insulin sensitivity elderly type diabetic patient diabetic med kumar boulton aj beck nielsen h et al troglitazone insulin action enhancer improve metabolic control niddm patient diabetologia valiquett balogtas c whitcomb r troglitazone dose response study patient niddm diabetes suppl krentz aj ferner bailey cj comparative tolerability profile oral antidiabetic agent drug safety cite literature volume issue may pages referencesrelatedinformation,Garber AJ,2000,Diabetes Obes Metab,https://doi.org/10.1046/j.1463-1326.2000.00054.x,11220549,Garber AJ,article,D016428: Journal Article; D016454: Review,"D020909: Acarbose; D001786: Blood Glucose; D002839: Chromans; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004359: Drug Therapy, Combination; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008687: Metformin; D013453: Sulfonylurea Compounds; D013844: Thiazoles; D045162: Thiazolidinediones; D000077288: Troglitazone",,,https://openalex.org/W2156462071,100,13,1,11244,2274,188,en,en
true,fda approves nateglinide treatment type diabetes,,Lieder TR,2001,Am J Health Syst Pharm,https://doi.org/10.1093/ajhp/58.4.285,11225164,Lieder TR,article,D016433: News,"D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D017277: Drug Approval; D007004: Hypoglycemic Agents; D000077715: Nateglinide; D010649: Phenylalanine; D014481: United States; D014486: United States Food and Drug Administration",,,https://openalex.org/W2417301005,57,9,1,0,0,0,en,
false,leptin concentration relate glycaemic control change short term oral antidiabetic therapy female patient type diabetes mellitus,study evaluate relation leptin glycaemic control effect day diet diet combine gliclazide glipizide gits metformin treatment leptin concentration female patient type diabetes mellitus leptin level similar baseline treatment diabetic control group diabetic patient basal fast plasma glucose fpg mmol l basal postprandial plasma glucose pppg mmol l significantly high leptin level diabetic patient basal fpg mmol l basal pppg mmol l vs microg l p vs microg l p respectively mode treatment influence leptin level delta leptin show weak correlation basal fpg r p basal post treatment pppg r p r p respectively moderate correlation post treatment fpg r p conclusion leptin level affect presence type diabetes mellitus short term treatment diet oral antidiabetic drug directly relate glycaemic control female patient type diabetes mellitus,Güler S,2000,Diabetes Obes Metab,https://doi.org/10.1046/j.1463-1326.2000.00073.x,11225747,Güler S; Cakir B; Demirbaş B; Gürsoy G; Serter R; Aral Y,article,D016428: Journal Article,"D000284: Administration, Oral; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D005215: Fasting; D005260: Female; D005913: Glipizide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D020738: Leptin; D008875: Middle Aged; D019518: Postprandial Period; D012016: Reference Values; D012044: Regression Analysis",,,https://openalex.org/W2085589411,164,25,1,1265,242,6,en,en
false,effect antihyperglycaemic therapy proinsulin relation proinsulin cardiovascular risk factor type diabetes,summary aim assess effect oral antihyperglycaemic therapy fast proinsulin relation proinsulin level cardiovascular risk factor type diabetes method one hundred sixty five patient type diabetes fast blood glucose concentration fbg mmol l recruit five diabetes outpatient clinic primary health care diet antihyperglycaemic medication aim fbg mmol l maintain month complete dose titration randomized double blind double dummy trial metformin glibenclamide g primary combination drug mg study compare g mg low dose mgl also different high dose regimen e g add g add g g primary combination mgh outcome measure fast proinsulin glycaemia body mass index blood pressure lipid insulin c peptide result low proinsulin level find therapy initiate metformin vs g p g vs g p g equally effective glucose level group whole fbg decrease mean mmol l change proinsulin proinsulin associate cardiovascular risk factor link high proinsulin atherogenic risk marker profile mean proinsulin change baseline inconsistently associate marker insulin resistance meal stimulated glucose net auc decrease treatment low baseline proinsulin level conclusion may advantageous initiate oral antihyperglycaemic therapy metformin rather sulphonylurea high proinsulin level associate atherogenic risk marker profile impaired therapeutic postprandial glucose response treatment patient type diabetes proinsulin change therapy inconsistently associate marker insulin resistance unrelated fast blood glucose reduction,Hermann LS,1999,Diabetes Obes Metab,https://doi.org/10.1046/j.1463-1326.1999.00034.x,11228758,Hermann LS; Ranstam J; Vaaler S; Melander A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D015415: Biomarkers; D001786: Blood Glucose; D001794: Blood Pressure; D015992: Body Mass Index; D002318: Cardiovascular Diseases; D002784: Cholesterol; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D015588: Observer Variation; D011384: Proinsulin; D012307: Risk Factors; D014280: Triglycerides",,,https://openalex.org/W2060518308,136,18,1,2024,364,16,en,en
true,management type diabetes mellitus elderly,principle manage type diabetes mellitus elderly different young patient priority therapeutic strategy need cautiously individualise objective treatment improve glycaemic control stepwise approach involve nonpharmacological method include diet exercise pharmacological therapy include mixture oral antihyperglycaemic agent alone combination insulin although goal treatment may elderly young patient certain aspect type diabetes elderly require special consideration treatment decision influence age life expectancy comorbid condition severity vascular complication adherence dietary therapy physical activity medication regimen may compromise comorbid condition psychosocial limitation drug induced hypoglycaemia main consideration serious potential complication addition long term macrovascular microvascular complication type diabetes source significant morbidity mortality indeed vascular neuropathic complication already present time diagnosis significant number patient impact improved diabetes control depend age life expectancy patient age related change pharmacokinetics potential adverse effect drug interaction also consider choose appropriate pharmacological therapy general conservative stepwise approach treatment elderly patient type diabetes suggest treatment may initiate monotherapy follow early intervention combination oral agent include sulphonylurea foundation insulin secretagogue addition supplemental insulin sensitiser insulin therapy eventually require significant hyperglycaemia glycosylated haemoglobin hba c persist despite oral combination therapy combination therapy even insulin long acting sulphonylurea glimepiride effective strategy improve hyperglycaemia elderly patient type diabetes polypharmacy oral agent unsuccessful addition regimen simple follow patient may able adhere complicated insulin regimen hyperglycaemia elderly manage well practical intervention straightforward treatment plan enhance compliance optimal glycaemic control possible every patient treatment individualise however strict glycaemic control may achievable patient even desirable many elderly patient,Rosenstock J,2001,Drugs Aging,https://doi.org/10.2165/00002512-200118010-00003,11232737,Rosenstock J,article,D016428: Journal Article; D016454: Review,"D000368: Aged; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005853: Geriatrics; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D013453: Sulfonylurea Compounds",,,https://openalex.org/W63541796,53,9,1,2784,433,15,en,en
false,short term effect switch glybenclamide metformin blood pressure microalbuminuria patient type diabetes mellitus,renal hyperfiltration albuminuria deleterious effect kidney function therefore study effect metformin blood pressure renal hemodynamics microalbuminuria type diabetic patients clinical trial design type diabetic patient incipient nephropathy patient age normotensive without evidence malignant hepatic cardiovascular disorder randomly allocate receive glibenclamide metformin baseline week thereafter measure body mass index bmi serum insulin blood glucose lipid profile glycosylated hemoglobin blood pressure glomerular filtration rate renal plasma flow urine albumin study patient glibenclamide group metformin group difference baseline variable group metabolic control obtain group metformin group following variable decrease microalbuminuria reduce mean mg day p systolic diastolic blood pressure mean mmhg p mmhg p respectively insulin level average microiu ml p total cholesterol level triglyceride average mmol l respectively insulin resistance measure homeostasis model decrease metformin group glibenclamide group patient treat glibenclamide increase hdl cholesterol mmol l p metformin significantly decrease urine albumin excretion rate none expect change renal hemodynamics probably due favorable effect blood pressure lipid profile metabolic control insulin resistance,Amador-Licona N,2000,Arch Med Res,https://doi.org/10.1016/s0188-4409(00)00241-1,11257323,Amador-Licona N; Guízar-Mendoza J; Vargas E; Sánchez-Camargo G; Zamora-Mata L,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000419: Albuminuria; D001786: Blood Glucose; D001794: Blood Pressure; D015992: Body Mass Index; D003924: Diabetes Mellitus, Type 2; D003928: Diabetic Nephropathies; D005260: Female; D005919: Glomerular Filtration Rate; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007333: Insulin Resistance; D007668: Kidney; D008055: Lipids; D008297: Male; D008687: Metformin; D008875: Middle Aged; D012079: Renal Circulation; D016896: Treatment Outcome",,,https://openalex.org/W2046159055,146,22,1,1778,313,10,en,en
false,serum insulin assay important therapeutic tool management freshly diagnose type diabetes mellitus,study perform see whether metabolic control response treatment freshly diagnosed patient type diabetes mellitus affect primary pathology hyperinsulinemia inappropriate insulin secretion one hundred eight freshly diagnose patient type diabetes mellitus age range year follow period three month blood glucose serum triglyceride serum insulin level determine patient patient find either high normal low serum insulin value fasting accordingly patient distribute two group group one normal low initial fasting serum insulin level e microu ml group two high fasting serum insulin level e microu ml group far divide two subgroup b subgroup treat glipizide b metformin diabetic patient fast hyperinsulinemia n blood pressure time presentation patient fast serum insulin within normal range n hypertension patient group one good recovery hyperglycemia reduction triglyceride value treat sulphonylurea subgroup compare patient treat biguanide subgroup b contrary patient group two show poor glycemic control increase blood pressure rise serum triglyceride titre treat sulphonylurea subgroup group biguanide effectively produce euglycemia normalization blood pressure decrease triglyceride level subgroup b assessment initial serum insulin level helpful guide decide type oral hypoglycemic agent use freshly diagnose patient type diabetes mellitus,Saxena T,2000,J Assoc Physicians India,,11273476,Saxena T; Maheshwari S; Goyal RK,article,D003160: Comparative Study; D016428: Journal Article,"D000328: Adult; D000368: Aged; D001786: Blood Glucose; D001794: Blood Pressure; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005500: Follow-Up Studies; D005913: Glipizide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D016896: Treatment Outcome; D014280: Triglycerides",,,https://openalex.org/W2415490967,111,18,1,1847,326,9,en,en
false,insulin release isolate human islet acute prolonged exposure glimepiride,,Del Guerra S,2000,Acta Diabetol,https://doi.org/10.1007/s005920070017,11277315,Del Guerra S; Parentini C; Bracci C; Lupi R; Marselli L; Aragona M; Navalesi R; Marchetti P,article,"D016422: Letter; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D005260: Female; D005947: Glucose; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D007515: Islets of Langerhans; D008297: Male; D008875: Middle Aged; D013453: Sulfonylurea Compounds,,,https://openalex.org/W2010576859,92,14,1,0,0,0,en,
false,role common sequence variant insulin secretion familial type diabetic kindred,demonstrate high heritability insulin secretion measure acute insulin response glucose time insulin sensitivity disposition index furthermore show obese normoglycemic family member type diabetic proband fail compensate insulin resistance obesity increase insulin secretion study test primary hypothesis previously describe variant pancreatic sulfonylurea receptor gene sur abcc glucokinase gck gene hepatocyte nuclear factor alpha tcf hnf alpha gene contribute inherited deficiency insulin secretion beta cell compensation insulin resistance well secondary hypothesis variant alter insulin sensitivity type nondiabetic member familial type diabetic kindred undergone tolbutamide modified intravenous glucose tolerance test two variant abcc sulfonylurea gene two variant gck gene one common amino acid variant tcf hnf alpha gene family member classify normal impair glucose tolerance base oral glucose tolerance test use minimal model analysis calculate insulin sensitivity index glucose effectiveness sg acute insulin response glucose calculate mean insulin excursion baseline first min glucose bolus disposition index di measure beta cell compensation insulin sensitivity calculate insulin sensitivity time acute insulin response effect polymorphism determine use mixed effect model incorporate family membership likelihood analysis account family structure polygenic inheritance intronic variant abcc gene upstream exon significant determinant di analogous index base acute insulin response tolbutamide surprisingly heterozygous individual show low index whereas di two homozygous state differ significantly neither exon variant variant gck tcf gene significant model however combine genotype abcc exon variant significantly predict index glucose tolbutamide stimulated insulin secretion unexpectedly variant untranslated region gck gene interact significantly bmi predict insulin sensitivity exon variant abcc gene reduce beta cell compensation decreased insulin sensitivity heterozygous state may explain observation several group association abcc variant diabetes consistent study show role abcc variant pancreatic beta cell function however study focus individual relatively family ascertainment bias family structure interact gene might influence unexpected result additional study need replicate observed deficit beta cell compensation individual heterozygous abcc variant likewise role gck variant reduced insulin sensitivity obesity require study,Elbein SC,2001,Diabetes Care,https://doi.org/10.2337/diacare.24.3.472,11289470,Elbein SC; Sun J; Scroggin E; Teng K; Hasstedt SJ,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.","D018528: ATP-Binding Cassette Transporters; D004268: DNA-Binding Proteins; D003924: Diabetes Mellitus, Type 2; D005260: Female; D014644: Genetic Variation; D005838: Genotype; D005941: Glucokinase; D051537: Hepatocyte Nuclear Factor 1; D051538: Hepatocyte Nuclear Factor 1-alpha; D051539: Hepatocyte Nuclear Factor 1-beta; D006801: Humans; D007328: Insulin; D007333: Insulin Resistance; D000078790: Insulin Secretion; D007515: Islets of Langerhans; D008297: Male; D009687: Nuclear Proteins; D009765: Obesity; D015221: Potassium Channels; D024661: Potassium Channels, Inwardly Rectifying; D011955: Receptors, Drug; D064233: Sulfonylurea Receptors; D014157: Transcription Factors",,,https://openalex.org/W2099424987,90,14,1,3280,529,16,en,en
false,blood pressure rise onset microalbuminuria child follow diagnosis type diabetes,objective examine whether rise blood pressure could detect onset microalbuminuria cohort child follow diagnosis type diabetes research design methods oxford regional prospective study incident cohort study child type diabetes age mean sd year diagnosis subject assess annually diagnosis measurement hba c arterial blood pressure random zero three urine sample estimation albumin creatinine ratio follow child develop one annual assessment designate case nested case control study case match sex age diagnosis two normoalbuminuric control subject blood pressure bp data compare correspond year diabetes duration results cases similar normoalbuminuric control subject respect age bmi high mean hba c level mean difference p lt year onset diastolic bp standard deviation score sd significantly high zero case mean p lt control subject p lt difference could detect case control subject onset either systolic diastolic bp mean difference systolic mmhg ci mean difference diastolic mmhg however within case onset associate elevation systolic diastolic bp sdss f p lt f p lt bmi hba c associate systolic diastolic bp sdss subject f p f p however association bp remain significant systolic bp p diastolic bp p lt adjust bmi conclusions rise systemic bp detect first appearance child type diabetes bp rise concurrently onset also closely relate bmi,Schultz CJ,2001,Diabetes Care,https://doi.org/10.2337/diacare.24.3.555,11289484,Schultz CJ; Neil HA; Dalton RN; Konopelska Bahu T; Dunger DB; Oxford Regional Prospective Study Group,article,"D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't","D000419: Albuminuria; D015415: Biomarkers; D001794: Blood Pressure; D015992: Body Mass Index; D002648: Child; D015331: Cohort Studies; D003404: Creatinine; D003922: Diabetes Mellitus, Type 1; D003971: Diastole; D005260: Female; D005500: Follow-Up Studies; D006442: Glycated Hemoglobin; D006801: Humans; D006973: Hypertension; D008297: Male; D012016: Reference Values; D013599: Systole; D013997: Time Factors",,,https://openalex.org/W2052652736,120,19,1,2153,450,14,en,en
false,lipid lipoprotein response oral combine hormone replacement therapy normolipemic obese woman controlled type diabetes mellitus,study investigate effect oral combine hormone replacement therapy ochrt lipid concentration subpopulation distribution lipoprotein nine postmenopausal woman type diabetes mellitus moderate glycemic control week continuous daily therapy conjugated estrogen mg medroxyprogesterone mg mean concentration high density lipoprotein hdl cholesterol show statistically significant increase predominantly hdl subfraction statistically significant change mean concentration total cholesterol low density lipoprotein ldl cholesterol triglyceride low density lipoprotein vldl triglyceride apolipoprotein apolipoprotein b evident likewise change find average diameter vldl ldl hdl particle triglyceride concentration vldl subfractions cholesterol concentration ldl subfractions chemical composition plasma ldl finding lend support use ochrt postmenopausal woman diabetes decrease risk coronary artery disease,Lilley SH,1998,J Clin Pharmacol,https://doi.org/10.1177/009127009803801204,11301562,Lilley SH; Spivey JM; Vadlamudi S; Otvos J; Cummings DM; Barakat H,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000284: Administration, Oral; D000368: Aged; D003924: Diabetes Mellitus, Type 2; D015914: Estrogen Replacement Therapy; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D008055: Lipids; D008074: Lipoproteins; D008875: Middle Aged; D009765: Obesity; D010316: Particle Size",,,https://openalex.org/W2130703044,145,20,1,1135,178,5,en,en
true,hemodynamic metabolic hormonal response oral glibenclamide patient cirrhosis receive glucose,patient cirrhosis glucose may induce splanchnic renal vasodilation since antidiabetic sulfonylurea glibenclamide know induce splanchnic renal vasoconstriction portal hypertensive animal drug may inhibit glucose induced hemodynamic response patient cirrhosis aim present study investigate patient cirrhosis short term effect glibenclamide hemodynamic humoral response glucose patients randomly assign receive either glibenclamide mg tablet placebo patient receive infusion glucose ml h h start time glibenclamide placebo administration study perform prior min glibenclamide placebo glibenclamide e glibenclamide plus glucose significantly increase plasma insulin concentration glycemia placebo e glucose alone significantly increase glycemia change plasma insulin level glibenclamide significantly change hepatic venous pressure gradient value significantly increase follow glucose alone glibenclamide significantly change renal blood flow glomerular filtration rate glucose alone significantly increase renal blood flow without affect glomerular filtration rate glibenclamide significantly decrease cardiac index glucose alone change value patient cirrhosis receive glucose glibenclamide blunt glucose induced splanchnic renal vasodilation addition glibenclamide per se induce decrease cardiac index finding take account glibenclamide administer patient cirrhosis type diabetes,Moreau R,2001,Scand J Gastroenterol,https://doi.org/10.1080/003655201750074654,11305519,Moreau R; Chagneau C; Heller J; Chevenne D; Langlet P; Deltenre P; Hillaire S; Lefilliatre P; Pateron D; Sogni P; Valla D; Lebrec D,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D005260: Female; D005947: Glucose; D005905: Glyburide; D006439: Hemodynamics; D006801: Humans; D007004: Hypoglycemic Agents; D007262: Infusions, Intravenous; D007328: Insulin; D008099: Liver; D008103: Liver Cirrhosis; D008111: Liver Function Tests; D008297: Male; D008875: Middle Aged; D011336: Probability; D012016: Reference Values; D012129: Respiratory Function Tests; D016896: Treatment Outcome",,,https://openalex.org/W2106707298,112,15,1,1779,266,12,en,en
false,sulfonylurea treatment type diabetic patient reduce vasodilator response ischemia,sulfonylurea block activation vascular potassium dependent atp channel impair vasodilating response ischcmia nondiabetic individual know whether occur type diabetic patient chronic treatment drug glimepiride new sulfonylurea apparently cardiovascular interaction aim study compare effect widely use compound glibenclamide pancreas specific glimepiride diet treatment alone brachial artery response acute forearm ischemia brachial artery examination perform high resolution ultrasound technique type diabetic patient age mean sd year nondiabetic patient match age hypertension dislipidemia diabetic subject underwent three separate evaluation end week treatment period receive glibenclamide glimepiride diet alone accord crossover design scan obtain min forearm ischemia postischemic vasodilation hyperemia express percent variation vessel diameter blood flow postischemic vasodilation hyperemia respectively glibenclamide glimepiride diet treatment ns result similar find nondiabetic patient n type diabetic patient vasodilating response forearm ischemia whether patient treat diet treatment alone glibenclamide glimepiride blood glucose lowering equipotent close,Spallarossa P,2001,Diabetes Care,https://doi.org/10.2337/diacare.24.4.738,11315840,Spallarossa P; Schiavo M; Rossettin P; Cordone S; Olivotti L; Cordera R; Brunelli C,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D001794: Blood Pressure; D001916: Brachial Artery; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D005260: Female; D005542: Forearm; D005907: Gliclazide; D005905: Glyburide; D006801: Humans; D006949: Hyperlipidemias; D006973: Hypertension; D007004: Hypoglycemic Agents; D007511: Ischemia; D008297: Male; D008687: Metformin; D008875: Middle Aged; D012016: Reference Values; D012039: Regional Blood Flow; D013453: Sulfonylurea Compounds; D014463: Ultrasonography",,,https://openalex.org/W2095567616,103,15,1,1709,283,7,en,en
true,combination therapy insulin type diabetes,u k prospective diabetes study ukpds demonstrate intensive glucose control insulin sulfonylurea markedly reduce risk microvascular complication myocardial infarction reduction risk decrease hba c borderline significance correspond closely epidemiological prediction decrease drop hba c data demonstrate neither insulin sulfonylurea despite cause hyperinsulinemia weight gain adverse effect cardiovascular outcome glycemic control deteriorate continuously however even intensively treated patient ukpds ukpds worsening glycemic control attribute natural course type diabetes lack efficacy current antihyperglycemic therapy insulin therapy consist single injection ultralente isophane insulin daily dose exceed u regular insulin add home glucose monitoring encourage combination therapy regimens insulin oral agent use know u long acting insulin insufficient control fast glycemia type diabetic patient since ukpds start several study try define optimal insulin treatment regimen type diabetic patient study focus review include study compare insulin alone combination therapy insulin sulfonylurea subject meta analyses recent trial use metformin glitazones acarbose insulin combination therapy regimen contain data cardiovascular end point surrogate marker risk micro macrovascular complication mostly data glycemia body weight insulin dos lipid study also accurate data frequency hypoglycemia accord medline search,Yki-Järvinen H,2001,Diabetes Care,https://doi.org/10.2337/diacare.24.4.758,11315844,Yki-Järvinen H,article,D016428: Journal Article; D016454: Review,"D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D008055: Lipids; D016239: MEDLINE; D015430: Weight Gain",,,https://openalex.org/W2148717983,53,8,1,1991,355,14,en,en
false,postprandial blood glucose,,American Diabetes Association,2001,Diabetes Care,https://doi.org/10.2337/diacare.24.4.775,11315848,American Diabetes Association,article,"D016446: Consensus Development Conference; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review",D001786: Blood Glucose; D003920: Diabetes Mellitus; D005215: Fasting; D006442: Glycated Hemoglobin; D006801: Humans; D006943: Hyperglycemia; D019518: Postprandial Period,,,https://openalex.org/W4213149640,26,3,1,0,0,0,en,
false,clinical review glimepiride,article review pharmacological clinical aspect glimepiride late second generation sulfonylurea treatment type diabetes mellitus dm glimepiride therapy ameliorate relative insulin secretory deficit find patient type dm direct insulin secretagogue indirectly also increase insulin secretion response fuel glucose action augment insulin secretion require bind high affinity sulfonylurea receptor result closure atp sensitive potassium channel beta cells pancreas question raise whether insulin secretagogues act vascular myocardial potassium channel may prevent ischaemic preconditioning physiological adaptation could affect outcome coronary heart disease evidence concern applicable glimepiride glimepiride antihyperglycaemic efficacy equal secretagogues pharmacokinetic property make less prone cause hypoglycaemia renal dysfunction insulin secretagogues particularly glyburide also know glibenclamide europe convenient daily dosing may enhance compliance diabetic patient often also require medication co morbid condition hypertension hyperlipidaemia cardiac disease glimepiride approve monotherapy combination metformin insulin clinically reduce risk hypoglycaemia make preferable insulin secretagogues attempt achieve recommended glycaemic control haemoglobin c hgba c use suppertime neutral protamine hagedorn nph regular insulin morning glimepiride overweight diabetic patient achieve glycaemic goal quickly insulin alone low insulin dos,McCall AL,2001,Expert Opin Pharmacother,https://doi.org/10.1517/14656566.2.4.699,11336617,McCall AL,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review","D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D004347: Drug Interactions; D006801: Humans; D007004: Hypoglycemic Agents; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2099466477,30,4,1,1890,297,11,en,en
false,hour glycemic profile type diabetic patient treat gliclazide modify release daily,type diabetes primary secondary prevention long term micro macrovascular complication require control blood glucose level hour day present study undertake assess effect new formulation gliclazide administer daily gliclazide modify release plasma glucose level hours type diabetic patient previously treat diet alone oral antidiabetic agent glycemic profile pm pm pm pm overall glycemic control acceptability compliance treatment assess week treatment gliclazide modify release mg give daily breakfast result indicate significant decrease plasma glucose level point cycle mean plasma glucose level hour mean plasma glucose level fasting postprandial period significantly improve treatment previous drug naive patient decrease hba c observe p acceptability good hypoglycemic event high compliance treatment also observed therefore conclude gliclazide modify release give daily breakfast effective hour reduce plasma glucose level type diabetes daily administration lead optimal patient compliance treatment,Guillausseau PJ,2001,Diabetes Metab,,11353879,Guillausseau PJ; Greb W,article,D016430: Clinical Trial; D016428: Journal Article,"D000328: Adult; D000368: Aged; D001786: Blood Glucose; D015992: Body Mass Index; D002940: Circadian Rhythm; D003692: Delayed-Action Preparations; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D005260: Female; D005907: Gliclazide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D010349: Patient Compliance; D012107: Research Design",,,https://openalex.org/W1586183545,105,16,1,1446,258,6,en,en
true,importance early insulin secretion,objective study compare effect nateglinide glyburide placebo postmeal glucose excursion insulin secretion previously diet treated patient type diabetes research design methods randomize double blind placebo controlled multicenter study conduct patient receive either nateglinide mg three meal daily n glyburide mg q titrate mg q week n placebo n week glucose insulin c peptide profile liquid meal challenge measure week week point daytime glucose insulin profile comprise three solid meal measure results liquid meal challenge nateglinide reduce incremental glucose area curve auc effectively glyburide vs mmol h l p lt whereas glyburide reduce fast plasma glucose effectively nateglinide vs mmol l respectively p lt contrast c peptide induce glyburide great induce nateglinide vs nmol h l p lt glyburide increase fast insulin level solid meal challenge nateglinide glyburide elicit similar overall glucose control h incremental auc vs mmol h l insulin auc induce nateglinide significantly less induce glyburide h auc vs pmol h l p conclusions study demonstrate nateglinide selectively enhance early insulin release provide good mealtime glucose control less total insulin exposure glyburide,Hollander PA,2001,Diabetes Care,https://doi.org/10.2337/diacare.24.6.983,11375357,Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D019540: Area Under Curve; D001786: Blood Glucose; D002096: C-Peptide; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D004311: Double-Blind Method; D005215: Fasting; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D008297: Male; D008875: Middle Aged; D000077715: Nateglinide; D010649: Phenylalanine; D010919: Placebos; D019518: Postprandial Period; D011384: Proinsulin; D016037: Single-Blind Method; D013997: Time Factors",,,https://openalex.org/W1994361841,37,5,1,1735,327,10,en,en
false,effect inorganic chromium brewer yeast supplementation glucose tolerance serum lipid drug dosage individual type diabetes,study effect supplementation organic inorganic chromium glucose tolerance serum lipid drug dosage type diabetes patient hope find good economical method control seventy eight type diabetes patient divide randomly two group give brewer yeast ug cr day crcl ug cr day sequentially placebo double blind cross design four stage last week beginning end stage subject weigh dietary data drug dosage record blood urine sample collect analysis glucose fast hour post g glucose load fructosamine triglyceride total hdl cholesterol serum urinary chromium supplement cause significant decrease mean glucose fast hour post glucose load fructosamine triglyceride mean hdl cholesterol serum urinary chromium increase mean drug dosage decrease slightly significantly case glibenclamide supplement patient longer required insulin change note dietary intake body mass index high percentage subject respond positively brewer yeast chromium retain body effect fructosamine triglyceride hdl cholesterol maintain subject placebo follow mean urinary chromium remain significantly high zero time mean chromium supplementation give good control glucose lipid variable decrease drug dosage type diabetes patient large scale study need help decide convenient chemical form dosage require achieve optimal response,Bahijiri SM,2000,Saudi Med J,,11376359,Bahijiri SM; Mira SA; Mufti AM; Ajabnoor MA,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D002712: Chlorides; D017608: Chromium Compounds; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D005951: Glucose Tolerance Test; D006801: Humans; D007004: Hypoglycemic Agents; D008055: Lipids; D008297: Male; D008875: Middle Aged; D012441: Saccharomyces cerevisiae; D016896: Treatment Outcome",,,https://openalex.org/W1739919717,156,26,1,1801,310,7,en,en
true,match treatment pathophysiology type diabetes,type diabetes progressive condition patient whose disease initially control diet exercise eventually need single multiple pharmacologic agent maintain adequate glycemic control although current treatment standard require combination therapy institute failure monotherapy result diabetes control complication trial united kingdom prospective diabetes study suggest aggressive initial treatment crucial slow evolution long term complication associate disease article review diagnosis classification type diabetes describe multiple defect glucose metabolism associate disease discuss various pharmacologic option achieve glycemic control patients information review compile search medline search term include limit type diabetes antihyperglycemic agent addition abstract identify use web site diabetes related professional organizations two pathophysiologic mechanism insulin resistance impaired insulin secretion usually present diagnosis type diabetes several study show combination therapy antihyperglycemic agent different mechanism action provide great efficacy treatment single agents current research suggest early aggressive treatment combination therapy achieve glycemic control low dos side effect monotherapy either component,Gerich JE,2001,Clin Ther,https://doi.org/10.1016/s0149-2918(01)80017-5,11394726,Gerich JE,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D018149: Glucose Intolerance; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007333: Insulin Resistance; D000078790: Insulin Secretion",,,https://openalex.org/W2046224702,56,8,1,1633,235,5,en,en
false,effect month ingestion ginkgo biloba extract egb pancreatic cell function response glucose load individual non insulin dependent diabetes mellitus,first report journal clinical pharmacology show ingestion mg ginkgo biloba extract egb daily month normal glucose tolerant individual cause significant increase pancreatic beta cell insulin c peptide response measure area curve auc hour standard g oral glucose tolerance test ogtt follow study design determine effect ginkgo biloba treatment glucose stimulated pancreatic beta cell function non insulin dependent diabetes mellitus niddm subject diet controlled subject fast plasma glucose fpg mg dl fast plasma insulin fpi microu ml n ingestion ginkgo biloba produce significant effect insulin auc vs microu ml h ingest ginkgo biloba respectively hyperinsulinemic niddm subject take oral hypoglycemic medication n fpg mg dl fpi microu ml ingestion ginkgo biloba cause blunted plasma insulin level minute ogtt lead reduction insulin auc vs microu ml h ginkgo biloba respectively c peptide level increase auc parallel insulin auc create dissimilar insulin c peptide ratio indicative enhanced hepatic extraction insulin relative c peptide thus pancreatic beta cells already maximally stimulate ingestion ginkgo biloba may cause reduction plasma insulin level niddm subject pancreatic exhaustion fpg mg dl fpi microu ml n also take oral hypoglycemic agent ginkgo biloba ingestion significantly increase pancreatic beta cell function response glucose loading insulin auc increase microu ml h p parallel c peptide auc increase p whether increase due resuscitation previously exhaust islet increased activity remain functional islet unclear however even group increase pancreatic beta cell activity cause reduction blood glucose ogtt conclude ingestion ginkgo biloba extract niddm subject may increase hepatic metabolic clearance rate insulin also hypoglycemic agent result reduce insulin mediated glucose metabolism elevate blood glucose,Kudolo GB,2001,J Clin Pharmacol,https://doi.org/10.1177/00912700122010483,11402628,Kudolo GB,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D004032: Diet; D005260: Female; D020441: Ginkgo biloba; D005951: Glucose Tolerance Test; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007515: Islets of Langerhans; D008297: Male; D008875: Middle Aged; D008517: Phytotherapy; D010936: Plant Extracts; D014665: Vasodilator Agents",,,https://openalex.org/W2045016419,194,34,1,2645,494,11,en,en
false,lesson glitazones story drug development,troglitazone first thiazolidinedione class oral hypoglycaemic agent launch usa march reach europe later year withdraw within week ground liver toxicity meanwhile go generate sale billion usa cause least case liver failure result death transplantation withdraw march rosiglitazone pioglitazone reach u market first line agent use alone combination drug europe dossier use one year later apply limited licence second line agent restrict oral combination therapy use glitazones achieve blockbuster status without clear evidence advantage exist therapy,Gale EA,2001,Lancet,https://doi.org/10.1016/s0140-6736(00)04960-6,11410214,Gale EA,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D016907: Adverse Drug Reaction Reporting Systems; D056486: Chemical and Drug Induced Liver Injury; D002839: Chromans; D003924: Diabetes Mellitus, Type 2; D017277: Drug Approval; D004359: Drug Therapy, Combination; D005060: Europe; D006801: Humans; D007004: Hypoglycemic Agents; D017093: Liver Failure; D000077205: Pioglitazone; D000077154: Rosiglitazone; D013844: Thiazoles; D045162: Thiazolidinediones; D000077288: Troglitazone; D014481: United States",,,https://openalex.org/W2124084557,56,10,1,852,158,6,en,en
false,tissue triglyceride level type diabetes role thiazolidinediones reverse effect tissue hypertriglyceridemia review evidence animal human,insulin resistance chronic low grade acute phase reaction mediate increase cytokine level van der poll romijn j endert e borm j j buller h r sauerwein h p tumor necrosis factor mimic metabolic response acute infection healthy human j physiol pt e e google scholar prominent cytokine tumor necrosis factor tnf probably link among adiposity insulin resistance type diabetes hotamisligil g spiegelman b tumor necrosis factor alpha key component obesity diabetes link diabetes crossref pubmed google scholar adipose tissue express tnf surface tnf stimulates production leptin adipocyte increase basal metabolic rate hotamisligil g shargill n spiegelman b adipose expression tumor necrosis factor alpha direct role obesity linked insulin resistance science crossref pubmed scopus google scholar kirchgessner g choi hormonal cytokine regulation leptin production adipocytes abstract diabetes suppl google scholar addition tnf stimulating lipolysis suppress lipogenesis decrease preadipocyte differentiation increase apoptosis adipocytes preadipocytes increase insulin resistance weight gain prevent grunfeld c zhao c fuller j et al endotoxin cytokine induce expression leptin ob gene product hamster j clin invest crossref pubmed scopus google scholar result action tnf free fatty acid ffas increase blood tissue situation lead decreased peripheral glucose utilization increase hepatic gluconeogenesis least initially increased insulin production overcome insulin resistance prolonged increase ffas however excessive accumulation triglyceride pancreatic beta cell result damage pancreatic beta cell insulin deficiency,Bell DS,2001,Endocr Pract,https://doi.org/10.4158/ep.7.2.135,11421558,Bell DS; Ovalle F,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D015228: Hypertriglyceridemia; D007004: Hypoglycemic Agents; D013844: Thiazoles; D014280: Triglycerides",,,https://openalex.org/W2080153104,182,28,1,2115,387,31,en,en
true,randomize dose range study reduction fasting postprandial glucose type diabetes nateglinide,randomize crossover double blind placebo controlled study aim assess efficacy nateglinide novel phenylalanine derived insulin secretagogue type diabetic subject fast min standard meal single dose nateglinide mg placebo give eight diet treated overnight fasted type diabetic patient seven patient min standard breakfast plasma glucose radioimmunoassay insulin nateglinide measure baseline min time averaged min postdose mean decrease fast plasma glucose concentration great nateglinide mmol l ci placebo mmol l ci p hypoglycemia develop subject insulin concentration increase fold mg dos respectively p peak approximately min dose nateglinide concentration peak approximately min decrease peak min meal test mean increase mmol l plasma glucose min placebo reduce mmol l p two high dos nateglinide single dose nateglinide administer diet treated type diabetic patient fasting hyperglycemia increase insulin secretion reduced fasting glucose without hypoglycemia administer min meal nateglinide reduce postprandial glucose excursion rapid onset short duration action nateglinide promising oral prandial therapy type diabetes,Gribble FM,2001,Diabetes Care,https://doi.org/10.2337/diacare.24.7.1221,11423506,Gribble FM; Manley SE; Levy JC,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D001786: Blood Glucose; D018592: Cross-Over Studies; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005215: Fasting; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D000077715: Nateglinide; D010649: Phenylalanine; D019518: Postprandial Period",,,https://openalex.org/W2117255195,125,21,1,1662,296,8,en,en
false,pioglitazone hydrochloride combination sulfonylurea therapy improve glycemic control patient type diabetes mellitus randomized placebo controlled study,evaluate efficacy tolerability pioglitazone combination sulfonylurea treatment type diabetes mellitus week double blind study include patient stable regimen sulfonylurea day glycosylated hemoglobin hba c level patient randomly assign receive daily pioglitazone mg n pioglitazone mg n placebo plus sulfonylurea n patients receive pioglitazone sulfonylurea significant p decrease baseline hba c fast plasma glucose level compare patient treat placebo sulfonylurea compare placebo hba c decrease confidence interval ci pioglitazone mg ci mg pioglitazone fast plasma glucose level decrease mg dl ci mg dl pioglitazone mg mg dl ci mg dl mg pioglitazone pioglitazone sulfonylurea group significant p mean percent decrease triglyceride level ci mg ci mg increase high density lipoprotein cholesterol level ci mg ci mg compare placebo sulfonylurea small statistically significant mean percent increase low density lipoprotein cholesterol level group pioglitazone well tolerate rate adverse event similar groups patient type diabetes pioglitazone plus sulfonylurea significantly improve hba c fast plasma glucose level beneficial effect serum triglyceride hdl cholesterol level,Kipnes MS,2001,Am J Med,https://doi.org/10.1016/s0002-9343(01)00713-6,11448655,Kipnes MS; Krosnick A; Rendell MS; Egan JW; Mathisen AL; Schneider RL,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D001786: Blood Glucose; D002096: C-Peptide; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008055: Lipids; D008297: Male; D008875: Middle Aged; D000077205: Pioglitazone; D013453: Sulfonylurea Compounds; D013844: Thiazoles; D045162: Thiazolidinediones; D013997: Time Factors; D016896: Treatment Outcome; D014280: Triglycerides; D014481: United States",,,https://openalex.org/W2023447984,175,23,1,1767,362,6,en,en
true,nateglinide,pharmacology pharmacokinetics clinical efficacy adverse effect interaction dosage nateglinide review nateglinide oral hypoglycemic agent approve use alone combination metformin adjunct diet exercise treatment type diabetes mellitus nateglinide amino acid derivative phenylalanine stimulate secretion insulin bind atp potassium channel pancreatic beta cell result increase beta cell calcium influx lead rapid short lived insulin release drug rapidly completely absorb small intestine estimated bioavailability nateglinide highly bind plasma protein metabolize extensively liver elimination half life hour several clinical trial nateglinide alone combination oral hypoglycemic agent find drug safe effective well tolerate common adverse effect nausea diarrhea dizziness lightheadedness potential interaction nateglinide medication affect cytochrome p isoenzyme system dosage regimens range mg evaluate maximum effective dosage mg take minute meal three time day nateglinide alternative second generation sulfonylurea treatment type diabetes mellitus additional comparative trial need fully elucidate nateglinide role,Halas CJ,2001,Am J Health Syst Pharm,https://doi.org/10.1093/ajhp/58.13.1200,11449877,Halas CJ,article,D016428: Journal Article; D016454: Review,"D001682: Biological Availability; D001786: Blood Glucose; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D006207: Half-Life; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D000077715: Nateglinide; D010649: Phenylalanine; D016032: Randomized Controlled Trials as Topic",,,https://openalex.org/W4234855498,11,1,1,1533,259,14,it,en
false,mechanism acute chronic hypoglycemic action gliclazide,extrapancreatic effect sulfonylurea postulate however vivo result dispute amelioration insulin action follow sulfonylurea may represent relief glucose toxicity rather direct effect drug therefore study hypoglycemic action gliclazide acutely month therapy seven type diabetic patient patient receive minute v glucose infusion h glucose random order mg gliclazide study placebo study give orally glucose infusion finally effect mg gliclazide reassess two month treatment sulfonylurea mg basal plasma glucose insulin c peptide endogenous glucose production egp similar two initial study glucose infusion egp suppressed gliclazide spite comparable increase plasma insulin c peptide two month therapy basal plasma glucose level hba c low plasma insulin c peptide high respect baseline p gliclazide far reduce plasma glucose incremental area baseline egp glucose infusion plasma insulin c peptide achieve high plateau p data pool plasma glucose concentration egp correlate basal state r last hour glucose infusion r p data suggest gliclazide enhance suppression egp induce insulin effect great chronic treatment concomitant improvement insulin secretion,da Tos V,2000,Acta Diabetol,https://doi.org/10.1007/s005920070006,11450504,da Tos V; Maran A; Vigili de Kreutzenberg S; Marchetto S; Tadiotto F; Bettio M; Marescotti MC; Tiengo A; Del Prato S,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000208: Acute Disease; D001786: Blood Glucose; D002096: C-Peptide; D002908: Chronic Disease; D003924: Diabetes Mellitus, Type 2; D005907: Gliclazide; D005943: Gluconeogenesis; D015309: Glucose Clamp Technique; D006442: Glycated Hemoglobin; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D007700: Kinetics; D008875: Middle Aged; D010919: Placebos; D012044: Regression Analysis; D013997: Time Factors; D014316: Tritium",,,https://openalex.org/W2086006962,65,9,1,1691,304,13,en,en
false,oral antidiabetic treatment patient coronary disease time related increased mortality combined glyburide metformin therapy year follow,sulfonylurea usually glyburide plus metformin constitute widely used oral antihyperglycemic combination clinical practice medication present undesirable cardiovascular effect issue whether adverse effect pharmacologic agent may additive detrimental prognosis coronary patient yet specifically addressed study design examine survival type diabetic proven coronary artery disease cad receive combined glyburide metformin antihyperglycemic treatment long term follow period study sample comprise diabetic patient age year proven cad screen include bezafibrate infarction prevention study addition nondiabetic patient cad represent reference group diabetic divide four group basis therapeutic regimen diet alone n glyburide n metformin n combination latter two n diabetic group present similar clinical characteristic upon recruitment crude mortality rate year follow low nondiabetics vs p among diabetic patient die diet mortality glyburide metformin alone patient combine treatment p time related mortality almost equal patient metformin combined therapy intermediate follow period year survival rate respectively group combined treatment present bad prognosis long term follow time related survival rate year versus glyburide metformin respectively adjustment variable prognosis use combined treatment associate increase hazard ratio hr cause mortality confidence interval ci whereas glyburide metformin alone yield hr ci hr ci respectively conclude year follow monotherapy either glyburide metformin diabetic patient cad yield similar outcome associate modest increase mortality however time related mortality markedly increase combined glyburide metformin treatment use,Fisman EZ,2001,Clin Cardiol,https://doi.org/10.1002/clc.4960240210,11460818,Fisman EZ; Tenenbaum A; Boyko V; Benderly M; Adler Y; Friedensohn A; Kohanovski M; Rotzak R; Schneider H; Behar S; Motro M,article,D016428: Journal Article,"D000284: Administration, Oral; D003327: Coronary Disease; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005500: Follow-Up Studies; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D008875: Middle Aged; D016019: Survival Analysis; D013997: Time Factors",,,https://openalex.org/W2004657369,161,20,1,2439,434,11,en,en
false,lipoic acid multifunctional antioxidant improve insulin sensitivity patient type diabetes,alpha lipoic acid la disulfide compound produce small quantity cell function naturally co enzyme pyruvate dehydrogenase alpha ketoglutarate dehydrogenase mitochondrial enzyme complex pharmacological dos la multifunctional antioxidant la use germany year treatment diabetes induced neuropathy patient type diabetes recent study report intravenous v infusion la increase insulin mediated glucose disposal whereas oral administration la marginal effect limitation oral therapy overcome la could emerge safe effective adjunctive antidiabetic agent insulin sensitize activity,Evans JL,2000,Diabetes Technol Ther,https://doi.org/10.1089/15209150050194279,11467343,Evans JL; Goldfine ID,article,D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D000975: Antioxidants; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D003929: Diabetic Neuropathies; D006801: Humans; D007004: Hypoglycemic Agents; D007262: Infusions, Intravenous; D007328: Insulin; D018384: Oxidative Stress; D008063: Thioctic Acid",,,https://openalex.org/W2175479903,111,16,1,756,123,6,en,en
true,comparison repaglinide glipizide type diabetes mellitus year multicentre study,evaluate long term effectiveness safety repaglinide novel prandial glucose regulator comparison glipizide treatment patient type diabetes diet tablet treated patient type diabetes n age year body mass index bmi kg hba c without sign severe microvascular macrovascular complication include double blind multicentre parallel group comparative trial patient randomize ratio repaglinide mg mealtime glipizide mg daily changes fast blood glucose fbg hba c month treatment show significant difference favour repaglinide oral hypoglycaemic agent oha naive patient hba c decrease repaglinide glipizide group respectively p group fast blood glucose decrease repaglinide group mmol l increase glipizide group mmol l p group study population whole repaglinide able maintain glycaemic control hba c level year study period whereas control deteriorate significantly glipizide change hba c baseline significantly well repaglinide glipizide month p addition fbg deteriorate significantly glipizide group compare repaglinide group p patient either group experience major hypoglycaemic event number patient experience minor hypoglycaemia similar repaglinide glipizide group respectively repaglinide give prandial glucose regulator show effective safe treatment patient type diabetes well glipizide control hba c fbg level overall oha naive patient,Madsbad S,2001,Diabet Med,https://doi.org/10.1046/j.1464-5491.2001.00490.x,11472451,Madsbad S; Kilhovd B; Lager I; Mustajoki P; Dejgaard A; Scandinavian Repaglinide Group,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001786: Blood Glucose; D002096: C-Peptide; D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D003928: Diabetic Nephropathies; D003929: Diabetic Neuropathies; D003930: Diabetic Retinopathy; D004311: Double-Blind Method; D005215: Fasting; D005260: Female; D005913: Glipizide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D010880: Piperidines",,,https://openalex.org/W2132308332,100,15,1,1894,341,8,en,en
true,acute short term administration sulfonylurea gliclazide increase pulsatile insulin secretion type diabetes,high frequency oscillatory pattern insulin release disturb type diabetes although sulfonylurea drug widely use treatment disease effect insulin release pattern well establish aim present study assess impact acute treatment week sulfonylurea gliclazide treatment insulin secretory dynamic type diabetic patient end patient type diabetes age year bmi kg fast plasma glucose mmol l hba c study double blind placebo controlled prospective crossover design patient receive mg gliclazide placebo twice daily week week washout period intervene insulin pulsatility assess min interval blood sample min baseline condition baseline h first dose mg gliclazide acute plasma glucose concentration clamp baseline value week treatment week week treatment plasma glucose concentration clamp sampling value baseline assessment weeks elevated serum insulin concentration time series analyze deconvolution approximate entropy apen spectral autocorrelation method quantitate pulsatility regularity p value give gliclazide versus placebo result mean se fast plasma glucose reduce gliclazide treatment baseline vs week gliclazide vs mmol l placebo vs mmol l p insulin secretory burst mass increase baseline vs acute gliclazide vs pmol l pulse placebo vs pmol l pulse p weeks elevated gliclazide vs placebo vs pmol l pulse p similar rise burst amplitude basal e nonoscillatory insulin secretion also increase baseline vs acute gliclazide vs pmol l pulse placebo vs pmol l pulse p weeks elevated gliclazide vs placebo vs pmol l pulse p frequency regularity insulin pulse modify significantly antidiabetic therapy however correlation individual value acute improvement regularity measure apen decrease fast plasma glucose short term week gliclazide treatment r p r p fine coarse apen respectively conclusion sulfonylurea agent gliclazide augments insulin secretion concurrently increase pulse mass basal insulin secretion without change secretory burst frequency regularity data suggest possible relationship improvement short term glycemic control acute improvement regularity vivo insulin release process,Juhl CB,2001,Diabetes,https://doi.org/10.2337/diabetes.50.8.1778,11473038,Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D002096: C-Peptide; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D019277: Entropy; D005230: Fatty Acids, Nonesterified; D005907: Gliclazide; D005934: Glucagon; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D008875: Middle Aged; D010919: Placebos; D011446: Prospective Studies; D013997: Time Factors",,,https://openalex.org/W2116253955,123,18,1,3130,634,27,en,en
true,utilization oral hypoglycemic agent drug insured u population,clinical trial provide information regard safety efficacy medication use manage type diabetes elucidate drug effectiveness typical manage care environment aim study characterize real world drug utilization pattern prescriber patient perspective conduct retrospective analysis large administrative pharmacy claim database use data continuously pharmacy benefit eligible member prescribe oral hypoglycemic agent ohas month persistence rate oha cohort low range alpha glucosidase inhibitor metformin compliance rate vary first month therapy patient remain therapy month one therapy modification mean number therapy change increase length patient follow half patient experience least one therapy change duration follow finding document wide variation utilization pattern associate pharmacological management type diabetes suggest opportunity exist optimize pharmacological management,Boccuzzi SJ,2001,Diabetes Care,https://doi.org/10.2337/diacare.24.8.1411,11473078,Boccuzzi SJ; Wogen J; Fox J; Sung JC; Shah AB; Kim J,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D002219: Carbamates; D002839: Chromans; D015331: Cohort Studies; D019992: Databases as Topic; D003924: Diabetes Mellitus, Type 2; D004791: Enzyme Inhibitors; D065089: Glycoside Hydrolase Inhibitors; D006801: Humans; D007004: Hypoglycemic Agents; D007356: Insurance, Pharmaceutical Services; D008137: Longitudinal Studies; D008329: Managed Care Programs; D008687: Metformin; D010880: Piperidines; D012189: Retrospective Studies; D013453: Sulfonylurea Compounds; D013844: Thiazoles; D045162: Thiazolidinediones; D013997: Time Factors; D000077288: Troglitazone; D014481: United States",,,https://openalex.org/W2169735327,73,10,1,1224,196,4,en,en
false,hypoglycemic treatment type diabetes,hyperglycaemia type diabetes result reduced beta cell function insulin resistance treatment type diabetes must target condition reduce symptom hyperglycaemia risk diabetic late complications review cover recent scientific documentation long term study treatment effect also discuss different treatment available recent clinical trial show lower blood glucose level time significantly reduce development microvascular complication type diabetes several treatment option available make adequate blood glucose control possible patient type diabetes reduction development microvascular complication type diabetes achievable goal,Thorsby P,2000,Tidsskr Nor Laegeforen,,11475233,Thorsby P; Kilhovd B; Sletmo R; Martinsen S; Birkeland KI,article,D004740: English Abstract; D016428: Journal Article; D016454: Review,"D001786: Blood Glucose; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D003927: Diet, Diabetic; D004359: Drug Therapy, Combination; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007333: Insulin Resistance; D012016: Reference Values",,,https://openalex.org/W2411776094,44,9,1,806,118,4,en,en
true,pharmacokinetics pharmacodynamics dose response relationship repaglinide type diabetes,background pharmacodynamics dose response relationship repaglinide novel oral hypoglycemic agent evaluate steady state treatment patient type diabetes method efficacy repaglinide mg mg mg mg mg compare placebo double blind randomize parallel group week dose response clinical trial patient repaglinide administer minute meal breakfast lunch dinner efficacy repaglinide therapy assess measure change baseline mean level blood glucose bgmean fast serum glucose fsg mean level serum insulin insmean result blood concentration repaglinide proportional dose administer insmean value increase repaglinide treatment group mu u ml dos repaglinide significantly decrease value bgmean fsg compare placebo group bgmean value stabilize second third week repaglinide treatment well defined dose response relationship observe bgmean fsg value dos repaglinide well tolerate serious adverse event conclusion finding show therapeutic reduction serum glucose level produce repaglinide dose dependent mg dose range dos repaglinide test effective well tolerate patient type diabetes,Strange P,1999,Diabetes Technol Ther,https://doi.org/10.1089/152091599317143,11475269,Strange P; Schwartz SL; Graf RJ; Polvino W; Weston I; Marbury TC; Huang WC; Goldberg RB,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001786: Blood Glucose; D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005006: Ethnicity; D005215: Fasting; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D010880: Piperidines; D010919: Placebos; D014481: United States",,,https://openalex.org/W1969061933,100,13,1,1477,258,12,en,en
false,pharma clinics medication month repaglinide novonorm,repaglinide novonorm antidiabetic oral agent new glinide class insulinotropic activity action insulin secretion rapid short sulphonylurea compound thanks property repaglinide able better control postprandial hyperglycaemia associate low risk delayed hypoglycaemic episode indicate treatment type non insulin dependent diabetes mellitus monotherapy diet failure combination metformin biguanide insufficient novonorm commercialize tablet mg take meal initial dosis mg meal diabetic patient diet alone mg meal patient already receive hypoglycaemic agent necessary dosis progressively increase depend individual response mg meal maximal daily dosage mg order optimize blood glucose control,Scheen AJ,2001,Rev Med Liege,,11496727,Scheen AJ,article,D004740: English Abstract; D016428: Journal Article,"D000284: Administration, Oral; D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D006801: Humans; D007004: Hypoglycemic Agents; D010880: Piperidines; D019518: Postprandial Period",,,https://openalex.org/W169739665,66,14,3,1002,179,7,en,en
false,difference pharmacotherapy glucose control type diabetes patient two neighbouring town longitudinal population based study,compare prescribing dosage blood glucose level patient type diabetes two community difference anti hyperglycaemic drug utilization retrospective longitudinal population based study two neighbour town southern sweden mean prescribed daily dose express fraction defined daily dose ddd drug town prescribing oral agent insulin predominantly make one specialized diabetes clinician town b spread among several different general practitioner one specialist altogether medical visit patient identify town patient treat without anti hyperglycaemic drug oral agent insulin however pronounced town difference dosage glucose control mean prescribed daily dose sulphonylurea monotherapy decrease gradually approximately approximately ddd town b remain approximately ddd town proportion patient sulphonylurea metformin increase substantially town town b patient mean prescribed daily dose sulphonylurea exceed ddd town although decrease time town b mean prescribed daily dose insulin increase ddd town remain virtually unchanged ddd town b mean fasting blood glucose low town town b overall vs mmol l treat without anti hyperglycaemic drug vs mmol l sulphonylurea monotherapy vs mmol l treat insulin vs mmol l glucose control routine care well patient treat diabetes specialist expose intense pharmacotherapy,Olsson J,2001,Diabetes Obes Metab,https://doi.org/10.1046/j.1463-1326.2001.00110.x,11520304,Olsson J; Lindberg G; Gottsäter M; Lindwall K; Sjöstrand A; Tisell A; Melander A,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001786: Blood Glucose; D002747: Chlorpropamide; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005913: Glipizide; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008137: Longitudinal Studies; D008297: Male; D012189: Retrospective Studies; D013548: Sweden; D013997: Time Factors; D014505: Urban Population",,,https://openalex.org/W1983809431,146,21,1,1905,334,10,en,en
false,repaglinide potentially therapeutic improvement diabetes mellitus type,type diabetes patient good diabetes control attainable oral blood glucose lowering drug furthermore many people diabetes disease deteriorate despite use blood glucose lower medication due decline pancreatic beta cell development new drug repaglinide therefore important repaglinide insulin secretion enhancer different mechanism action sulphonylureas mean continuously stimulate insulin secretion tablet take meal oral ingestion repaglinide resorbed quickly half life minute hour clinical trial repaglinide find equally effective glibenclamide repaglinide find particularly effective sulphonylurea na patient skip meal plus tablet combination result less frequent hypoglycaemic symptom compare glibenclamide repaglinide result great reduction postprandial glucose level glibenclamide affect insulin resistance long term data lack regard efficacy side effect repaglinide deserve place diabetes treatment newly diagnosed type diabetes patient well informed disease well patient renal failure also consider patient whose diabetes poorly control metformin monotherapy,Rutten GE,2001,Ned Tijdschr Geneeskd,,11525087,Rutten GE,article,D016428: Journal Article; D016454: Review,"D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005905: Glyburide; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D008687: Metformin; D010880: Piperidines; D013810: Therapeutic Equivalency",,,https://openalex.org/W2417003911,82,14,1,1477,240,14,en,en
false,effect improved glycaemic control endothelial function patient type diabetes,patient type diabetes abnormal endothelial function certain whether improvement glycaemic control improve endothelial function examine effect short term improved glycaemic control endothelial function patient inadequately regulate type diabetes mellitus forty three patient type diabetes glycosylated haemoglobin hba c randomize either improved glycaemic control ic n usual glycaemic control uc n week use high resolution b mode ultrasound brachial artery flow mediated dilatation fmd glyceryl trinitrate mediated dilatation gtn measure baseline week later week hba c significantly low ic versus uc ic versus uc p change fmd gtn different group fmd baseline week ic versus uc versus p gtn ic versus uc versus p ic group weight increase kg week compare kg uc p blood pressure serum lipid concentration change either group short term reduction hba c level appear affect endothelial function patient type diabetes previously poorly regulate glycaemic control,Bagg W,2001,Intern Med J,https://doi.org/10.1046/j.1445-5994.2001.00072.x,11529585,Bagg W; Whalley GA; Gamble G; Drury PL; Sharpe N; Braatvedt GD,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D001916: Brachial Artery; D003924: Diabetes Mellitus, Type 2; D004730: Endothelium, Vascular; D005260: Female; D005913: Glipizide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D005996: Nitroglycerin; D013997: Time Factors; D016896: Treatment Outcome; D014463: Ultrasonography",,,https://openalex.org/W2150407995,94,14,1,1470,276,4,en,en
false,objetivos estrategia terap utica en la diabetes mellitus tipo,united kingdom prospective diabetes study ukpds demonstrate definitively patient type diabetes mellitus dm benefit intensive blood glucose control diminish risk develop microvascular complication therapeutic target type dm modify order reduce risk complication however aggressive treatment may disastrous patient microvascular complication increase risk hypoglycemic unawareness neither would advise old patient short life expectancy available drug treatment type dm offer many option achieve therapeutic target base need individual patient job review target metabolic control type dm background describe briefly therapeutic strategy recommend reach target special attention new oral antidiabetic agent repaglinide thiazolidinediones,Calvo Romero JM,2001,An Med Interna,https://doi.org/10.4321/s0212-71992001000700010,11534426,Calvo Romero JM; Lima Rodríguez EM,article,D004740: English Abstract; D016428: Journal Article; D016454: Review,"D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D006801: Humans; D006946: Hyperinsulinism; D007004: Hypoglycemic Agents; D007333: Insulin Resistance; D010880: Piperidines; D013844: Thiazoles",,,https://openalex.org/W2032661550,65,10,1,1019,168,5,es,en
false,endothelial dysfunction type diabetes part alter endothelial function effect treatment type diabetes mellitus,coronary artery cerebrovascular peripheral vascular disease principal cause morbidity mortality type diabetes mellitus accelerated macrovascular disease type diabetes mellitus due partly increase incidence cardiovascular risk factor hypertension obesity dyslipidemia advanced glycation end product glycoxidised oxidize low density lipoprotein reactive oxygen specie link hyperglycemia identify type diabetes mellitus could accelerate macroangiopathy hence resistance insulin additional independent risk factor association oxidant stress dyslipidemias prothrombic hypofibrinolytic state endothelium major organ involve cardiovascular risk factor hypercholesterolemia hypertension inflammation age postmenopausal status smoking change endothelium function may lead coronary artery circulation unable cope increased metabolism myocardial muscle independently reduced coronary artery diameter way endothelial function alter diabetic patient yet fully understood loss normal endothelial function could involve pathogenesis diabetic angiopathy endothelial dysfunction associate diabetic microangiopathy macroangiopathy finally recent report indicate improved metabolic control diabetic patient whatever treatment use associate near normalization restoration normal endothelial function,Guerci B,2001,Diabetes Metab,,11547217,Guerci B; Böhme P; Kearney-Schwartz A; Zannad F; Drouin P,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D003927: Diet, Diabetic; D004730: Endothelium, Vascular; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D018384: Oxidative Stress",,,https://openalex.org/W277842572,140,24,2,1596,240,8,en,en
false,intramuscular injection insulin lispro soluble human insulin pharmacokinetics glucodynamics type diabetes,abstract aim aim study compare pharmacokinetics glucodynamics insulin lispro soluble human insulin follow intramuscular injection patient type diabetes secondary failure sulphonylureas method single u dos insulin lispro soluble human insulin administer patient two way randomize crossover design glucodynamic pharmacokinetic parameter determine h insulin injection use clamp technique result insulin c max significantly high vs pmol l p max significantly short vs min p insulin lispro glucose infusion rate gir curve show clear separation min injection significantly great insulin lispro minute time interval total glucose infuse approximately large insulin lispro h follow due lower insulinaemia late time point glucose r max tr max statistically different insulin treatment conclusion study show injection insulin lispro follow rapid absorption result strong metabolic effect first h compare soluble human insulin test condition diabet med,Milicevic Z,2001,Diabet Med,https://doi.org/10.1046/j.1464-5491.2001.00522.x,11553186,Milicevic Z; Profozic V; Wyatt J; Ristic S; Woodworth JR; Seger M; Kaliterna D; Bates P; Metelko Z,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D001786: Blood Glucose; D015992: Body Mass Index; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007273: Injections, Intramuscular; D007328: Insulin; D061268: Insulin Lispro; D016018: Least-Squares Analysis; D008875: Middle Aged",,,https://openalex.org/W1996687073,121,17,1,1411,254,14,en,en
true,beta cell function evaluate homa predictor secondary sulphonylurea failure type diabetes,secondary failure oral hypoglycaemic agent common evolution long standing type diabetes usually assess non standardized index require fine clinical assessment include hyperglycaemia resistant maximum dos sulphonylureas despite appropriate diet follow goal study evaluate homa modelized plasma insulin glucose ratio allow simple evaluation residual insulin secretion sensitivity good predictor insulin require stage clinical indices homa measure type diabetic patient age sd year diabetes duration year hospitalize hyperglycaemia resistant maximal dos sulphonylureas e g glibenclamide mg day apparent external reason hyperglycaemia despite reinforced appropriate diet recommendation patient remain hyperglycaemic insulin requiring group age duration diabetes body mass index bmi homa value insulin sensitivity vs normal value comparable two group hba c high vs p homa insulin secretion value low vs normal value p insulin requiring group following potential predictor hba c duration diabetes year hba c combine diabetes duration insulin sensitivity insulin secretion latter show best positive predictivity patient low insulin secretion insulin requiring homa simple good predictor insulin requiring stage type diabetes mellitus ii stage diabetes characterize decline insulin secretion rather insulin sensitivity diabet med,Taverna MJ,2001,Diabet Med,https://doi.org/10.1046/j.1464-5491.2001.00534.x,11553190,Taverna MJ; Pacher N; Bruzzo F; Slama G; Selam JL,article,D016428: Journal Article,"D015415: Biomarkers; D001786: Blood Glucose; D002138: Calibration; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007328: Insulin; D000078790: Insulin Secretion; D007515: Islets of Langerhans; D008297: Male; D008875: Middle Aged; D011237: Predictive Value of Tests; D012680: Sensitivity and Specificity; D013453: Sulfonylurea Compounds; D017211: Treatment Failure",,,https://openalex.org/W2049927786,105,16,1,1873,359,10,en,en
false,review rosiglitazone type diabetes mellitus,thiazolidinedione rosiglitazone maleate work primarily improve insulin sensitivity muscle adipose tissue may additional pharmacologic effect however main target peroxisome proliferator activated receptor data use homeostasis model assessment proinsulin insulin ratio patient type diabetes mellitus suggest rosiglitazone may potential sustain improve cell function patient drug reduce fast plasma glucose glycosylated hemoglobin insulin c peptide clinical trial rosiglitazone monotherapy significantly reduce glycosylated hemoglobin compare placebo lead significant improvement glycemic control give combination metformin sulfonylurea insulin dosage mg twice day significantly reduce fast plasma glucose level produce comparable reduction glycosylated hemoglobin compare glyburide rosiglitazone low risk gastrointestinal side effect hypoglycemia reduce insulin demand potential sparing effect cells favorable drug interaction profile adverse event clinical significance edema anemia weight gain premarketing data indicate significant difference liver enzyme elevation rosiglitazone placebo active control another drug thiazolidinedione class troglitazone associate idiosyncratic hepatotoxicity remove market therefore long term data available rosiglitazone liver enzyme monitoring recommend,Werner AL,2001,Pharmacotherapy,https://doi.org/10.1592/phco.21.13.1082.34615,11560198,Werner AL; Travaglini MT,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D004347: Drug Interactions; D006801: Humans; D007004: Hypoglycemic Agents; D000077154: Rosiglitazone; D013844: Thiazoles; D045162: Thiazolidinediones",,,https://openalex.org/W2111938066,53,9,1,1600,241,11,en,en
true,effect food oral bioavailability pharmacodynamic action insulinotropic agent nateglinide healthy subject,nateglinide starlix sdz djn new insulinotropic agent intend administer prior meal order improve early insulin release non insulin dependent diabetes mellitus patient effect meal oral bioavailability pharmacodynamic action nateglinide investigate twelve healthy male subject complete randomize single dose four way crossover study subject receive mg dose nateglinide minute start immediately high fat breakfast meal addition subject receive single mg dose nateglinide underfasting condition plasma urine concentration nateglinide determine hplc method plasma glucose insulin concentration measure standard immunoassay method compare fasted state administration nateglinide minute meal associate increase rate absorption increase cmax decrease tmax significant effect extent absorption auc alternatively nateglinide give meal food effect observe characterize decrease rate absorption decrease cmax increase tmax significant effect auc nateglinide rapidly eliminate plasma hour plasma renal clearance ml min appear due mostly active tubular secretion however dose recover nateglinide urine mg tablet dose proportional term auc cmax tmax dose independent regardless timing combination meal nateglinide produce large increase insulin level nateglinide alone meal related glucose excursion eliminate nateglinide take prior meal thus rapid onset short duration stimulation insulin release nateglinide allow good control prandial hyperglycemia limit exposure hyperinsulinemia,Karara AH,1999,J Clin Pharmacol,https://doi.org/10.1177/00912709922007606,11563410,Karara AH; Dunning BE; McLeod JF,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D000704: Analysis of Variance; D001682: Biological Availability; D001786: Blood Glucose; D018592: Cross-Over Studies; D003510: Cyclohexanes; D004041: Dietary Fats; D005215: Fasting; D018565: Food-Drug Interactions; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D000077715: Nateglinide; D010649: Phenylalanine",,,https://openalex.org/W2009455605,138,20,1,2109,372,14,en,en
false,clx calyx therapeutic,calyx therapeutic develop insulin sensitizer clx antidiabetic agent clx synthetic analog clx originally isolate plant source phase toxicological study indicate compound safe well tolerate march phase ii study commence antidiabetic investigate calyx include clx clx clx clx clx,Barlocco D,2001,Curr Opin Investig Drugs,,11569941,Barlocco D,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D002986: Clinical Trials as Topic; D000075202: Contraindications; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D007333: Insulin Resistance; D013267: Stilbenes; D013329: Structure-Activity Relationship",,,https://openalex.org/W2465333128,30,6,1,463,83,5,en,en
true,insulin glucose excursion follow premeal insulin lispro repaglinide cystic fibrosis related diabetes,insulin glucose level response premeal insulin lispro repaglinide evaluate adult patient cystic fibrosis related diabetes cfrd without fast hyperglycemia seven patient cfrd feed kcal liquid mixed meal three study condition administer random order separate morning premeal diabetes medication insulin lispro unit kg body wt premeal repaglinide mg premeal glucose insulin level measure every min h fasting insulin glucose level normal patient cfrd peak glucose level elevate insulin lispro significantly decrease peak glucose level p h p h p glucose area curve auc repaglinide significantly decrease h glucose auc p neither drug completely normalize cystic fibrosis glucose excursion dos use study insulin lispro significantly increase h insulin auc p response subcutaneous insulin lispro postprandial glucose excursion significantly diminish insulin secretion enhance compare control meal medication give patient cfrd oral agent repaglinide result lesser correction parameter neither drug completely normalize glucose insulin level suggest dos choose study suboptimal placebo controlled longitudinal study compare effectiveness repaglinide insulin glucose metabolic control well overall nutrition body weight need help determine optimal medical treatment cfrd,Moran A,2001,Diabetes Care,https://doi.org/10.2337/diacare.24.10.1706,11574430,Moran A; Phillips J; Milla C,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D001786: Blood Glucose; D002219: Carbamates; D003550: Cystic Fibrosis; D003920: Diabetes Mellitus; D005260: Female; D005502: Food; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D061268: Insulin Lispro; D008297: Male; D010880: Piperidines,,,https://openalex.org/W2082563297,113,14,1,1679,283,10,en,en
false,postchallenge hyperglycemia national sample u adult type diabetes,postchallenge hyperglycemia pch know contribute suboptimal glycemic control adult non insulin requiring type diabetes objective study estimate prevalence pch among individual diabetes conduct cross sectional analysis data third national health nutrition examination survey adult age year diabetes use insulin e use oral hypoglycemics receive pharmacological therapy respondent undergo standard g oral glucose tolerance test pch define h glucose level mg dl overall pch present diagnosed diabetes although present virtually diabetic adult suboptimal glycemic control hba c pch also common among optimal control hba c likewise among sulfonylurea user pch present suboptimal control good control similar pattern observe undiagnosed diabetes isolate pch h glucose mg dl fast glucose mg dl present adult diagnosed diabetes data suggest pch common among diabetic adult u even setting optimal glycemic control sulfonylurea use intervention design lower postprandial glucose excursion may help improve overall glycemic control general population u adult diabetes,Erlinger TP,2001,Diabetes Care,https://doi.org/10.2337/diacare.24.10.1734,11574434,Erlinger TP; Brancati FL,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D003430: Cross-Sectional Studies; D003924: Diabetes Mellitus, Type 2; D005215: Fasting; D005502: Food; D005951: Glucose Tolerance Test; D006442: Glycated Hemoglobin; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D007700: Kinetics; D008875: Middle Aged; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2170897377,84,14,2,1536,281,9,en,en
true,repaglinide,repaglinide carbamoylmethyl benzoic acid derivative first new class oral antidiabetic agent design normalise postprandial glucose excursion patient type diabetes mellitus like sulphonylureas repaglinide reduces blood glucose stimulate insulin release pancreatic beta cells differs antidiabetic agent structure bind profile duration action mode excretion clinical trial year duration repaglinide maintain improved glycaemic control patient type diabetes mellitus comparative year double blind randomised trial n patient receive repaglinide mg daily meal achieve similar glycaemic control patient receive glibenclamide glyburide mg day great control patient receive glipizide mg day change baseline glycosylated haemoglobin fast blood glucose level similar patient receive repaglinide glibenclamide study however repaglinide slightly good glibenclamide reduce postprandial blood glucose short term study n patient vary meal timetable repaglinide glucose lowering efficacy repaglinide similar patient consume meal day repaglinide show additive effect use combination oral antidiabetic agent include metformin troglitazone rosiglitazone pioglitazone intermediate acting insulin nph give bedtime year trial common adverse event report repaglinide recipient n hypoglycaemia upper respiratory tract infection rhinitis bronchitis headache overall incidence hypoglycaemia similar record patient receive glibenclamide glipizide gliclazide n however incidence serious hypoglycaemia appear slightly high sulphonylurea recipient unlike glibenclamide risk hypoglycaemia patient receive repaglinide increase meal miss trial conclusion repaglinide useful addition currently available treatment type diabetes mellitus preprandial repaglinide display antihyperglycaemic efficacy least equal various sulphonylureas associate reduced risk serious hypoglycaemia well tolerate wide range patient include elderly even meal miss furthermore glycaemic control improve repaglinide use combination metformin thus repaglinide consider use patient type diabetes mellitus whose blood glucose control diet exercise alone adjunct patient whose glucose level inadequately control metformin alone,Culy CR,2001,Drugs,https://doi.org/10.2165/00003495-200161110-00008,11577798,Culy CR; Jarvis B,article,D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D000328: Adult; D000368: Aged; D000375: Aging; D000818: Animals; D001682: Biological Availability; D001786: Blood Glucose; D002219: Carbamates; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004347: Drug Interactions; D006442: Glycated Hemoglobin; D006207: Half-Life; D006801: Humans; D007004: Hypoglycemic Agents; D007408: Intestinal Absorption; D008657: Metabolic Clearance Rate; D010880: Piperidines",,,https://openalex.org/W2027974633,11,1,1,2957,509,15,en,en
true,nateglinide new rapid acting insulinotropic agent,united kingdom prospective diabetes study show tight glycaemic control significantly reduce microvascular complication type diabetes effect macrovascular complication less impressive reach statistical significance epidemiological study show post prandial hyperglycaemia rather fast hyperglycaemia closely relate cardiovascular complication therefore possible previous study may overlook possible benefit tight control post prandial hyperglycaemia important factor reduce cardiovascular mortality nateglinide novel phenylalanine derivative inhibit atp sensitive k channel pancreatic beta cells presence glucose thereby restores first phase insulin response patient type diabetes help reduce post prandial glucose excursion combination study metformin show effective control hyperglycaemia metformin reduce basal plasma glucose nateglinide help control post prandial peak nateglinide provide new therapeutic option treat type diabetes specifically target post prandial hyperglycaemia,Hanif W,2001,Expert Opin Pharmacother,https://doi.org/10.1517/14656566.2.6.1027,11585005,Hanif W; Kumar S,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D002986: Clinical Trials as Topic; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D017408: Guidelines as Topic; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D008687: Metformin; D008833: Microcirculation; D015394: Molecular Structure; D000077715: Nateglinide; D010649: Phenylalanine; D019518: Postprandial Period",,,https://openalex.org/W2104235401,52,7,1,1247,176,8,en,en
true,glibenclamide improve postprandial hypertriglyceridaemia type diabetic patient reduce chylomicron low density lipoprotein subfraction level,scarce data deal degree postprandial lipaemia sulphonylurea administration aim study examine effect acute glibenclamide administration postprandial lipaemia type diabetic patients eight randomly select type diabetic individual age year mean year never receive anti diabetic drug include study patient give kcal mixed meal fat carbohydrate protein twice separate day overnight fast placebo mg glibenclamide per random order two test perform interval day venous blood sample draw h h h meal consumption total triglyceride level plasma chylomicron cm cm deficient plasma low density lipoprotein vldl subfractions vldl vldl intermediate density lipoprotein idl determine free fatty acid ffa total cholesterol level plasma well high density lipoprotein hdl cholesterol low density lipoprotein ldl cholesterol level cm deficient plasma also measure finally serum glucose insulin c peptide concentration measure sample expect significant decrease postprandial glycaemia glibenclamide administration compare placebo mean area curve value auc mm h p addition mean auc value insulin c peptide significantly great drug administration auc value total plasma triglyceride cm triglyceride follow glibenclamide administration significantly low compare placebo auc value postprandial triglyceride cm deficient plasma postprandial triglyceride vldl vldl idl different drug administration compare placebo finally significant difference note auc value total cholesterol ldl cholesterol hdl cholesterol plasma ffa level glibenclamide administration result demonstrate glibenclamide administration improve postprandial hypertriglyceridaemia acutely reduce postprandial triglyceride intestinal origin,Skrapari I,2001,Diabet Med,https://doi.org/10.1046/j.1464-5491.2001.00538.x,11678967,Skrapari I; Perrea D; Ioannidis I; Karabina SA; Elisaf M; Tselepis AD; Karagiannacos P; Katsilambros N,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D019540: Area Under Curve; D001786: Blood Glucose; D002096: C-Peptide; D002784: Cholesterol; D002914: Chylomicrons; D003327: Coronary Disease; D003924: Diabetes Mellitus, Type 2; D005230: Fatty Acids, Nonesterified; D005905: Glyburide; D006801: Humans; D015228: Hypertriglyceridemia; D007004: Hypoglycemic Agents; D007328: Insulin; D008079: Lipoproteins, VLDL; D008875: Middle Aged; D019518: Postprandial Period; D014280: Triglycerides",,,https://openalex.org/W2022069451,170,20,1,2319,392,11,en,en
true,improve glycaemic control addition glimepiride metformin monotherapy type diabetic patient,compare effect glimepiride combination metformin monotherapy drug glycaemic control type diabetic patients randomized double blind double dummy parallel group multicentre study conduct france type diabetic patient age year inadequately control metformin monotherapy mg daily least week randomize either metformin glimepiride metformin glimepiride three hundred seventy two patient age year treat month combination treatment significantly efficient control hba c change metformin glimepiride combination treatment p fast blood glucose fbg mmol l change metformin glimepiride combination treatment p post prandial blood glucose ppbg mmol l change metformin glimepiride combination treatment p either glimepiride metformin alone significant difference metformin glimepiride monotherapy respect change hba c fbg however glimepiride significantly effective metformin reduce ppbg incidence symptomatic hypoglycaemia higher combination group either monotherapy group p addition glimepiride metformin type diabetic patient inadequately control metformin alone result superior glycaemic control compare glimepiride metformin monotherapy,Charpentier G,2001,Diabet Med,https://doi.org/10.1046/j.1464-5491.2001.00582.x,11678974,Charpentier G; Fleury F; Kabir M; Vaur L; Halimi S,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D015992: Body Mass Index; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D008875: Middle Aged; D012107: Research Design; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2138470202,106,15,1,1637,276,5,en,en
true,effect sibutramine obese female subject type diabetes poor blood glucose control,study evaluate efficacy sibutramine combination hypoglycemic drug obese type diabetic woman whose glucose level poorly regulated female patient type diabetes poorly control glucose level hba c randomly assign one two group addition prescribed hypoglycemic agent maximum dos sulfonylurea metformin one group n receive placebo twice daily month n receive sibutramine mg b period one patient sibutramine group exclude study period hypertension thus total data set analyze group placebo group five patient exclude low treatment efficacy leave total complete study compare change occur month sibutramine placebo group former show significantly great reduction fast blood glucose p second hour postprandial blood glucose p insulin resistance p waist circumference p bmi p hba c p diastolic blood pressure pulse rate uric acid level element lipid profile except hdl cholesterol apolipoprotein addition sibutramine oral hypoglycemic therapy result significant weight loss improvement metabolic parameter patient group sibutramine effective adjunct oral hypoglycemic therapy obese woman type diabetes,Gokcel A,2001,Diabetes Care,https://doi.org/10.2337/diacare.24.11.1957,11679464,Gokcel A; Karakose H; Ertorer EM; Tanaci N; Tutuncu NB; Guvener N,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D001067: Appetite Depressants; D001786: Blood Glucose; D002784: Cholesterol; D003503: Cyclobutanes; D003920: Diabetes Mellitus; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005215: Fasting; D005260: Female; D005913: Glipizide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008687: Metformin; D009765: Obesity; D010919: Placebos; D013453: Sulfonylurea Compounds; D014280: Triglycerides; D015431: Weight Loss",,,https://openalex.org/W1983356415,99,16,1,1573,297,6,en,en
false,genetic variability sur promoter relation beta cell function type ii diabetes mellitus,aim examine promoter sur genetic variation determine variant associate type ii non insulin dependent diabetes mellitus measure beta cell function examine bp upstream atg site type ii diabetic patient glucose tolerant control subject sscp heteroduplex analysis identify substitution bp upstream atg site allelic frequency similar unrelated type ii diabetic patient glucose tolerant control subject match age ci v ci p among glucose tolerant subject difference non carriers n carrier n variant fast value min value plasma glucose serum insulin oral glucose tolerance test study glucose tolerant offspring spouse danish caucasian type ii diabetic patient non carriers n carrier n polymorphism differ glucose tolbutamide stimulate insulin response intravenous glucose tolerance test intravenous tolbutamide injection aucs insulin min v pmol l min aucs insulin min vs pmol l min respectively identify novel polymorphism sur gene promoter associate type ii diabetes mellitus measure beta cell function previous report non functional variant sur associate type ii diabetes mellitus still need account diabetologia,Hansen T,2001,Diabetologia,https://doi.org/10.1007/s001250100651,11692183,Hansen T; Ambye L; Grarup N; Hansen L; Echwald SM; Ferrer J; Pedersen O,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D018528: ATP-Binding Cassette Transporters; D000328: Adult; D000368: Aged; D000483: Alleles; D001786: Blood Glucose; D002096: C-Peptide; D004252: DNA Mutational Analysis; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005787: Gene Frequency; D014644: Genetic Variation; D005951: Glucose Tolerance Test; D006801: Humans; D007328: Insulin; D007515: Islets of Langerhans; D007700: Kinetics; D008297: Male; D008875: Middle Aged; D011110: Polymorphism, Genetic; D018807: Polymorphism, Single-Stranded Conformational; D015221: Potassium Channels; D024661: Potassium Channels, Inwardly Rectifying; D011401: Promoter Regions, Genetic; D011955: Receptors, Drug; D064233: Sulfonylurea Receptors; D014044: Tolbutamide",,,https://openalex.org/W2065354183,104,16,1,1670,313,9,en,en
false,thiazolidinediones new class oral antidiabetic,two member group thiazolidinediones approve treatment type diabetes mellitus novel oral antihyperglycaemic agent reduce insulin resistance bind activation nuclear receptor ppar gamma subsequent effect glucose lipid homoeostasis compound probably exhibit beneficial effect facet metabolic syndrome effectiveness glycaemic control appear comparable assess literature available hba c lower drug approve combination therapy either metformin sulphonylureas monotherapy combination insulin disturbed heart function nyha iv contra indication contrast troglitazone far evidence liver toxicity spite limited literature anticipate present class oral hypoglycaemic agent turn important contribution improve metabolic control patient type diabetes safety profile remain unchanged long term study,Schmitz OE,2001,Ugeskr Laeger,,11715152,Schmitz OE; Brock B; Madsbad S; Beck-Nielsen H,article,D004740: English Abstract; D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D007333: Insulin Resistance; D018160: Receptors, Cytoplasmic and Nuclear; D013844: Thiazoles",,,https://openalex.org/W2408724544,56,11,1,1107,186,9,en,en
false,medical care childhood adulthood type type diabetes,diabetes mellitus comprise heterogeneous group disease common development macro microvascular complication possible identify subject high risk type type diabetes especially patient family member preventive intervention quickly become available help delay onset disease thereby reduce complication subject furthermore correct etiological diagnosis diabetes fundamental provide best treatment patient maturity onset diabetes young mody syndrome suspect case subtle onset diabetes autosomal dominant inheritance mitochondrial dna mutation consider diabetic patient also suffer deafness family history combination mother side family atypical diabetes identify physician avoid mistake patient enter non insulin dependent phase case wolfram syndrome gene analysis family member perform identify heterozygote subject recently many discovery genetics help u good understand pathogenesis disease diagnose monogenic form diabetes easily family member follow center clue family history readily available differential diagnosis preventive intervention establish effectively,Costi G,2001,J Endocrinol Invest,https://doi.org/10.1007/bf03343914,11716156,Costi G; Ten S; Maclaren NK,article,D016428: Journal Article; D016454: Review,"D000293: Adolescent; D000328: Adult; D001323: Autoantibodies; D002648: Child; D002675: Child, Preschool; D004272: DNA, Mitochondrial; D003922: Diabetes Mellitus, Type 1; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007223: Infant; D007231: Infant, Newborn",,,https://openalex.org/W2009857406,70,13,1,1490,243,10,en,en
false,prescribe pattern therapeutic implication diabetic hypertension bahrain,determine drug prescription pattern extent conformity world health organization international society hypertension ish guideline diabetic hypertension retrospective prescription based survey seven primary care health center comprise approximately one third primary care health center bahrain patients type diabetes hypertension prescribing pattern antihypertensive antidiabetic drugs among study sample patient type diabetes hypertension antidiabetic agent prescribe monotherapy following descending order glyburide gliclazide insulin metformin combination sulfonylureas plus metformin popular follow metformin plus insulin sulfonylureas plus insulin sulfonylurea metformin insulin rarely use significant difference prescribing glyburide metformin elderly young middle aged diabetic patient many patient old year treat beta blocker along long acting sulfonylurea monotherapy overall use beta blockers angiotensin converting enzyme ace inhibitor calcium channel blocker often prescribe among patient treat antihypertensive combination various two three drug combination beta blockers ace inhibitor calcium channel blocker diuretic often use proportion patient take atenolol mg high combination regimen hydrochlorothiazide mg equivalent thiazide diuretic extensively used prescribe pattern antihypertensive diabetic hypertension differs many instance ish guideline especially regard choice antihypertensive drug combination appropriateness antidiabetic drug choice questionable relation antihypertensive use,Al Khaja KA,2001,Ann Pharmacother,https://doi.org/10.1345/aph.10399,11724081,Al Khaja KA; Sequeira RP; Mathur VS,article,D016428: Journal Article,D000319: Adrenergic beta-Antagonists; D000367: Age Factors; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001445: Bahrain; D001581: Benzothiadiazines; D048909: Diabetes Complications; D004232: Diuretics; D004338: Drug Combinations; D011307: Drug Prescriptions; D017723: Drug Utilization Review; D006801: Humans; D006973: Hypertension; D007004: Hypoglycemic Agents; D007328: Insulin; D012189: Retrospective Studies; D049993: Sodium Chloride Symporter Inhibitors,,,https://openalex.org/W2142987171,86,10,1,1931,272,9,en,en
true,nateglinide therapy type diabetes mellitus,review pharmacology pharmacokinetics dose guideline adverse effect drug interaction clinical efficacy nateglinide primary review article regard nateglinide identify medline search january abstract identify institute scientific information web science january american diabetes association additional information obtain nateglinide product information article meet abstract identify data source evaluate information deem relevant include review much information abstract product labeling since clinical study publish medical literature nateglinide novel nonsulfonylurea oral antidiabetic agent stimulate insulin secretion pancreas rapid onset short duration action allow administration meal reduce postprandial hyperglycemia improvement glycemic control nateglinide monotherapy demonstrate patient previously treat antidiabetic medication great improvement glycemic control observe nateglinide administer combination metformin nateglinide similar repaglinide quicker onset action quicker reversal usually require dosage titration base pharmacodynamics nateglinide repaglinide nateglinide produce rapid postprandial increase insulin secretion duration response short repaglinide risk postabsorptive hypoglycemia low either sulfonylurea repaglinide,Levien TL,2001,Ann Pharmacother,https://doi.org/10.1345/aph.1a061,11724096,Levien TL; Baker DE; Campbell RK; White JR,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D002986: Clinical Trials as Topic; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D000077715: Nateglinide; D010649: Phenylalanine",,,https://openalex.org/W2127429233,48,7,1,1730,259,7,en,en
false,glycemic control humalog mix type diabetes inadequately control glyburide,humalog mix mix premixed insulin mixture insulin lispro neutral protamine lispro aim study quantitate improvement glycemic control achieve mix versus maximum dose glyburide gb patient type diabetes inadequately control gb randomize parallel open label comparative study patient type diabetes receive either mix morning evening meal month gb mg daily month glycemic control assess glycosylated hemoglobin hba c measurement point self monitored blood glucose profile patient reported hypoglycemia patient also complete treatment satisfaction questionnaire end study patient white randomize receive mix mean age year men mean body mass index kg mean duration type diabetes year mean duration sulfonylurea treatment year mean hba c fast blood glucose level mmol l respectively glyburide group mmol l respectively mix group statistically significant difference treatment group baseline demographic efficacy variable end point mean hba c significantly low mix group gb group mix gb p large decrease baseline hba c self monitored blood glucose value observe mix group versus hba c p mmol l versus mmol l fast blood glucose p mmol l versus mmol l morning hour postprandial blood glucose p mmol l versus mmol l evening preprandial blood glucose p mmol l versus mmol l evening hour postprandial blood glucose p patient express satisfaction mix gb measure weighted combine score treatment satisfaction questionnaire vs mean hypoglycemia rate event per patient per day significantly high mix group end point mix gb p compared maximum dose gb twice daily injection mix result improved glycemic control treatment satisfaction associate predictably high rate hypoglycemia group patient type diabetes inadequately control maximum dose gb although inclusion patient inadequately control gb intend allow comparison treatment respect efficacy tolerability real life setting double blind comparison treatment naive individual may result different outcome,Roach,2001,Clin Ther,https://doi.org/10.1016/s0149-2918(01)80140-5,11726007,Roach; Koledova E; Metcalfe S; Hultman C; Milicevic Z; Romania/Russia Mix25 Study Group,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D001786: Blood Glucose; D015992: Body Mass Index; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D061268: Insulin Lispro; D008297: Male; D008875: Middle Aged; D011795: Surveys and Questionnaires; D016896: Treatment Outcome",,,https://openalex.org/W2104740506,95,13,1,2996,556,13,en,en
true,insulinotropic meglitinide analogue,loss early phase insulin secretion important early event natural history type diabetes normal pattern insulin secretion essential effective control postprandial metabolism rational basis development agent target early phase insulin release exist conventional oral hypoglycaemic agent target adequately control postprandial glycaemia emergence new class oral agent specific mode action provide first time opportunity restore early phase insulin release one drug class meglitinide analogue repaglinide nateglinide mitiglinide drug ideally suit combination use metformin could also prove effective combination thiazolidinedione drug class target insulin resistance exogenous insulin frequently require late management type diabetes however one hope new combination diabetic drug functional life beta cell extend thereby delay need insulin injection,Dornhorst A,2001,Lancet,https://doi.org/10.1016/s0140-6736(01)06715-0,11728565,Dornhorst A,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D000328: Adult; D000818: Animals; D001549: Benzamides; D002219: Carbamates; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D000077715: Nateglinide; D010649: Phenylalanine; D010880: Piperidines; D051381: Rats",,,https://openalex.org/W2110544725,36,3,1,1124,190,9,en,en
true,orlistat,orlistat nonsystemically act gastric pancreatic lipase inhibitor limit absorption dietary fat retrospective pooled analysis three year double blind randomised placebo controlled trial involve patient obesity reveal orlistat recipient likely experience improvement less likely experience deterioration glucose tolerance status placebo recipient comparison placebo orlistat recipient significantly great reduction glycosylated haemoglobin fast plasma glucose level large double blind randomised placebo controlled study week duration involve patient obesity type diabetes mellitus one study dosage concomitant sulphonylureas able reduce orlistat placebo recipient vs discontinuation sulphonylurea therapy achieve orlistat recipient common adverse effect report orlistat recipient type diabetes mellitus relate gastrointestinal system similar report study involve patient without type diabetes mellitus,Keating GM,2001,Drugs,https://doi.org/10.2165/00003495-200161140-00011,11735640,Keating GM; Jarvis B,article,D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004791: Enzyme Inhibitors; D005767: Gastrointestinal Diseases; D006442: Glycated Hemoglobin; D006801: Humans; D007783: Lactones; D009765: Obesity; D000077403: Orlistat; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome",,,https://openalex.org/W2008615649,8,1,1,1192,185,5,ca,en
false,hepatotoxicity thiazolidinediones,decrease insulin sensitivity play major role various human disease particularly type diabetes mellitus associate high risk atherosclerosis cardiovascular complication thiazolidinediones commonly term glitazones first drug specifically target muscular insulin resistance prove efficacy reduce plasma glucose level patient type diabetes mellitus treat diet alone sulphonylureas metformin insulin addition associate improvement cardiovascular risk profile however troglitazone first compound approve food drug administration u prove hepatotoxic withdraw market report several dozen death case severe hepatic failure require liver transplantation remain unclear whether hepatotoxicity class effect relate unique property troglitazone rosiglitazone pioglitazone two glitazones appear similar efficacy regard blood glucose control patient type diabetes mellitus compare troglitazone controlled clinical trial incidence significant x upper limit normal increase liver enzyme level alt particular similar rosiglitazone pioglitazone compare placebo whereas troglitazone associate fold great incidence contrast numerous case report acute liver failure patient receive troglitzone case report hepatotoxicity report patient treat rosiglitazone causal relationship remain uncertain furthermore single case severe hepatotoxicity report yet pioglitazone mention troglitazone unlike pioglitazone rosiglitazone induce cytochrome p isoform partly responsible metabolism may prone drug interaction importantly enough obesity insulin resistance type diabetes mellitus associate liver abnormality especially non alcoholic steatohepatitis independent pharmacological treatment association obviously complicate selection patient good candidate treatment glitazones well monitoring liver test initiation therapy thiazolidinedione compound regular monitoring liver enzyme still recommend long term data desirable current evidence clinical trial postmarketing experience u support conclusion rosiglitazone pioglitazone share hepatotoxic profile troglitazone,Scheen AJ,2001,Drug Saf,https://doi.org/10.2165/00002018-200124120-00002,11735645,Scheen AJ,article,D016428: Journal Article; D016454: Review,"D000368: Aged; D056486: Chemical and Drug Induced Liver Injury; D002839: Chromans; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D000077205: Pioglitazone; D000077154: Rosiglitazone; D013329: Structure-Activity Relationship; D013844: Thiazoles; D045162: Thiazolidinediones; D000077288: Troglitazone",,,https://openalex.org/W120815510,38,3,1,2743,434,15,en,en
false,post stenotic coronary blood flow rest alter therapeutic dos oral antidiabetic drug glibenclamide patient coronary artery disease,investigate whether blood flow normal post stenotic coronary artery alter therapeutic dos sulfonylurea agent glibenclamide patient high grade stenosis left anterior descend coronary artery n leave circumflex coronary artery n angiographically normal correspond leave circumflex artery leave anterior descend artery respectively two doppler ultrasound wire position normal post stenotic artery simultaneous measurement coronary blood flow velocity baseline condition intravenous glibenclamide mg kg body weight local coronary blood flow calculate average peak velocity cross sectional area derive quantitative coronary angiographic analysis coronary flow reserve determine intracoronary injection microg adenosine mg papaverine one hour glibenclamide serum insulin increase mean sd mu l p c peptide ng l p normal coronary artery coronary flow reserve adenosine papaverine post stenotic arterial segment adenosine p papaverine p significant difference glibenclamide non stenotic artery average peak velocity cm calculate coronary blood flow ml min alter glibenclamide cm ml min respectively post stenotic artery baseline average peak velocity ml min coronary blood flow ml min without significant change glibenclamide cm ml min glibenclamide mg kg intravenously effective increase serum insulin suggest k atp channel block effect pancreatic beta cell compromise coronary blood flow vasodilatation response adenosine papaverine post stenotic angiographically normal coronary artery rest,Reffelmann T,2002,Heart,https://doi.org/10.1136/heart.87.1.54,11751665,Reffelmann T; Klues HG; Hanrath P; Schwarz ER,article,D016428: Journal Article,"D000284: Administration, Oral; D001786: Blood Glucose; D017023: Coronary Angiography; D003326: Coronary Circulation; D023921: Coronary Stenosis; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D010455: Peptides",,,https://openalex.org/W2136464574,162,24,1,2134,391,8,en,en
false,current future treatment strategy type diabetes beta cell therapeutic target,diabetes affect million people worldwide common variant type diabetes autoimmune destruction pancreatic beta cells type diabetes peripheral insulin resistance beta cell dysfunction spite tremendous research current pharmacological regimen still sub optimal adequate blood glucose control consequence patient diabetes significant risk development serious long term complication blindness kidney disease review discuss present future strategy treatment type diabetes focus recently recognize problem beta cell dysfunction loss treatment strategy present include promotion beta cell proliferation differentiation glucagon like peptide receptor agonist,Tyrberg B,2001,Curr Opin Investig Drugs,,11763159,Tyrberg B; Levine F,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D003924: Diabetes Mellitus, Type 2; D016503: Drug Delivery Systems; D005544: Forecasting; D006801: Humans; D007515: Islets of Langerhans; D013453: Sulfonylurea Compounds",,,https://openalex.org/W175013378,99,17,1,836,125,6,en,en
false,pramlintide amylin,pramlintide human amylin analog development amylin originally collaboration johnson johnson adjunct insulin potential prevention complication type diabetes single agent type ii diabetes december amylin submit u nda seek approval market pramlintide adjunctive therapy type diabetic use insulin application accept review fda january schedule review endocrinologic metabolic drug advisory committee july may amylin submit maa pramlintide emea october amylin receive approvable letter fda type insulin using type ii diabetes however time discussion fda ongoing regard additional clinical work require nda would approve,Barlocco D,2001,Curr Opin Investig Drugs,,11763160,Barlocco D,article,D016428: Journal Article; D016454: Review,D000682: Amyloid; D000818: Animals; D003920: Diabetes Mellitus; D006801: Humans; D007004: Hypoglycemic Agents; D058228: Islet Amyloid Polypeptide,,,https://openalex.org/W4300613943,21,5,1,991,193,3,es,en
false,standard medical care patient diabetes mellitus,,American Diabetes Association,2002,Diabetes Care,https://doi.org/10.2337/diacare.25.1.213,11772918,American Diabetes Association,article,D016431: Guideline; D016428: Journal Article; D017065: Practice Guideline,"D003920: Diabetes Mellitus; D008403: Mass Screening; D011785: Quality Assurance, Health Care; D012955: Societies, Medical; D014481: United States",,,https://openalex.org/W4229863678,61,9,1,0,0,0,en,
false,oral antihyperglycemic therapy type diabetes,diabetes mellitus affect u population great majority type diabetes mellitus dm old group prevalence dm metabolic forerunner impair glucose tolerance igt approach throughout past decade increase prevalence dm record united state dramatic increase young individual long term complication disease cost consider implication statistic sober whether relationship exist macrovascular complication myocardial infarction stroke less clear simultaneously rapidly expand therapeutic armamentarium available treat hyperglycemia type dm number oral antihyperglycemic agent class unique mechanism action increase fold throughout past years often confuse increase new category drug biguanides glucosidase inhibitor thiazolidinediones tzds nonsulfonylurea insulin secretagogues therapeutic option translate complex decision making primary care physician diabetic pa tients article review individual oral agent drug class publish evidence demonstrate,Inzucchi SE,2002,JAMA,https://doi.org/10.1001/jama.287.3.360,11790216,Inzucchi SE,article,D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D001645: Biguanides; D001786: Blood Glucose; D002219: Carbamates; D002839: Chromans; D003924: Diabetes Mellitus, Type 2; D004032: Diet; D004359: Drug Therapy, Combination; D004791: Enzyme Inhibitors; D015444: Exercise; D006442: Glycated Hemoglobin; D065089: Glycoside Hydrolase Inhibitors; D006801: Humans; D007004: Hypoglycemic Agents; D008687: Metformin; D010880: Piperidines; D016032: Randomized Controlled Trials as Topic; D013453: Sulfonylurea Compounds; D013844: Thiazoles; D045162: Thiazolidinediones; D000077288: Troglitazone",,,https://openalex.org/W2069150029,50,7,1,1331,222,6,en,en
false,oral antihyperglycemic therapy type diabetes,oral agent mainstay pharmacologic treatment type diabetes physician number agent choose however choice translate complex decision making many patient diabetes associate comorbidities diabetic patient require agent achieve good glycemic control article illustrate several pharmacologic approach type diabetes situation use principle evidence based medicine scenario also highlight difficulty choose optimal pharmacologic treatment regimen individual patient physician also recognize type diabetes multisystem disorder require multidisciplinary care include education ongoing counsel effective patient self management disease finally patient preference vital component informed decision making pharmacologic treatment diabetes,Holmboe ES,2002,JAMA,https://doi.org/10.1001/jama.287.3.373,11790217,Holmboe ES,article,D002363: Case Reports; D016428: Journal Article,"D000368: Aged; D001645: Biguanides; D015897: Comorbidity; D003657: Decision Making; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D004791: Enzyme Inhibitors; D019317: Evidence-Based Medicine; D005260: Female; D065089: Glycoside Hydrolase Inhibitors; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D010353: Patient Education as Topic; D010358: Patient Participation; D010817: Physician-Patient Relations; D017410: Practice Guidelines as Topic; D013453: Sulfonylurea Compounds; D013844: Thiazoles",,,https://openalex.org/W1988203022,50,7,1,976,149,7,en,en
false,glimepiride type diabetes mellitus thai patient,study aim confirm efficacy glimepiride give daily treatment thai type diabetic patient find optimum dosage thai patient patient enrol diabetic clinic hospital rajavithi chulalongkorn pramongkutklao siriraj theptarin hospital patient start glimepiride mg daily escalate mg every week fasting plasma glucose fpg exceed mg dl subject female male average age year mean bmi kg fifty seven patient drug na thirty two patient previously treat oral hypoglycemic agent seventy three per cent drug na per cent previously treat patient could control mg glimepiride daily twelfth week treatment mean fast plasma glucose decrease mg dl reduction mean hba c decrease per cent reduction end study per cent patient hba c per cent per cent hba c per cent per cent hba c per cent adverse event probably possibly relate drug report patient three hypoglycemia two patient skin rash hypoglycemic episode mild glimepiride indicate safe clinically significant change clinical laboratory value physical examination vital sign conclusion glimepiride efficacious safe type diabetes thai patient mg glimepiride appear sufficient dose newly diagnose type diabetic patient,Deerochanawong C,2001,J Med Assoc Thai,,11800292,Deerochanawong C; Chandraprasert S; Suthijumroon A; Vichayanrat A; Himathongkam T; Nitiyanant W; Benjasuratawong Y; Suwanwalaikorn S; Sarinnapakorn V; Vongterapak S,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D013453: Sulfonylurea Compounds; D013785: Thailand; D016896: Treatment Outcome",,,https://openalex.org/W95788833,54,9,1,1774,343,15,en,en
false,sulfonylurea inadequacy,objective evaluate efficacy addition insulin maximal sulfonylurea therapy inadequate individual type diabetes research design methods glycemic control hypoglycemia body weight monitor year patient newly diagnose type diabetes u k prospective diabetes study ukpds center use modified protocol patient randomly allocate conventional glucose control policy primarily diet n intensive policy insulin alone n main study however patient randomize intensive policy sulfonylurea n insulin add automatically fasting plasma glucose remain gt mg dl mmol l despite maximal sulfonylurea dos results year patient allocate treatment sulfonylurea require additional insulin therapy median hba c sulfonylurea insulin group significantly low interquartile range iqr group take insulin alone iqr p significantly patient sulfonylurea insulin group hba c lt vs respectively p weight gain similar intensive therapy group major hypoglycemia occur less frequently sulfonylurea insulin group compare insulin alone group vs per annum respectively p conclusions early addition insulin maximal sulfonylurea therapy inadequate significantly improve glycemic control without promote increase hypoglycemia weight gain,Wright A,2002,Diabetes Care,https://doi.org/10.2337/diacare.25.2.330,11815505,Wright A; Burden AC; Paisey RB; Cull CA; Holman RR; U.K. Prospective Diabetes Study Group,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005260: Female; D005500: Follow-Up Studies; D006442: Glycated Hemoglobin; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D013453: Sulfonylurea Compounds; D006113: United Kingdom",,,https://openalex.org/W1996441843,23,2,1,1658,309,9,ceb,en
true,optimize insulin secretagogue therapy patient type diabetes,objective repaglinide novel antidiabetic agent rapid onset short duration action develop mealtime dosing purpose pharmacodynamic study validate prandial regimen repaglinide compare meal related dosing regimen total daily dose divide two dos morning evening meal research design methods study double blind randomize parallel group trial antidiabetic agent naive subject type diabetes mean age year know duration diabetes year hba c bmi kg patient randomly assign receive repaglinide either three main meal breakfast evening meal patient group receive total daily dose repaglinide twenty four hour profile blood glucose plasma insulin plasma c peptide concentration measure baseline week treatment results repaglinide increase postprandial insulin level markedly reduce postprandial glucose level relative baseline group significant reduction also record fast blood glucose hba c level repaglinide regimen dose take main meal effective improve glycemic control include postprandial glucose hba c level total dose repaglinide divide morning evening mealtime dose conclusions data support strategy mealtime dose repaglinide improvement glycemic control observe patient encourage addition classic parameter glycemic control improvement postprandial glucose excursion may prove important postprandial hyperglycemia suggest independent risk factor cardiovascular disease diabetes,Schmitz O,2002,Diabetes Care,https://doi.org/10.2337/diacare.25.2.342,11815507,Schmitz O; Lund S; Andersen PH; Jønler M; Pørksen N,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004435: Eating; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D008875: Middle Aged; D010880: Piperidines; D019518: Postprandial Period",,,https://openalex.org/W2152759529,72,10,1,1900,306,12,en,en
false,sibutramine new preparation slight weight loss also slight rise blood pressure,reference treatment achieve weight loss obese patient combination dietary measure exercise behavioural intervention currently drug treatment demonstrated efficacy morbidity mortality associate excess body weight sibutramine serotonin noradrenaline reuptake inhibitor structurally relate amphetamine grant market authorisation france treatment obesity excess body weight patient associated risk factor clinical file sibutramine contain trial focus morbidity mortality end point accord comparative clinical trial weight loss month course sibutramine average kg great placebo patient regain weight sibutramine cessation sibutramine little benefit blood sugar lipid parameter main known adverse effect sibutramine increase blood pressure sibutramine also amphetamine like side effect practice sibutramine currently place management obesity,,2001,Prescrire Int,,11824428,,article,D003160: Comparative Study; D016428: Journal Article,D001066: Appetite; D001067: Appetite Depressants; D002986: Clinical Trials as Topic; D003503: Cyclobutanes; D005602: France; D006801: Humans; D006973: Hypertension; D009765: Obesity; D016896: Treatment Outcome,,,https://openalex.org/W4300802408,94,18,2,1140,198,10,en,en
false,comparative efficacy preprandial postprandial humalog mix versus glyburide patient year age type diabetes mellitus,humalog mix mix novel premixed insulin contain neutral protamine lispro intermediate acting insulin insulin lispro purpose study compare glycemic control hypoglycemia rate mix versus glyburide preprandial versus postprandial mix patient age year type diabetes mellitus persistent hyperglycemia sulfonylurea therapy open label week parallel group study patient randomize treatment glyburide mg maximum daily dose mix mix group randomly subdivide preprandial immediately breakfast dinner postprandial within minute start breakfast dinner injection subgroup primary outcome glycemic control rate hypoglycemia total patient randomize complete study change glycosylated hemoglobin hba c baseline end point significantly great mix glyburide mean sem vs p hba c change preprandial postprandial mix significantly different vs p fast blood glucose bg hour postprandial bg mean daily bg reduction great mix glyburide p preprandial postprandial mix administration differ significantly respect bg variable hypoglycemia rate increase mix episode per patient per day change glyburide p body weight increase kg mix decrease kg glyburide p compared glyburide mix significantly improve glycemic control old patient type diabetes mellitus could administer meal without compromise glycemic control well tolerate,Herz M,2002,Clin Ther,https://doi.org/10.1016/s0149-2918(02)85006-8,11833837,Herz M; Sun B; Milicevic Z; Erickson P; Fövènyi J; Grzywa M; Pelikanova T,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D001786: Blood Glucose; D001835: Body Weight; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D061268: Insulin Lispro; D008297: Male; D008875: Middle Aged; D010342: Patient Acceptance of Health Care; D019518: Postprandial Period; D011994: Recombinant Proteins; D016896: Treatment Outcome",,,https://openalex.org/W2147986782,151,23,1,2022,366,8,en,en
false,glibenclamide v gliclazide reduce oxidative stress patient noninsulin dependent diabetes mellitus double blind randomize study,parameter oxidative stress quantitated patient type diabetes mellitus uncontrolled state control use oral glibenclamide gliclazide estimate far compare two group irrespective drug use evaluate difference study double blind uncontrolled noncrossover randomized trial fifty patient uncontrolled type diabetes divide two group group patient receive capsule glibenclamide group ii patient receive capsule b gliclazide parameter study superoxide dismutase sod malonyl dialdehyde mda reduce glutathione gsh uncontrolled stage fbs mg dl pp mg dl hba group fbs mg dl pp mg dl hba group ii control stage week fbs mg dl pp mg dl hba group fbs mg dl pp mg dl hba group ii patient significantly raise level mda sod decreased level reduce glutathione gsh uncontrolled stage diabetes indicate free radical stress induce lipid peroxidation significant fall mda sod increased level gsh blood group control reveal beneficial effect glycemic control oxidative stress level normalize stay high control intergroup comparison control diabetes gliclazide group ii show improvement oxidative stress mda gsh good p glibenclamide group oxidative stress uncontrolled diabetes decrease glycemic control control diabetes gliclazide reduce oxidative stress glibenclamide indicate high antioxidant property gliclazide normalization oxidative stress achieve study require see long term effect drug therapy combat oxidative stress achieve acceptable control diabetes,Chugh SN,2001,J Assoc Physicians India,,11837468,Chugh SN; Dhawan R; Kishore K; Sharma A; Chugh K,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005260: Female; D005907: Gliclazide; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D018384: Oxidative Stress",,,https://openalex.org/W89184296,144,21,1,2147,403,12,en,en
false,model pharmacokinetics pharmacodynamics unique oral hypoglycemic agent use neural network,purpose develop predictive population pharmacokinetic pharmacodynamic pk pd model repaglinide rep oral hypoglycemic agent use artificial neural network anns method rep glucose concentration demographic data dose range phase trial divide training set test set neuroshell predictor use create predictive pk pk pd model use population covariates evaluate relative significance different covariates simulate effect covariates pk pd rep predictive performance evaluate calculate root mean square error mean error training test set value compare naive averaging na randomly generate number rn result covariates find influence pk rep include dose gender race age weight covariates affect glucose response include dose gender weight difference expect clinically significant conclusion come following three conclusion anns precise na rn pk pd bias acceptable anns compare na rn neural network offer quick simple method predicting identify significant covariates generate hypothesis,Haidar SH,2002,Pharm Res,https://doi.org/10.1023/a:1013611617787,11837705,Haidar SH; Johnson SB; Fossler MJ; Hussain AS,article,"D016430: Clinical Trial; D017427: Clinical Trial, Phase II; D016428: Journal Article; D016449: Randomized Controlled Trial","D001786: Blood Glucose; D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D016571: Neural Networks, Computer; D010880: Piperidines; D011237: Predictive Value of Tests",,,https://openalex.org/W27918916,109,15,1,1338,252,9,en,en
false,new trend development oral antidiabetic drug,large number oral antidiabetic agent available today article provide short review pharmacology clinical aspect various oral antidiabetic drug focus mainly new developing drug therapy near future commonly use old group common approach every day practice sulphonylureas primary goal review compare electrophysiological effect glibenclamide isolated normal streptozotocin induce diabetic rat alloxan induce rabbit ventricular preparation hand differentiate hypoglycaemic sulphonylureas mmol kg accord cardiovascular activity healthy diabetic animal vitro micromol l well chronically treat mg kg week glibenclamide prolong action potential duration normal fail affect diabetic ventricular preparation result suggest sensitivity glibenclamide k atp channel diabetic ventricular fiber drastically decrease effect different sulphonylureas tolbutamide glibenclamide gliclazide glimepiride ventricular ectopic beat well duration ventricular fibrillation induce min ischemia min reperfusion healthy diabetic rat compare tolbutamide gliclazide dose dependently enhanced parameter healthy diabetic group glibenclamide healthy rat increase diabetic rat decrease arrhythmogenicity glimepiride depress arrhythmogenicity healthy diabetic animal glimepiride prove dose dependently enhance myocardial tissue flow dog contrast glibenclamide result confirm glimepiride less cardiovascular action sulphonylureas new oral antidiabetic review try emphasize important basic pharmacological property mechanism action therapeutic use,Kecskemeti V,2002,Curr Med Chem,https://doi.org/10.2174/0929867023371427,11860348,Kecskemeti V; Bagi Z; Pacher P; Posa I; Kocsis E; Koltai MZ,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D000284: Administration, Oral; D000818: Animals; D050260: Carbohydrate Metabolism; D003920: Diabetes Mellitus; D006801: Humans; D007004: Hypoglycemic Agents; D007333: Insulin Resistance; D007408: Intestinal Absorption",,,https://openalex.org/W2105654121,56,9,1,2007,310,13,en,en
false,vascular katp channel blockade glibenclamide acarbose patient type ii diabetes,glibenclamide inhibit opening vascular atp sensitive potassium katp channel represent protective mechanism ischaemia effect may imply harmful cardiovascular effect glibenclamide use condition ischaemia patient type ii diabetes acarbose associate effect cardiovascular system drug absorb bowel therefore hypothesize treatment type ii diabetes patient glibenclamide impair vasodilator function katp opening unlike treatment acarbose double blind randomized cross study patient type ii diabetes perform compare effect glibenclamide acarbose vasodilator responses katp channel open forearm vascular bed study consist two period week treatment orally administer glibenclamide mg day follow week treatment acarbose mg day vice versa end treatment period forearm blood flow venous occlusion plethysmography response intra arterially administered diazoxide acetylcholine dipyridamole forearm ischaemia measure diazoxide mediated increase forearm blood flow ratio infused control arm significantly less pronounced glibenclamide acarbose respectively p forearm blood flow response acetylcholine dipyridamole forearm ischaemia similar glibenclamide acarbose treatment thus patient type ii diabetes mellitus treatment glibenclamide associate attenuated response katp opening compare treatment acarbose imply glibenclamide may affect defensive mechanism condition katp channel activation,Abbink EJ,2002,Clin Sci (Lond),https://doi.org/10.1042/cs1020307,11869171,Abbink EJ; Pickkers P; van Rosendaal AJ; Lutterman JA; Tack CJ; Russel FG; Smits P,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D020909: Acarbose; D000109: Acetylcholine; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D003981: Diazoxide; D004176: Dipyridamole; D004311: Double-Blind Method; D005260: Female; D005542: Forearm; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007511: Ischemia; D008297: Male; D008875: Middle Aged; D010991: Plethysmography; D026902: Potassium Channel Blockers; D014665: Vasodilator Agents",,,https://openalex.org/W2059818469,103,18,1,1866,295,11,en,en
false,effect treatment sulfonylurea drug insulin ischemia induced myocardial dysfunction type diabetes,patient diabetes coronary artery disease potential negative role sulfonylurea drug intensive investigation assess effect treatment glibenclamide insulin extension left ventricular myocardial dysfunction induce acute ischemia nineteen consecutive patient type diabetes coronary artery disease enter study patient randomly assign either insulin glibenclamide therapy treatment cross week maintain another week end treatment leave ventricular myocardial function rest dipyridamole infusion study two dimensional echocardiography condition metabolic control glibenclamide insulin treatment influence rest value left ventricular dimension leave ventricular ejection fraction lvef wall motion score index wmsi dipyridamole infusion patient receive glibenclamide treatment decrease lvef vs p increase wmsi vs p compare baseline value insulin treatment lvef vs n wmsi vs ns change significantly peak stress lvef high vs p wmsi low vs p patient receive insulin result indicate patient type diabetes coronary artery disease ischemic myocardial dysfunction induce dipyridamole infusion less severe treatment insulin glibenclamide restitution preconditioning mechanism insulin treated patient may potential beneficial mechanism,Scognamiglio R,2002,Diabetes,https://doi.org/10.2337/diabetes.51.3.808,11872684,Scognamiglio R; Avogaro A; Vigili de Kreutzenberg S; Negut C; Palisi M; Bagolin E; Tiengo A,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D009202: Cardiomyopathies; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004176: Dipyridamole; D025401: Echocardiography, Stress; D005260: Female; D005905: Glyburide; D006352: Heart Ventricles; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D016896: Treatment Outcome; D018487: Ventricular Dysfunction, Left",,,https://openalex.org/W2110947926,117,16,1,1774,316,11,en,en
false,vascular effect glibenclamide vs glimepiride metformin type diabetic patient,glibenclamide attenuate protective response opening vascular atp sensitive potassium k atp channel ischaemia therefore glibenclamide treatment type diabetes mellitus may hazardous cardiovascular effect use condition ischaemia glimepiride metformin seem lack characteristic base data hypothesize contrast glibenclamide chronic treatment type diabetic patient glimepiride metformin impair vasodilator function k atp opening vivo two group type diabetes mellitus patient participate double blind randomized cross study consist two week period treatment orally administer glibenclamide mg day compare either glimepiride metformin mg mg day respectively end treatment period increase forearm blood flow fbf venous occlusion plethysmography response intra arterial administer diazoxide k atp opener acetylcholine endothelium dependent vasodilator dipyridamole adenosine uptake blocker forearm ischaemia measured significant difference vasodilator response diazoxide acetylcholine dipyridamole forearm ischaemia glibenclamide compare glimepiride metformin chronic treatment type diabetes mellitus glimepiride metformin similar effect vascular k atp channel compare chronic glibenclamide treatment,Abbink EJ,2002,Diabet Med,https://doi.org/10.1046/j.1464-5491.2002.00663.x,11874430,Abbink EJ; Pickkers P; Jansen van Rosendaal A; Lutterman JA; Tack CJ; Russel FG; Smits P,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000109: Acetylcholine; D000328: Adult; D000368: Aged; D001783: Blood Flow Velocity; D001794: Blood Pressure; D015992: Body Mass Index; D001835: Body Weight; D002096: C-Peptide; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D003981: Diazoxide; D004176: Dipyridamole; D004311: Double-Blind Method; D005260: Female; D005542: Forearm; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D008875: Middle Aged; D013453: Sulfonylurea Compounds; D014664: Vasodilation",,,https://openalex.org/W1501298608,91,13,1,1529,240,5,en,en
false,amylin amyloid type diabetes mellitus,amyloid deposit within islet pancreas know century islet amyloid precursor polypeptide iapp amylin amino acid discover recently explosion amylin importance development type diabetes mellitus dm review intend share understood amylin derive amyloid role play dm whether islet amyloid epiphenomenona tombstone trigger leave indelible footprint great patient dm current data support damaging role intermediate size toxic amyloid particle beta cell result beta cell defect contribute relative deficiency loss insulin secretion within islet intense redox stress may associate unfolding amylin native secondary structure compound amyloidogenic property addition beta cell defect may absorptive defect result amyloid deposition basement membrane form envelope around inta islet capillary endothelium opportunity change current treatment modality new medication attempt diagnose dm earlier use newer treatment strategy combination decrease glucotoxicity without elevate endogenous insulin amylin st century goal prevent remodeling save pancreatic islet conquer islet amyloid amyloid diabetes,Hayden MR,2001,JOP,,11875249,Hayden MR; Tyagi SC,article,D016428: Journal Article; D016454: Review,"D000595: Amino Acid Sequence; D000682: Amyloid; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D058228: Islet Amyloid Polypeptide; D008969: Molecular Sequence Data",,,https://openalex.org/W1528156951,58,14,1,1546,268,10,en,en
false,glucose tolerance insulin secretion insulin sensitivity polycystic ovary syndrome,polycystic ovary syndrome pcos disorder affect approximately reproductive age woman initially describe stein leventhal combination polycystic ovary amenorrhoea hirsutism obesity define different way year finally national institute health nih establish new diagnostic criterion disorder base presence hyperandrogenism chronic oligo anovulation exclusion cause hyperandrogenism non classical adrenal steroid hydroxylase deficiency hyperprolactinemia androgen secreting neoplasm past decade become apparent syndrome also associate metabolic disturbance burghen colleague first report woman pcos high basal glucose stimulated insulin level weight matched control subsequently number study worldwide demonstrate hyperinsulinemia insulin resistance common feature large number patient affect pcos addition hyperinsulinemia insulinresistance alter first phase insulin secretion impair glucose tolerance dyslipidemia hypertension impaired fibrinolysis also describe pcos cluster metabolic disturbance place woman pcos high risk development cardiovascular disease diabetes implies pcos may consider hyperandrogenic disorder exclusively relate young fertile age woman syndrome may health implication later life,Pasquali R,2002,JOP,,11884761,Pasquali R; Pelusi C; Ragazzini C; Hasanaj R; Gambineri A,article,D016421: Editorial; D016454: Review,D005260: Female; D005951: Glucose Tolerance Test; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007333: Insulin Resistance; D000078790: Insulin Secretion; D011085: Polycystic Ovary Syndrome,,,https://openalex.org/W2111666151,90,13,1,1672,279,8,en,en
false,type diabetes management comprehensive clinical review oral medication,diabetes major grow health problem u incredible array different oral medication market clinician understand new medication clinical picture work best,Quillen DM,2002,Compr Ther,https://doi.org/10.1007/s12019-002-0042-8,11894443,Quillen DM; Kuritzky L,article,D016428: Journal Article; D016454: Review,"D001549: Benzamides; D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D065089: Glycoside Hydrolase Inhibitors; D006801: Humans; D007004: Hypoglycemic Agents; D008687: Metformin; D010880: Piperidines; D013453: Sulfonylurea Compounds; D013844: Thiazoles; D045162: Thiazolidinediones",,,https://openalex.org/W1993252892,79,12,1,235,42,3,en,en
false,alternative therapy type diabetes,type diabetes chronic metabolic disease significant impact health quality life life expectancy patient well health care system exercise diet weight control continue essential effective mean improve glucose homeostasis however lifestyle management measure may insufficient patient compliance difficult rendering conventional drug therapy e oral glucose lowering agent insulin injection necessary many patient addition adverse effect drug treatment always satisfactory maintain euglycemia avoid late stage diabetic complication alternative approach medicinal herb antihyperglycemic activity increasingly seek diabetic patient health care professional commonly use herb alternative therapy less likely side effect conventional approach type diabetes review,Dey L,2002,Altern Med Rev,,11896745,Dey L; Attele AS; Yuan CS,article,D016428: Journal Article; D016454: Review,"D015670: Acupuncture Therapy; D003924: Diabetes Mellitus, Type 2; D019587: Dietary Supplements; D006801: Humans; D006875: Hydrotherapy; D007004: Hypoglycemic Agents; D008517: Phytotherapy",,,https://openalex.org/W2161639066,42,7,1,966,156,6,en,en
false,effect serum level glibenclamide active metabolite patient type diabetes,summary objective study effect serum level glibenclamide gb active metabolite patient chronic gb medication different daily dos material method fifty patient type diabetes regular gb therapy mg daily blood sample take immediately min regular gb intake standardized breakfast serve min drug intake serum insulin proinsulin level determine elisa method without cross reactivities serum drug level determine hplc fischer r z test correlation coefficient paired student tests use compare value within entire group unpaired non parametric mann whitney test use compare high low dose level p value consider significant result significant correlation daily gb dose one hand hbal c r insulin r proinsulin r level significant correlation gb therapy duration insulin r proinsulin r secretion gb dose ratio proinsulin insulin rpi time point r also find rpi low gb intake patient mg steady state serum metabolite level ml ml high ng ml gb ng ml great inter subject variability gb level time point see conclusion result indicate patient chronic medication gb capable stimulate insulin proinsulin secretion effect insulin release relatively great effect pronounced patient low gb dose either less impaired cells receive low dos due reduce sulphonylurea sensitivity high dosage regulation patient daily dose mg serum metabolite level clinical relevance demonstrate metabolite may contribute hypoglycaemic event,Jönsson A,2001,Diabetes Obes Metab,https://doi.org/10.1046/j.1463-1326.2001.00152.x,11903411,Jönsson A; Hallengren B; Rydberg T; Melander A,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001711: Biotransformation; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D008875: Middle Aged; D011384: Proinsulin; D013548: Sweden; D044465: White People",,,https://openalex.org/W2065601871,101,16,1,2107,405,16,en,en
false,effect intensive glycaemic control body composition patient type diabetes,summary aim examine effect improved glycaemic control week type distribution weight change patient type diabetes baseline poor glycaemic control method forty three patient type diabetes hba c randomise either intensive glycaemic control ic n usual glycaemic control uc n week dual energy x ray absorptiometry use assess type distribution weight change study result week hba c significantly low patient randomise ic uc hba c ic vs uc p ic group weight increase kg week fat free mass increase kg compare kg uc p gain total body fat mass comprise trunk fat mass ic kg vs uc kg p peripheral fat mass total body fat trunk fat ic kg vs uc kg p blood pressure serum lipid concentration change time either group conclusion intensive glycaemic control associate weight gain distribute similar proportion central peripheral region consist similar proportion fat fat free mass blood pressure serum lipid concentration adversely affect,Bagg W,2001,Diabetes Obes Metab,https://doi.org/10.1046/j.1463-1326.2001.00153.x,11903412,Bagg W; Plank LD; Gamble G; Drury PL; Sharpe N; Braatvedt GD,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D015502: Absorptiometry, Photon; D000273: Adipose Tissue; D001786: Blood Glucose; D001823: Body Composition; D001835: Body Weight; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D004562: Electrocardiography; D005006: Ethnicity; D005260: Female; D006801: Humans; D008055: Lipids; D008297: Male; D008875: Middle Aged; D009520: New Zealand; D015430: Weight Gain",,,https://openalex.org/W2025353246,95,15,1,1410,288,9,en,en
false,nepi antidiabetes study nansy short term dose effect relation glimepiride subject impaired fast glucose,summary aim nansy randomised placebo controlled swedish norwegian study aim include male female subject impaired fast glucose ifg assess whether conversion type diabetes delay addition sulphonylurea dietary regulation increase exercise pilot study conduct find optimum dose glimepiride nansy method double blind trial primary care ifg subject random order expose single dos one week treatment placebo mg glimepiride daily optimum dose assess measure blood glucose oral g glucose tolerance test ogtt compare fast blood glucose area blood glucose curve auc monitor hypoglycaemic event result single dos clear dose response relationship reduction auc statistically significant difference placebo mean confidence interval ci mg glimepiride mean ci however follow week treatment significant difference placebo mean ci mg glimepiride mean ci correspondingly statistically significant difference fast blood glucose day placebo mmol l ci mmol l mg glimepiride mmol l ci mmol l chemical hypoglycaemia common hypoglycaemic symptom rare similar active dos easily counter subject conclusion sulphonylurea dose effect curve may bell shaped perhaps due regulation sulphonylurea receptor chronic exposure alternatively finding could rebound phenomenon secondary precede hypoglycaemia optimum dose nansy find mg glimepiride,Lindblad U,2001,Diabetes Obes Metab,https://doi.org/10.1046/j.1463-1326.2001.00166.x,11903417,Lindblad U; Lindwall K; Sjöstrand A; Ranstam J; Melander A; NEPI Antidiabetes Sstudy (NANSY),article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D001824: Body Constitution; D015992: Body Mass Index; D002784: Cholesterol; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005215: Fasting; D005260: Female; D018149: Glucose Intolerance; D006801: Humans; D006949: Hyperlipidemias; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009664: Norway; D010919: Placebos; D013453: Sulfonylurea Compounds; D013548: Sweden; D014280: Triglycerides",,,https://openalex.org/W2077994345,130,22,2,1921,349,11,en,en
false,effect dietary treatment alone diet voglibose glyburide abdominal adipose tissue metabolic abnormality patient newly diagnose type diabetes,objective examine effect diet diet voglibose glyburide abdominal adiposity metabolic abnormality patient type diabetes total japanese patient newly diagnose type diabetes year age bmi kg normal control subject study patient treat month diet alone kcal kg per day n diet voglibose n diet glyburide n undergo g oral glucose tolerance testing assessment insulin sensitivity si acute insulin response air intravenous glucose tolerance test base minimal model measurement abdominal visceral adipose tissue area vat subcutaneous adipose tissue area sit compute tomography treatment diabetic patient comparable sat large vat control subject mean weight loss kg vat sat decrease similarly treatment group vat sat ratio decrease voglibose group glycemic control serum lipid profile improve group change glycemic control diet closely correlate change vat change sat si air unchanged diet group improve voglibose glyburide groups japanese patient newly diagnose type diabetes relatively lean excess vat diet without voglibose glyburide effectively reduce vat decrease vat closely associate improvement glycemic control diet additional use voglibose low dose glyburide detrimental effect abdominal adiposity beneficial effect si air,Takami K,2002,Diabetes Care,https://doi.org/10.2337/diacare.25.4.658,11919121,Takami K; Takeda N; Nakashima K; Takami R; Hayashi M; Ozeki S; Yamada A; Kokubo Y; Sato M; Kawachi S; Sasaki A; Yasuda K,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000005: Abdomen; D000273: Adipose Tissue; D000328: Adult; D001786: Blood Glucose; D015992: Body Mass Index; D001835: Body Weight; D002784: Cholesterol; D008076: Cholesterol, HDL; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D002149: Energy Intake; D005215: Fasting; D005230: Fatty Acids, Nonesterified; D005260: Female; D005951: Glucose Tolerance Test; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007294: Inositol; D007328: Insulin; D008297: Male; D014280: Triglycerides",,,https://openalex.org/W2112182833,175,26,1,1760,322,10,en,en
true,patient compliance persistence anti hyperglycemic therapy evaluation population type diabetic patient,persistence compliance type diabetic patient different regimen anti hyperglycemic therapy assess retrospectively pharmacy claim pharmacy benefit management organization analyse third quarter fourth quarter patient enrol initiate anti diabetic therapy start treatment monotherapy insulin alone polytherapy insulin plus another therapy monotherapy patient characterize receive metformin sulfonylurea another agent year follow period metformin patient sulfonylurea patient polytherapy patient underwent regimen modification except discontinuation patient modification medication regimen persistence sulfonylurea metformin monotherapy great polytherapy year period compliance sulfonylurea metformin monotherapy great polytherapy,Dailey G,2002,J Int Med Res,https://doi.org/10.1177/147323000203000111,11921502,Dailey G; Kim MS; Lian JF,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D015331: Cohort Studies; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D010349: Patient Compliance; D012189: Retrospective Studies; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2118597037,122,17,1,1058,171,7,en,en
false,evaluation innovative skin marking technique perform thyroid ultrasound guided fine needle aspiration biopsy,objective introduce innovative skin marking technique perform ultrasound guided fine needle aspiration biopsy us fnab thyroid method study patient thyroid nodule classify basis physical examination two groups palpable nodule n nonpalpable difficult palpate nodule n group far subdivide accord size thyroid nodule mm versus mm us fnab perform skin marking technique aid catheter permanent marker ultrasound guidance establish point needle entry indicate skin chi square test use compare result group patient result proportion adequate insufficient biopsy material overall group patient respectively patient stratify palpable nonpalpable thyroid nodule biopsy specimen adequate insufficient palpable nodule whereas corresponding proportion nonpalpable nodule respectively statistically significant difference note two group comparison patient thyroid nodule mm large diameter versus nodule mm also show statistically significant difference term insufficient biopsy material conclusion technique create marking skin lead directly thyroid nodule facilitate acquisition adequate cytologic material particularly relevant small transducer available physician need reassurance accuracy thyroid biopsy site endocr pract,Brenta G,2002,Endocr Pract,https://doi.org/10.4158/ep.8.1.5,11939753,Brenta G; Schnitman M; Bonnahon L; Besuschio S; Zuk C; De Barrio G; Peruzzotti C; Saubidet G,article,D016428: Journal Article,"D000328: Adult; D001707: Biopsy, Needle; D018276: Carcinoma, Medullary; D002291: Carcinoma, Papillary; D003581: Cytodiagnosis; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010173: Palpation; D012867: Skin; D013964: Thyroid Neoplasms; D016606: Thyroid Nodule; D014463: Ultrasonography",,,https://openalex.org/W1964511936,122,12,1,1818,306,14,en,en
false,pharmacokinetics tolerability fructosamine lowering effect novel controlled release formulation lipoic acid,abstractobjective determine pharmacokinetics safety tolerability novel controlled release oral formulation lipoic acid la investigate whether sustain concentration la plasma would beneficial effect glycemic control patient type diabetes method pharmacokinetic study single mg dose either controlled release la crla quick release la qrla administer orally normal human subject plasma profile la determine hour administration dose pharmacokinetic analysis perform safety tolerability study patient type diabetes give mg crla daily week follow mg crla daily additional week active treatment follow week washout period throughout study patient continue take prestudy antidiabetic medication include metformin glucophage sulfonylurea amaryl glyburide glucotrol acarbose precose troglitazone rezulin insulin either monotherapy combination crla evaluate safety tolerability well effect glycemic control result tmax time maximal plasma concentration la administer crla hour approximately fold longer comparison tmax qrla tmax hour p severe side effect change either liver kidney function hematologic profile note administration crla patient mean plasma fructosamine concentration reduce mol l p week treatment crla conclusion crla increase plasma concentration la time healthy subject crla safe well tolerate effective reduce plasma fructosamine patient type diabetes endocr pract,Evans JL,2002,Endocr Pract,https://doi.org/10.4158/ep.8.1.29,11951812,Evans JL; Heymann CJ; Goldfine ID; Gavin LA,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D020909: Acarbose; D000368: Aged; D000975: Antioxidants; D001786: Blood Glucose; D002839: Chromans; D003692: Delayed-Action Preparations; D003924: Diabetes Mellitus, Type 2; D005260: Female; D019270: Fructosamine; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D013453: Sulfonylurea Compounds; D013844: Thiazoles; D045162: Thiazolidinediones; D008063: Thioctic Acid; D000077288: Troglitazone",,,https://openalex.org/W1989219139,124,16,1,2033,424,13,en,en
false,rapid increase cell function multiple insulin injection type diabetic patient far enhance prolong treatment,intensive insulin treatment type diabetes improve beta cell function know duration treatment achieves maximal improvement address question type diabetic patient display feature secondary failure ten patient randomize multiple insulin injection mi therapy week another patient start bedtime insulin bti continue peroral medication follow week treatment patient mi switch bti glibenclamide three day mi lead decrease fast proinsulin insulin ratio vs p increase glucagon stimulated c peptide baseline vs nmol l p nine week mi treatment successively decrease fasting nonfasting blood glucose parallel increase insulin dosage initial improvement secretion parameter upheld far enhance week proinsulin insulin ratio glucagon stimulated c peptide value obtain day treatment eight week termination mi persist total weight gain tend large continuous peroral medication bti improvement insulin secretion intensive insulin treatment rapidly gain effect obtain longer treatment period finding well undesirable effect mi body weight argue prolonged mi treatment prelude therapeutic regimen type diabetic patient,Kärvestedt L,2002,J Intern Med,https://doi.org/10.1046/j.1365-2796.2002.00956.x,11952881,Kärvestedt L; Andersson G; Efendic S; Grill V,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D005260: Female; D005934: Glucagon; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D007515: Islets of Langerhans; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2168315405,142,22,1,1587,265,9,en,en
false,oral antihyperglycemics efficacious reduce hemoglobin c diabetic patient,,Abrahamson L,2002,J Fam Pract,,11978249,Abrahamson L; Newton W,article,D016420: Comment; D016428: Journal Article,,,,https://openalex.org/W2402933879,99,14,1,0,0,0,en,
false,current oral agent type diabetes,increasingly type diabetes take toll public health healthcare cost united state although remedy grow problem complex two critical component control prevention effective therapy progress diabetes prevention likely take decade fortunately growth understanding occur chronic disease lead advance pharmacologic option aim decrease hyperglycemia main clinically measurable metabolic consequence diabetes article drs ahmann riddle provide overview oral agent available treatment diabetes discuss clinical factor help determine use medication outcome expect,Ahmann AJ,2002,Postgrad Med,https://doi.org/10.3810/pgm.2002.05.1194,12040862,Ahmann AJ; Riddle MC,article,D016428: Journal Article; D016454: Review,"D002219: Carbamates; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D016903: Drug Monitoring; D004359: Drug Therapy, Combination; D006026: Glycoside Hydrolases; D006801: Humans; D007004: Hypoglycemic Agents; D008687: Metformin; D000077715: Nateglinide; D010649: Phenylalanine; D010880: Piperidines; D018160: Receptors, Cytoplasmic and Nuclear; D013453: Sulfonylurea Compounds; D014157: Transcription Factors",,,https://openalex.org/W1603309621,39,7,1,766,129,5,en,en
false,thiazolidinediones type diabetes new drug old disease,medical journal australiavolume issue p new drug old drug thiazolidinediones type diabetes new drug old disease correction article thiazolidinediones type diabetes new drug old disease trisha moore sullivan mb b fracp johannes b prins mb b phd fracp volume issue medical journal australia page first publish online october trisha moore sullivan mb b fracp correspond author trisha moore sullivan mb b fracp visit endocrinologist senior lecturer department medicine university queensland nmhrc postgraduate medical research fellow tomoore medicine pa uq edu au department diabetes endocrinology princess alexandra hospital woolloongabba brisbane qld correspondence tomoore medicine pa uq edu ausearch paper authorjohannes b prins mb b phd fracp johannes b prins mb b phd fracp director associate professor department medicine university queensland wellcome senior research fellow department diabetes endocrinology princess alexandra hospital woolloongabba brisbane qld search paper author trisha moore sullivan mb b fracp correspond author trisha moore sullivan mb b fracp visit endocrinologist senior lecturer department medicine university queensland nmhrc postgraduate medical research fellow tomoore medicine pa uq edu au department diabetes endocrinology princess alexandra hospital woolloongabba brisbane qld correspondence tomoore medicine pa uq edu ausearch paper authorjohannes b prins mb b phd fracp johannes b prins mb b phd fracp director associate professor department medicine university queensland wellcome senior research fellow department diabetes endocrinology princess alexandra hospital woolloongabba brisbane qld search paper author first publish april http doi org j tb xcitations read full textaboutpdf toolsrequest permissionexport citationadd favoritestrack citation shareshare give accessshare full text accessshare full text accessplease review term condition use check box share full text version article read accept wiley online library term condition useshareable linkuse link share full text version article friend colleague learn copy url share linkshare onfacebooktwitterlinkedinredditwechat cite literature volume issue april pages relatedinformation,O'Moore-Sullivan TM,2002,Med J Aust,https://doi.org/10.5694/j.1326-5377.2002.tb04461.x,12041635,O'Moore-Sullivan TM; Prins JB,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D000328: Adult; D000368: Aged; D001315: Australia; D002986: Clinical Trials as Topic; D000075202: Contraindications; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D000077205: Pioglitazone; D000077154: Rosiglitazone; D013844: Thiazoles; D045162: Thiazolidinediones",,,https://openalex.org/W2137057476,68,12,1,2702,424,2,en,en
false,multiple drug target management type diabetes,diabetes mellitus dm diagnose alarm rate around world estimate million affected person diabetes worldwide type dm often clinically silent disorder united state nearly half estimate million person diabetes remain undiagnosed type diabetes precede long period impaired glucose tolerance igt potentially reversible metabolic state associate increase risk macrovascular complication time diagnosis one third patient already develop long term complication diabetes genetic acquire factor contribute pathogenesis type diabetes pathophysiological hallmark consist progressive insulin resistance pancreatic cell dysfunction excessive hepatic glucose production ideal treatment type diabetes correct insulin resistance cell dysfunction normalize hepatic glucose output well prevent delay reverse diabetic complication emerge target therapy type diabetes include inhibition gluconeogenesis lipolysis fatty acid oxidation well stimulation adrenergic receptor drug intervention obesity legitimate adjunct diabetes management additional drug target include intervention prevent delay progression specific complication finally primary prevention type diabetes important emerging strategy specific pharmacological agent act various target discuss review targeted approach multiple underlying pathophysiologic process offer best chance control diabetes complication,Moneva MH,2002,Curr Drug Targets,https://doi.org/10.2174/1389450023347803,12041735,Moneva MH; Dagogo-Jack S,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review","D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D007333: Insulin Resistance; D007515: Islets of Langerhans; D009765: Obesity",,,https://openalex.org/W1529940825,58,10,1,1728,275,14,en,en
true,pharmacokinetics pharmacodynamics extended release glipizide git compare immediate release glipizide patient type ii diabetes mellitus,study design compare pharmacokinetic short term pharmacodynamic profile extended release glipizide git glucotrol xl give dosage mg daily immediate release glipizide glucotrol mg twice daily patient type ii diabetes mellitus open label randomize two way crossover study glipizide formulation administer day serial blood sample draw baseline th day treatment phase measurement glipizide glucose insulin c peptide concentration steady state mean cmax immediate release glipizide significantly great glipizide git tmax considerably short although mean cmin glipizide git high immediate release glipizide mean auc significantly low despite low plasma concentration glipizide git short term study two formulation similar effect serum concentration glucose insulin c peptide absence pronounced peak plasma concentration git formulation might confer advantage term maintain clinical effectiveness reduce potential cause adverse effect,Chung M,2002,J Clin Pharmacol,https://doi.org/10.1177/00970002042006007,12043953,Chung M; Kourides I; Canovatchel W; Sutfin T; Messig M; Chaiken RL,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D005913: Glipizide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2055404233,157,18,1,1264,205,7,en,en
true,nateglinide improve glycaemic control add metformin monotherapy result randomized trial type diabetes patient,aims hypothesis study evaluate addition nateglinide phenylalanine derivative restore early phase insulin release metformin type diabetes patient stabilize high dose metformin method multicentre double blind parallel group trial include metformin treated patient glycosylated haemoglobin hba c patient randomize add nateglinide mg mg placebo three meal metformin mg b week result hba c significantly reduce nateglinide mg mg plus metformin compare metformin control p p respectively great benefit occur patient elevate hba c baseline nateglinide mg patient hba c modest fasting plasma glucose reduction observe symptoms suggestive hypoglycaemia occur patient low hba c level baseline although confirmed case hypoglycaemia occur nateglinide mg patient group event suggestive hypoglycaemia confirm case plasma glucose mmol l weight gain week kg nateglinide mg vs metformin alone plasma lipid remain unchanged conclusions interpretation patient stabilize high dose metformin addition nateglinide improve glycaemic control combination agent well tolerate dos nateglinide prove effective efficacy nateglinide mg low rate hypoglycaemia observe dose make suitable patient close therapeutic target metformin monotherapy,Marre M,2002,Diabetes Obes Metab,https://doi.org/10.1046/j.1463-1326.2002.00196.x,12047396,Marre M; Van Gaal L; Usadel KH; Ball M; Whatmough I; Guitard C,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001786: Blood Glucose; D015992: Body Mass Index; D001835: Body Weight; D002784: Cholesterol; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D008875: Middle Aged; D000077715: Nateglinide; D010649: Phenylalanine; D010919: Placebos; D044469: Racial Groups; D012449: Safety; D014280: Triglycerides",,,https://openalex.org/W2032747159,135,20,1,1716,306,13,en,en
false,simultaneous glyburide metformin therapy superior component monotherapy initial pharmacological treatment type diabetes,evaluate whether simultaneous initial treatment insulin resistance impaired beta cell insulin secretion glyburide metformin tablet superior monotherapy component agent randomize parallel group placebo controlled multicentre study patient type diabetes mean duration year fail diet exercise randomly assign week therapy placebo glyburide mg metformin mg glyburide metformin mg glyburide metformin mg daily dos titrate week base glycaemic response primary outcome measure change baseline mean hba c week change fast plasma glucose lipid body weight also assess along h postprandial glucose insulin value standardized meal week patient take glyburide metformin mg mg tablet great reduction hba c level respectively compare placebo p glyburide p p respectively metformin p fast plasma glucose concentration reduce glyburide metformin group compare placebo metformin p patient combination therapy group also significantly low postprandial glucose concentration compare placebo glyburide metformin initial combination treatment glyburide metformin tablet produce great improvement glycaemic control either glyburide metformin monotherapy superiority initial therapy glyburide metformin tablet may arise simultaneous treatment pathophysiological defect type diabetes,Garber AJ,2002,Diabetes Obes Metab,https://doi.org/10.1046/j.1463-1326.2002.00211.x,12047399,Garber AJ; Larsen J; Schneider SH; Piper BA; Henry D; Glyburide/Metformin Initial Therapy Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D001835: Body Weight; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005215: Fasting; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D008875: Middle Aged; D010919: Placebos; D019518: Postprandial Period; D044469: Racial Groups; D012449: Safety; D014481: United States",,,https://openalex.org/W1995404454,137,17,1,1770,284,6,en,en
false,nateglinide new agent postprandial glucose control type diabetes,,Kotapati S,2002,Conn Med,,12071108,Kotapati S,article,D016428: Journal Article; D016454: Review,"D001786: Blood Glucose; D002986: Clinical Trials as Topic; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D004347: Drug Interactions; D006801: Humans; D007004: Hypoglycemic Agents; D000077715: Nateglinide; D010649: Phenylalanine",,,https://openalex.org/W2409817055,77,14,1,0,0,0,en,
false,efficacy safety pioglitazone type diabetes randomised placebo controlled study patient receive stable insulin therapy,glycaemic lipid effect treatment pioglitazone combination stable insulin regimen evaluate patient type diabetes patient n receive stable insulin regimen day yet hba c c peptide microg l randomise receive daily mg pioglitazone mg pioglitazone placebo week multicentre double blind placebo controlled trial per study protocol insulin dose remain unchanged could decrease response hypoglycaemia end double blind treatment patient receive pioglitazone mg mg show statistically significant mean decrease relative baseline hba c respectively p fast plasma glucose fpg mg dl mmol l mg dl mmol l respectively p difference compare placebo also significant p pioglitazone mg yield significant increase hdl c level mean increase range compare baseline placebo p mg dose also significantly reduce mean triglyceride level compare placebo p consistent change tc ldl c level observe incidence adverse event similar treatment group although incidence weight increase hypoglycaemia oedema high among patient receive insulin plus pioglitazone evidence hepatotoxicity drug induced elevation serum alt x uln pioglitazone add stable insulin regimen significantly improve hba c fpg type diabetes pioglitazone treatment also provide significant benefit respect plasma hdl c triglyceride level whether lipid change impact overall diabetic complication remain determine,Rosenstock J,2002,Int J Clin Pract,,12074206,Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S; Pioglitazone 014 Study Group,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D002784: Cholesterol; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007333: Insulin Resistance; D008297: Male; D008875: Middle Aged; D000077205: Pioglitazone; D013844: Thiazoles; D045162: Thiazolidinediones; D014280: Triglycerides",,,https://openalex.org/W40400977,139,21,1,1903,347,12,en,en
true,gliclazide modify release,gliclazide modify release mr new formulation drug gliclazide give daily hydrophilic matrix hypromellose based polymer new formulation effect progressive release drug parallel hour glycaemic profile untreated patient type diabetes mellitus formulation show high bioavailability absorption profile unaffected coadministration food mean plasma glucose level significantly reduce hour period patient type diabetes mellitus treat gliclazide mr daily fasting postprandial state cardiovascular atp sensitive potassium channel interaction observe therapeutic concentration gliclazide mr gliclazide mr also demonstrate antioxidant property independent glycaemic control randomised double blind multicentre study gliclazide mr mg daily show similar efficacy gliclazide immediate release ir mg day divide dos dos mg patient type diabetes mellitus month period reduce glycosylated haemoglobin hba c fast plasma glucose fpg similar extent drug appear efficacious patient previously treat diet alone significant reduction hba c baseline see month similarly sustained effect gliclazide mr observe subgroup elderly patient define priori hba c decrease similar degree observe general study population gliclazide mr show similar tolerability gliclazide ir month treatment randomised trial commonly observed adverse event arthralgia arthritis back pain bronchitis bodyweight remain stable study episode nocturnal hypoglycaemia hypoglycaemia require third party assistance observe treatment gliclazide mr episode symptomatic hypoglycaemia infrequent occur approximately patient,McGavin JK,2002,Drugs,https://doi.org/10.2165/00003495-200262090-00010,12076188,McGavin JK; Perry CM; Goa KL,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D001682: Biological Availability; D003692: Delayed-Action Preparations; D003924: Diabetes Mellitus, Type 2; D005907: Gliclazide; D006801: Humans; D007004: Hypoglycemic Agents; D016032: Randomized Controlled Trials as Topic",,,https://openalex.org/W2053463749,27,3,1,2125,362,12,en,en
false,clinical pharmacokinetics pharmacodynamics repaglinide,repaglinide novel fast acting prandial oral hypoglycaemic agent develop treatment patient type diabetes whose disease control diet exercise alone although repaglinide bind sulphonylurea bind site pancreatic beta cells similar mechanism action repaglinide exhibit distinct pharmacological property compare agent follow administration repaglinide absorb rapidly fast onset dose dependent blood glucose lowering effect drug eliminate rapidly via biliary route without accumulation plasma multiple dos repaglinide well tolerate patient type diabetes include elderly patient patient hepatic renal impairment pharmacokinetic profile repaglinide improvement post prandial hyperglycaemia overall glycaemic control make repaglinide suitable administration preprandially opportunity flexible meal arrangement include skipped meal without risk hypoglycaemia,Hatorp V,2002,Clin Pharmacokinet,https://doi.org/10.2165/00003088-200241070-00002,12083976,Hatorp V,article,D016428: Journal Article; D016454: Review,"D000328: Adult; D000368: Aged; D001786: Blood Glucose; D002219: Carbamates; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004347: Drug Interactions; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D008107: Liver Diseases; D008297: Male; D010880: Piperidines; D051437: Renal Insufficiency; D012293: Rifampin",,,https://openalex.org/W2020010218,61,6,1,1080,160,6,en,en
false,orlistat use type diabetes,review use orlistat type diabetes medline search english language literature august perform use key term orlistat obesity glucose diabetes article pertain orlistat consider inclusion emphasis place randomized placebo controlled double blind clinical trials april orlistat approve food drug administration treatment obesity randomized placebo controlled study report specific data individual type diabetes report significant weight reduction improved glycemic control placebo since weight loss difficult goal achieve patient type diabetes orlistat safe effective addition multidisciplinary approach,Snider LJ,2002,Ann Pharmacother,https://doi.org/10.1345/aph.1a422,12086556,Snider LJ; Malone M,article,D016428: Journal Article; D016454: Review,"D019440: Anti-Obesity Agents; D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D006442: Glycated Hemoglobin; D006207: Half-Life; D006801: Humans; D007408: Intestinal Absorption; D007783: Lactones; D009765: Obesity; D000077403: Orlistat; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome",,,https://openalex.org/W2107902273,31,6,1,807,130,3,en,en
false,desensitization insulin secretion,desensitization insulin secretion describe reversible state decreased secretory responsiveness pancreatic beta cell induce prolonged exposure multitude stimulus include main physiological stimulator glucose also nutrient like free fatty acid practically pharmacological stimulators act depolarization ca influx beta cell desensitization insulin secretion appear important step manifestation type diabetes secondary failure oral antidiabetic treatment commentary basic concept controversial issue field outline regard glucose induced desensitization two fundamentally oppose concept emerge first desensitization consequence functional change beta cell impair glucose recognition second long term increased secretory activity lead depletion releasable insulin often spite increased insulin synthesis latter concept appropriately termed beta cell exhaustion dichotomy applies desensitization evoke pharmacological stimulus relative contribution decreased insulin content versus alteration signal transduction dispute action tolbutamide beta cells may example desensitization cause lack releasable insulin since signaling mechanism nearly unchanged whereas action phentolamine imidazoline induce strong desensitization without reduce insulin content secretory granule apparently abolish ca influx pharmacological agent seem alteration signal transduction decreased availability releasable insulin contribute desensitized state beta cell relative contribution variable depend upon exact nature secretory stimulus,Rustenbeck I,2002,Biochem Pharmacol,https://doi.org/10.1016/s0006-2952(02)00996-6,12093468,Rustenbeck I,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D000818: Animals; D003924: Diabetes Mellitus, Type 2; D004734: Energy Metabolism; D005230: Fatty Acids, Nonesterified; D005947: Glucose; D006801: Humans; D007328: Insulin; D000078790: Insulin Secretion; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2026241715,36,4,1,1963,298,11,en,en
false,oral hypoglycemic agent pregnant diabetic bench bedside,today criterion diagnosis treatment evolve evidence based medicine approach need evidence based information especially critical management gestational diabetes general especially use oral hypoglycemic agent agent categorically contraindicate decade united state base anecdotal weak evidence recommendation article similarity gestational type diabetes describe rationale use oral hypoglycemic agent treatment discuss author show research basic science placental transfer clinical study perinatal outcome lead significant evidence base management recommendation,Langer O,2002,Semin Perinatol,https://doi.org/10.1053/sper.2002.33960,12099312,Langer O,article,D016428: Journal Article; D016454: Review,"D003924: Diabetes Mellitus, Type 2; D016640: Diabetes, Gestational; D019317: Evidence-Based Medicine; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D011247: Pregnancy; D011254: Pregnancy in Diabetics; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2039991857,75,14,1,809,130,5,en,en
false,change treatment start oral hypoglycaemic therapy type diabetes population based study,abstract aim determine change oral hypoglycaemic therapy time incidence insulin therapy people type diabetes method retrospective incidence cohort construct subject type diabetes obtain first prescription oral hypoglycaemic medication july december tayside scotland primary endpoint change oral hypoglycaemic therapy time insulin determine end follow december result overall subject switch insulin initially sulphonylurea initially metformin switch insulin therapy approximately three quarters remain class drug throughout study period median follow day die follow differ appreciably drug group male likely switch insulin compare female vs switch slightly young mean age year compare mean age year switch median time switch insulin day approximately month cohort give rate switch insulin per year poor glycaemic control hba c low body mass index bmi associate switch insulin conclusion follow initial therapy oral hypoglycaemic medication population switch insulin occur rate per year switch insulin associate young male low bmi high hba c diabet med,Donnan PT,2002,Diabet Med,https://doi.org/10.1046/j.1464-5491.2002.00743.x,12099966,Donnan PT; Steinke DT; Newton RW; Morris AD; DARTS/MEMO Collaboration,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D015992: Body Mass Index; D015331: Cohort Studies; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005500: Follow-Up Studies; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D010349: Patient Compliance; D012189: Retrospective Studies; D012606: Scotland; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2072642789,111,18,1,1668,319,14,en,en
false,bioequivalence evaluation two brand gliclazide mg tablet glyzide diamicron healthy human volunteer,abstract randomized two way crossover bioequivalence study fasting healthy male volunteer conduct compare two brand gliclazide mg tablet glyzide julphar uae test diamicron servier industry france reference product study perform international pharmaceutical research centre iprc joint venture speciality hospital amman jordan drug administer ml glucose solution h overnight fasting dose serial blood sample collect period h plasma harvest blood analyze gliclazide validated hplc method various pharmacokinetic parameter include auc auc c max max elimination rate constant determine plasma concentration formulation statistical module anova confidence interval apply auc auc c max bioequivalence evaluation two brand reveal significant difference ci fell within u fda accepted bioequivalence range base statistical inference glyzide judge bioequivalent diamicron copyright john wiley son ltd,Najib N,2002,Biopharm Drug Dispos,https://doi.org/10.1002/bdd.310,12116051,Najib N; Idkaidek N; Beshtawi M; Bader M; Admour I; Alam SM; Zaman Q; Dham R,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D019540: Area Under Curve; D002851: Chromatography, High Pressure Liquid; D018592: Cross-Over Studies; D005907: Gliclazide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D013607: Tablets; D013810: Therapeutic Equivalency",,,https://openalex.org/W2006920189,146,36,1,1260,238,8,en,en
false,oral hypoglycaemics use,first oral hypoglycaemic agent sulphonylureas metformin become available remain agent next year last five year three new class release general practitioner wide range effective hypoglycaemic agent choose article focus patient particular agent use e use general however must remember problem oral hypoglycaemics rare great majority patient problem prescribed hypoglycaemic medication,Phillips P,2002,Aust Fam Physician,,12143325,Phillips P; Braddon J,article,D002363: Case Reports; D016428: Journal Article; D016454: Review,"D020909: Acarbose; D000140: Acidosis, Lactic; D000368: Aged; D000075202: Contraindications; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D000077205: Pioglitazone; D051437: Renal Insufficiency; D000077154: Rosiglitazone; D013844: Thiazoles; D045162: Thiazolidinediones",,,https://openalex.org/W2417532462,42,9,2,625,106,6,en,en
false,improve glycaemic control metformin glibenclamide combine tablet therapy glucovance type diabetic patient inadequately control metformin,abstract aim evaluate efficacy safety two dosage strength single tablet metformin glibenclamide glyburide combination compare respective monotherapies patient type diabetes mellitus dm inadequately control metformin monotherapy method week double blind multicentre parallel group trial patient randomize receive metformin mg glibenclamide mg metformin glibenclamide mg mg metformin glibenclamide mg mg titrate intention achieve fast plasma glucose fpg mmol l result decrease glycated haemoglobin hba c fpg great p metformin glibenclamide mg mg mmol l mg mg mmol l compare metformin mmol l glibenclamide mmol l hba c achieve patient receive metformin glibenclamide mg mg mg mg respectively compare glibenclamide metformin p benefit achieve low mean dos metformin glibenclamide metformin glibenclamide mg mg mg mg mg mg mg mg glibenclamide mg metformin mg treatment related serious adverse event occur two patient receive glibenclamide plasma lipid profile unaffected mean change body weight kg conclusion intensive management type dm new metformin glibenclamide combination tablet improved glycaemic control facilitate attainment glycaemic target low dos metformin glibenclamide compare respective monotherapies without compromise tolerability diabet med,Marre M,2002,Diabet Med,https://doi.org/10.1046/j.1464-5491.2002.00774.x,12147149,Marre M; Howlett H; Lehert P; Allavoine T,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D001835: Body Weight; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004338: Drug Combinations; D005260: Female; D019270: Fructosamine; D005767: Gastrointestinal Diseases; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D006943: Hyperglycemia; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D008055: Lipids; D008297: Male; D008687: Metformin; D008875: Middle Aged; D013607: Tablets; D016896: Treatment Outcome",,,https://openalex.org/W2151921086,169,27,1,1835,326,11,en,en
false,rosiglitazone,unlabelled rosiglitazone thiazolidinedione different side chain troglitazone pioglitazone reduce plasma glucose level glucose production increase glucose clearance patient type diabetes mellitus insulin sensitivity pancreatic beta cell function surrogate marker cardiovascular risk factor significantly improve rosiglitazone double blind trial week rosiglitazone mg day monotherapy indicate significant decrease fast plasma glucose mmol l mg day glycosylated haemoglobin level hba c drug naive patient mg day significant decrease hyperglycaemic marker occur rosiglitazone combine metformin hba c sulphonylurea insulin week versus little change active comparator monotherapy efficacy maintain trial year also apparent various ethnic subgroup elderly patient obese nonobese patient rosiglitazone currently indicate combination injected insulin administer conjunction diet exercise regimen rosiglitazone generally well tolerate despite rare individual report liver function abnormality rosiglitazone recipient incidence clinical trial year duration similar placebo active comparator group fluid retention associate rosiglitazone may cause increased incidence anaemia clinical trial also mean patient monitor sign heart failure therapy although bodyweight increase overall rosiglitazone therapy increase subcutaneous visceral fat hepatic fat decrease pharmacokinetic profile rosiglitazone substantially alter age renal impairment important drug interaction rosiglitazone indicate patient active liver disease increase liver enzymes conclusion oral rosiglitazone mg day provide significant antihyperglycaemic efficacy generally well tolerate monotherapy combination antihyperglycaemic agent patient type diabetes mellitus active liver disease long term data require conclusion draw clinical significance positive change surrogate marker cardiovascular disease risk improvement pancreatic beta cell function rosiglitazone significantly improve insulin sensitivity welcome addition treatment option patient type diabetes mellitus,Wagstaff AJ,2002,Drugs,https://doi.org/10.2165/00003495-200262120-00007,12149047,Wagstaff AJ; Goa KL,article,D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D000368: Aged; D019540: Area Under Curve; D003924: Diabetes Mellitus, Type 2; D004347: Drug Interactions; D006207: Half-Life; D006801: Humans; D007004: Hypoglycemic Agents; D007408: Intestinal Absorption; D008099: Liver; D008875: Middle Aged; D016032: Randomized Controlled Trials as Topic; D000077154: Rosiglitazone; D013329: Structure-Activity Relationship; D013844: Thiazoles; D045162: Thiazolidinediones; D016896: Treatment Outcome",,,https://openalex.org/W2071326073,13,1,1,2764,455,16,es,en
false,combination therapy nateglinide thiazolidinedione improve glycemic control type diabetes,objective compare effect monotherapy use nateglinide thiazolidinedione troglitazone initial combination two agent glycated hemoglobin hba c patient type diabetes inadequately control diet alone research design methods study consist week double blind randomize multicenter study include week single blind placebo run period week shorten week double blind active treatment period results week end point nateglinide mg troglitazone mg combination agent achieve statistically significant decrease hba c comparison placebo baseline hba c p lt reduction hba c similar nateglinide troglitazone monotherapy group reduction hba c great combination group patient combination group achieve hba c level lt combination group high number adverse event primarily due increase incidence mild hypoglycemia treatment group conclusions nateglinide troglitazone equally effective decrease hba c level however reduction baseline hba c value gt adequate achieve hba c level lt contrast combination nateglinide thiazolidinedione show additive effect highly effective reduce hba c level target lt patient baseline hba c,Rosenstock J,2002,Diabetes Care,https://doi.org/10.2337/diacare.25.9.1529,12196422,Rosenstock J; Shen SG; Gatlin MR; Foley JE,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D000077715: Nateglinide; D010649: Phenylalanine; D013844: Thiazoles; D045162: Thiazolidinediones; D016896: Treatment Outcome",,,https://openalex.org/W2149283639,105,14,1,1593,303,9,en,en
false,glimepiride improve first second phase insulin secretion type diabetes,objective purpose study assess effect glimepiride insulin sensitivity secretion subject type diabetes research design methods week washout prior sulfonylurea therapy obese subject type diabetes underwent euglycemic hyperglycemic clamp study glimepiride therapy results glimepiride result mmol l decrease fast plasma glucose p correlate reduction postabsorptive endogenous glucose production egp vs mol kg min p r p postabsorptive egp glimepiride similar control subject mol kg min n fast plasma insulin vs pmol l p first phase vs pmol l p second phase incremental insulin response glucose vs pmol l p improve glimepiride therapy insulin sensitivity change treatment vs mol kg min pmol remain control subject mol kg min pmol p conclusions current study demonstrate glimepiride improve first second phase insulin secretion insulin sensitivity individual type diabetes,Korytkowski M,2002,Diabetes Care,https://doi.org/10.2337/diacare.25.9.1607,12196435,Korytkowski M; Thomas A; Reid L; Tedesco MB; Gooding WE; Gerich J,article,"D016430: Clinical Trial; D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000368: Aged; D001786: Blood Glucose; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D005215: Fasting; D005260: Female; D015309: Glucose Clamp Technique; D006442: Glycated Hemoglobin; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D007333: Insulin Resistance; D000078790: Insulin Secretion; D008297: Male; D008875: Middle Aged; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2128061198,89,14,1,1370,270,7,en,en
false,gliclazide improve anti oxidant status nitric oxide mediated vasodilation type diabetes,abstract aim evaluate effect gliclazide oxidative status vascular response systemic administration l arginine natural precursor nitric oxide type diabetic patient method thirty type diabetic patient receive glibenclamide n gliclazide n week randomize observer blinded parallel study plasma lipid peroxide total radical trapping anti oxidant parameter trap blood pressure responses intravenous bolus l arginine measure pre post treatment result week gliclazide patient low plasma lipid peroxide mol l vs mol l p high plasma trap mol l vs mol l p glibenclamide patient gliclazide glibenclamide significantly reduce systolic diastolic blood pressure p p respectively two way repeat measure analysis variance response intravenous l arginine conclusion gliclazide reduces oxidative stress type diabetic patient improve plasma anti oxidant status effect associate enhanced mediated vasodilation,Fava D,2002,Diabet Med,https://doi.org/10.1046/j.1464-5491.2002.00762.x,12207812,Fava D; Cassone-Faldetta M; Laurenti O; De Luca O; Ghiselli A; De Mattia G,article,"D016430: Clinical Trial; D003160: Comparative Study; D023362: Evaluation Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000975: Antioxidants; D001120: Arginine; D001794: Blood Pressure; D003924: Diabetes Mellitus, Type 2; D005609: Free Radicals; D005907: Gliclazide; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007275: Injections, Intravenous; D008054: Lipid Peroxides; D008297: Male; D008875: Middle Aged; D009569: Nitric Oxide; D018384: Oxidative Stress; D014664: Vasodilation",,,https://openalex.org/W2114299222,97,12,1,1201,206,7,en,en
true,patient perception prandial oral therapy type diabetes,purpose survey conduct assess patient perception glycemic control convenience flexibility prescribed prandial oral therapy type diabetes mellitus method questionnaire distribute physician yield baseline response patient begin repaglinide treatment data analyze respondent also complete follow questionnaire week treatment result among respondent take repaglinide antidiabetic agent combination therapy take metformin take troglitazone respondent indicate satisfied satisfied repaglinide therapy wish continue use believe treatment improve attitude toward take antidiabetic medication patient perceive fast blood glucose level reduce treatment incidence hyperglycemia correspond change perceived frequency hypoglycemia repaglinide treatment minimal conclusion patient perception prandial oral therapy repaglinide predominantly positive due mostly perception glucose control achieve minimal perception increase hypoglycemic episode,Bonneville M,2001,Diabetes Educ,https://doi.org/10.1177/014572170102700507,12212016,Bonneville M; Colgin J; Nalesnick JA; Perez J; Wentz L,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D000368: Aged; D001294: Attitude to Health; D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D004435: Eating; D005260: Female; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D008875: Middle Aged; D010880: Piperidines; D011795: Surveys and Questionnaires",,,https://openalex.org/W2110230137,64,10,1,1303,205,8,en,en
false,tablet breaking ability old person type diabetes mellitus,purpose study assess ability old person type diabetes accurately break half different formulation micronized glyburide tablets thirty person type diabetes age recruit st louis university geriatric clinic participant randomly assign group group break glynase prestabs generic tablet use different manual tablet breaking method group b break glynase prestabs generic tablet without instruction visual analog scale use assess pain difficulty tablet breaking high percentage successful tablet breaking report glynase prestabs compare generic tablet mean pain score break glynase prestabs group group b high pain score obtain generic tablet group group b glynase prestabs easy break group resultant half tablet show less variance expected theoretical weight whole parent tablet weight older adult break glynase prestabs accurately less difficulty generic micronized glyburide tablet variation ease tablet breaking accuracy different tablet formulation affect bioavailability patient compliance,Wilson MG,2001,Diabetes Educ,https://doi.org/10.1177/014572170102700408,12212341,Wilson MG; Kaiser FE; Morley JE,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000368: Aged; D000369: Aged, 80 and over; D003924: Diabetes Mellitus, Type 2; D016568: Drugs, Generic; D006801: Humans; D007004: Hypoglycemic Agents; D011597: Psychomotor Performance; D013607: Tablets",,,https://openalex.org/W2130864096,70,10,1,1351,234,9,en,en
false,repaglinide versus metformin combination bedtime nph insulin patient type diabetes establish insulin metformin combination therapy,objective compare effect glycemic control weight gain repaglinide versus metformin combine bedtime nph insulin patient type diabetes research design methods total subject treat mg metformin combine bedtime nph insulin randomize week open label treatment mg repaglinide n metformin dose unchanged n insulin dose titrate clinician discretion aim fasting blood glucose fbg mmol l results baseline age diabetes duration insulin requirement weight bmi fbg hba c diabetes control complication trial aligned assay normal range similar glycemic control improve nonsignificantly insulin metformin mean p deteriorate insulin repaglinide mean p p group weight gain less insulin metformin kg mean se p versus kg p lt p group diabetes treatment satisfaction questionnaire score potential range minimum maximum increase p insulin metformin decrease p lt insulin repaglinide conclusions combined bedtime nph insulin metformin provide superior glycemic control repaglinide less weight gain improve diabetes treatment satisfaction,Furlong NJ,2002,Diabetes Care,https://doi.org/10.2337/diacare.25.10.1685,12351462,Furlong NJ; Hulme SA; O'Brien SV; Hardy KJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D002219: Carbamates; D003404: Creatinine; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007336: Insulin, Isophane; D008297: Male; D008687: Metformin; D008875: Middle Aged; D010880: Piperidines; D013997: Time Factors",,,https://openalex.org/W2127352898,154,20,1,1538,311,10,en,en
false,diabetes outcome progression trial adopt,objective therapies metformin sulfonylurea insulin improve glycemic control short term prevent progressive islet cell failure long term deterioration glycemia goal evaluate patient recently diagnose type diabetes lt year long term efficacy monotherapy rosiglitazone glycemic control progression pathophysiological abnormality associate type diabetes compare metformin glyburide monotherapy research design methods diabetes outcome progression trial adopt randomized double blind parallel group study consist screening visit week placebo run year treatment period observational follow drug nai patient type diabetes diagnose within previous year run patient randomize rosiglitazone glyburide metformin titrate maximum effective daily dos mg rosiglitazone mg glyburide g metformin primary outcome time monotherapy failure define time follow titration maximal effective tolerate dose fast plasma glucose exceeds mg dl mmol l secondary outcome include measure islet cell function insulin sensitivity dyslipidemia change urinary albumin excretion plasminogen activator inhibitor antigen fibrinogen c reactive protein safety tolerability also evaluate patient reported outcome resource utilization data collect analyze conclusions adopt provide data effect mechanistically differ treatment option metabolic control cell function marker macrovascular disease risk type diabetes,Viberti G,2002,Diabetes Care,https://doi.org/10.2337/diacare.25.10.1737,12351470,Viberti G; Kahn SE; Greene DA; Herman WH; Zinman B; Holman RR; Haffner SM; Levy D; Lachin JM; Berry RA; Heise MA; Jones NP; Freed MI,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000419: Albuminuria; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D018450: Disease Progression; D004311: Double-Blind Method; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008687: Metformin; D012107: Research Design; D000077154: Rosiglitazone; D012449: Safety; D013844: Thiazoles; D045162: Thiazolidinediones; D013997: Time Factors; D017211: Treatment Failure; D016896: Treatment Outcome",,,https://openalex.org/W2134315188,44,8,1,1775,288,9,en,en
false,metformin evidence based versus rational pharmacotherapy,retroperitoneal fibrosis rpf uncommon collagen vascular disease unclear aetiology characterise chronic non specific inflammation retroperitoneum entrap obstruct retroperitoneal structure notably ureter protean manifestation rpf awareness disease important still uncommon detect rpf severe renal failure present comprehensive review deal various aspect rpf try provide framework diagnosis treatment follow intriguing condition although may various cause chronic periaortitis appear increasingly encountered form secondary rpf patient advanced atherosclerosis irrespective cause case non malignant rpf active cellular stage respond treatment corticosteroid thereby obviate need surgical treatment clinical radiographic improvement see start steroid therapy often impressive reassure diagnosis treatment corticosteroid may also make aneurysmectomy indicate feasible patient present perianeurysmal fibrosis renal failure accumulate data suggest alternative treatment strategy steroid resistant case e intensive immunosuppression steroid feasible e form immunosuppression hormonal treatment particularly tamoxifen although early diagnosis treatment provide excellent renal patient outcome long term follow mandatory case n r u c n retroperitoneal fibrosis rpf uncommon disorder unclear aetiology characterise chronic non specific inflammation retroperitoneum entrap obstruct retroperitoneal structure notably ureter protean manifestation rpf condition frequently detect evaluation newly diagnose renal failure hypertension true incidence unknown estimate vary per year although paper devote various aspect rpf find literature still accepted diagnostic therapeutic strategy however routine use sophisticated image technique refine diagnostic process addition increase number author propound view non surgical approach rpf support comprehensive review deal recent advance understanding intriguing condition current diagnostic therapeutic procedure discuss attempt assess present role non surgical treatment particularly corticosteroid treatment rpf c l n c l n f e n retroperitoneal fibrosis occur predominantly men fifth sixth decade life male female ratio approximate date however least case condition report child year age early symptom non specific correct diagnosis often make obstructive uropathy renal failure occur duration symptom prior diagnosis usually four six month sometimes one year symptom result entrapment ureter great vessel branch surrounding nerve majority patient presenting symptom pain low back flank abdomen insidious onset pain dull non colicky disease progress become severe frequent symptom loss weight malaise anorexia non specific gastrointestinal symptom less frequently urinary symptom present frequent micturition oliguria anuria rare symptom include fever testicular pain abdominal angina intermittent claudication oedema gross haematuria physical examination usually unremarkable except presence hypertension probably renal origin urinary tract obstruction may lead acute hypertension patient possibly rise renin release volumedependent hypertension occur result obstructive nephropathy reversibility hypertension depend history success ureterolysis rare case hypertension result entrapment renal artery note patient present malignant hypertension hypertensive encephalopathy describe occasionally abdominal pelvic mass present rare physical finding include peripheral oedema thrombosis ascites hydrocele jaundice small bowel colonic obstruction spinal cord compression scoliosis laboratory investigation primarily reflect systemic response inflammatory disease impairment renal function elevated erythrocyte sedimentation rate esr almost invariably present commonly normochromic normocytic anaemia less extent polyclonal gammopathy mild thrombocytosis although azotaemia present patient early review less common today patient diagnose renal insufficiency develop however raise serum creatinine level vary degree still frequent finding typically normal finding routine urinalysis,Smits P,2002,Neth J Med,,12365465,Smits P; Tack CJ,article,D016420: Comment; D016421: Editorial,"D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D019317: Evidence-Based Medicine; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008687: Metformin",,,https://openalex.org/W2184070395,58,7,1,5401,900,42,en,en
false,factor associate switch oral hypoglycaemic agent insulin therapy,aim study determine factor associate switch oral hypoglycaemic agent insulin therapy patient type diabetes mellitus general practice longitudinal observational study dutch general healthcare centre pharmacologically treat patient type diabetes mellitus include n comorbidity laboratory result medication use obtain general practitioner files total patient switch oral hypoglycaemic agent insulin therapy significantly young onset diabetes versus year fast blood glucose level hba c value significantly high switch compare patient oral treatment mmol l versus mmol l versus respectively concern comorbidity suffer frequently acute myocardial infarction lipid disorder depression retinopathy atrial fibrillation cardiovascular disease general often present patient switch insulin versus ci patients switch insulin therapy young diagnosis suffer health problem besides diabetes especially cardiovascular disease bad metabolic control compare user oral hypoglycaemic agent,Spoelstra JA,2002,Neth J Med,,12365467,Spoelstra JA; Stol RP; de Bruyne MC; Erkens JA; Herings RM; Leufkens HG; Grobbee DE,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D017668: Age of Onset; D001786: Blood Glucose; D002318: Cardiovascular Diseases; D015897: Comorbidity; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008137: Longitudinal Studies; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W111300407,84,12,1,1367,230,6,en,en
false,discontinuation metformin type diabetes patient treat insulin,metformin add insulin therapy type diabetic patient improve glycaemic control decrease required daily dose insulin ddi metformin discontinue cardiac hepatic renal failure develop examine whether glycaemic control maintain metformin cessation include type diabetic patient treat insulin plus metformin match control treat insulin discontinuation metformin first group aim tight fasting postprandial blood glucose level mmol l respectively group week assess glycaemic control every two week necessary adjust insulin dosage group metformin discontinue ddi increase iu p leave glycaemic control unchanged control glycated haemoglobin ghb decrease p ddi increase slightly iu p increase ddi large patient metformin discontinue control p type diabetic patient treat insulin plus metformin glycaemic control maintain discontinuation metformin increase ddi substantially application intensified treatment protocol,Wulffelé MG,2002,Neth J Med,,12365468,Wulffelé MG; Kooy A; Lehert P; Bets D; Oom JA; Borger van der Burg B; Donker AJ; Stehouwer CD,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D001786: Blood Glucose; D016022: Case-Control Studies; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged",,,https://openalex.org/W170438156,78,12,1,1377,248,7,en,en
false,durability efficacy long term safety profile glyburide metformin tablet patient type diabetes mellitus open label extension study,intensive glycemic control substantially reduce microvascular macrovascular complication type diabetes mellitus although less half patient diabetes achieve target glycosylated hemoglobin hba c value recommend american diabetes association monotherapy oral agent address multiple pathophysiologic defect diabetes use combination therapy appear warrant previous week randomize double blind placebo controlled trial find treatment glyburide metformin tablet associate great reduction hba c value compare glyburide monotherapy metformin monotherapy placebo study evaluate durability efficacy long term safety profile therapy glyburide metformin tablet weeks patients enrol open label extension study draw group complete week double blind study discontinue double blind study ineligible double blind study enrol directly open label extension study patient hba c receive glyburide metformin mg mg tablet bid hba c receive glyburide metformin mg mg tablet bid primary efficacy variable include change baseline hba c fast plasma glucose fpg body weight week safety assess base adverse event data result physical examination laboratory tests total patient enrol study complete week double blind study discontinue double blind study directly enrol week mean hba c value entire population decrease baseline value ci patient enrol directly poor glycemic control baseline experience great reduction hba c ci reduction mean fpg total population observe early week mg dl ci symptom hypoglycemia occur patient although one third patient document finger stick blood glucose value mg dl week open label extension study glyburide metformin tablet well tolerate effective patient type diabetes provide rapid sustainable reduction hba c value fpg concentration,Garber AJ,2002,Clin Ther,https://doi.org/10.1016/s0149-2918(02)80044-3,12380632,Garber AJ; Bruce S; Fiedorek FT,article,D016428: Journal Article,"D001786: Blood Glucose; D001835: Body Weight; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004359: Drug Therapy, Combination; D005215: Fasting; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008137: Longitudinal Studies; D008297: Male; D008687: Metformin; D008875: Middle Aged; D019518: Postprandial Period; D013607: Tablets",,,https://openalex.org/W2164789983,155,22,1,2584,439,11,en,en
false,lipid effect glyburide metformin tablet patient type diabetes mellitus poor glycemic control dyslipidemia open label extension study,type diabetes elevate plasma lipid level important independent risk factor cardiovascular disease coronary heart disease choice antihyperglycemic agent patient type diabetes abnormal plasma lipid level often seen take account effect lipid well marker glycemic control study assess effect lipid level glyburide metformin tablet treatment type diabetes particularly group patient poor glycemic control dyslipidemia baseline week open label study extension week double blind placebo controlled study patient population draw group complete double blind study discontinue double blind study ineligible double blind study base predefined measure glycemic control screen fast plasma glucose mg dl glycosylated hemoglobin hba c hba c directly enrol open label extension study patient hba c receive glyburide metformin tablet mg mg bid hba c receive glyburide metformin tablet mg mg bid change total cholesterol tc low density lipoprotein cholesterol ldl c high density lipoprotein cholesterol hdl c triglyceride tg level assess weeks study population include patient complete double blind study discontinue double blind study enrol directly direct enrollee poor glycemic control dyslipidemia baseline improvement plasma lipid level see early week week mean change tc baseline mg dl total population ci p mg dl direct enrollee ci p mean decrease ldl c baseline total population mg dl ci p compare reduction mg dl direct enrollee ci p mean hdl c level minimally affect mean tg level decrease mg dl entire population ci p mg dl direct enrollee ci p open label extension study treatment glyburide metformin tablet type diabetes durable favorable effect lipid level particularly poor glycemic control dyslipidemia baseline,Dailey GE,2002,Clin Ther,https://doi.org/10.1016/s0149-2918(02)80046-7,12380634,Dailey GE; Mohideen P; Fiedorek FT,article,D016428: Journal Article,"D001786: Blood Glucose; D002318: Cardiovascular Diseases; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005215: Fasting; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D006949: Hyperlipidemias; D007004: Hypoglycemic Agents; D008137: Longitudinal Studies; D008297: Male; D008687: Metformin; D008875: Middle Aged; D012307: Risk Factors; D014280: Triglycerides",,,https://openalex.org/W2012633033,163,23,1,2637,498,10,en,en
false,quality care diabetes understand guideline,midst global pandemic diabetes despite increase burden disease measurement quality repeatedly show poor adherence implementation current guideline diabetes care article provide brief review significant randomize controlled clinical trial relevant current guideline discuss essential treatment goal evidence support several practical clinical question relate implementation modern diabetes guideline raise answer finally reason poor quality performance observe examine,Bouldin MJ,2002,Am J Med Sci,https://doi.org/10.1097/00000441-200210000-00006,12385492,Bouldin MJ; Low AK; Blackston JW; Duddleston DN; Holman HE; Hicks GS; Brown CA,article,D016428: Journal Article; D016454: Review,"D000894: Anti-Inflammatory Agents, Non-Steroidal; D001241: Aspirin; D001786: Blood Glucose; D002986: Clinical Trials as Topic; D003920: Diabetes Mellitus; D017408: Guidelines as Topic; D006801: Humans; D007668: Kidney; D050356: Lipid Metabolism; D011787: Quality of Health Care; D016032: Randomized Controlled Trials as Topic; D012160: Retina; D012307: Risk Factors",,,https://openalex.org/W1999467765,57,9,1,637,101,5,en,en
false,retrospective cohort analysis clinical effectiveness physician pharmacist collaborative drug therapy management diabetes clinic,glycemic control patient diabetes physician supervised pharmacist managed primary care clinic compare patient receive standard care health care system retrospectively analyze glycemic control men type type diabetes whose diabetes related drug therapy manage clinical pharmacist compare control group similar patient whose care augment clinical pharmacist primary outcome difference fast blood glucose fbg glycosylated hemoglobin c level group secondary outcome relative risk rr achieve c frequency diabetes related schedule unscheduled clinic visit frequency hypoglycemic event study group clinic visit control group october june statistical difference note fbg c group rr achieve c significantly high study cohort rr confidence interval ci frequency hypoglycemic event differ group mean sd frequency unscheduled diabetes related clinic visits patient year higher control group study group p pharmacist managed diabetes care effective improve glycemic control associate increase risk hypoglycemic event unscheduled diabetes related clinic visit,Irons BK,2002,Pharmacotherapy,https://doi.org/10.1592/phco.22.15.1294.33476,12389879,Irons BK; Lenz RJ; Anderson SL; Wharton BL; Habeger B; Anderson HG,article,D016428: Journal Article,"D000328: Adult; D000554: Ambulatory Care Facilities; D015190: Blood Glucose Self-Monitoring; D003922: Diabetes Mellitus, Type 1; D003924: Diabetes Mellitus, Type 2; D019468: Disease Management; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D017063: Outcome Assessment, Health Care; D010348: Patient Care Team; D010353: Patient Education as Topic; D010595: Pharmacists; D010820: Physicians; D012189: Retrospective Studies",,,https://openalex.org/W2059266698,141,17,1,1541,265,10,en,en
false,oral antihyperglycemic agent pregnancy lactation,treatment approach diabetes mellitus pregnancy require combination diet exercise multiple home glucose determination intensive insulin regimen last decade increased interest use oral antihyperglycemic agent oahas alternative insulin achieve good glycemic control oahas divide four group derivative sulfonylurea biguanides glucosidase inhibitor thiazolidinediones review describe possible teratogenic effect use oahas pregnancy effect drug lactation animal human study assess teratogenic effect oahas yield conflicting data risk major malformation infant mother diabetes appear relate maternal glycemic control rather antidiabetic therapy major concern use oahas pregnancy neonatal hypoglycemia may severe persist day therefore insulin still drug choice implicate teratogen human pregnancy addition lack data regard use oahas pregnancy draw firm conclusion available drug however oahas especially glibenclamide glyburide may beneficial situation proper use insulin problematic limited clinical data exposure oahas infant via breast milk potentially serious effect neonatal hypoglycemia safe recommendation breast feed take oahas well conducted prospective controlled study regard feasibility oahas pregnant woman diabetes lactation need,Merlob P,2002,Paediatr Drugs,https://doi.org/10.2165/00128072-200204110-00007,12390047,Merlob P; Levitt O; Stahl B,article,D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D001645: Biguanides; D003924: Diabetes Mellitus, Type 2; D016640: Diabetes, Gestational; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007774: Lactation; D008895: Milk, Human; D011247: Pregnancy; D011256: Pregnancy Outcome; D011254: Pregnancy in Diabetics; D013453: Sulfonylurea Compounds; D013844: Thiazoles",,,https://openalex.org/W1536422180,60,7,1,1774,298,11,en,en
false,troglitazone discovery development novel therapy treatment type diabetes mellitus,prior introduction troglitazone year since last significant improvement antidiabetic therapy view press need effective oral agent treatment type diabetes mellitus troglitazone grant priority review fda launch usa first thiazolidinedione insulin sensitize agent troglitazone quickly follow rosiglitazone pioglitazone glitazones prove effective lower blood glucose also beneficial effect cardiovascular risk troglitazone subsequently withdraw concern hepatotoxicity appear less problem rosiglitazone pioglitazone recent insight molecular mechanism action glitazones ligands peroxisome proliferator activated receptor open prospect design effective selective safer antidiabetic agent document review history troglitazone discovery clinical development,Parker JC,2002,Adv Drug Deliv Rev,https://doi.org/10.1016/s0169-409x(02)00093-5,12393300,Parker JC,article,D016428: Journal Article; D016454: Review,"D002839: Chromans; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D013844: Thiazoles; D045162: Thiazolidinediones; D000077288: Troglitazone",,,https://openalex.org/W2081092754,108,18,1,1088,173,7,en,en
false,comparison effect rosiglitazone glyburide cardiovascular function glycemic control patient type diabetes,open label active controlled study investigate cardiac safety antihyperglycemic effect rosiglitazone rsg patient type diabetes patient randomly assign rsg mg b glyburide glb titrate achieve optimal glycemic control first week limit risk hypoglycemia mean mg day echocardiogram perform week leave ventricular lv mass index ejection fraction leave ventricular end diastolic volume assess mode echocardiography baseline week h ambulatory blood pressure assess baseline week glycemic control assess measure fast plasma glucose fpg hba c neither treatment produce increase lv mass index exceed sd ejection fraction change either group group clinically insignificant increase lv end diastolic volume rsg glb cause statistically significant reduction ambulatory diastolic blood pressure treatment reduce hba c fpg total week therapy rsg mg b adversely affect cardiac structure function patient type diabetes produce significant sustained reduction hyperglycemia decrease ambulatory diastolic blood pressure rsg superior glb,St John Sutton M,2002,Diabetes Care,https://doi.org/10.2337/diacare.25.11.2058,12401757,St John Sutton M; Rendell M; Dandona P; Dole JF; Murphy K; Patwardhan R; Patel J; Freed M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001786: Blood Glucose; D001794: Blood Pressure; D015992: Body Mass Index; D002320: Cardiovascular Physiological Phenomena; D002319: Cardiovascular System; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006439: Hemodynamics; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D010919: Placebos; D044469: Racial Groups; D000077154: Rosiglitazone; D012449: Safety; D013844: Thiazoles; D045162: Thiazolidinediones; D013997: Time Factors; D016277: Ventricular Function, Left",,,https://openalex.org/W2102319947,139,21,1,1397,251,10,en,en
false,glyburide metformin combination product safe efficacious patient type diabetes fail sulphonylurea therapy,compare efficacy safety tolerability fixed combination glyburide metformin preparation glyburide metformin alone patient type diabetes inadequately control sulphonylurea diet exercise week randomize double blind parallel group study patient inadequate glycaemic control least half maximal dose sulphonylurea randomly assign glyburide mg b n metformin mg n glyburide metformin mg mg n glyburide metformin mg mg n titration allow maximum dos mg metformin mg mg mg mg glyburide metformin mg mg mg mg respectively primary outcome measure hba c level week secondary end points include fasting h post prandial plasma glucose adverse event aes record summarize treatment group strength glyburide metformin equally reduced mean hba c glyburide alone p metformin alone p final mean fast plasma glucose concentration also low glyburide metformin group glyburide mmol l mg dl p metformin group mmol l mg dl p safety tolerability similar across treatment group except high incidence gastrointestinal aes metformin monotherapy group patient report mild moderate symptom hypoglycaemia take glyburide metformin glyburide metformin tablet strength produce equal efficacy significantly good glycaemic control monotherapy either agent data also confirm glycaemic efficacy require maximal sulphonylurea dos combination metformin,Blonde L,2002,Diabetes Obes Metab,https://doi.org/10.1046/j.1463-1326.2002.00229.x,12406033,Blonde L; Rosenstock J; Mooradian AD; Piper BA; Henry D,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004338: Drug Combinations; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D008875: Middle Aged; D017211: Treatment Failure",,,https://openalex.org/W1999398484,126,16,1,1873,321,8,en,en
false,plasminogen activator inhibitor physiologic role regulation influence common pharmacologic agent,plasminogen activator inhibitor pai major inhibitor endogenous thrombolysis thereby promote thrombosis pai also primary contributor development recurrence acute myocardial infarction renin angiotensin system hypertriglyceridemia hyperglycemia hyperinsulinemia estrogen influence fibrinolytic system pai particular available data strongly suggest angiotensin converting enzyme ace inhibitor hormone replacement therapy estrogen beneficially reduce pai production metformin agent commonly use non insulin dependent diabetes mellitus niddm appear favorably decrease pai production niddm patient nondiabetic patient among cholesterollowering statin clinical literature evaluate pravastatin provide compelling data support agent favorable effect pai available statin either display effect pai clear data conclusively define effect fibrinolytic system,Tsikouris JP,2002,J Clin Pharmacol,https://doi.org/10.1177/009127002762491271,12412817,Tsikouris JP; Suarez JA; Meyerrose GE,article,D016428: Journal Article; D016454: Review,D057911: Angiotensin Receptor Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D002986: Clinical Trials as Topic; D003328: Coronary Thrombosis; D015914: Estrogen Replacement Therapy; D005342: Fibrinolysis; D006801: Humans; D019161: Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006943: Hyperglycemia; D006946: Hyperinsulinism; D006949: Hyperlipidemias; D007004: Hypoglycemic Agents; D009203: Myocardial Infarction; D017395: Plasminogen Activator Inhibitor 1; D012084: Renin-Angiotensin System,,,https://openalex.org/W2009310911,113,16,1,1065,158,7,en,en
true,differential effect glyburide glibenclamide metformin qt dispersion potential adenosine triphosphate sensitive k channel effect,glyburide glibenclamide specific blocker adenosine triphosphate atp sensitive potassium k channel report result prolongation qt interval qt interval dispersion qtd potentially sensitive marker increase risk arrhythmia sudden cardiac death aim present study evaluate effect glyburide qtd compare metformin hypoglycemic agent block adenosine triphosphate sensitive k channel thirty patient type diabetes randomize glyburide metformin group lead electrocardiogram obtain month glyburide metformin therapy qt qtd measure qt correct rate qtc significant difference glyburide metformin group age v year baseline rr interval v qt v qtc v glyburide associate significant increase qtc p qtd p qtc dispersion qtcd p contrast metformin associate decrease qtc p affect qtd p n qtcd p n glyburide unlike metformin cause increase qt dispersion increase dispersion may factor underlie increase risk arrhythmia sudden cardiac death,Najeed SA,2002,Am J Cardiol,https://doi.org/10.1016/s0002-9149(02)02776-5,12423711,Najeed SA; Khan IA; Molnar J; Somberg JC,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D000368: Aged; D001145: Arrhythmias, Cardiac; D003924: Diabetes Mellitus, Type 2; D004562: Electrocardiography; D005905: Glyburide; D006442: Glycated Hemoglobin; D006329: Heart Conduction System; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D008875: Middle Aged; D016896: Treatment Outcome",,,https://openalex.org/W2057842213,143,21,1,1560,354,12,en,en
false,therapeutic option management type diabetes mellitus,incidence diabetes mellitus steadily increase united state currently united state spend approximately billion healthcare cost annually management diabetes cost attribute hospitalization treatment diabetes complication prevent complication tight glycemic control key reduce morbidity mortality healthcare cost secondary diabetes mellitus recently american college endocrinology also stress earlier screen diabetes endorse lower goal percent hemoglobin glycosylation strategy help identify patient diabetes early stage turn prevent complication good control diabetes feasible recent approval new antidiabetic product pioglitazone rosiglitazone agent novel mechanism action metformin xr insulin aspart miglitol agent similar previously market product different pharmacokinetic pharmacodynamic property metformin glyburide first combination product treatment diabetes nateglinide represent first agent new class antidiabetic agent insulin glargine novel insulin preparation agent unique characteristic may render useful specific patient population,Takiya L,2002,Am J Manag Care,,12437315,Takiya L; Chawla S,article,D016428: Journal Article; D016454: Review,"D017485: 1-Deoxynojirimycin; D000328: Adult; D003924: Diabetes Mellitus, Type 2; D019468: Disease Management; D004502: Education, Medical, Continuing; D004513: Education, Pharmacy, Continuing; D005944: Glucosamine; D006801: Humans; D007004: Hypoglycemic Agents; D050112: Imino Pyranoses; D007328: Insulin; D061267: Insulin Aspart; D008329: Managed Care Programs; D008687: Metformin; D013844: Thiazoles; D045162: Thiazolidinediones; D014481: United States",,,https://openalex.org/W115503630,67,11,1,1403,219,12,en,en
false,contentious nature gestational diabetes diet insulin glyburide metformin,gestational diabetes gd develop pregnancy increase requirement insulin secretion increase insulin resistance woman gd often impair pancreatic beta cell compensation insulin resistance nature gd currently contentious debate existence diagnosis ramification mother offspring pregnancy late life also contentious outcome intervention diet insulin glyburide glynase trade mark pharmacia upjohn metformin glucophage trade mark bristol myers squibb consensus woman unequivocal gd significant risk adverse perinatal outcome increase risk late type diabetes mellitus foetus pregnancy gd high risk macrosomia associate high rate birth injury asphyxia neonatal hypoglycaemia hyperinsulinaemia uncontrolled gd predispose foetus accelerate excessive fat accumulation insulin resistance pancreatic exhaustion secondary prenatal hyperglycaemia possible high risk child adult obesity type diabetes mellitus later adult life however consensus whether glucose intolerance severity unequivocal gd relate adverse maternal fetal perinatal outcome whether relationship continuous one dietary intervention sufficient treatment gd historically insulin add recent study suggest glyburide may efficaciously substitute insulin preliminary study suggest metformin may unique potential prevent development gd,Glueck CJ,2002,Expert Opin Pharmacother,https://doi.org/10.1517/14656566.3.11.1557,12437490,Glueck CJ; Goldenberg N; Streicher P; Wang P,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D016640: Diabetes, Gestational; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008687: Metformin; D011085: Polycystic Ovary Syndrome; D011247: Pregnancy",,,https://openalex.org/W2069657814,86,14,1,1681,272,11,en,en
false,combination therapy bedtime nph insulin sulphonylureas give similar glycaemic control low weight gain insulin twice daily patient type diabetes,study effect body weight glycaemic control two insulin treatment regimen patient type diabetes moderate failure oral hypoglycaemic agents sixteen patient treat oral hypoglycaemic agent men woman include open label randomize parallel group study age mean sem year range year body weight kg body mass index bmi kg patient switch insulin treatment bedtime nph insulin combine daytime sulphonylurea combination group twice daily injection premixed combination regular human nph insulin insulin twice daily group measurement give week treatment hba c lower insulin twice daily group p combination group p n treatment group body weight increase kg kg insulin twice daily group p kg kg combination group ns p group dose insulin week insulin twice daily group u u combination group p combination treatment reduce fasting stimulate c peptide levels treatment improve glycaemic control extent combination bedtime nph insulin daytime sulphonylurea give small increase body weight month period conclude combination therapy attractive alternative start insulin treatment patient type diabetes critical period weight gain patient,Olsson PO,2002,Diabetes Metab,,12442064,Olsson PO; Lindström T,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D000368: Aged; D001786: Blood Glucose; D015992: Body Mass Index; D001835: Body Weight; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D006801: Humans; D007004: Hypoglycemic Agents; D007336: Insulin, Isophane; D008875: Middle Aged; D013453: Sulfonylurea Compounds; D015430: Weight Gain",,,https://openalex.org/W1591966662,176,26,1,1777,349,7,en,en
false,pharmacokinetics pharmacodynamics glyburide metformin tablet glucovance versus equivalent dos glyburide metformin patient type diabetes,objective compare effect two different formulation glibenclamide glyburide combine metformin postprandial glucose excursion assess pharmacokinetics formulation combination glibenclamide metformin tablet glucovance controlled particle size glibenclamide metformin versus glibenclamide micronase metformin glucophage coadministered separately design randomised double blind two way crossover study patient type diabetes receive either glibenclamide metformin mg tablet glibenclamide mg metformin mg twice daily day week washout patient cross treatment day patient consume standardised meal day pharmacokinetic pharmacodynamic evaluation perform participant forty patient type diabetes enrol randomise men woman complete study mean age year mean body mass index kg baseline glycated haemoglobin hba c treatment group main outcome measure two hour postprandial glucose excursion ppge use assess postprandial glucose dynamic result treatment glibenclamide metformin result significantly small mean ppge attain treatment glibenclamide plus metformin accord measurement take day afternoon standardise meal vs mg dl p mean glibenclamide peak concentration c max significantly great approximately glibenclamide metformin treatment day glibenclamide metformin treatment associate fold great area concentration time curve hour glibenclamide auc p although auc administration interval equivalent formulation conclusion patient type diabetes glibenclamide metformin result low ppge suggest high glibenclamide auc observe formulation may contribute good postprandial glycaemic control attain glibenclamide plus metformin separately,Donahue SR,2002,Clin Pharmacokinet,https://doi.org/10.2165/00003088-200241150-00004,12452739,Donahue SR; Turner KC; Patel S,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D019540: Area Under Curve; D001786: Blood Glucose; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004338: Drug Combinations; D005260: Female; D005905: Glyburide; D006207: Half-Life; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D019518: Postprandial Period; D013607: Tablets",,,https://openalex.org/W2047511891,168,25,2,2208,364,13,en,en
false,effect combination glipizide gits metformin fibrinolytic metabolic parameter poorly control type diabetic subject,epidemiological study implicate increase plasminogen activated inhibitor pai marker predictor accelerated coronary atherosclerotic disease type diabetes seek determine whether metabolic control independent oral mode implementation affect pai patient marked hyperglycemia total subject screen subject week drug washout randomize daily treatment glipizide git maximum mg n metformin maximum mg n monotherapy monotherapy combination therapy initiate add second agent regimen plasma glucose fast postprandial hba c fructosamine pai assay randomization sequentially thereafter subject hepatic glucose output hgo abdominal fat distribution measure subset subjects glycemic control markedly impair baseline mean hba c glipizide git metformin improve comparably agent monotherapy combination p vs baseline assess meal tolerance study fructosamine value hgo body weight abdominal fat distribution change significantly either group pai concentration extraordinarily high fold normal baseline ng ml glipizide git ng ml metformin decline comparably significantly treatment either agent monotherapy decrease far combination therapy hyperglycemia profound increase pai also profound control hyperglycemia either glipizide git insulin secretagogue metformin monotherapy comparably ameliorate elevated pai,Cefalu WT,2002,Diabetes Care,https://doi.org/10.2337/diacare.25.12.2123,12453948,Cefalu WT; Schneider DJ; Carlson HE; Migdal P; Gan Lim L; Izon MP; Kapoor A; Bell-Farrow A; Terry JG; Sobel BE,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D019540: Area Under Curve; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005342: Fibrinolysis; D005913: Glipizide; D005951: Glucose Tolerance Test; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008687: Metformin; D008875: Middle Aged; D012107: Research Design",,,https://openalex.org/W2161538498,133,17,1,1796,310,7,en,en
false,nateglinide improve early insulin secretion control postprandial glucose excursion prediabetic population,purpose study evaluate metabolic effectiveness safety tolerability nateglinide subject impaired glucose tolerance igt identify dose appropriate use diabetes prevention study multicenter double blind randomize parallel group fixed dose study week duration perform total subject igt use randomization subject receive nateglinide mg placebo main meal metabolic effectiveness assess standardized meal challenge perform week treatment adverse event aes record confirm hypoglycemia define symptom accompany self monitoring blood glucose measurement mmol l plasma glucose mmol l nateglinide elicit dose related increase insulin decrease glucose standardized meal challenge predominant effect early insulin release lead substantial reduction peak plasma glucose level nateglinide well tolerate symptom hypoglycemia treatment emergent aes confirm hypoglycemia occur subject receive nateglinide mg mg mg subject receive placebo nateglinide safe effective reduce postprandial hyperglycemia subject igt preprandial dos mg nateglinide would appropriate use longer term study determine whether rapid onset rapidly reversible insulinotropic agent delay prevent development type diabetes,Saloranta C,2002,Diabetes Care,https://doi.org/10.2337/diacare.25.12.2141,12453951,Saloranta C; Guitard C; Pecher E; De Pablos-Velasco P; Lahti K; Brunel P; Groop L,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D001786: Blood Glucose; D015992: Body Mass Index; D003510: Cyclohexanes; D004311: Double-Blind Method; D005260: Female; D005951: Glucose Tolerance Test; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D008297: Male; D008875: Middle Aged; D000077715: Nateglinide; D010649: Phenylalanine; D019518: Postprandial Period; D011236: Prediabetic State,,,https://openalex.org/W2154717294,117,14,1,1654,291,7,en,en
false,oral anti diabetic polychemotherapy type diabetes mellitus,therapeutic guideline seventy type diabetic patient monotherapy choice base bmi patient bitherapy case blood glucose increase pathophysiologic knowledge type diabetes move disease nowadays complex loss beta cell mass insulin resistance state liver muscle adipocyte tissue associate defect gastro intestinal hormone postprandial state pathophysiologic knowledge existence new therapeutic agent lead u discuss oral antidiabetic polychemotherapy first drug prescription intuitive proposition evidence based argument prospective long term study would demonstrate benefit proposition moreover nowadays imagine tritherapy proposition progress chemistry research conduct quadri penta therapy expect difficulty therapeutic compliance patient,Gin H,2002,Diabetes Metab,,12461471,Gin H; Rigalleau V,article,D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D006801: Humans; D007004: Hypoglycemic Agents; D007333: Insulin Resistance; D008687: Metformin; D013844: Thiazoles; D045162: Thiazolidinediones",,,https://openalex.org/W2436787042,64,10,1,1002,160,5,en,en
false,high throughput inhibition screening major human cytochrome p enzymes use vitro cocktail liquid chromatography tandem mass spectrometry,method develop high throughput inhibition screening major human cytochrome p cyp enzymes cyp cyp c cyp c cyp cyp use vitro substrate cocktail liquid chromatography tandem mass spectrometry lc ms ms cocktail consisting selective substrate phenacetin cyp tolbutamide cyp c omeprazole cyp c bufuralol cyp midazolam cyp incubate human liver microsome metabolic reaction terminate methanol contain dextrorphan internal standard follow centrifugation supernatant analyze lc ms ms employ fast gradient concentration substrate metabolites paracetamol hydroxytolbutamide hydroxyomeprazole hydroxybufuralol hydroxymidazolam sample determine lc ms ms single assay method validate incubate know cyp inhibitor furafylline cyp sulfaphenazole cyp c mephenytoin cyp c quinidine cyp troleandomycin cyp individual substrate know inhibit substrate cocktail ic microm determine use substrate cocktail good agreement obtain individual substrate furafylline vs sulfaphenazole vs mephenytoin vs quinidine vs troleandomycin vs previously report value literature,Testino SA,2003,J Pharm Biomed Anal,https://doi.org/10.1016/s0731-7085(02)00480-6,12467917,Testino SA; Patonay G,article,D016428: Journal Article,"D003577: Cytochrome P-450 Enzyme System; D008401: Gas Chromatography-Mass Spectrometry; D006801: Humans; D008862: Microsomes, Liver; D004364: Pharmaceutical Preparations; D015203: Reproducibility of Results; D013379: Substrate Specificity",,,https://openalex.org/W2093394597,153,19,1,1464,245,7,en,en
false,rosiglitazone pioglitazone new preparation two new oral antidiabetic poorly assess,treatment type non insulin dependent diabetes base lifestyle measure management cardiovascular risk reference first line drug therapy type diabetes drug therapy need single agent treatment metformin biguanide overweight patient glibenclamide glucose lowering sulphonylurea patient monotherapy fail control blood glucose level adequately clinical guideline recommend combination metformin glucose lowering sulphonylurea although available comparative clinical data raise possibility excess mortality treatment rosiglitazone pioglitazone glitazones reduce insulin resistance authorize european union combination glucose lowering sulphonylurea patient metformin ineffective poorly tolerate metformin obese patient none available trial rosiglitazone pioglitazone include data mortality morbidity data pioglitazone rosiglitazone accord short term comparative trial rosiglitazone pioglitazone effective placebo blood glucose level combination rosiglitazone pioglitazone metformin glucose lowering sulphonylureas compare metformin glucose lowering sulphonylurea combination insulin rosiglitazone pioglitazone frequently cause weight gain pioglitazone slightly favourable effect lipid profile unlike rosiglitazone increase ldl cholesterol level main side effect rosiglitazone pioglitazone sodium water retention provoke oedema anaemia haemodilution even heart failure rosiglitazone pioglitazone also hepatotoxic combine rosiglitazone insulin contraindicate owe increase risk heart failure applies pioglitazone practice neither rosiglitazone pioglitazone place management type diabetes except context strictly control long term comparative clinical trial,,2002,Prescrire Int,,12469695,,article,D003160: Comparative Study; D016428: Journal Article,"D000284: Administration, Oral; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D017277: Drug Approval; D004341: Drug Evaluation; D005060: Europe; D005069: Evaluation Studies as Topic; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008687: Metformin; D013453: Sulfonylurea Compounds; D013844: Thiazoles",,,https://openalex.org/W4302066179,98,15,2,2213,368,15,en,en
false,type diabetes mellitus delay renal failure autosomal dominant polycystic kidney disease,autosomal dominant polycystic kidney disease adpkd common renal disease without effective therapeutic intervention delay renal failure within kindred renal dysfunction often develop similar age affected individual although know modifying factor two kindred adpkd show striking pattern delayed onset renal insufficiency individual also suffer type diabetes mellitus eight nondiabetic patient adpkd onset dialysis renal death age year mean sem n compare four diabetic start dialysis still dialysis age year p two four diabetic still reasonable renal function age diabetes diagnose age year treat oral hypoglycemics year institution insulin cardiovascular disease dominate clinical picture diabetic conclusion onset renal failure adpkd delay year individual also suffer type diabetes mellitus two adpkd kindred possible mechanism discuss include glibenclamide inhibition cystic fibrosis transmembrane conductance regulator striking delay associate type diabetes mellitus adpkd induce renal failure evaluate far,Backenroth R,2002,Ren Fail,https://doi.org/10.1081/jdi-120015682,12472202,Backenroth R; Popovtzer MM,article,D002363: Case Reports; D016428: Journal Article,"D000328: Adult; D017668: Age of Onset; D000368: Aged; D003924: Diabetes Mellitus, Type 2; D018450: Disease Progression; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010375: Pedigree; D016891: Polycystic Kidney, Autosomal Dominant; D051437: Renal Insufficiency; D013997: Time Factors",,,https://openalex.org/W2113644746,98,15,1,1402,245,10,en,en
false,aspect antihyperglycemic oral bitherapy case non insulindependent diabetes dakar,reason justify introduction association sulfonylurea metformine monotherapy ineffective hereafter period monotherapy sulfonylurea metformine bitherapy institute socio demography number consultation type monotherapy association duration treatment body mass index fast blood glycemia post prandial glycemia blood pressure type complication study time woman men low mean age woman majority patient dakar half patient woman home present obesity plethoric diabetes past obesity metaplethoric diabetes concern patient patient consultation bitherapy gliclazide metformin association observe time glibenclamide metformin association time duration monotherapy month bitherapy month variation body mass index show diminution kg fast blood glycemia augmentation g l post prandial diminution g l body mass index variation diabetic patient show diminution weight plethoric patient bitherapy compare monotherapy study retrospective show optimal efficacy bitherapy combination enhancement glucose captation lowering hepatic glucose production show bitherapeutic association addition metformine treatment sulfonylurea make combination significatively improve glycemic control also cholesterol level allow obtation good weight type non insulin dependent diabetes insulinoresistance,Sidibé EH,2002,Sante,,12473527,Sidibé EH; Badiane MK; Gueye A,article,D004740: English Abstract; D016428: Journal Article,"D000328: Adult; D000368: Aged; D001786: Blood Glucose; D001835: Body Weight; D002784: Cholesterol; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D008875: Middle Aged; D009765: Obesity; D012675: Senegal",,,https://openalex.org/W2286175882,100,17,1,1797,291,15,en,en
false,effect inhibition atp sensitive potassium channel metabolic vasodilation human forearm,experimental data suggest vascular atp sensitive potassium katp channel may important determinant functional hyperaemia contribution katp channel exercise induced hyperaemia human unknown forearm blood flow assess healthy subject males female age year use technique venous occlusion plethysmography rest forearm blood flow functional hyperaemic blood flow fhbf measure brachial artery infusion katp channel inhibitor glibenclamide two different dos g min gliclazide g min fhbf induce min non ischaemic wrist flexion extension exercise cycles min compare vehicle isotonic saline glibenclamide either g min g min significantly alter rest forearm blood flow peak fhbf blood volume repay min exercise diminish glibenclamide serum glucose unchanged glibenclamide plasma insulin rise units l p units l p g min infusion respectively gliclazide also affect rest forearm blood flow peak fhbf blood volume repay min exercise compare vehicle isotonic glucose gliclazide induce fall serum glucose p increase plasma insulin p thus inhibition vascular katp channel glibenclamide gliclazide appear affect rest forearm blood flow fhbf healthy human finding suggest vascular katp channel may play important role regulate basal vascular tone skeletal muscle metabolic vasodilation forearm healthy human subject,Farouque HM,2003,Clin Sci (Lond),https://doi.org/10.1042/cs1040039,12519086,Farouque HM; Meredith IT,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000255: Adenosine Triphosphate; D000328: Adult; D004305: Dose-Response Relationship, Drug; D005260: Female; D005542: Forearm; D005907: Gliclazide; D005905: Glyburide; D006801: Humans; D006940: Hyperemia; D008297: Male; D018482: Muscle, Skeletal; D010991: Plethysmography; D026902: Potassium Channel Blockers; D015221: Potassium Channels; D012039: Regional Blood Flow; D014664: Vasodilation",,,https://openalex.org/W1964487125,104,14,1,1828,321,11,en,en
false,pharmacokinetics repaglinide healthy caucasian japanese subject,objective study investigate pharmacokinetics three different single dos mg repaglinide healthy caucasian japanese subject single center open label randomize three period crossover study healthy male subject caucasian japanese receive three different single dos repaglinide mg consecutive hour interval pharmacokinetic profile include area curve auc maximum serum concentration c max time c max max half life determine dose repaglinide relative change blood glucose level rc h area blood glucose curve augc hour dose also measure oral dosing c max auc increase linearly dose within mg dose range regardless ethnic group c max auc significantly high japanese subject caucasian subject dose repaglinide c max auc statistically significantly higher japanese caucasian subject p respectively discrepancy body weight body mass index bmi caucasian japanese subject could explain group difference c max auc statistically significant difference pharmacodynamic parameter rc h augc find ethnic group p difference pronounce rc h augc dose mg mean decrease rc h japanese subject caucasian subject hypoglycemic reaction common high dose mg observe frequently japanese case caucasian subject case conclude high serum level repaglinide great reduction blood glucose level find japanese caucasian subject follow single oral dose repaglinide within mg dose range repaglinide well tolerate ethnic group result indicate glycemic control target may achieve low dos within recommended range mg meal repaglinide use treat japanese patient comparison caucasian patient,Thomsen MS,2003,J Clin Pharmacol,https://doi.org/10.1177/0091270002239702,12520624,Thomsen MS; Chassard D; Evène E; Nielsen KK; Jørgensen M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D044466: Asian People; D002219: Carbamates; D018592: Cross-Over Studies; D004305: Dose-Response Relationship, Drug; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D010880: Piperidines; D044465: White People",,,https://openalex.org/W1994456278,74,9,1,2326,439,14,en,en
false,tolbutamide flurbiprofen losartan probe cyp c activity human,metabolic activity cyp c subject express four different genotype cyp c evaluate single oral dos tolbutamide flurbiprofen losartan administer randomized crossover design plasma urine collect hour urinary metabolic ratio amount metabolite excrete correlate formation clearance formation clearance tolbutamide cyp c mediated metabolite demonstrate strong association genotype compare flurbiprofen losartan respectively r vs vs statistically significant correlation observe formation clearance tolbutamide hour urinary amount hydroxytolbutamide carboxytolbutamide r compare tolbutamide correlation observe respective measure flurbiprofen losartan metabolism strong tolbutamide good cyp c probe flurbiprofen losartan hour amount hydroxytolbutamide carboxytolbutamide best urinary measure metabolism,Lee CR,2003,J Clin Pharmacol,https://doi.org/10.1177/0091270002239710,12520632,Lee CR; Pieper JA; Frye RF; Hinderliter AL; Blaisdell JA; Goldstein JA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D001189: Aryl Hydrocarbon Hydroxylases; D018592: Cross-Over Studies; D065729: Cytochrome P-450 CYP2C9; D005260: Female; D005480: Flurbiprofen; D005838: Genotype; D006801: Humans; D019808: Losartan; D008297: Male; D010641: Phenotype; D014044: Tolbutamide,,,https://openalex.org/W1974766025,78,13,1,1162,200,8,en,en
false,angiotensin receptor blocker antihypertensive cardiovascular round medication year,angiotensin receptor blocker part antihypertensive treatment armamentarium since mid period number agent increase greatly number indication drug test randomize controlled clinical trial begin efficacious well tolerated antihypertensive angiotensin receptor blocker show benefit patient diabetes heart failure attributable reduce blood pressure support recently conclude trial expand treatment area agent widen interest applicability across entire cardiovascular continuum number large scale study set report within next year far determine effect angiotensin receptor blocker range cardiovascular indication beyond hypertension,Maggioni AP,2002,Blood Press,https://doi.org/10.1080/080370502321095285,12523675,Maggioni AP; Latini R,article,D016428: Journal Article; D016454: Review,"D057911: Angiotensin Receptor Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D000818: Animals; D000959: Antihypertensive Agents; D002317: Cardiovascular Agents; D002318: Cardiovascular Diseases; D003924: Diabetes Mellitus, Type 2; D006333: Heart Failure; D006801: Humans; D009203: Myocardial Infarction; D012084: Renin-Angiotensin System",,,https://openalex.org/W2086389738,110,14,1,907,136,5,en,en
false,molecular basis kir channel inhibition adenine nucleotide,k atp channel comprise pore forming protein kir x sulfonylurea receptor surx interaction adenine nucleotide kir positively charge amino acid k r c terminus cause channel closure substitution amino acid positively charge residue small effect inhibition adenine nucleotide substitution neutral negative residue major effect suggest electrostatic interaction kir positive charge adenine nucleotide negative phosphate group furthermore r mutation decrease channel sensitivity atp adp amp similar extent k mutation decrease primarily atp adp sensitivity leave amp sensitivity relatively unaffected thus channel inhibition atp may involve interaction alpha phosphate r interaction beta phosphate k addition decrease open probability due rundown sulfonylureas cause increase atp sensitivity k mutant r mutant thus beta phosphate may bind state independent fashion k destabilize channel opening r interacts alpha phosphate stabilize channel close configuration substitution r c terminus r n terminus different charge residue also affect atp sensitivity base result structural scheme propose include feature recently publish model,Ribalet B,2003,Biophys J,https://doi.org/10.1016/s0006-3495(03)74847-4,12524280,Ribalet B; John SA; Weiss JN,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000227: Adenine Nucleotides; D000255: Adenosine Triphosphate; D000596: Amino Acids; D004305: Dose-Response Relationship, Drug; D005905: Glyburide; D006801: Humans; D015640: Ion Channel Gating; D007668: Kidney; D024661: Potassium Channels, Inwardly Rectifying; D011994: Recombinant Proteins; D012680: Sensitivity and Specificity; D014162: Transfection",,,https://openalex.org/W1985451719,68,9,1,1513,243,9,en,en
false,influence treatment acarbose glibenclamide insulin sensitivity type diabetic patient,aim double blind placebo controlled study compare effect acarbose glibenclamide insulin sensitivity type diabetes investigate patient mean age year mean bmi kg treat diet alone least week subject randomize three treatment group week mg acarbose n mg glibenclamide n one placebo n therapy level fast plasma glucose glycosylated haemoglobin fast insulin plasma glucose insulin h standardized breakfast measure insulin sensitivity determine euglycaemic hyperinsulinaemic clamp test treatment period bmi acarbose placebo group decrease significantly whereas glibenclamide group significant increase observe fast plasma glucose significant reduce glibenclamide postprandial glucose decrease significantly acarbose vs mmol l p glibenclamide treatment vs mmol l p unchanged placebo vs mmol l fasting insulin level remain unchanged three group whereas postprandial insulin value increase significantly glibenclamide neither acarbose glibenclamide significantly change insulin sensitivity acarbose glucose disposal rate treatment mg kg body weight min insulin treatment glibenclamide vs placebo vs result show substantial improvement glucose control glibenclamide acarbose however associate increase insulin sensitivity,Fischer S,2003,Diabetes Obes Metab,https://doi.org/10.1046/j.1463-1326.2003.00239.x,12542723,Fischer S; Patzak A; Rietzsch H; Schwanebeck U; Köhler C; Wildbrett J; Fuecker K; Temelkova-Kurktschiev T; Hanefeld M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D020909: Acarbose; D000328: Adult; D000368: Aged; D001786: Blood Glucose; D015992: Body Mass Index; D001835: Body Weight; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D015309: Glucose Clamp Technique; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007333: Insulin Resistance; D008055: Lipids; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W1930639259,104,15,1,1718,294,10,en,en
false,plasma adiponectin play important role improve insulin resistance glimepiride elderly type diabetic subject,investigate effect glimepiride third generation sulfonylurea hypoglycemic agent insulin resistance elderly patient type diabetes connection plasma adiponectin epi prostagrandin f alpha epi pgf alpha oxidative stress marker total elderly patient type diabetes receive week treatment glimepiride homeostasis assessment model insulin resistance homa ir homeostasis assessment model beta cell function hba c c peptide h pooled urine urine cpr plasma concentration epi pgf alpha tumor necrosis factor alpha tnf alpha plasminogen activator inhibitor type adiponectin measure various time metabolic clearance rate glucose mcr g also assess hyperinsulinemic euglycemic clamp week glimepiride treatment significant reduction observe hba c homa ir plasma tnf alpha concentration pg ml mcr g significantly increase mg kg min plasma adiponectin increase micro g ml control subject maintain conventional treatment significant change observe markers glimepiride remarkably improve insulin resistance suggest significant reduction homa ir increase mcr g reduction hba c without change extrapancreatic beta cell function urine cpr increase plasma adiponectin decreased plasma tnf alpha may underlie improvement insulin resistance glimepiride,Tsunekawa T,2003,Diabetes Care,https://doi.org/10.2337/diacare.26.2.285,12547850,Tsunekawa T; Hayashi T; Suzuki Y; Matsui-Hirai H; Kano H; Fukatsu A; Nomura N; Miyazaki A; Iguchi A,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D052242: Adiponectin; D000368: Aged; D003924: Diabetes Mellitus, Type 2; D015237: Dinoprost; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007333: Insulin Resistance; D036341: Intercellular Signaling Peptides and Proteins; D008297: Male; D008875: Middle Aged; D009994: Osmolar Concentration; D017395: Plasminogen Activator Inhibitor 1; D011506: Proteins; D013453: Sulfonylurea Compounds; D014409: Tumor Necrosis Factor-alpha",,,https://openalex.org/W2159693162,127,18,1,1706,296,8,en,en
true,pharmacotherapy diabetes mellitus implication prevention treatment cardiovascular disease,diabetes mellitus adult associate increase risk premature vascular disease high mortality rate presence risk factor often see diabetic patient systemic hypertension augment rate vascular disease evidence grow tight control hyperglycemia use insulin oral hypoglycemic agent modify risk aggressive control concomitant hypertension hyperlipidemia also require diabetic patient myocardial infarction bad nondiabetic patient various strategy improve outcome include use tight blood glucose control various coronary intervention currently clinical study,Ragucci E,2003,Heart Dis,https://doi.org/10.1097/01.hdx.0000050411.62103.f5,12549986,Ragucci E; Zonszein J; Frishman WH,article,D016428: Journal Article; D016454: Review,"D002318: Cardiovascular Diseases; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D004359: Drug Therapy, Combination; D006801: Humans; D006949: Hyperlipidemias; D006973: Hypertension; D007004: Hypoglycemic Agents; D007328: Insulin; D009203: Myocardial Infarction; D012307: Risk Factors; D019851: Thrombophilia",,,https://openalex.org/W2032007955,109,14,1,724,112,6,en,en
false,multifactorial intervention cardiovascular disease patient type diabetes,cardiovascular morbidity major burden patient type diabetes steno study compare effect targeted intensified multifactorial intervention conventional treatment modifiable risk factor cardiovascular disease patient type diabetes microalbuminuria primary end point open parallel trial composite death cardiovascular cause nonfatal myocardial infarction nonfatal stroke revascularization amputation eighty patient randomly assign receive conventional treatment accordance national guideline receive intensive treatment stepwise implementation behavior modification pharmacologic therapy target hyperglycemia hypertension dyslipidemia microalbuminuria along secondary prevention cardiovascular disease aspirin mean age patient year mean follow year decline glycosylated hemoglobin value systolic diastolic blood pressure serum cholesterol triglyceride level measure overnight fast urinary albumin excretion rate significantly great intensive therapy group conventional therapy group patient receive intensive therapy also significantly low risk cardiovascular disease hazard ratio percent confidence interval nephropathy hazard ratio percent confidence interval retinopathy hazard ratio percent confidence interval autonomic neuropathy hazard ratio percent confidence interval target driven long term intensified intervention aim multiple risk factor patient type diabetes microalbuminuria reduce risk cardiovascular microvascular event percent,Gaede P,2003,N Engl J Med,https://doi.org/10.1056/nejmoa021778,12556541,Gaede P; Vedel P; Larsen N; Jensen GV; Parving HH; Pedersen O,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000671: Amputation, Surgical; D000804: Angiotensin II; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002318: Cardiovascular Diseases; D003131: Combined Modality Therapy; D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D018752: Diet, Fat-Restricted; D015444: Exercise; D005260: Female; D006801: Humans; D006949: Hyperlipidemias; D006973: Hypertension; D007004: Hypoglycemic Agents; D000960: Hypolipidemic Agents; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D009765: Obesity; D012307: Risk Factors; D016540: Smoking Cessation; D020521: Stroke; D014815: Vitamins",,,https://openalex.org/W2139634859,87,11,1,1912,305,5,en,en
false,treatment diabetes mellitus old people oral therapy option,journal american geriatrics societyvolume issue p treatment diabetes mellitus old people oral therapy option jill crandall md jill crandall md albert einstein college medicine division endocrinology geriatrics bronx new york search paper authornir barzilai md nir barzilai md albert einstein college medicine division endocrinology geriatrics bronx new york search paper author jill crandall md jill crandall md albert einstein college medicine division endocrinology geriatrics bronx new york search paper authornir barzilai md nir barzilai md albert einstein college medicine division endocrinology geriatrics bronx new york search paper author first publish january http doi org j xcitations address correspondence dr jill crandall albert einstein college medicine division endocrinology geriatrics blondell avenue suite bronx ny e mail crandall aecom yu edu read full textaboutpdf toolsrequest permissionexport citationadd favoritestrack citation shareshare give accessshare full text accessshare full text accessplease review term condition use check box share full text version article read accept wiley online library term condition useshareable linkuse link share full text version article friend colleague learn copy url share linkshare onfacebooktwitterlinkedinredditwechat cite literature volume issue february pages relatedinformation,Crandall J,2003,J Am Geriatr Soc,https://doi.org/10.1046/j.1532-5415.2003.51070.x,12558728,Crandall J; Barzilai N,article,D016428: Journal Article,"D000284: Administration, Oral; D000368: Aged; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents",,,https://openalex.org/W1966964603,68,11,1,1719,265,3,en,en
false,rosiglitazone reduces urinary albumin excretion type ii diabetes,study examine effect rosiglitazone urinary albumin excretion uae patient type ii diabetes urinary albumin creatinine ratio acr measure week open label cardiac safety study compare rosiglitazone glyburide patient randomise treatment rosiglitazone mg b glyburide acr measure baseline week treatment statistically significant reduction baseline acr observe treatment group week week rosiglitazone group show significant reduction baseline similar result observe overall study population subset patient baseline microalbuminuria patient microalbuminuria baseline reduction acr correlate strongly reduction glycosylated haemoglobin fast plasma glucose show strong correlation change mean h systolic diastolic blood pressure rosiglitazone treated patient deltaacr v deltamean h systolic blood pressure r deltaacr vs deltamean h diastolic blood pressure r p correlation observe glyburide treated patient conclusion rosiglitazone treatment associate decrease urinary albumin excretion finding suggest potential beneficial effect rosiglitazone treatment prevention renal vascular complication type ii diabetes,Bakris G,2003,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001444,12571611,Bakris G; Viberti G; Weston WM; Heise M; Porter LE; Freed MI,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000368: Aged; D000419: Albuminuria; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D003928: Diabetic Nephropathies; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D007004: Hypoglycemic Agents; D007677: Kidney Function Tests; D008297: Male; D008875: Middle Aged; D012016: Reference Values; D000077154: Rosiglitazone; D012680: Sensitivity and Specificity; D013844: Thiazoles; D045162: Thiazolidinediones; D016896: Treatment Outcome",,,https://openalex.org/W2007437966,67,9,1,1491,242,12,en,en
false,population pkpd modelling long term hypoglycaemic effect gliclazide give day modify release mr formulation,aim study relationship pharmacokinetics pk gliclazide long term pharmacodynamic pd effect large population type diabetic patient identify factor predict intersubject variability method pkpd database type diabetic patient total fast plasma glucose fpg sample build data collect clinical development modified release formulation gliclazide gliclazide mr pkpd analysis use nonlinear mixed effect model approach mixture model use identify patient fpg response treatment patient identify responder decrease fpg relate gliclazide exposure auc e max relationship effect compartment use describe link pk pd linear disease progression model use assess glycaemic deterioration observable several month treatment simulation perform evaluate predictive performance pkpd model illustrate time course antidiabetic effect gliclazide mr result disease state find main explanatory factor intersubject variability response gliclazide percentage responder gliclazide use monotherapy increase inversely number class antidiabetic agent receive prior entry study responder initial dose mg gliclazide mr dose regimen induce half maximum hypoglycaemic effect equilibration half life pk pd steady state week intersubject variability rate disease progression mmol l year intersubject variability pkpd model adequately predict fpg profile patient receive current formulation gliclazide simulation year parallel dose range clinical trial illustrate influence dose time type previous antidiabetic treatment percentage patient clinically significant improvement blood glucose control conclusion population pkpd analysis characterize relationship exposure gliclazide long term hypoglycaemic effect establish intersubject variability response mostly relate disease state result underline clinical interest quickly increase dose gliclazide mr accord response treatment order achieve effective blood glucose control,Frey N,2003,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.2003.01751.x,12580986,Frey N; Laveille C; Paraire M; Francillard M; Holford NH; Jochemsen R,article,"D016430: Clinical Trial; D017427: Clinical Trial, Phase II; D017428: Clinical Trial, Phase III; D016428: Journal Article","D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D018450: Disease Progression; D004305: Dose-Response Relationship, Drug; D005260: Female; D005907: Gliclazide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D008954: Models, Biological",,,https://openalex.org/W1492642476,133,20,1,2542,423,17,en,en
false,beneficial effect glyburide metformin combination preparation type diabetes mellitus,type diabetes mellitus characterize insulin deficiency insulin resistance effective treatment often require therapy direct abnormality patient monotherapy might benefit combination agent glyburide metformin increase insulin secretion reduces insulin resistance patient take glyburide metformin preparation carl hayden vamc identify pharmacy record patient documented hemoglobin value within week prior week initiation therapy subject examined glyburide metformin combination therapy reduce hemoglobin level p significant reduction see patient initial level high p significant reduction see patient initial level low patient monotherapy dual oral therapy inadequate control change glyburide metformin combination preparation may improve glucose control,Bokhari SU,2003,Am J Med Sci,https://doi.org/10.1097/00000441-200302000-00003,12589230,Bokhari SU; Gopal UM; Duckworth WC,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.","D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004338: Drug Combinations; D005905: Glyburide; D006441: Hemoglobin A; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007333: Insulin Resistance; D008687: Metformin",,,https://openalex.org/W2082917156,95,12,1,1063,164,6,en,en
true,treatment type diabetes inadequate assessment oral antidiabetic combination,metformin glibenclamide oral antidiabetic proven impact complication type diabetes treatment one drug often fail achieve recommended target hba c level one randomise trial assess preventive efficacy combination oral antidiabetic hyperglycaemia persist despite treatment glucose lowering sulphonylurea trial show combine metformin glucose lowering sulphonylurea associate high mortality therapy sulphonylurea alone despite result clinical guideline recommend metformin glucose lowering sulphonylurea combination oral antidiabetic monotherapy fails absence convince data support particular strategy option discuss patient include continue oral antidiabetic monotherapy start insulin,,2003,Prescrire Int,,12602406,,article,D016428: Journal Article,"D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008687: Metformin; D016032: Randomized Controlled Trials as Topic",,,https://openalex.org/W4300281121,86,13,1,945,154,6,en,en
false,use octreotide treat prolonged sulfonylurea induced hypoglycemia patient chronic renal failure,diabetic patient chronic renal failure develop recurrent prolong episode hypoglycemia associate use sulfonylurea agent present patient hospitalize neuroglycopenic symptom hypoglycemia persist spite large dos parenteral glucose replacement administration somatostatin analogue octreotide hypoglycemia resolve blood glucose level maintain even cessation parenteral glucose patient receive subcutaneous dos octreotide hour apart make complete recovery experience suggest use octerotide treat refractory prolong sulfonylurea included hypoglycemia renal failure patient safe effective large prospective study would need validate finding,Nzerue CM,2003,Int J Artif Organs,https://doi.org/10.1177/039139880302600113,12602474,Nzerue CM; Thomas J; Volcy J; Edeki T,article,D002363: Case Reports; D016428: Journal Article,"D000328: Adult; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D005765: Gastrointestinal Agents; D005913: Glipizide; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007676: Kidney Failure, Chronic; D008297: Male; D015282: Octreotide; D012640: Seizures",,,https://openalex.org/W2414394732,110,15,1,818,121,5,en,en
true,safety efficacy repaglinide type diabetic patient without impaired renal function,objective evaluate influence renal impairment safety efficacy repaglinide type diabetic patient research design methods multinational open label study comprise week run period continue prestudy antidiabetic medication follow titration period week month maintenance period patient normal renal function n various degree renal impairment n treat repaglinide maximal dose mg three time daily safety efficacy assessment perform baseline end run end study treatment results type severity adverse event repaglinide treatment similar run period number patient adverse event significantly relate renal function run repaglinide treatment percentage patient hypoglycemic episode increase significantly p increase severity renal impairment run repaglinide treatment p metabolic control hba c fast blood glucose repaglinide unchanged previous antidiabetic medication final repaglinide dose tend low patient severe extreme renal impairment patient less severe renal impairment normal renal function p conclusions repaglinide good safety efficacy profile type diabetic patient complicate renal impairment appropriate treatment choice even individual severe degree renal impairment,Hasslacher C,2003,Diabetes Care,https://doi.org/10.2337/diacare.26.3.886,12610054,Hasslacher C; Multinational Repaglinide Renal Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001786: Blood Glucose; D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D003928: Diabetic Nephropathies; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D008055: Lipids; D008297: Male; D008875: Middle Aged; D010880: Piperidines; D012720: Severity of Illness Index",,,https://openalex.org/W1996059294,103,16,1,1610,269,10,en,en
false,pharmacokinetics nateglinide renally impaired diabetic patient,treatment hyperglycemia patient diabetes mellitus renal insufficiency complicate altered pharmacokinetics hypoglycemic agent study evaluate pharmacokinetic profile safety nateglinide amino acid derivative improve early phase insulin secretion reduces mealtime glucose excursion open label single dose two center study include patient mean age year type diabetes impaired renal function irf n renal failure undergo hemodialysis n group compare age sex height weight matched healthy control n participant receive single mg dose nateglinide immediately breakfast pharmacokinetic safety evaluation undertake hour postdose subject complete study plasma nateglinide concentration increase rapidly patient undergoing dialysis match healthy subject tmax vs h respectively comparable patient irf match healthy subject tmax vs h respectively statistically significant difference cmax auc group nateglinide eliminate rapidly group h correlation level renal function systemic exposure low extent renal excretion nateglinide healthy subject diabetic patient irf nateglinide well tolerate data suggest nateglinide suitable use diabetic patient irf renal failure undergoing dialysis give comparable absorption elimination profile nateglinide renally impaired healthy subject dose adjustment appear necessary renally impaired,Devineni D,2003,J Clin Pharmacol,https://doi.org/10.1177/0091270002239825,12616669,Devineni D; Walter YH; Smith HT; Lee JS; Prasad P; McLeod JF,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D019540: Area Under Curve; D001786: Blood Glucose; D016022: Case-Control Studies; D003510: Cyclohexanes; D003922: Diabetes Mellitus, Type 1; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006207: Half-Life; D006801: Humans; D007004: Hypoglycemic Agents; D007676: Kidney Failure, Chronic; D008297: Male; D008657: Metabolic Clearance Rate; D008875: Middle Aged; D000077715: Nateglinide; D010649: Phenylalanine; D006435: Renal Dialysis",,,https://openalex.org/W2056857160,69,8,1,1829,314,15,en,en
true,efficacy safety profile glimepiride mexican american patient type diabetes mellitus randomized placebo controlled study,background mexican american fast grow ethnic group united state fold high prevalence type diabetes mellitus relative non hispanic white population estimate mexican american year age diabetes objective goal study evaluate efficacy safety glimepiride long acting sulfonylurea adjunct diet exercise mexican american type diabetes mellitus method multicenter randomize double blind placebo controlled study mexican american uncontrolled type diabetes define fasting plasma glucose fpg level mg dl mg dl glycated hemoglobin hba c value month diet exercise enrol patient randomize ratio use low available treatment assignment number eligibility establish receive week glimepiride match placebo daily continued diet exercise start glimepiride dose mg titration mg mg fpg level mg dl primary efficacy variable change hba c baseline study end point secondary efficacy variable hba c response rat excellent good marginal change fpg fast insulin fibrinogen plasminogen activator inhibitor pai level baseline study end point tolerability glimepiride study population determine evaluate adverse event hypoglycemic episode physical examination well laboratory finding analysis perform intent treat basis per protocol analysis also conduct support primary efficacy analysis result seventy patient randomize treatment glimepiride n placebo n glimepiride placebo group similar respect mean se age year respectively sex male respectively however glimepiride group high mean body weight v kg significantly high mean fast insulin level v u ml p mean se hba c value study end point patient receive glimepiride placebo respectively adjusted mean difference hba c reduction baseline end point statistically significant favor glimepiride p pronounced hba c impairment baseline associate great glimepiride placebo difference hba c reduction glimepiride treated patient also achieve significantly great improvement fpg adjust mean se treatment difference mg dl p glimepiride appear affect fibrinogen pai level associate significantly great mean increase fast insulin v u ml p body weight vs kg p compare placebo glimepiride well tolerate adverse event profile similar placebo conclusion result indicate daily glimepiride plus diet exercise effective mexican american type diabetes whose disease inadequately control diet exercise alone appear well tolerate population study weight gain see glimepiride compare placebo give high prevalence type diabetes among mexican american far clinical study glimepiride glucose lowering therapy need ethnic subset,Luis Bautista J,2003,Clin Ther,https://doi.org/10.1016/s0149-2918(03)90025-7,12637120,Luis Bautista J; Bugos C; Dirnberger G; Atherton T,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005215: Fasting; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D017058: Mexican Americans; D008875: Middle Aged; D019518: Postprandial Period; D013453: Sulfonylurea Compounds; D014481: United States",,,https://openalex.org/W2064635494,141,21,1,3694,684,25,en,en
false,relative contribution insulin resistance beta cell dysfunction pathophysiology type diabetes,relative contribution insulin resistance beta cell dysfunction pathophysiology type diabetes debate extensively concept feedback loop govern interaction insulin sensitive tissue beta cell well elucidation hyperbolic relationship insulin sensitivity insulin secretion explain insulin resistant subject exhibit markedly increase insulin response insulin sensitive low response consideration hyperbolic relationship help identify critical role beta cell dysfunction development type diabetes demonstration reduced beta cell function high risk subject furthermore assessment number ethnic group emphasise beta cell function major determinant oral glucose tolerance subject normal reduced glucose tolerance population progression normal impair glucose tolerance subsequently type diabetes associate decline insulin sensitivity beta cell function genetic molecular basis reduction insulin sensitivity beta cell function fully understood seem body fat distribution especially intra abdominal fat major determinant insulin resistance reduction beta cell mass contribute beta cell dysfunction base great understanding relative role insulin resistance beta cell dysfunction type diabetes anticipate advance identification gene contribute development disease well approach treatment prevention type diabetes,Kahn SE,2003,Diabetologia,https://doi.org/10.1007/s00125-002-1009-0,12637977,Kahn SE,article,"D016428: Journal Article; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review","D000273: Adipose Tissue; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007328: Insulin; D007333: Insulin Resistance; D007515: Islets of Langerhans",,,https://openalex.org/W2004014076,116,16,1,1738,257,6,en,en
false,maternal fetal transport hypoglycaemic drug,due legal ethical monetary problem drug study pregnancy rare numerous pharmacokinetic pharmacodynamic change occur pregnancy affect efficacy safety drug difficult predict without appropriate study drug potentially useful safe pregnancy either cross placenta harmless fetus clinically relevant concentration first characteristic predict use vitro model placenta perfusion model case glibenclamide glyburide vitro experiment show minimal maternal fetal transfer lead completion successful clinical trial drug gestational diabetes insulin main drug use diabetes pregnancy also show cross placenta vitro insulin lispro animal insulin may cross placenta complexed anti insulin antibody sulphonylurea drug tolbutamide chlorpropamide show cross placenta vitro vivo produce toxicity fetus review summarise pharmacokinetic data available hypoglycaemic drug pregnancy well potential role vitro placenta perfusion model preclinical evaluation drug potential usefulness pregnancy,Garcia-Bournissen F,2003,Clin Pharmacokinet,https://doi.org/10.2165/00003088-200342040-00001,12648023,Garcia-Bournissen F; Feig DS; Koren G,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D000014: Abnormalities, Drug-Induced; D001692: Biological Transport; D002986: Clinical Trials as Topic; D016640: Diabetes, Gestational; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008431: Maternal-Fetal Exchange; D010920: Placenta; D011247: Pregnancy; D011254: Pregnancy in Diabetics; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2097429326,47,5,1,1350,225,9,en,en
false,oral magnesium supplementation improve insulin sensitivity metabolic control type diabetic subject,determine whether oral magnesium supplementation magnesium chloride mgcl solution improve insulin sensitivity metabolic control type diabetic subject decreased serum magnesium levels study clinical randomized double blind placebo controlled trial total subject type diabetes decrease serum magnesium serum magnesium level mmol l treat glibenclamide receive either ml mgcl solution contain g mgcl per ml solution placebo daily week chronic diarrhea alcoholism use diuretic calcium antagonist drug reduce renal function exclusion criterion homeostasis model assessment insulin resistance homa ir use parameter insulin sensitivity glucose hba c parameter metabolic control end study subject receive magnesium supplementation show significant high serum magnesium concentration vs mmol l p low homa ir index vs p fast glucose level vs mmol l p hba c vs p control subjects oral supplementation mgcl solution restore serum magnesium level improve insulin sensitivity metabolic control type diabetic patient decreased serum magnesium level,Rodríguez-Morán M,2003,Diabetes Care,https://doi.org/10.2337/diacare.26.4.1147,12663588,Rodríguez-Morán M; Guerrero-Romero F,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D001794: Blood Pressure; D001824: Body Constitution; D003924: Diabetes Mellitus, Type 2; D019587: Dietary Supplements; D004311: Double-Blind Method; D005500: Follow-Up Studies; D006801: Humans; D007328: Insulin; D008055: Lipids; D015636: Magnesium Chloride; D008875: Middle Aged; D018579: Patient Selection; D010919: Placebos; D013997: Time Factors",,,https://openalex.org/W2110534134,109,14,1,1439,265,4,en,en
false,oral hypoglycaemic agent failure,type diabetic patient initially respond satisfactorily diet exercise oral hypoglycaemic agent oha fraction acquire resistance drug right beginning primary oha failure due course time secondary oha failure become insulin require ultimately poor diet compliance deterioration beta cell function major cause oha failure annual incidence keep mind benefit organ salvage diabetes failure oha treatment detect early necessary measure adopt early possible recognition appraisal assessment total problem help diabetic enjoy normal life,Banerjee S,2002,J Indian Med Assoc,,12674170,Banerjee S; Sinharoy K; Singh AK,article,D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005907: Gliclazide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008687: Metformin; D017211: Treatment Failure",,,https://openalex.org/W178805811,33,5,1,695,124,4,en,en
false,efficacy safety nateglinide treatment type ii diabetes mellitus,nateglinide new short acting phenylalanine derivative represent new chemical class drug treat type diabetes pharmacologically therapeutically distinct currently exist agent study normal patient type diabetes show nateglinide reduces mealtime blood glucose excursion physiologic regulation insulin secretion nateglinide bind inhibit k atp channel beta cell cause membrane depolarisation subsequent influx extracellular calcium result insulin secretion total patient centre type ii diabetes mellitus take accord inclusion criterion give drug treatment evaluate improvement fasting postprandial plasma glucose glycosylated haemoglobin value efficacy besides physician assessment overall safety efficacy nateglinide dose mg three main meal give increase maximum mg thrice daily first week nateglinide take minute meal duration treatment week patient show decrease fast plasma glucose nd week onwards reduction glycosylated haemoglobin th week onwards postprandial glucose reduction also significant end th week frequency adverse effect low serious adverse effect encounter,Chandrasekharan S,2002,J Indian Med Assoc,,12674176,Chandrasekharan S; Rao PP; Jayaram S; Jain SD; Ganesan R; Desai A,article,D016430: Clinical Trial; D023362: Evaluation Study; D016428: Journal Article; D016448: Multicenter Study,"D001786: Blood Glucose; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D000077715: Nateglinide; D010649: Phenylalanine; D011446: Prospective Studies; D016896: Treatment Outcome",,,https://openalex.org/W2441957391,81,14,1,1457,237,10,en,en
false,obesity type diabetes elderly,type diabetes common elderly compound obesity present major challenge physician obesity play central role aetiology pathogenesis type diabetes body weight determine interaction genetic environmental psychosocial factor act physiological mediator energy intake expenditure obesity think predispose type diabetes primarily cause insulin resistance education change lifestyle remain key issue obesity management anti obesity drug may delay onset diabetes limited experience use elderly patient obesity view cosmetic problem affect individual major health hazard preventable amenable treatment,Dewan S,2003,Gerontology,https://doi.org/10.1159/000069176,12679603,Dewan S; Wilding JP,article,D016428: Journal Article; D016454: Review,"D000328: Adult; D000368: Aged; D000886: Anthropometry; D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D005260: Female; D020022: Genetic Predisposition to Disease; D015438: Health Behavior; D006801: Humans; D008297: Male; D008875: Middle Aged; D009765: Obesity; D044469: Racial Groups; D012959: Socioeconomic Factors",,,https://openalex.org/W2078380314,42,7,1,828,135,7,en,en
false,insulin analogue critical review,multiple important technological innovation field insulin therapy appear last decade insulin analogue novel pharmacokinetics develop first analogue appear market insulin lispro believe part stu dies carry molecule comparison regular insulin unfair long short duration action ignore since many study administer meal one dose intermediate insulin give night several study mainly italian investigator prove concept true study adequate baseline insulin coverage insulin aspart appear recently market united state similar effect lispro fda recently approve new ultralong act analogue main advantage long peakless action good effect hour low incidence hypoglycaemia also review approach novel insulin molecule attach thyroxin fatty acid order create bridge bind plasmatic protein molecule long effect selective site action finally include brief review route insulin administration,Gómez-Pérez FJ,2002,Rev Invest Clin,,12685221,Gómez-Pérez FJ; Hernández-Jiménez S; Aguilar-Salinas CA; Rull JA,article,D016428: Journal Article; D016454: Review,"D003920: Diabetes Mellitus; D006801: Humans; D007328: Insulin; D061267: Insulin Aspart; D000069036: Insulin Glargine; D061268: Insulin Lispro; D049528: Insulin, Long-Acting",,,https://openalex.org/W1879463822,37,7,2,1320,224,11,en,en
false,slowly progress type diabetes persistence islet cell autoantibody relate glibenclamide treatment,several experimental study rat demonstrate sulfonylurea treatment increase autoantigen expression b cells phenomenon may deleterious preservation residual beta cell function patient slowly progress type diabetes latent autoimmune diabetes adult lada aim present study evaluate whether exclusion glibenclamide treatment ica positive type diabetic patient may diminish halt humoral autoimmune response b cells well improve metabolic control insulin secretion fourteen type diabetic patient pancreatic autoimmunity ica gaba treat insulin glibenclamide duration disease range year age range year study patient randomly assign two treatment group group insulin monotherapy n age year exclusion glibenclamide group insulin plus glibenclamide n age unmodified treatment group investigate beginning study one year following parameter ica anti gad antibody fast glucose fast c peptide group six eight patient become ica negative patient group remain ica positive p fast glucose concentration improve group relation group p one year treatment difference find anti gad antibody fast c peptide groups data show exclusion glibenclamide treatment ica type diabetic patient partially decrease specific autoimmunity endocrine pancreatic cell improve metabolic control may reflect decreased expression b cell autoantigens suggest insulin monotherapy good choice treatment lada,Cabrera-Rode E,2002,Autoimmunity,https://doi.org/10.1080/0891693021000050574,12685875,Cabrera-Rode E; Perich P; Diaz-Horta O; Tiberti C; Molina G; Arranz C; Martin JM; Licea M; De Leiva AD; Puig-Domingo M; Dimario U,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001323: Autoantibodies; D001786: Blood Glucose; D015992: Body Mass Index; D002096: C-Peptide; D003922: Diabetes Mellitus, Type 1; D003924: Diabetes Mellitus, Type 2; D005968: Glutamate Decarboxylase; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007515: Islets of Langerhans; D007527: Isoenzymes",,,https://openalex.org/W1999644625,114,16,1,1935,334,7,en,en
false,evaluation effect nateglinide postprandial glycemia patient type diabetes mellitus multicenter multinational non randomized non controlled latin american study,one hundred sixteen latin american type diabetic patient previously diet enrol multicenter multinational nonrandomized noncontrolled study complete study week treatment mg nateglinide administer prior meal postprandial h glucose concentration decrease mg dl p hba c value decrease p response difference detect relation age gender ethnicity encounter good response recently diagnose patient year serious adverse event observe therefore conclude nateglinide well tolerated safe effective insulinotropic agent,Islas-Andrade S,2003,Pharmacology,https://doi.org/10.1159/000069534,12711836,Islas-Andrade S; Revilla-Monsalve MC; Martínez de Hurtado E; Chacín LF; Caminos QR; Yupanqui H; López G; de la Torre W; Latin American Study Group,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D007843: Latin America; D008297: Male; D008875: Middle Aged; D000077715: Nateglinide; D010649: Phenylalanine; D019518: Postprandial Period; D016896: Treatment Outcome",,,https://openalex.org/W1993904895,190,28,1,760,147,6,en,en
false,addition rosiglitazone exist sulfonylurea treatment chinese patient type diabetes exposure hepatitis b c,effect add rosiglitazone exist sulfonylurea su treatment previously study chinese patient type diabetes know pre existing hepatic impairment patient randomize receive rosiglitazone mg twice daily r su mg twice daily r su placebo su p week addition exist su treatment patient take concomitant glibenclamide gliclazide change glycosylated hemoglobin hba c fast plasma glucose fpg plasma insulin concentration measure patient enrol male mean age year su p group r su group r su group mean baseline hba c fpg mg dl compare placebo addition rosiglitazone mg twice daily produce significant decrease mean hba c respectively p fpg mg dl respectively p statistically significant p reduction baseline insulin concentration pmol l r su r su group respectively despite high prevalence seropositivity hepatitis b c baseline evidence hepatotoxicity clinically significant change routine hematology biochemistry electrocardiogram observe addition rosiglitazone su produce clinically significant improvement glycemic control chinese patient type diabetes rosiglitazone plus su well tolerated irrespective hepatitis b c serological status,Zhu XX,2003,Diabetes Technol Ther,https://doi.org/10.1089/152091503763816445,12725705,Zhu XX; Pan CY; Li GW; Shi HL; Tian H; Yang WY; Jiang J; Sun XC; Davies C; Chow WH,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D044466: Asian People; D001786: Blood Glucose; D002681: China; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004781: Environmental Exposure; D005260: Female; D005907: Gliclazide; D005905: Glyburide; D006442: Glycated Hemoglobin; D006509: Hepatitis B; D006526: Hepatitis C; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D000077154: Rosiglitazone; D013453: Sulfonylurea Compounds; D013844: Thiazoles; D045162: Thiazolidinediones",,,https://openalex.org/W2070238084,134,21,1,1648,326,12,en,en
true,comparison repaglinide glimepiride patient type diabetes mellitus one year randomize double blind assessment metabolic parameter cardiovascular risk factor,background repaglinide glimepiride relatively new oral hypoglycemic agent data available concern effect metabolic parameter measure glycemic control objective addition assess effect repaglinide glimepiride glycemic control patient type diabetes mellitus study also examine effect agent metabolic parameter know cardiovascular risk factors lipoprotein lp plasminogen activator inhibitor pai homocysteine hcy method randomize placebo controlled double blind trial conduct single center italy eligible patient nonsmoker hypertension coronary heart disease take hypolipidemic drug diuretic beta blockers thyroxin normal renal function initial week placebo washout period patient randomize receive repaglinide mg glimepiride mg dose study drug optimize week titration period follow month treatment period measure glycemic control glycated hemoglobin hba c fast plasma glucose fpg postprandial plasma glucose ppg fast plasma insulin fpi postprandial plasma insulin ppi metabolic parameter interest assess month treatment result one hundred twenty four patient woman men complete study treatment group significant difference demographic characteristic group month treatment fpg level hba c value significantly reduce baseline group month p month p month ppg level significantly decrease repaglinide group p vs baseline month however ppg level significantly reduce baseline group p repaglinide p glimepiride significant change baseline fpi ppi level see either group month although fpi level significantly increase repaglinide group month p repaglinide significantly lower level lp pai hcy month p vs baseline glimepride significantly lower level lp hcy month p v baseline level lp p vs baseline hcy p vs baseline pai p vs baseline month conclusion repaglinide glimepiride improved glycemic control reduced level metabolic parameter interest population patient type diabetes possible reduction lp pai hcy result improve glucose metabolism however possibility repaglinide glimepiride may direct effect parameter exclude,Derosa G,2003,Clin Ther,https://doi.org/10.1016/s0149-2918(03)80090-5,12749508,Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D001786: Blood Glucose; D001794: Blood Pressure; D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005260: Female; D006710: Homocysteine; D006801: Humans; D007004: Hypoglycemic Agents; D017270: Lipoprotein(a); D008297: Male; D008875: Middle Aged; D010880: Piperidines; D017395: Plasminogen Activator Inhibitor 1; D012307: Risk Factors; D013453: Sulfonylurea Compounds; D013997: Time Factors; D016896: Treatment Outcome",,,https://openalex.org/W2160389935,193,27,1,2928,560,17,en,en
false,chromium adjunctive treatment type diabetes,review chemistry pharmacology efficacy safety trivalent chromium treatment type diabetes hyperlipidemia english literature search may use medline international pharmaceutical abstract embase key word include chromium glucose lipid diabetes pertinent reference review article study use additional sources trivalent chromium essential nutrient key role lipid glucose metabolism supplementation chromium appear reduce glucose level euglycemia may however efficacy reduce glucose level hyperglycemia effect chromium lipid level variable chromium dos microg appear safe short term administration kidney function dermatologic change need monitored chromium appear safe supplement may role adjunctive therapy treatment type diabetes additional large scale long term randomize double blind study examine effect various dos form chromium need,Ryan GJ,2003,Ann Pharmacother,https://doi.org/10.1345/aph.1c304,12773078,Ryan GJ; Wanko NS; Redman AR; Cook CB,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D002857: Chromium; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D006801: Humans",,,https://openalex.org/W2170336030,52,8,1,1135,187,9,en,en
false,nn novo nordisk,novo nordisk license scios inc develop nn stable analog naturally occur peptide hormone glucagon like peptide glp stimulate insulin release response increase blood sugar level potential treatment type diabetes,Mark M,2003,IDrugs,,12789615,Mark M,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D005934: Glucagon; D052216: Glucagon-Like Peptide 1; D006801: Humans; D000069450: Liraglutide; D013678: Technology, Pharmaceutical",,,https://openalex.org/W13618630,21,4,1,291,52,1,cs,en
false,oral antidiabetic therapy cardiovascular complication theoretical problem clinical evidence,theoretical experimental research data well human epidemiological study large population suggest great difference influence cardiovascular process alteration among oral antidiabetic drug use treatment type ii diabetes mellitus drug delay inhibit carbohydrate absorption well insulin sensitizer unambiguous reduce effect diabetic cardiovascular complication fluid retention need precaution treatment thiazolidinedions patient suffer heart disease among insulin secretizers repaglinid glibenclamid glipizide atp sensitive potassium channel inhibit effect vascular smooth muscle cell reduce hereby vasodilation glibenclamide also inhibit ischaemic preconditioning therefore antidiabetic drug choice decisive diabetic patient suffer ischaemic heart diseases peripheral obliterative disorder case secondary sulphonylurea resistance severe ischaemic alteration insulin treatment becomes necessary avoid cardiovascular complication,Pogátsa G,2003,Orv Hetil,,12795025,Pogátsa G,article,D004740: English Abstract; D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D002318: Cardiovascular Diseases; D002319: Cardiovascular System; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D019194: Ischemic Preconditioning; D015221: Potassium Channels",,,https://openalex.org/W2411033941,104,16,2,1136,155,7,en,en
true,effect prandial glucose regulation repaglinide treatment satisfaction wellbeing health status patient pharmacotherapy na type diabetes placebo controlled multicentre study,prospective week randomised double blind parallel group study assess differential impact prandial glucose regulate oral hypoglycaemic drug repaglinide placebo upon perception quality life qol treatment satisfaction pharmacotherapy naive patient type diabetes addition study assess whether outcome influence patient level glycaemic control total patient randomise ratio repaglinide placebo dos take flexibly main meal per day whenever eat repaglinide initiate mg per meal increase mg week fasting plasma glucose exceed mmol l qol treatment satisfaction outcome compare use generic disease specific self assessment measure previously apply diabetes wellbeing questionnaire wbq diabetes treatment satisfaction questionnaire dtsq euroqol eq trial period repaglinide treated patient report significant improvement dtsq treatment satisfaction score p significant increase associate placebo correlation decrease glycated haemoglobin hba c increase treatment satisfaction dtsq p score obtain measure change significantly trial either group cohort exhibit slight reduction wellbeing wbq health status eq baseline compare background population conclusion flexible mealtime dose oral medication appear well accept pharmacotherapy na patient type diabetes result suggest repaglinide provide high level treatment satisfaction placebo may part relate improve glycaemic control,Bech P,2003,Qual Life Res,https://doi.org/10.1023/a:1023495106160,12797714,Bech P; Moses R; Gomis R,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D006304: Health Status; D006305: Health Status Indicators; D006801: Humans; D007004: Hypoglycemic Agents; D017060: Patient Satisfaction; D010880: Piperidines; D011446: Prospective Studies; D011788: Quality of Life; D011795: Surveys and Questionnaires; D014175: Translating",,,https://openalex.org/W9598279,210,31,1,1884,317,11,en,en
false,thiazolidinediones diabetes current status future outlook,thiazolidinediones recently emerge promising antidiabetic drug unlike oral antidiabetic drug thiazolidinediones function ameliorate insulin resistance primary factor development type diabetes thiazolidinediones ligand nuclear receptor peroxisome proliferator activated receptor gamma antidiabetic effect appear mediate activation receptor two currently market thiazolidinediones rosiglitazone pioglitazone display similar efficacy glucose lowering activity interestingly display slightly different clinical side effect profile understand molecular basis difference help development next generation thiazolidinediones efficacious safer treatment type diabetes,Camp HS,2003,Curr Opin Investig Drugs,,12808879,Camp HS,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D056486: Chemical and Drug Induced Liver Injury; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D004353: Drug Evaluation, Preclinical; D006801: Humans; D007004: Hypoglycemic Agents; D008055: Lipids; D013844: Thiazoles; D015430: Weight Gain",,,https://openalex.org/W2416376001,66,10,1,842,119,5,en,en
false,nn novo nordisk,novo nordisk develop nn orally active beta cell selective regulator insulin release potential treatment type type diabetes phase efficacy trial underway november trial ongoing february conclude february,Choi JK,2003,Curr Opin Investig Drugs,,12808887,Choi JK,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D019086: Bridged Bicyclo Compounds, Heterocyclic; D017321: Clinical Trials, Phase I as Topic; D000075202: Contraindications; D003499: Cyclic S-Oxides; D003922: Diabetes Mellitus, Type 1; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D013329: Structure-Activity Relationship",,,https://openalex.org/W187408858,21,5,2,300,52,2,cs,en
false,glimepiride combine morning insulin glargine bedtime neutral protamine hagedorn insulin bedtime insulin glargine patient type diabetes,patient type diabetes often treat oral antidiabetic agent plus basal insulin investigate efficacy safety glimepiride combine either morning bedtime insulin glargine bedtime neutral protamine hagedorn nph insulin patient type diabetes open label randomize control trial center european countries patient type diabetes previously treat oral antidiabetic agents randomization treatment morning insulin glargine bedtime nph insulin bedtime insulin glargine week addition mg glimepiride insulin dose titrate use predefined regimen achieve fast blood glucose level mmol l low mg dl hemoglobin c value blood glucose level insulin dose body weight hemoglobin c level improve two sided ci morning insulin glargine ci bedtime insulin glargine ci bedtime nph insulin hemoglobin c improvement pronounced morning insulin glargine nph insulin ci p bedtime insulin glargine ci p baseline end point fasting blood glucose level improve similarly three group nocturnal hypoglycemia less frequent morning patient bedtime insulin glargine patient bedtime nph insulin patient p risk nocturnal hypoglycemia low glimepiride combination morning bedtime insulin glargine glimepiride combination bedtime nph insulin patient type diabetes morning insulin glargine provide good glycemic control bedtime insulin glargine bedtime nph insulin,Fritsche A,2003,Ann Intern Med,https://doi.org/10.7326/0003-4819-138-12-200306170-00006,12809451,Fritsche A; Schweitzer MA; Häring HU; 4001 Study Group,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D000069036: Insulin Glargine; D007336: Insulin, Isophane; D049528: Insulin, Long-Acting; D008297: Male; D008875: Middle Aged; D012307: Risk Factors; D013453: Sulfonylurea Compounds; D015430: Weight Gain",,,https://openalex.org/W2063423309,156,23,1,1916,371,6,en,en
false,comparison micro macro vascular effect glimepiride gliclazide metformin treated patient type diabetes double blind crossover study,compare metabolic vascular effect two sulphonylureas su gliclazide specific pancreatic sur receptor glimepiride nonspecific agent also bind vascular cardiac sur receptor chronic administration metformin treated patient type diabetes dm randomize double blind crossover study gliclazide mg bid glimepiride mg od week add therapy metformin week washout period patient attend four study morning first dose week su treatment measurement arterial distensibility ax pressor responsiveness v angiotensin ii angii cutaneous microvascular vasodilator response iontophoresis acetylcholine ach sodium nitroprusside snp glycaemic response similar e g serum fructosamine vs micro mol l week change augmentation index treatment either su vs mmhg week confidence interval similarly difference treatment pressor responsiveness e g pd dose agonist require increase mean bp mmhg angii vs ng kg min cutaneous microvascular vasodilator response peak ach response vs perfusion unit evidence sur specific nonspecific sus differential effect arterial distensibility endothelial function vasodilator mechanism metformin treated patient dm,Dhindsa P,2003,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.2003.01781.x,12814458,Dhindsa P; Davis KR; Donnelly R,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005907: Gliclazide; D006801: Humans; D007004: Hypoglycemic Agents; D008687: Metformin; D008833: Microcirculation; D008875: Middle Aged; D013453: Sulfonylurea Compounds; D014664: Vasodilation",,,https://openalex.org/W1565615929,165,24,1,1571,290,6,en,en
true,influence drug interact cyp pharmacokinetics pharmacodynamics safety prandial glucose regulator repaglinide,object study analyze drug interaction repaglinide short acting insulin secretagogue five drug interact cyp ketoconazole rifampicin ethinyloestradiol levonorgestrel oral contraceptive simvastatin nifedipine two open label two period randomize crossover study healthy subject receive repaglinide alone repaglinide day ketoconazole treatment repaglinide day rifampicin treatment three open label three period randomize crossover study healthy subject receive day repaglinide alone day ethinyloestradiol levonorgestrel simvastatin nifedipine alone day repaglinide concomitant ethinyloestradiol levonorgestrel simvastatin nifedipine compare administration repaglinide alone concomitant ketoconazole increase mean auc repaglinide mean c max concomitant rifampicin decrease mean auc repaglinide mean c max concomitant treatment cyp substrate alter mean auc h mean c max repaglinide ethinyloestradiol levonorgestrel simvastatin nifedipine profile blood glucose concentration follow repaglinide dose alter less ketoconazole rifampicin five study adverse event relate hypoglycemia expect normal population give blood glucose regulator safety profile repaglinide alter pretreatment ketoconazole rifampicin coadministration ethinyloestradiol levonorgestrel incidence adverse event increase coadministration simvastatin nifedipine compare either repaglinide simvastatin nifedipine treatment alone clinically relevant pharmacokinetic interaction occur repaglinide cyp substrates ethinyloestradiol levonorgestrel simvastatin nifedipine pharmacokinetic profile repaglinide alter administration potent inhibitor inducer ketoconazole rifampicin less degree expect result probably explain metabolic pathway repaglinide involve enzyme cyp reflect extent small change repaglinide pharmacodynamics thus careful monitoring blood glucose repaglinide treated patient receive strong inhibitor inducer cyp recommend increase repaglinide dose may necessary safety concern observe except high incidence adverse event patient receive repaglinide simvastatin nifedipine,Hatorp V,2003,J Clin Pharmacol,https://doi.org/10.1177/0091270003253704,12817528,Hatorp V; Hansen KT; Thomsen MS,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D019540: Area Under Curve; D001786: Blood Glucose; D002219: Carbamates; D051544: Cytochrome P-450 CYP3A; D003577: Cytochrome P-450 Enzyme System; D004347: Drug Interactions; D005260: Female; D006207: Half-Life; D006801: Humans; D007004: Hypoglycemic Agents; D007654: Ketoconazole; D008297: Male; D010880: Piperidines; D012293: Rifampin; D019821: Simvastatin,,,https://openalex.org/W2091099367,142,20,1,2700,426,15,en,en
false,glimepiride oral antidiabetic agent,glimepiride oral antidiabetic second generation sulfonylurea structurally similar glyburide glimepiride exhibit potent glucose lowering effect glyburide long duration hypoglycemic effect glimepiride useful treatment non insulin dependent type ii diabetes mellitus glimepiride indicate adjunct diet exercise non insulin dependent diabetes mellitus glimepiride reduces glucose level blood stimulate insulin release functional pancreatic beta cell response glucose glimepiride daily dose mg cause dose related decrease blood glucose level glycosylated hemoglobin fast state postprandially maximum dose glimepiride fails lower blood glucose sufficiently metformine insuline may add glimepiride monotherapy glimepiride safe drug adverse effect cause glimepiride rare risk hypoglycemia use glimepiride small therefore therapy glimepiride preferable therapy glibenclamide,Becić F,2003,Med Arh,,12822388,Becić F; Kapić E; Becić E,article,D004740: English Abstract; D016428: Journal Article; D016454: Review,"D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D013453: Sulfonylurea Compounds",,,https://openalex.org/W28050928,42,9,1,1107,170,10,en,en
false,case report inadvertent sulfonylurea overdosage hypoglycemia elderly woman failure serum hypoglycemia screen,report case year old woman two episode documented hypoglycemia initial laboratory test reveal hyperinsulinemia negative serum sulfonylurea screen data suggest presence insulinoma evaluation case reveal inadvertent ingestion glimepiride sulfonylurea include standard serum sulfonylurea screen,Earle KE,2003,Diabetes Technol Ther,https://doi.org/10.1089/152091503765691956,12828829,Earle KE; Rushakoff RJ; Goldfine ID,article,D002363: Case Reports; D016420: Comment; D016428: Journal Article,"D000368: Aged; D000369: Aged, 80 and over; D001786: Blood Glucose; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D062787: Drug Overdose; D005260: Female; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D013453: Sulfonylurea Compounds",,,https://openalex.org/W1992638756,126,18,1,391,61,3,en,en
false,analysis flaw use sulfonylurea screen diagnose sulfonylurea overdosages,diabetes technology therapeuticsvol original papersanalysis flaw use sulfonylurea screen diagnose sulfonylurea overdosagesdavid c klonoffdavid c klonoffsearch paper authorpublished online jul https doi org aboutsectionspdf epub toolspermissionsdownload citationstrack citationsadd favorites back publication shareshare onfacebooktwitterlinked inredditemail analysis flaw use sulfonylurea screen diagnose sulfonylurea overdosages pp figuresreferencesrelateddetailscited byinsulin c peptide level sulfonylurea induced hypoglycemia systematic reviewjournal medical toxicology vol emergency management oral hypoglycemic drug toxicityemergency medicine clinic north america vol volume issue jun cite article david c klonoff analysis flaw use sulfonylurea screen diagnose sulfonylurea overdosages diabetes technology therapeutics jun http doi org published volume issue july pdf download,Klonoff DC,2003,Diabetes Technol Ther,https://doi.org/10.1089/152091503765691965,12828830,Klonoff DC,article,D016428: Journal Article,D001786: Blood Glucose; D062787: Drug Overdose; D006801: Humans; D007004: Hypoglycemic Agents; D015203: Reproducibility of Results; D013453: Sulfonylurea Compounds,,,https://openalex.org/W2223564701,90,14,1,1145,161,9,en,en
true,glimerpiride type diabetes mellitus review worldwide therapeutic experience,sulfonylurea sus use many year first line therapy patient type diabetes mellitus whose blood glucose level effectively control diet exercise alone glimepiride daily su introduce since considerable body evidence amass regard use type diabetes review provide comprehensive summary available data pharmacology pharmacokinetics efficacy safety profile glimepiride treatment type diabetes also examine use glimepiride achieve maintain good glycemic control patient type diabetes current clinical practice relevant article identify search medline english language study publish search term use glimepiride sulfonylureas type diabetes mellitus manufacturer glimepiride provide additional information glimepiride differs sus number respect clinical study glimepiride generally associate low risk hypoglycemia less weight gain sus result study suggest glimepiride use old patient renal compromise evidence glimepiride preserve myocardial preconditioning protective mechanism limit damage event ischemic event glimepiride use combination oral antidiabetic agent insulin optimize glycemic control based evidence date glimepiride effective well tolerated daily antidiabetic drug provide important treatment option management type diabetes,Massi-Benedetti M,2003,Clin Ther,https://doi.org/10.1016/s0149-2918(03)80109-1,12852703,Massi-Benedetti M,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D001786: Blood Glucose; D001835: Body Weight; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D014943: Global Health; D006801: Humans; D007004: Hypoglycemic Agents; D013453: Sulfonylurea Compounds; D016896: Treatment Outcome",,,https://openalex.org/W2141358021,90,14,1,1720,276,10,en,en
false,multicenter randomize double masked parallel group assessment simultaneous glipizide metformin second line pharmacologic treatment patient type diabetes mellitus inadequately control sulfonylurea,many patient type diabetes mellitus dm inadequate long term blood glucose control sulfonylurea metformin monotherapy require additional treatment synergistic effect combine glipizide metformin glucose control may realize treat primary effect type dm impaired insulin secretion insulin resistance study assess therapy glipizide metformin combination tablet patient type dm uncontrolled least half maximum labeled daily dose sulfonylurea multicenter double masked parallel group active controlled study patient randomize receive glipizide mg metformin mg glipizide metformin mg tablet week metformin glipizide metformin dos titrate achieve blood glucose control maximum total daily dos glipizide mg metformin mg glipizide metformin mg total patient include study mean sd age year patient male white hispanic latino black asian pacific islander patient average obese mean sd body mass index kg moderate severe hyperglycemia mean sd glycated hemoglobin hba c mean sd dm duration year glipizide metformin tablet control hba c level effectively either glipizide metformin monotherapies mean treatment difference favor glipizide metformin respectively p study end hba c level achieve approximately fold patient treat glipizide metformin compare glipizide metformin monotherapies glipizide metformin tablet also reduce fasting plasma glucose fpg level hour postprandial glucose area concentration time curve effectively either monotherapy without increase fasting insulin level great blood glucose control glipizide metformin tablet achieve mean daily dose glipizide metformin mg compare mean dos glipizide mg metformin mg treatment well tolerate low incidence symptom hypoglycemia evidence fingerstick blood glucose measurement mg dl combination group patient discontinue study treatment reason patient require medical assistance hypoglycemia glipizide metformin tablet effective either glipizide metformin monotherapy control hba c reduce fpg compare baseline patient blood glucose uncontrolled previous sulfonylurea treatment addition patient receive glipizide metformin likely achieve hba c level result consistent synergistic effect insulin resistance beta cell dysfunction glipizide metformin well tolerate low incidence hypoglycemia,Goldstein BJ,2003,Clin Ther,https://doi.org/10.1016/s0149-2918(03)80112-1,12852706,Goldstein BJ; Pans M; Rubin CJ,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005215: Fasting; D005260: Female; D005913: Glipizide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D008875: Middle Aged",,,https://openalex.org/W2146089205,233,29,1,3126,542,14,en,en
false,economic model first line drug strategy achieve recommended glycaemic control newly diagnose type diabetes mellitus,objective assess short term direct medical cost effectiveness associate achieve recommended glycaemic goal use commonly prescribe first line oral antihyperglycaemic medication type diabetes mellitus material method literature based decision tree model develop project number patient achieve glycosylated haemoglobin value oral therapy associated cost year timeframe first line strategy patient could progress combination therapy use two agent prior introduction insulin overall cost treatment include cost value u dollar comprehensive medical care laboratory test patient education drug therapy home glucose monitoring adverse event result year overall cost treatment various first line strategy u dollar glipizide gastrointestinal therapeutic system u dollar metformin immediate release u dollar metformin extend release u dollar glibenclamide glyburide metformin u dollar rosiglitazone u dollar repaglinide cost comprehensive routine medical care range approximately u dollar year approximately u dollar subsequent year control uncontrolled patient respectively adverse event represent drug therapy represent approximately overall cost respectively substantial cost difference strategy see within first year regardless first line therapy patient progress quickly combination therapy effectiveness among agent similar conclusion short term cost require provide comprehensive diabetes care achieve glycemic goal substantial model suggest sulphonylurea strategy may provide similar effectiveness cost saving agent consider select initial drug therapy newly diagnose patient type diabetes mellitus,Ramsdell JW,2003,Pharmacoeconomics,https://doi.org/10.2165/00019053-200321110-00005,12859222,Ramsdell JW; Braunstein SN; Stephens JM; Bell CF; Botteman MF; Devine ST,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D002219: Carbamates; D015331: Cohort Studies; D003663: Decision Trees; D003924: Diabetes Mellitus, Type 2; D004180: Direct Service Costs; D016527: Drug Costs; D004359: Drug Therapy, Combination; D005913: Glipizide; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008329: Managed Care Programs; D008390: Markov Chains; D008687: Metformin; D018803: Models, Economic; D010880: Piperidines; D000077154: Rosiglitazone; D013844: Thiazoles; D045162: Thiazolidinediones; D014481: United States",,,https://openalex.org/W2049679961,129,18,1,2121,331,11,en,en
false,effect glycemic control exenatide synthetic exendin additive exist metformin sulfonylurea treatment patient type diabetes,objective ac synthetic exendin exenatide peptide enhance glucose dependent insulin secretion suppress inappropriately elevate glucagon secretion slow gastric empty ac also promote cell proliferation neogenesis vitro animal model study examine activity safety subcutaneously inject ac patient type diabetes currently treat diet oral antidiabetic agent oaas research design methods total patient treat diet sulfonylurea metformin enrol blinded study patient randomly assign one three subcutaneously sc inject regimen ac g kg placebo day results three ac regimen lead significant reduction serum fructosamine relative placebo p mean reduction range mol l ac group reduction hba c range p end study hba c lt achieve ac patient versus placebo patient confirm ac effect fasting postprandial glycemia day cell index homeostasis model assessment patient treat ac high baseline contrast unchanged level placebo common adverse event transient mild moderate nausea conclusions ac promising therapeutic patient type diabetes study significant effect hba c level patient currently achieve optimal glucose control diet oaas,Fineman MS,2003,Diabetes Care,https://doi.org/10.2337/diacare.26.8.2370,12882864,Fineman MS; Bicsak TA; Shen LZ; Taylor K; Gaines E; Varns A; Kim D; Baron AD,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D001794: Blood Pressure; D001835: Body Weight; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D000077270: Exenatide; D005260: Female; D019270: Fructosamine; D006442: Glycated Hemoglobin; D006339: Heart Rate; D006801: Humans; D007004: Hypoglycemic Agents; D007515: Islets of Langerhans; D008055: Lipids; D008297: Male; D008687: Metformin; D008875: Middle Aged; D010455: Peptides; D013453: Sulfonylurea Compounds; D016896: Treatment Outcome; D014688: Venoms",,,https://openalex.org/W2101718966,155,23,1,1620,280,13,en,en
false,possible heart failure exacerbation associate rosiglitazone case report literature review,increase evidence suggest neurohumoral manifestation heart failure may lead insulin resistance predispose patient heart failure development glucose intolerance worsening exist diabetes theoretically insulin sensitizing thiazolidinediones tzds beneficial patient population year old man well compensated systolic dysfunction longstanding type diabetes mellitus treat glyburide begin therapy rosiglitazone mg day increase mg day month two week later see kg weight gain shortness breath bibasilar rale gallop increase jugular venous distention twelve day later symptom worsen pulmonary edema chest radiograph continue weight gain pit edema resistant oral diuretic patient admit hospital exacerbation heart failure five day discharge readmitted similar symptom include kg weight gain report adherence drug therapy diet rosiglitazone immediately discontinue day later man weight stabilize kg remain kg month discharge case demonstrate tzds may precipitate weight gain pulmonary peripheral edema patient stable heart failure early report document similar symptom patient without history heart failure although current recommendation state tzds administer patient new york heart association class iii iv disease practitioner aware adverse effect also may occur patient milder form heart failure well without heart failure,Page RL,2003,Pharmacotherapy,https://doi.org/10.1592/phco.23.7.945.32721,12885108,Page RL; Gozansky WS; Ruscin JM,article,D002363: Case Reports; D016428: Journal Article; D016454: Review,"D000368: Aged; D003924: Diabetes Mellitus, Type 2; D006333: Heart Failure; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D000077154: Rosiglitazone; D045162: Thiazolidinediones",,,https://openalex.org/W2027464997,100,13,1,1766,287,12,en,en
true,nateglinide starlix update new antidiabetic agent,nateglinide new oral antidiabetic agent stimulate insulin release promptly pre meal administration strongly glucose dependent fashion insulinotropic effect short duration nateglinide specifically target postprandial hyperglycaemia low potential elicit hypoglycaemia sustain hyperinsulinaemia nateglinide excellent safety tolerability profile efficacy reduce hba c monotherapy mg meal comparable metformin sulphonylureas thiazolidinediones acarbose combine metformin primarily reduce fast glucose level nateglinide effect additive clinical experience nateglinide particularly good therapeutic option newly diagnose treatment naive patient elderly patient hypoglycaemia concern patient kidney failure mild hepatic impairment patient take low dose sulphonylureas encounter problem hypoglycaemia patient fail achieve adequate glycaemic control metformin thiazolidinedione monotherapy,Phillips LS,2003,Int J Clin Pract,,12918894,Phillips LS; Dunning BE,article,D016428: Journal Article; D016454: Review,"D001786: Blood Glucose; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D000077715: Nateglinide; D010649: Phenylalanine; D016896: Treatment Outcome",,,https://openalex.org/W2442976564,58,12,1,1131,168,5,en,en
false,pharmacokinetics nateglinide metabolite subject type diabetes mellitus renal failure,evaluate benefit safety nateglinide novel oral hypoglycemic agent type diabetes patient renal failure single dose pharmacokinetics study patient type diabetes low creatinine clearance range ml min hour mg nateglinide administration next treat another group patient undergoing regular hemodialysis nateglinide mg day month effect hemodialysis metabolite accumulation tested single mg dose nateglinide significantly increase post prandial secretion insulin thereby reduce plasma glucose level mean pharmacokinetic parameter auc mg l h h cl f l h comparable report healthy subject much large auc value previously report major metabolite urine healthy subject observe plasma concentration decline hour patient treat regular basis mark accumulation nateglinide could detect hour last dose plasma level significantly reduce hemodialysis sessions single mg dose nateglinide safe effective patient renal failure however repeat administration could cause prolonged hypoglycemia due accumulation know modest hypoglycemic activity hemodialysis may help eliminate excessive accumulation,Inoue T,2003,Clin Nephrol,https://doi.org/10.5414/cnp60090,12940610,Inoue T; Shibahara N; Miyagawa K; Itahana R; Izumi M; Nakanishi T; Takamitsu Y,article,D016430: Clinical Trial; D016428: Journal Article,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D019540: Area Under Curve; D003510: Cyclohexanes; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D000077715: Nateglinide; D010649: Phenylalanine; D051437: Renal Insufficiency; D013997: Time Factors",,,https://openalex.org/W2335284280,111,16,1,1530,263,9,en,en
false,lispro insulin metformin versus combination diabetes mellitus type management secondary oral antidiabetic drug failure,purpose study find difference treatment diabetes type secondary oral antidiabetic drug failure three different method treatment compare lispro insulin combination metformin glimepiride metformin combination two daily dos biphasic insulin together bed time nph insulin study include patient diabetes mellitus type randomly distribute different treatment group fasting postprandial glucose analyze enzymatic colorimetric method hba c measure ion exchange chromatography hba c significantly decrease three study group decrease mostly express among patient treat lispro metformin focus postprandial glucose control antihyperglycemic metformin insulin lispro therapy great impact overall metabolic control decrease level hba c comparison mention traditional approach,Kokić S,2003,Coll Antropol,,12974145,Kokić S; Buković D; Radman M; Capkun V; Gabrić N; Lesko V; Karelović D; Stancerić T,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000368: Aged; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D061268: Insulin Lispro; D008297: Male; D008687: Metformin; D008875: Middle Aged; D019518: Postprandial Period; D013453: Sulfonylurea Compounds; D016896: Treatment Outcome",,,https://openalex.org/W2187022835,144,21,1,998,153,7,en,en
false,cardiovascular risk type diabetic pharmacological regulation mealtime glucose excursion,type diabetic patient mealtime glucose fluctuation important determinant overall glucose control overall risk diabetes cardiovascular complication fact acute elevation plasma glucose concentration trigger array tissue response may contribute development vascular complication since may result thrombophilic condition cause endothelial dysfunction possibly reduction nitric oxide availability responsible non enzymatic glycation production free radical ensue oxidative stress keep post prandial glucose narrow range metiglinide analogue drug develop particular repaglinide nateglinide seem useful one fact drug improve st phase insulin release affect total daily amount insulin release pancreas due mechanism action pharmacokinetic property repaglinide nateglinide allow diabetic patient get tight metabolic glucose control contemporary reduction case severe hypoglycaemia conclusion repaglinide nateglinide new powerful pharmacological tool achieve good metabolic glucose control also prevent development diabetes related cardiovascular complication,Paolisso G,2003,Diabetes Metab,https://doi.org/10.1016/s1262-3636(07)70044-7,14526261,Paolisso G; Rizzo MR; Barbieri M; Manzella D; Ragno E; Maugeri D,article,D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D001786: Blood Glucose; D002318: Cardiovascular Diseases; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D004435: Eating; D006801: Humans; D007004: Hypoglycemic Agents; D019518: Postprandial Period; D012307: Risk Factors",,,https://openalex.org/W2007022610,101,13,1,1356,209,7,en,en
false,improvement glycemic control type diabetes patient switch sulfonylurea coadministered metformin glyburide metformin tablet,evaluate change hemoglobin c c patient type diabetes switch coadministration sulfonylurea su glyburide glipizide metformin su met single glyburide metformin tablet retrospective cohort study design patient type diabetes treat veteran affair medical center department defense medical center utilize one hundred percent patient receive glyburide metformin tablet screen inclusion patient least month prior su met combination therapy baseline c measure within day prior day switch glyburide metformin tablet include least one document follow c day switch glyburide metformin require inclusion glycemic control complication lipid parameter concomitant medication weight analyze prior follow switch glyburide metformin seventy two patient record include disqualification criterion exclude prospective patient mean age patient year average body mass index kg average baseline c average time since diagnosis year mean reduction c p mean follow day switch glyburide metformin tablet improvement glycemic control predominantly see patient baseline c mean reduction c p achieve despite low mean final dose glyburide result study suggest type diabetic patient c switch coadministration sulfonylurea plus metformin combination glyburide metformin tablet may provide improvement glycemic control range absolute percentage point decrease c randomized prospective trial compare method treatment need however determine precise effect provide unique formulation glyburide glyburide metformin tablet,Duckworth W,2003,J Manag Care Pharm,https://doi.org/10.18553/jmcp.2003.9.3.256,14613469,Duckworth W; Marcelli M; Padden M; Kellick K; Duhancik T; Wilhardt M; Colgan K; Romie A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D000368: Aged; D001786: Blood Glucose; D015897: Comorbidity; D003924: Diabetes Mellitus, Type 2; D004338: Drug Combinations; D004359: Drug Therapy, Combination; D005260: Female; D005913: Glipizide; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D008875: Middle Aged; D009765: Obesity; D011446: Prospective Studies; D012189: Retrospective Studies",,,https://openalex.org/W61885398,148,18,1,2087,352,9,en,en
true,pharmacokinetics pharmacodynamics glipizide daily divide dos,determine pharmacokinetics pharmacodynamics glipizide give single oral mg dose versus three different divided dose regimen total mg randomized order dose regimen open label crossover study university medical center clinical research center six subject noninsulin dependent diabetes mellitus patients study four separate occasion separate least day divided dose regimen design simulate delayed absorption drug hour blood sample measure glipizide glucose c peptide obtain hours glipizide peak concentration time peak differ significantly dosage schedule small dos administer often peak concentration low delayed mean value area curve time zero infinity range micrograms l hr nmol l hr clearance ml min kg ml sec kg post distribution phase volume l kg half life hr significantly different among regimen neither morning fasting glucose maximum minimum time concentration glucose c peptide hour statistically different among regimen similarly significant difference find area concentration time curve glucose c peptide measure hour meal time zero hours timing glipizide dose relation meal simulated delayed prolonged absorption appear little influence drug pharmacodynamic effect,Kradjan WA,1995,Pharmacotherapy,,7479199,Kradjan WA; Takeuchi KY; Opheim KE; Wood FC,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000284: Administration, Oral; D000368: Aged; D001786: Blood Glucose; D002096: C-Peptide; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D005260: Female; D005502: Food; D005913: Glipizide; D006801: Humans; D007004: Hypoglycemic Agents; D007408: Intestinal Absorption; D008297: Male; D008875: Middle Aged; D013997: Time Factors",,,https://openalex.org/W1915963975,85,10,1,1673,262,6,en,en
false,polymorphonuclear leukocyte non insulin dependent diabetes mellitus abnormality metabolism function,objective determine basal level cytosolic calcium ca phagocytic activity polymorphonuclear leukocyte pmnls patient non insulin dependent diabetes niddm design prospective cohort study setting university county hospital measurement cytosolic calcium level adenosine triphosphate atp content phagocytosis pmnls patient niddm control intervention patient niddm evaluate effect treatment oral hypoglycemic agent glyburide ca level atp content phagocytosis pmnls patient control patient niddm examine fifteen patient study month treatment glyburide result polymorphonuclear leukocyte patient niddm show significantly elevate basal level ca compare nmol l p reduce atp content compare nmol pmnls p impaired phagocytosis compare g oil pmnls per minute p compare control direct significant correlation p r ca level pmnls serum glucose level inverse correlation phagocytic ability ca level p r well phagocytic activity fast serum glucose level p r patient niddm glyburide therapy result significant reduction fast serum glucose level pmnls treatment result significant reduction ca level significant increase atp content significant improvement phagocytosis conclusion patient niddm elevate ca level pmnls abnormality probably induce hyperglycemia primarily responsible impaired phagocytosis see patient,Alexiewicz JM,1995,Ann Intern Med,https://doi.org/10.7326/0003-4819-123-12-199512150-00004,7486486,Alexiewicz JM; Kumar D; Smogorzewski M; Klin M; Massry SG,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000255: Adenosine Triphosphate; D000328: Adult; D000368: Aged; D002118: Calcium; D003600: Cytosol; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D009504: Neutrophils; D010587: Phagocytosis; D011446: Prospective Studies",,,https://openalex.org/W2059736175,113,12,1,1917,364,12,en,en
false,comparison insulin without continuation oral hypoglycemic agent treatment secondary failure niddm patient,objective optimal insulin regimen non insulin dependent diabetes mellitus niddm patient secondary failure controversial evaluate efficacy side effect quality life patient receive insulin either alone combination previous oral hypoglycemic agent ohas research design method fifty three chinese patient niddm mean age year duration diabetes year body wt kg correspond body mass index kg receive maximum dose sulfonylurea metformin confirm oha failure twenty seven patient randomize continue ohas give additional bedtime insulin combination group patient randomize insulin therapy alone twice daily insulin insulin group insulin dos increase incrementally aim fast plasma glucose fpg lt mmol l stabilization period week insulin dosage body weight glycemie control quality life assess month stabilization result group show similar improvement glycemie control combination group fpg decrease mmol l month p lt mmol l month p lt insulin group fpg decrease mmol l month p lt mmol l month p lt significant difference observe group similarly group significant improvement fructosamine glycosylated hemoglobin hbalc fructosamine fell mean mol l month p lt mol l month p lt mol month p lt mol l month p lt combination insulin group respectively hba cdecreased month p lt month p lt combination group month p lt month p lt insulin group despite similar improvement glycemia insulin requirement different month combination group receive mean u day compare u day insulin group p lt similar finding observe month vs u day p lt group gain weight however combination group weight gain kg month kg month p lt vs baseline whereas insulin group weight gain kg respectively p lt vs baseline weight gain significantly great insulin group p lt month p lt month fast plasma triglyceride decrease insulin group mmol l month p lt mmol l month p lt combination group change observe total high density lipoprotein cholesterol severe hypoglycemic reaction record either group mild reaction occur similar frequency group well quality life improve significantly group majority patient want continue insulin beyond month irrespective treatment group conclusion niddm patient secondary oha failure therapy combination ohas insulin insulin alone equally effective well tolerate however combination therapy associate low insulin dose less weight gain combination treatment may consider oha failure occur potential intermediate stage full insulin replacement,Chow CC,1995,Diabetes Care,https://doi.org/10.2337/diacare.18.3.307,7555472,Chow CC; Tsang LW; Sorensen JP; Cockram CS,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000704: Analysis of Variance; D015415: Biomarkers; D001786: Blood Glucose; D015992: Body Mass Index; D002096: C-Peptide; D002784: Cholesterol; D008076: Cholesterol, HDL; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005260: Female; D019270: Fructosamine; D005907: Gliclazide; D005913: Glipizide; D005905: Glyburide; D006442: Glycated Hemoglobin; D006595: Hexosamines; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D017211: Treatment Failure; D014280: Triglycerides",,,https://openalex.org/W1974657065,134,20,1,3943,839,28,en,en
false,treatment hypercholesterolemia niddm policosanol,objective determine whether elevated level cholesterol low density lipoprotein ldl cholesterol non insulin dependent diabetes mellitus niddm patient could decrease policosanol new cholesterol lowering drug niddm predispose patient coronary artery disease cad direct action hyperglycemia artery well dyslipidemia induce niddm research design method double blind placebo controlled trial perform patient niddm hypercholesterolemia stable glycemie control achieve diet oral hypoglycemic drug patient instruct follow cholesterol lowering diet week patient meet entry criterion receive double blind condition policosanol mg placebo tablet twice day week result policosanol mg day significantly reduce total cholesterol ldl cholesterol compare baseline placebo furthermore high density lipoprotein hdl cholesterol raise significant triglyceride show statistically nonsignificant decrease change lipid profile similar induce policosanol nondiabetic patient type ii hyperlipoproteinemia conclusion glycemie control unaffected treatment clinically biochemically adverse effect attributable treatment observe one patient placebo withdrew trial adverse experience erythema conclude policosanol effective safe patient niddm hypercholesterolemia,Torres O,1995,Diabetes Care,https://doi.org/10.2337/diacare.18.3.393,7555484,Torres O; Agramonte AJ; Illnait J; Más Ferreiro R; Fernández L; Fernández JC,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000924: Anticholesteremic Agents; D002784: Cholesterol; D002791: Cholesterol, Dietary; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D004311: Double-Blind Method; D005233: Fatty Alcohols; D005260: Female; D006801: Humans; D006937: Hypercholesterolemia; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D010919: Placebos; D014280: Triglycerides",,,https://openalex.org/W2046634803,59,7,1,1626,259,12,en,en
false,comparison miglitol glibenclamide diet treated type diabetic patient,efficacy new intestinal alpha glucosidase inhibitor miglitol glibenclamide compare month double blind control protocol involve non insulin dependent diabetic patient diet alone hba c level initially reduce p miglitol glibenclamide difference two treatment significant although glibenclamide appear active miglitol p week p week fast glycaemia decrease miglitol vs mmol l p glibenclamide vs p miglitol decrease note breakfast p lunch p true glibenclamide p p respectively significant reduction glucose incremental area standard meal test note end miglitol p glibenclamide treatment p subgroup nonresponders treatment identify miglitol glibenclamide side effect record patient treat miglitol flatulence meteorism diarrhoea discontinue therapy treated glibenclamide asthenia sensation hunger study indicate miglitol suitable initial application diet resistant type diabetic patient provide persistent effect acceptable side effect,Pagano G,1995,Diabete Metab,,7556806,Pagano G; Marena S; Corgiat-Mansin L; Cravero F; Giorda C; Bozza M; Rossi CM,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't","D017485: 1-Deoxynojirimycin; D001786: Blood Glucose; D002784: Cholesterol; D008076: Cholesterol, HDL; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D004311: Double-Blind Method; D004791: Enzyme Inhibitors; D005260: Female; D005944: Glucosamine; D005905: Glyburide; D006442: Glycated Hemoglobin; D065089: Glycoside Hydrolase Inhibitors; D006801: Humans; D007004: Hypoglycemic Agents; D050112: Imino Pyranoses; D008297: Male; D008875: Middle Aged; D015999: Multivariate Analysis; D013997: Time Factors; D017211: Treatment Failure; D014280: Triglycerides",,,https://openalex.org/W75050017,82,12,1,1516,291,10,en,en
true,veteran affair cooperative study glycemic control complication type ii diabetes va csdm result feasibility trial,objective clear whether intensive pharmacological therapy effectively sustain non insulin dependent diabetes mellitus niddm relative risk benefit intensive insulin therapy niddm well define accordingly design feasibility study compare standard therapy intensive therapy group niddm men require insulin due sustained hyperglycemia research design method prospective trial conduct five medical center men year age know diagnosis diabetes year randomly assign standard insulin treatment group one morning injection per day intensive therapy group design attain near normal glycemia clinically significant separation glycohemoglobin standard arm four step plan use intensive therapy group along daily self monitoring glucose evening insulin injection injection add daytime glipizide two injection insulin alone multiple daily injection patient accrual adherence glycohemoglobin hba c side effect measurement endpoint prospective long term trial assess result accrual goal meet mean follow time month range month patient keep scheduled visit month mean hba c intensive therapy group remain low standard group duration trial decrease mean hba c intensive group obtain single injection even intermediate insulin alone daytime glipizide end trial patient advance two injection insulin day aim normal hba c however small additional fall hba c attain severe hypoglycemia rare two event per patient per year significantly different group change weight blood pressure plasma lipid new cardiovascular event patient death due cardiovascular cause conclusion intense step insulin therapy niddm patient fail glycemic control pharmacological therapy effective maintain near normal glycemic control gt year without excessive severe hypoglycemia weight gain hypertension dyslipidemia cardiovascular event rate high stage niddm long term prospective trial need assess risk benefit ratio intensified treatment hyperglycemia niddm patient require insulin,Abraira C,1995,Diabetes Care,https://doi.org/10.2337/diacare.18.8.1113,7587846,Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.","D000368: Aged; D000419: Albuminuria; D000818: Animals; D015415: Biomarkers; D001786: Blood Glucose; D015190: Blood Glucose Self-Monitoring; D001794: Blood Pressure; D015992: Body Mass Index; D002784: Cholesterol; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D003930: Diabetic Retinopathy; D005240: Feasibility Studies; D005913: Glipizide; D006442: Glycated Hemoglobin; D006762: Hospitals, Animal; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D018579: Patient Selection; D011786: Quality Control; D012907: Smoking; D013997: Time Factors; D014280: Triglycerides; D014481: United States",,,https://openalex.org/W2091034695,136,23,1,2671,476,17,en,en
false,comparison bedtime nph preprandial regular insulin combine glibenclamide secondary sulfonylurea failure,objective compare effect bedtime nph insulin preprandial regular insulin combine glibenclamide metabolic control non insulin dependent diabetes mellitus niddm patient secondary failure sulfonylurea therapy research design method eighty niddm patient randomize treatment either three preprandial dos regular insulin daytime group bedtime dose nph insulin nocturnal insulinization group n regimen combine mg glibenclamide metabolic profile obtain week result glycemic control improve significantly group month fast blood glucose significantly low compare baseline group mean change sd group mmol l group n mmol l reduction pronounced group n compare group p lt hba c lower similarly group p lt group n p lt total daily insulin dos similar u group u group n circulate insulin level daytime high group group n total serum cholesterol triglyceride similarly significantly lower compare baseline group weight gain pronounced group kg group n kg vs n p lt change inversely correlate initial eight improvement hba c conclusion two insulin regimen exert similar effect glucose metabolism serum lipid niddm patient combination therapy weight gain pronounced patient give insulin daytime preprandial dos short acting insulin use,Landstedt-Hallin L,1995,Diabetes Care,https://doi.org/10.2337/diacare.18.8.1183,7587856,Landstedt-Hallin L; Adamson U; Arner P; Bolinder J; Lins PE,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D001835: Body Weight; D002096: C-Peptide; D002784: Cholesterol; D008076: Cholesterol, HDL; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D004435: Eating; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007336: Insulin, Isophane; D008875: Middle Aged; D013997: Time Factors; D017211: Treatment Failure; D014280: Triglycerides",,,https://openalex.org/W2057113744,118,15,1,1866,367,11,en,en
false,effect glucosidase inhibitor combine sulphonylurea treatment glucose metabolism patient non insulin dependent diabetes mellitus,ten patient non insulin dependent diabetes mellitus treat sulphonylureal compound whose glucose metabolism need improvement give combination usual sulphonylurea treatment alpha glucosidase inhibitor treatment alpha glucosidase inhibitor mg day addition glibenclamide mg day two patient mg day four mg day one tolbutamide mg day three patient week improve hyperglycaemia meal mg dl mg dl reduce glycosylated haemoglobin level without cause hypoglycaemia,Okada S,1995,J Int Med Res,https://doi.org/10.1177/030006059502300408,7589771,Okada S; Ishii K; Tanokuchi S; Hamada H; Ichiki K; Ota Z,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005260: Female; D005947: Glucose; D005905: Glyburide; D006442: Glycated Hemoglobin; D065089: Glycoside Hydrolase Inhibitors; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D013453: Sulfonylurea Compounds; D014044: Tolbutamide",,,https://openalex.org/W1922130271,153,18,1,650,105,2,en,en
true,u k prospective diabetes study overview year therapy type ii diabetes progressive disease u k prospective diabetes study group,objective u k prospective diabetes study determine whether improved blood glucose control type ii diabetes prevent complication diabetes whether specific therapy advantageous disadvantageous study report median duration randomization year report efficacy therapy year follow overall incidence diabetic complication subject comprise newly diagnose type ii diabetic patient month diet asymptomatic fast plasma glucose fpg mmol l study consist randomize control trial two main comparison patient allocate conventional therapy primarily diet allocate intensive therapy additional sulfonylurea insulin increase insulin supply aim fpg mmol l obese patient allocate conventional therapy allocate intensive therapy metformin enhance insulin sensitivity first comparison subject study year intensive therapy sulfonylurea insulin similarly improve glucose control compare conventional therapy median fpg year mmol l respectively p median hba c respectively p next year fpg increase progressively therapy p median year conventional intensive group fpg mmol l hba c respectively glycemic deterioration associate progressive loss beta cell function second comparison obese subject study year metformin improve glucose control similarly intensive therapy sulfonylurea insulin metformin increase body weight increase incidence hypoglycemia extent therapy sulfonylurea insulin high incidence clinical complication occur year follow subject suffer one diabetes related clinical endpoint macrovascular microvascular endpoint sulfonylurea metformin insulin therapy similarly effective improve glucose control compare policy diet therapy study examine whether continue improved glucose control obtain intensive therapy compare conventional therapy median year hba c compare clinically advantageous maintain health,,1995,Diabetes,https://doi.org/10.2337/diabetes.44.11.1249,7589820,,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D015331: Cohort Studies; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D005260: Female; D006801: Humans; D006943: Hyperglycemia; D006973: Hypertension; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D006113: United Kingdom",,,https://openalex.org/W4245063811,146,27,4,2621,454,16,en,en
false,metformin,biguanide metformin dimethylbiguanide oral antihyperglycaemic agent use management non insulin dependent diabetes mellitus niddm reduce blood glucose level predominantly improve hepatic peripheral tissue sensitivity insulin without affect secretion hormone metformin also appear potentially beneficial effect serum lipid level fibrinolytic activity although long term clinical implication effect unclear metformin possess similar antihyperglycaemic efficacy sulphonylureas obese nonobese patient niddm additionally interim data large multicentre unite kingdom prospective diabetes study ukpds indicate similar antihyperglycaemic efficacy metformin insulin newly diagnose patient niddm unlike sulphonylureas insulin however metformin treatment associate increased bodyweight addition metformin exist antidiabetic therapy confers enhance antihyperglycaemic efficacy may particular use improve glycaemic control patient niddm adequately control sulphonylurea monotherapy may serve reduce eliminate need daily insulin injection patient niddm require therapy acute reversible gastrointestinal adverse effect see metformin may minimise administration food use low dosage increase slowly necessary lactic acidosis due metformin rare risk complication may minimise observance prescribe precaution contraindication intend avoid accumulation drug lactate body unlike sulphonylureas metformin cause hypoglycaemia thus metformin effective antihyperglycaemic agent appear improve aberrant plasma lipid fibrinolytic profile associate niddm possible long term clinical benefit drug regard cardiovascular mortality morbidity yet establish assess major ongoing study since metformin promote weight gain hypoglycaemia consider first line pharmacotherapy obese patient niddm inadequately control nonpharmacological measure metformin appear similarly effective pharmacological management niddm nonobese patient,Dunn CJ,1995,Drugs,https://doi.org/10.2165/00003495-199549050-00007,7601013,Dunn CJ; Peters DH,article,D016428: Journal Article; D016454: Review,"D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D008687: Metformin",,,https://openalex.org/W2071723829,9,1,1,2429,362,15,fr,en
false,efficacy metformin patient non insulin dependent diabetes mellitus,sulfonylurea drug oral therapy available patient non insulin dependent diabetes mellitus niddm united state recently however metformin approve treatment niddm perform two large randomized parallel group double blind controlled study metformin another treatment give week moderately obese patient niddm whose diabetes inadequately control diet protocol metformin vs placebo patient diet plus glyburide protocol metformin glyburide vs metformin vs glyburide patient determine efficacy measure plasma glucose patient fast oral administration glucose lactate lipid insulin glycosylated hemoglobin end study protocol end study patient metformin group compare patient placebo group low mean se fast plasma glucose concentration vs mg per deciliter vs mmol per liter p glycosylated hemoglobin value percent vs percent p protocol patient give metformin glyburide compare patient treat glyburide alone low mean fast plasma glucose concentration vs mg per deciliter vs mmol per liter p glycosylated hemoglobin value percent vs percent p effect metformin alone similar glyburide alone eighteen percent patient give metformin glyburide symptom compatible hypoglycemia compare percent glyburide group percent metformin group protocol patient give metformin statistically significant decrease plasma total low density lipoprotein cholesterol triglyceride concentration whereas value respective control group change significant change fast plasma lactate concentration groups metformin monotherapy combination therapy metformin sulfonylurea well tolerate improve glycemic control lipid concentration patient niddm whose diabetes poorly control diet sulfonylurea therapy alone,DeFronzo RA,1995,N Engl J Med,https://doi.org/10.1056/nejm199508313330902,7623902,DeFronzo RA; Goodman AM,article,"D016430: Clinical Trial; D017426: Clinical Trial, Phase I; D017427: Clinical Trial, Phase II; D017428: Clinical Trial, Phase III; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D001835: Body Weight; D002784: Cholesterol; D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005215: Fasting; D005260: Female; D005492: Folic Acid; D005951: Glucose Tolerance Test; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007328: Insulin; D007773: Lactates; D019344: Lactic Acid; D008297: Male; D008687: Metformin; D008875: Middle Aged; D009765: Obesity; D017211: Treatment Failure; D014805: Vitamin B 12",,,https://openalex.org/W2324992560,78,9,1,2464,439,8,en,en
false,energy expenditure type diabetic patient metformin sulphonylurea therapy,insulin sulphonylurea therapy report cause weight gain type diabetic patient whereas metformin adverse effect mechanism difference unclear investigate cross study effect sulphonylurea metformin therapy energy expenditure body composition type diabetic patient female male various weight mean body mass index sd kg free living total energy expenditure measure day doubly label water method adjust urinary glucose energy loss rest energy expenditure ventilated hood indirect calorimetry overall total energy expenditure vs mj h rest metabolic rate vs mj h similar metformin sulphonylurea therapy respectively adjust difference fat free mass rest metabolic rate sulphonylurea therapy slightly significantly low mean difference kj h kg ci kj h kg p fat free mass also increase significantly kg ci kg p sulphonylurea therapy thus compensate low rest metabolic rate per kg fat free mass leave overall rest metabolic rate unchanged compare metformin therapy also investigate effect add metformin six type diabetic patient already insulin lead measurable change component energy expenditure abstract truncate word,Chong PK,1995,Diabet Med,https://doi.org/10.1111/j.1464-5491.1995.tb00503.x,7648802,Chong PK; Jung RT; Rennie MJ; Scrimgeour CM,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D004734: Energy Metabolism; D005260: Female; D006801: Humans; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2036996103,85,12,1,1605,298,10,en,en
false,influence orlistat pharmacokinetics pharmacodynamics glyburide healthy volunteer,assess influence orlistat pharmacokinetics pharmacodynamics blood glucose lowering effect glyburide open label placebo controlled randomize two way crossover study healthy male volunteer subject receive single mg oral dos glyburide micronase upjohn company kalamazoo mi fifth day treatment placebo treatment mg orlistat treatment b three time day day two treatment separate five day washout period serial blood sample collect appropriate interval glyburide dose determine plasma concentration blood glucose level value c max auc glyburide show equality two treatment analysis variance apparent correlation blood glucose level logarithm plasma glyburide concentration relationship appear alter glyburide administer orlistat conclusion orlistat administer dos mg three time daily significantly alter pharmacokinetics blood glucose lowering effect single mg oral dose glyburide healthy volunteer,Zhi J,1995,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1995.tb04098.x,7657854,Zhi J; Melia AT; Koss-Twardy SG; Min B; Guerciolini R; Freundlich NL; Milla G; Patel IH,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D001786: Blood Glucose; D018592: Cross-Over Studies; D004036: Diet, Atherogenic; D005215: Fasting; D005905: Glyburide; D006801: Humans; D007408: Intestinal Absorption; D007783: Lactones; D008049: Lipase; D008297: Male; D000077403: Orlistat",,,https://openalex.org/W2013934046,105,14,1,1227,206,6,en,en
true,insulin versus glipizide treatment patient non insulin dependent diabetes mellitus effect blood pressure glucose tolerance,insulin resistance exist patient essential hypertension non insulin dependent diabetes mellitus niddm may common denominator impaired glucose homeostasis elevate blood pressure bp level patient niddm therefore treatment improve insulin action may also improve bp level consequently four phase glipizide v insulin cross design study conduct determine good effect glipizide treatment insulin sensitivity effect bp niddm patient patient subject month diet phase follow month glipizide treatment phase ii additional month diet phase iii finally month insulin treatment phase iv end phase ii iv oral glucose tolerance test ogtt perform plasma glucose insulin c peptide level analyze fast plasma glucose insulin total cholesterol high density lipoprotein cholesterol low density lipoprotein cholesterol triglyceride glycated hemoglobin fructosamine h postprandial plasma glucose also analyze phase supine sit bp level body weight determined biweekly study exception high plasma insulin c peptide level ogtt area curve phase iv insulin v phase ii glipizide p high fast plasma insulin level p consistently significant metabolic difference phase iv ii abstract truncate word,Levy J,1995,Am J Hypertens,https://doi.org/10.1016/0895-7061(95)00052-q,7662219,Levy J; Vandenberg M; Grunberger G,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D001794: Blood Pressure; D002096: C-Peptide; D002784: Cholesterol; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D005260: Female; D005913: Glipizide; D005951: Glucose Tolerance Test; D006801: Humans; D007328: Insulin; D007333: Insulin Resistance; D008055: Lipids; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies",,,https://openalex.org/W2064352744,139,18,1,1607,297,9,en,en
false,dyslipidemias patient diabetes mellitus classification risk benefit therapy,characterize lipid lipoprotein abnormality patient diabetes mellitus evaluate risk benefit market pharmacologic therapy medline search national library medicine data base perform study publish january march clinical trial assess effect lipid lipoprotein adverse effect marketed lipid lowering agent extract review relevant article include provide information regard lipid lipoprotein metabolism guideline treatment dyslipidemias patient diabetes mellitus extensive review clofibrate include common dyslipidemia patient poorly control insulin dependent diabetes mellitus iddm combine elevated triglyceride cholesterol level reduced high density lipoprotein hdl cholesterol mixed hyperlipidemia hypertriglyceridemia combine reduced hdl cholesterol common dyslipidemia patient noninsulin dependent diabetes mellitus essentially pattern dyslipidemia may present small dense low density lipoprotein ldl glycosylation lipoprotein increase oxidize lipoprotein may present patient diabetes mellitus contribute accelerate atherosclerotic cardiovascular disease insulin therapy generally correct quantitative lipid abnormality patient iddm drug treatment seldom indicate diet exercise insulin oral sulfonylurea improve hypertriglyceridemia low hdl concentration always return normal drug therapy indicate nonpharmacologic measure inadequate administer base effect agent lipid lipoprotein patient age adverse effect profile patient tolerability drug disease drug drug interaction fibric acid derivative drug choice marked hypertriglyceridemia patient diabetes mellitus niacin worsen glycemic control may require severe hypertriglyceridemia hypercholesterolemia mixed hyperlipidemia bile acid bind resin may accentuate hypertriglyceridemia may useful select patient marked hypercholesterolemia normal triglyceride hydroxymethylglutaryl coenzyme reductase inhibitor prefer patient elevated ldl cholesterol mild hypertriglyceridemia patient marked lipid abnormality mixed hyperlipidemia may require carefully dosed combination lipid lowering drug,Oki JC,1995,Pharmacotherapy,,7667166,Oki JC,article,D016428: Journal Article; D016454: Review,"D000328: Adult; D000924: Anticholesteremic Agents; D001521: Behavior Therapy; D002784: Cholesterol; D048909: Diabetes Complications; D003920: Diabetes Mellitus; D005260: Female; D006801: Humans; D006949: Hyperlipidemias; D008055: Lipids; D008074: Lipoproteins; D008077: Lipoproteins, LDL; D008079: Lipoproteins, VLDL; D008297: Male; D008875: Middle Aged; D012307: Risk Factors; D014280: Triglycerides",,,https://openalex.org/W2140765134,98,14,1,2601,381,16,en,en
false,effect insulin glipizide combination skeletal muscle capillary basement membrane width diabetic patient,study investigate long term effect insulin combination insulin oral hypoglycemic compound glipizide skeletal muscle capillary basement membrane width insulin requiring diabetic patient seventy diabetic patient randomize treatment either insulin placebo insulin glipizide mg year patient complete study patient receive insulin placebo patient receive insulin glipizide three skeletal muscle quadriceps femoris biopsy perform patient year period glycosylated hemoglobin determine every day include plasma glucose level muscle capillary basement membrane width quantitated previously describe method approximately month glycosylated hemoglobin decrease significantly group baseline p insulin glipizide group p insulin placebo although statistically significant difference see two group year decrease statistically significant p insulin glipizide group baseline statistically significant difference find muscle capillary basement membrane width two group spite significant decrease glycosylated hemoglobin group month muscle capillary basement membrane width insulin glipizide group decrease significantly compare baseline patient receive insulin placebo show gradual increase muscle capillary basement membrane width year significantly high baseline p although mechanism addition glipizide insulin treatment reduce thickening muscle capillary basement membrane clearly understood current finding suggest diabetic microangiopathy necessarily progressive prophylaxis may attain,Camerini-Davalos RA,1994,Clin Ther,,7697692,Camerini-Davalos RA; Bloodworth JM; Velasco CA; Reddi AS,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.","D000328: Adult; D001485: Basement Membrane; D001786: Blood Glucose; D003922: Diabetes Mellitus, Type 1; D004359: Drug Therapy, Combination; D005260: Female; D005913: Glipizide; D006442: Glycated Hemoglobin; D006801: Humans; D007328: Insulin; D008297: Male; D008875: Middle Aged; D009132: Muscles",,,https://openalex.org/W2399511914,114,15,1,1994,311,12,en,en
true,prolongation near normoglycemic remission black niddm subject chronic low dose sulfonylurea treatment,microvascular neuropathic complication diabetes mellitus significantly decrease long term near normoglycemic regulation patient insulin dependent diabetes mellitus prevention delay onset hyperglycemia non insulin dependent diabetes mellitus niddm patient reduce morbidity mortality complication niddm nearly normoglycemic diagnose screen symptomatic stage clinically hyperglycemic niddm go remission one potential strategy delay onset hyperglycemia individual high risk chronic low dose sulfonylurea therapy thirty black niddm subject recently develop near normoglycemia follow treatment randomly assign year double blind glipizide placebo treatment baseline follow parameter include fast plasma glucose fpg hba c plasma insulin glucose response oral glucose tolerance test insulin action determine euglycemic insulin clamp baseline fpg hba c three group mg dl respectively relapse hyperglycemia define fpg level mg dl several consecutive visit fpg level mg dl symptom hyperglycemia course treatment follow hyperglycemia occur subject treatment group placebo group glipizide treatment group prolongation near normoglycemia significantly p lt increase low dose mg day glipizide compare placebo treatment low dose sulfonylurea therapy delay onset hyperglycemia niddm subject remission may useful method delay onset niddm high risk individual,Banerji MA,1995,Diabetes,https://doi.org/10.2337/diab.44.4.466,7698517,Banerji MA; Chaiken RL; Lebovitz HE,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D044383: Black People; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D005260: Female; D005913: Glipizide; D006801: Humans; D008297: Male; D016019: Survival Analysis; D013997: Time Factors",,,https://openalex.org/W2093957604,113,13,1,1810,296,11,en,en
false,minimal model analysis insulin sensitivity glucose dependent glucose disposal black white american study person risk type diabetes,abstract examine impact race positive family history type diabetes glucose insulin dynamic two component glucose disposal healthy first degree relative black white american patient type diabetes mellitus great risk disease healthy control subject seventeen black white relative study twenty two black people white people without family history type diabetes serve healthy control subject standard oral glucose tolerance test ogtt tolbutamide modified frequent sample intravenous glucose tolerance fsigt test perform subject insulin sensitivity index glucose effectiveness g calculate use mini mod method describe bergman et al mean fasting post stimulation serum glucose level significantly different black white relative however mean serum insulin response oral intravenous stimulation significantly great black white irrespective positive family history diabetes mean significantly p low black white time min mul relative compare healthy control mean significantly p low black white control vs time min mul mean g k g great p black white irrespective family history diabetes summary present study demonstrate non diabetic black people manifest insulin resistant hyperinsulinaemia irrespective family history diabetes compare white people speculate metabolic change could play potential role high prevalence type diabetes black american,Osei K,1994,Eur J Clin Invest,https://doi.org/10.1111/j.1365-2362.1994.tb02029.x,7705380,Osei K; Cottrell DA,article,D016428: Journal Article,"D000328: Adult; D044383: Black People; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005947: Glucose; D005951: Glucose Tolerance Test; D006706: Homeostasis; D006801: Humans; D007328: Insulin; D008297: Male; D012306: Risk; D044465: White People",,,https://openalex.org/W2105391872,161,26,1,1900,350,13,en,en
true,multicenter placebo controlled trial compare acarbose bay g placebo tolbutamide tolbutamide plus acarbose non insulin dependent diabetes mellitus,background acarbose delay release glucose complex carbohydrate disaccharide inhibit intestinal glucosidases thereby attenuate postprandial increment blood glucose insulin multicenter double blind placebo controlled study compare efficacy safety diet alone acarbose tolbutamide acarbose plus tolbutamide non insulin dependent diabetes mellitus niddm patient patient method total patient niddm fast plasma glucose level least mg dl randomize receive treatment tid acarbose mg tolbutamide mg combination drug placebo week run period follow double blind treatment week week follow period result active treatment superior p placebo reduce postprandial hyperglycemia hba c level ranking order efficacy acarbose plus tolbutamide tolbutamide acarbose placebo postprandial reduction glucose approximately mg dl acarbose plus tolbutamide mg dl tolbutamide mg dl acarbose mg dl placebo tolbutamide associate increase body weight postprandial insulin level take alone ameliorate tolbutamide take combination acarbose acarbose alone combination tolbutamide cause significantly gastrointestinal adverse event mainly flatulence soft stool diarrhea tolbutamide placebo generally well tolerate clinically significant elevation hepatic transaminase level occur patient acarbose group acarbose plus tolbutamide group transaminase level return normal therapy discontinue conclusion acarbose effective well tolerate treatment niddm control glycemia significantly well acarbose compare diet alone acarbose plus tolbutamide superior tolbutamide alone acarbose delay release glucose complex carbohydrate disaccharide inhibit intestinal glucosidases thereby attenuate postprandial increment blood glucose insulin multicenter double blind placebo controlled study compare efficacy safety diet alone acarbose tolbutamide acarbose plus tolbutamide non insulin dependent diabetes mellitus niddm patient total patient niddm fast plasma glucose level least mg dl randomize receive treatment tid acarbose mg tolbutamide mg combination drug placebo week run period follow double blind treatment week week follow period active treatment superior p placebo reduce postprandial hyperglycemia hba c level ranking order efficacy acarbose plus tolbutamide tolbutamide acarbose placebo postprandial reduction glucose approximately mg dl acarbose plus tolbutamide mg dl tolbutamide mg dl acarbose mg dl placebo tolbutamide associate increase body weight postprandial insulin level take alone ameliorate tolbutamide take combination acarbose acarbose alone combination tolbutamide cause significantly gastrointestinal adverse event mainly flatulence soft stool diarrhea tolbutamide placebo generally well tolerate clinically significant elevation hepatic transaminase level occur patient acarbose group acarbose plus tolbutamide group transaminase level return normal therapy discontinue acarbose effective well tolerate treatment niddm control glycemia significantly well acarbose compare diet alone acarbose plus tolbutamide superior tolbutamide alone,Coniff RF,1995,Am J Med,https://doi.org/10.1016/s0002-9343(99)80343-x,7733122,Coniff RF; Shapiro JA; Seaton TB; Bray GA,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D020909: Acarbose; D000704: Analysis of Variance; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008055: Lipids; D008297: Male; D008875: Middle Aged; D014044: Tolbutamide; D014312: Trisaccharides",,,https://openalex.org/W2027935771,169,22,1,4035,626,28,en,en
false,acute effect glyburide regulation peripheral blood flow normal human,recent animal study demonstrate selective blockade atp sensitive k katp channel vascular smooth muscle result significant increase peripheral vascular tone main aim study assess whether glyburide selective blocker katp channel commonly use antidiabetic agent influence rest blood flow reactive hyperemic response peripheral tissue normal subject baseline calf blood flow measure non invasively six normal subject femoral venous occlusive plethysmography calf blood flow also serially measure every release calf arterial occlusion min duration reactive hyperemia express term peak post occlusive flow duration hyperemia reactive hyperemic volume subject baseline flow reactive hyperemia measure control every hour h oral ingestion either mg glyburide placebo two separate day baseline calf flow decline control value h glyburide intake p return control value hour peak post occlusive flow h glyburide ingestion low control value respectively p duration reactive hyperemia h glyburide ingestion significantly long control value p whereas reactive hyperemic volume remain unaffected glyburide intake placebo elicit significant change baseline flow reactive hyperemia throughout h experimental period result indicate single dose glyburide therapeutic range elicits significant alteration regulation peripheral blood flow normal subject propose alteration mediate blockade vascular smooth muscle katp channel,Kosmas EN,1995,Eur J Pharmacol,https://doi.org/10.1016/0014-2999(94)00732-m,7768272,Kosmas EN; Levy RD; Hussain SN,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D018592: Cross-Over Studies; D005268: Femoral Vein; D005905: Glyburide; D006801: Humans; D006940: Hyperemia; D007866: Leg; D008297: Male; D010991: Plethysmography; D012016: Reference Values; D012039: Regional Blood Flow",,,https://openalex.org/W2085561130,86,14,1,1900,333,12,en,en
false,response insulin c peptide mixed meal non insulin dependent diabetic treat insulin chlorpropamide,glucose control niddm prone progressive deterioration due secondary failure oral hypoglycemic therapy insulin may subsequently require optimal control spite peripheral hyperinsulinemia mexico diabetes associate obesity common therefore design prospective study combine insulin chloropropamide order evaluate improvement insulin response standardized meal load consequent amelioration glucose control method twenty diabetic patient secondary failure full dos hypoglycemic drug moderate hyperglycemia recruit therapy initiate human insulin iu day mg cholopropamide titrate insulin dosage order achieve euglycemia treatment end study period glucose insulin c peptide response curve mixed standardized meal perform blood glucose serum lipid fructosamine glycosylated hemoglobin level also determine patient follow capillary glucose measurement three time week glucose fructosamine concentration every two week study period result patient require less insulin glucose control improve significantly glucose fructosamine glycosylated hemoglobin level decrease mg dl mmol l mg dl mmol l respectively difference statistically significant insulin c peptide level increase significantly mu ml ng ml mu ml ng ml respectively measure area curve total value improve respectively also statistically significant lipid level decrease significantly include triglicerides total ldl cholesterol whereas hdl cholesterol level increase conclusion glucose control improve patient cohort pancreatic insulin response probably due adequate glycemic microenvironment possible enhanced exogenous endogenous insulin function,García-Rubi E,1995,Rev Invest Clin,,7777712,García-Rubi E; Alemán-Hoey DD,article,D016428: Journal Article,"D001786: Blood Glucose; D002096: C-Peptide; D002747: Chlorpropamide; D015331: Cohort Studies; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D004435: Eating; D005260: Female; D019270: Fructosamine; D006442: Glycated Hemoglobin; D006595: Hexosamines; D006801: Humans; D007328: Insulin; D000078790: Insulin Secretion; D008055: Lipids; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012636: Secretory Rate",,,https://openalex.org/W2407415783,127,20,1,2077,328,18,en,en
false,effect insulin treatment serum lipoprotein non insulin dependent diabetes,order evaluate whether lp lipoprotein potentially thrombogenic atherogenic potential risk factor cad non insulin dependent diabetes niddm compare lp distribution niddm patient healthy control subject furthermore study effect insulin treatment serum lp patient niddm male female niddm patient similar lp concentration healthy control median value mg l range mg l vs mg l range mg l n range mg l vs mg l range mg l n also cumulative distribution lp differ niddm patient healthy subject insulin treatment increase lp diabetic lp concentration less mg l effect relate concomitant improvement metabolic control mean change sem hba c p subject elevated lp concentration mg l lp concentration unaffected insulin despite similar improvement glycaemic control result suggest insulin may modulate concentration lp,Kuusi T,1995,Eur J Clin Invest,https://doi.org/10.1111/j.1365-2362.1995.tb01548.x,7781667,Kuusi T; Yki-Järvinen H; Kauppinen-Mäkelin R; Jauhiainen M; Ehnholm C; Kauppila M; Seppälä P; Viikari J; Kujansuu E; Rajala S,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D001055: Apolipoproteins B; D002784: Cholesterol; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D015243: Cholesterol, VLDL; D003430: Cross-Sectional Studies; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D007328: Insulin; D017270: Lipoprotein(a); D008297: Male; D008875: Middle Aged; D012016: Reference Values; D012727: Sex Characteristics; D014280: Triglycerides",,,https://openalex.org/W2043547890,85,13,1,1237,262,7,en,en
false,effect metformin postprandial lipemia patient fairly poorly control niddm,quantify effect metformin metabolism triglyceride tg rich lipoprotein intestinal origin patient non insulin dependent diabetes mellitus niddm respond sulfonylurea still fast hyperglycemia sixteen patient niddm demonstrate fall fast plasma glucose concentration mmol l response glipizide treatment continue fast plasma glucose concentration mmol l study fast glucose ghb lipid lipoprotein concentration determine resistance insulin mediated glucose disposal estimate measure steady state plasma glucose sspg concentration end min infusion somatostatin glucose insulin addition plasma glucose insulin tg concentration measure frequent interval patient eat breakfast lunch vitamin also give lunch retinyl ester content plasma chylomicron svedberg flotation constant sf chylomicron remnant sf fraction use quantify concentration postprandial intestinal tg rich lipoprotein fasting plasma glucose concentration vs mmol l ghb level vs day long plasma glucose concentration significantly low metformin treatment p associate significant p fall sspg concentration mmol l addition postprandial concentration glucose insulin free fatty acid tg low p follow metformin treatment postprandial retinyl ester concentration also low plasma p chylomicron p chylomicron remnant p fractions addition metformin sulfonylurea treated patient niddm less optimal glycemic control associate improved glycemic control low postprandial insulin tg concentration decrease postprandial concentration tg rich lipoprotein intestinal origin change might expect decrease risk coronary heart disease,Jeppesen J,1994,Diabetes Care,https://doi.org/10.2337/diacare.17.10.1093,7821127,Jeppesen J; Zhou MY; Chen YD; Reaven GM,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D001786: Blood Glucose; D003327: Coronary Disease; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005230: Fatty Acids, Nonesterified; D005260: Female; D005502: Food; D005913: Glipizide; D006801: Humans; D007328: Insulin; D007413: Intestinal Mucosa; D008074: Lipoproteins; D008297: Male; D008687: Metformin; D008875: Middle Aged; D012307: Risk Factors; D014280: Triglycerides",,,https://openalex.org/W2056288576,94,14,1,2295,403,7,en,en
true,therapeutic comparison metformin sulfonylurea alone various combination double blind control study,objective assess compare therapeutic efficacy safety metformin sulfonylurea glyburide g alone various combination patient non insulin dependent diabetes mellitus niddm research design method patient fast blood glucose fbg mmol l initially treat diet alone fbg still mmol l randomize double blind double dummy control treatment g primary combination therapy mg dose titrate withfbg lt mmol l target use six dose level first three dose level comprise increase single drug therapy g primary combination increase low dosage mgl second three level compose various high dose combination e add therapy g g primary combination escalate high dosage mgh medication maintain month complete dose titration result fbg target achieve patient diet alone single drug therapy insufficient mgl ns randomized patient improvement glucose control high dose combination mean fbg se reduce p mmol l maintain single drug treatment low dose primary combination treat different high dose combination large mean fbg reduction mmol l hba c level show corresponding reduction glycemic level rise drug discontinuation fast c peptide rise treatment g mgl fast insulin significantly change meal stimulated c peptide insulin level unchanged increase g less extent mgl significant insulin c peptide difference different high dose combination g g mgh body weight change follow treatment combination increase kg follow g alone blood pressure unchanged overall effect plasma lipid small significant difference group drug safety satisfactory even reporting usually modest adverse event high profile frequency differ group conclusion dose effect titrate treatment either metformin glyburide promotes equal degree glycemic control former latter able achieve control without increase body weight hyperinsulinemia near normal glycemia obtain combination metformin sulfonylurea even advanced niddm,Hermann LS,1994,Diabetes Care,https://doi.org/10.2337/diacare.17.10.1100,7821128,Hermann LS; Scherstén B; Bitzén PO; Kjellström T; Lindgärde F; Melander A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D001794: Blood Pressure; D001835: Body Weight; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005260: Female; D005905: Glyburide; D006801: Humans; D007328: Insulin; D008055: Lipids; D008297: Male; D008687: Metformin; D008875: Middle Aged",,,https://openalex.org/W2059649085,120,17,1,2679,495,21,en,en
false,improve visual evoke potential latency poorly control diabetic patient short term strict metabolic control,objective determine whether short term strict control blood glucose improve abnormal visual evoke potential veps poorly control diabetic patient overt diabetic complication research design method veps p wave latency record poorly control diabetic patient insulin dependent diabetes mellitus non insulin dependent diabetes mellitus least day near normoglycemia obtain continuous subcutaneous insulin infusion csii exclusion criterion overt diabetic neuropathy retinopathy control subject healthy subject match age sex fifty two subject form reference control population intra individual coefficient variation p latency lt result p latency longer diabetic patient control subject mean eye sd vs p lt diabetic patient abnormal veps day close blood glucose control mean blood glucose profile fell mmol l mmol l p lt mean p latency significantly short p lt still significantly long control value long initial p latency great decrease csii correlation fall blood glucose improvement veps conclusion short term blood glucose normalization associate improved p wave latency uncomplicated diabetic patient data suggest abnormal veps partly reversible include functional disturbance relate glucose metabolism,Ziegler O,1994,Diabetes Care,https://doi.org/10.2337/diacare.17.10.1141,7821133,Ziegler O; Guerci B; Algan M; Lonchamp P; Weber M; Drouin P,article,D016428: Journal Article,"D000328: Adult; D001786: Blood Glucose; D003922: Diabetes Mellitus, Type 1; D003924: Diabetes Mellitus, Type 2; D005074: Evoked Potentials, Visual; D005260: Female; D005905: Glyburide; D006801: Humans; D007328: Insulin; D008297: Male; D008875: Middle Aged; D011930: Reaction Time",,,https://openalex.org/W2022323467,123,15,1,1721,307,12,en,en
true,comparison pharmacokinetics pharmacodynamics short long term glyburide therapy niddm,objective examine pharmacokinetics pharmacodynamics glyburide single multiple dose administration patient type ii diabetes research design method twenty patient type ii diabetes year age participate study h pharmacokinetic evaluation include h sustacal tolerance test conduct institute glyburide therapy baseline first mg test dose glyburide week chronic glyburide therapy glyburide dos titrate target goal achieve fasting plasma glucose mmol l reach maximum daily dos mg result significant prolongation elimination half life week h week h week h increased volume distribution glyburide observe chronic dosing result strongly suggest possible drug accumulation difference pharmacokinetic parameter note evaluation week week change pharmacodynamic response glucose insulin c peptide chronic glyburide therapy observe glyburide therapy significantly reduce plasma glucose level week percent change auc glucose baseline week week week pancreatic insulin secretion acutely enhanced maintain long term therapy responsiveness therapy assess ratio auc glucose auc c peptide significantly improve week compare baseline pharmacodynamic response difference observe week week evaluation conclusion study demonstrate significant difference glyburide pharmacokinetics pharmacodynamics exist single dose steady state condition difference support need careful dosage titration glyburide achieve desired therapeutic response patient type ii diabetes,Jaber LA,1994,Diabetes Care,https://doi.org/10.2337/diacare.17.11.1300,7821171,Jaber LA; Antal EJ; Slaughter RL; Welshman IR,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006207: Half-Life; D006801: Humans; D007328: Insulin; D008055: Lipids; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2057691777,102,13,1,2026,344,15,en,en
false,control diabetes rehabilitation diabetic stroke,change diabetic control rehabilitation therapy study retrospectively case diabetic stroke diabetic control deteriorate case rehabilitation therapy case treatment diabetes change rehabilitation therapy level fast plasma glucose decrease dos hypoglycemic agent reduce without significant deterioration diabetic control case whose diabetic control excellent case experience hypoglycemic attack rehabilitation therapy case oral hypoglycemic agent reduce tablet insulin unit per day average result indicate training stroke rehabilitation moderately improve diabetic control,Sato T,1994,Tohoku J Exp Med,https://doi.org/10.1620/tjem.173.399,7825173,Sato T; Hiwatari M,article,D003160: Comparative Study; D016428: Journal Article,"D000368: Aged; D001786: Blood Glucose; D002561: Cerebrovascular Disorders; D003924: Diabetes Mellitus, Type 2; D004035: Diet Therapy; D005260: Female; D005905: Glyburide; D006801: Humans; D007328: Insulin; D008297: Male; D008875: Middle Aged; D012189: Retrospective Studies",,,https://openalex.org/W2085078424,62,9,1,805,129,6,en,en
true,united kingdom prospective diabetes study ukpds relative efficacy randomly allocate diet sulphonylurea insulin metformin patient newly diagnose non insulin dependent diabetes follow three year,assess relative efficacy treatment non insulin dependent diabetes three year diagnosis multicentre randomise control trial allocate patient treatment diet alone additional chlorpropamide glibenclamide insulin metformin obese achieve fast plasma glucose concentration mmol l outpatient diabetic clinic british hospitals subject three month dietary run period fast plasma glucose concentration mmol l hyperglycaemic symptoms fasting plasma glucose glycated haemoglobin fast plasma insulin concentration body weight compliance hypoglycaemia median fasting plasma glucose concentration significantly low three year patient allocate chlorpropamide glibenclamide insulin rather diet alone mmol l respectively p low mean glycated haemoglobin value respectively p mean body weight increase significantly chlorpropamide glibenclamide insulin diet kg p similar pattern see mean fasting plasma insulin concentration mu l p obese subject metformin effective drug change mean body weight significant reduction mean fasting plasma insulin concentration mu l p hypoglycaemic episode occur sulphonylurea insulin diet metformin drug similar glucose lowering efficacy although patient remain hyperglycaemic long term follow require determine risk benefit ratio glycaemic improvement side effect change body weight plasma insulin concentration,,1995,BMJ,https://doi.org/10.1136/bmj.310.6972.83,7833731,,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D001835: Body Weight; D002747: Chlorpropamide; D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005500: Follow-Up Studies; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D009765: Obesity; D010349: Patient Compliance; D013453: Sulfonylurea Compounds",,,https://openalex.org/W4250413101,225,35,1,1834,320,6,en,en
false,lack interaction glipizide co trimoxazole,identify effect co trimoxazole elimination disposition kinetics glipizide eight healthy male volunteer study unblinded randomize cross trial two phase treatment co trimoxazole mg twice day phase subject treat home day one treatment regimens follow hour hospitalization single dose challenge mg oral glipizide detailed blood study day washout period intersperse phase pharmacokinetic pharmacodynamic parameter determine compare use student test paired observation glipizide area curve auc clearance half life treatment control phase versus g l hour p versus ml min kg p versus hour p respectively twenty four hour glucose auc treatment control phase versus mmol l hour p respectively parameter reach statistical significance glipizide half life difference doubtful clinical significance difficulty identify clear elimination phase several subject conclude co trimoxazole administration significantly alter glipizide disposition elimination kinetics study population,Kradjan WA,1994,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1994.tb01972.x,7836551,Kradjan WA; Witt DM; Opheim KE; Wood FC,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D001786: Blood Glucose; D018592: Cross-Over Studies; D005913: Glipizide; D006207: Half-Life; D006801: Humans; D008297: Male; D015662: Trimethoprim, Sulfamethoxazole Drug Combination",,,https://openalex.org/W1969550995,56,7,1,1447,250,8,en,en
true,one year comparative trial metformin glipizide type diabetes mellitus,forty eight diabetic subject diet failed type mellitus age year randomise metformin patient glipizide patient therapy follow prospectively month subject obese metformin give well fast plasma glucose control compare glipizide p p week p low hba concentration week p metformin treat patient lose weight whereas glipizide treat subject gain weight weight change treatment group reach significance week p highly significant p week significant change either fast plasma lipid blood lactate level either metformin glipizide treat group drug cause similar reduction albumin excretion rate conclusion metformin give good glycaemic control glipizide weight loss rather weight gain obese type patient,Campbell IW,1994,Diabete Metab,,7843470,Campbell IW; Menzies DG; Chalmers J; McBain AM; Brown IR,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001786: Blood Glucose; D001835: Body Weight; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005913: Glipizide; D006801: Humans; D007773: Lactates; D019344: Lactic Acid; D008055: Lipids; D008297: Male; D008687: Metformin; D008875: Middle Aged; D011446: Prospective Studies",,,https://openalex.org/W2337243793,82,14,1,1010,195,8,en,en
true,comparative tolerability profile oral antidiabetic agent,sulphonylureas biguanides widely use adjunct dietary measure treatment non insulin dependent type diabetes mellitus niddm adverse effect profile differ markedly sulphonylureas biguanides reflect difference chemical structure mode action sulphonylureas generally well tolerate although pharmacokinetic difference agent important clinical implication main adverse effect associate sulphonylureas hypoglycaemia effect predictable consequence principal pharmacological effect drug e sensitisation islet beta cell glucose result enhance endogenous insulin secretion sulphonylurea induced suppression hepatic glucose production may cause profound protracted hypoglycaemia especially elderly patient individual intercurrent illness reduced caloric intake take combination compound hypoglycaemic potential e g alcohol ethanol sulphonylureas long duration action notably chlorpropamide glibenclamide glyburide liable induce serious hypoglycaemia particularly drug elimination reduce renal impairment drug salicylate may potentiate action sulphonylureas thereby increase risk hypoglycaemia biguanide therapy associate alteration lactate homeostasis certain clinical circumstance may result fatal lactic acidosis phenformin associate markedly great risk lactic acidosis metformin phenformin withdraw many country reason biguanides must avoid patient renal impairment hepatic dysfunction cardiac failure condition drug accumulation disorder lactate metabolism may predispose lactic acidosis phenformin give individual exhibit severe genetically confer hepatic defect hydroxylation impede metabolism drug less seriously biguanides associate relatively high incidence gastrointestinal adverse effect limit compliance acarbose competitive inhibitor intestinal alpha glucosidases recently introduce contrast sulphonylureas biguanides acarbose associate life threatening adverse effect reflect low systemic absorption drug predictably principal unwanted effect gastrointestinal disturbance result iatrogenic carbohydrate malabsorption,Krentz AJ,1994,Drug Saf,https://doi.org/10.2165/00002018-199411040-00002,7848543,Krentz AJ; Ferner RE; Bailey CJ,article,D016430: Clinical Trial; D016428: Journal Article; D016454: Review,"D020909: Acarbose; D000284: Administration, Oral; D001645: Biguanides; D001682: Biological Availability; D003924: Diabetes Mellitus, Type 2; D004342: Drug Hypersensitivity; D065089: Glycoside Hydrolase Inhibitors; D006801: Humans; D007003: Hypoglycemia; D007328: Insulin; D009026: Mortality; D011446: Prospective Studies; D013329: Structure-Activity Relationship; D013453: Sulfonylurea Compounds; D014312: Trisaccharides",,,https://openalex.org/W2089477934,61,7,1,2618,388,19,en,en
false,ethnic difference secretion sensitivity hepatic extraction insulin black white american,hyperinsulinaemia abnormality hepatic insulin extraction commonly coexist ethnic group severe insulin resistance therefore compare effect ethnicity glucose insulin c peptide dynamic hepatic insulin extraction insulin sensitivity healthy black n white n american standard oral glucose tolerance test ogtt tolbutamide modified frequently sample intravenous glucose tolerance fsivgt test perform subject insulin sensitivity index calculate use minimod method describe bergman et al basal post stimulation hepatic insulin extraction calculate molar ratio c peptide insulin concentration basal steady state area post stimulation hormone curve respectively apart slightly great mean serum glucose peak response oral glucose white mean glucose level identical black white stimulation contrast serum insulin level basal stimulation significantly great fold black white however corresponding c peptide response identical group basal postprandial hepatic insulin extraction low black compare white respectively mean significantly p low black white mu l conclude ethnicity may major determinant mechanism peripheral hyperinsulinaemia insulin insensitivity black white american,Osei K,1994,Diabet Med,https://doi.org/10.1111/j.1464-5491.1994.tb00349.x,7851069,Osei K; Schuster DP,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article,"D000284: Administration, Oral; D000328: Adult; D044383: Black People; D001786: Blood Glucose; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005947: Glucose; D005951: Glucose Tolerance Test; D006801: Humans; D006946: Hyperinsulinism; D007328: Insulin; D007333: Insulin Resistance; D000078790: Insulin Secretion; D008099: Liver; D008297: Male; D014481: United States; D044465: White People",,,https://openalex.org/W2055945824,108,17,1,1644,287,11,en,en
false,effect glibenclamide ventricular fibrillation non insulin dependent diabetic acute myocardial infarction,glibenclamide hypoglycemic sulfonylurea show antiarrhythmic effect acutely ischemic myocardium aim present study evaluate effectiveness drug prevent ventricular fibrillation diabetic patient acute myocardial infarction study patient non insulin dependent diabetes mellitus glibenclamide group treat another hypoglycemic drug diet group non diabetic people patient admit coronary care unit first myocardial infarction ventricular fibrillation occur group group non diabetic versus p versus non diabetic group ns versus non diabetic group p sustain ventricular tachycardia significantly different among groups antiarrhythmic effectiveness glibenclamide might relate block action atp dependent potassium channel consequent attenuation efflux potassium induce ischemia also observe high mortality rate result heart failure group group non diabetic group since glibenclamide never show significant effect myocardial contractility finding remain elucidate glibenclamide therefore appear antifibrillatory effect acute myocardial infarction respect acute coronary event drug might able prevent ventricular fibrillation often fatal occur hospitalization,Lomuscio A,1994,Coron Artery Dis,,7858767,Lomuscio A; Vergani D; Marano L; Castagnone M; Fiorentini C,article,D016430: Clinical Trial; D016428: Journal Article,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006801: Humans; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D014693: Ventricular Fibrillation",,,https://openalex.org/W2438627669,121,14,1,1587,259,7,en,en
true,bedtime insulin daytime glipizide effective therapy sulfonylurea failure niddm,bedtime insulin bi daytime sulfonylurea dsu therapy study double blind non insulin dependent diabetes mellitus subject sulfonylurea su therapy fail subject switch glipizide month phase confirm failure fast plasma glucose fpg mmol randomly assign three group bi dsu bi dsu dsu bi phase ii month bi dose fix u low dose phase iii month bi titrate high dose achieve good control hypoglycemie symptom prevent far dose increase phase iv month original subject receive open labeled high dose bi dsu low dose bi dsu markedly reduce fpg mmol p lt mean h glucose p lt hba c p basal hepatic glucose production hgp p lt positive correlation r p lt decline fpg hgp observe neither low dose bi alone dsu alone reduce fpg mean h glucose hba c basal hgp high dose u day bi plus dsu far reduce fpg mmom hba c mean h plasma glucose basal hgp p lt vs phase ii high dose bi alone u day improve fpg p lt vs phase ii mean h plasma glucose p lt vs phase ii hba c p lt vs phase ii basal hgp p lt vs phase degree similar low dose bi dsu less high dose bi dsu regardless prior treatment fpg hba c control phase iv weight gain bi dsu largely attributable reduce glucosuria conclusion bi dsu bi alone improve glycemia su failure patient bi dsu superior bi alone low high dose bi efficacy bi relate suppression basal hgp good long term glycemie control month achieve combined bi dsu therapy,Shank ML,1995,Diabetes,https://doi.org/10.2337/diab.44.2.165,7859936,Shank ML; Del Prato S; DeFronzo RA,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D015190: Blood Glucose Self-Monitoring; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005913: Glipizide; D005947: Glucose; D005951: Glucose Tolerance Test; D006442: Glycated Hemoglobin; D006801: Humans; D007328: Insulin; D008055: Lipids; D008099: Liver; D008875: Middle Aged; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2163280918,87,11,1,2071,487,13,en,en
false,evaluation biguanide metformin mechanism action tolerability,metformin biguanide antidiabetic medication use year mechanism action unknown year ago link improved peripheral sensitivity insulin stimulated tissue glucose uptake transporter link system interest metformin revive recent observation specific activity agent major trait called polymetabolic syndrome syndrome x characterize insulin resistance hypertriglyceridemia hypertension reduced fibrinolytic activity metformin study examine one show possibly peripheral insulin sensitize mechanism correct major symptom characterize insulin resistance syndrome metformin similarly biguanide phenformin rat potentially dangerous possible induction lactic acidosis case fatal outcome metformin however associate low incidence lactic acidosis differently phenformin undergo liver metabolism consequence high risk group display impaired metabolic handling review addition overall evaluation recent data mechanism action clinical use metformin detailed clinical analysis publish case lactic acidosis provide data indicate risk metformin use negligible provide care take prescribe drug patient suspected clinical risk lactic acidosis,Sirtori CR,1994,Pharmacol Res,https://doi.org/10.1016/1043-6618(94)80104-5,7862618,Sirtori CR; Pasik C,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D000140: Acidosis, Lactic; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006801: Humans; D007333: Insulin Resistance; D008297: Male; D008687: Metformin; D012307: Risk Factors",,,https://openalex.org/W2062632254,77,12,1,1642,287,8,en,en
true,low dose oral glyburide reduces fast blood glucose decrease hepatic glucose production healthy volunteer without increase carbohydrate oxidation,glyburide effective hypoglycemic agent patient type ii diabetes even loss ability increase insulin secretion exact mechanism unknown attempt describe direct effect glyburide glucose metabolism low dose glyburide micrograms kg body weight give orally healthy volunteer attempt increase blood concentration drug without cause marked increase insulin secretion fast hepatic glucose production hgp carbohydrate oxidation co leucine appearance leucine oxidation fat oxidation determine hour hour change see glyburide treated volunteer compare change see non treated healthy volunteer hour period mean blood glucose decrease great glyburide treated volunteer vs p insulin c peptide concentration glyburide administration hour differ significantly baseline hour value insulin pmol l v pmol l c peptide ng ml v ng ml low dose glyburide result significantly great decrease hgp p see fast alone p abstract truncate word,Tayek JA,1995,Am J Med Sci,https://doi.org/10.1097/00000441-199503000-00003,7879817,Tayek JA,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D001786: Blood Glucose; D002096: C-Peptide; D002153: Calorimetry, Indirect; D005215: Fasting; D005260: Female; D005947: Glucose; D005951: Glucose Tolerance Test; D005905: Glyburide; D006801: Humans; D007328: Insulin; D007700: Kinetics; D007930: Leucine; D008099: Liver; D008297: Male; D010084: Oxidation-Reduction",,,https://openalex.org/W2035256114,158,19,1,1357,266,9,en,en
true,comparative efficacy daily controlled release formulation glipizide immediate release glipizide patient niddm,objective compare efficacy safety controlled release glipizide glipizide gits gastrointestinal therapeutic system immediate release glipizide patient non insulin dependent diabetes mellitus niddm research design method multicenter open label randomize two way crossover study patient niddm receive daily dos mg either glipizide gits immediate release glipizide week follow week alternate formulation plasma glucose serum insulin c peptide plasma glipizide level measure fast post sustacal challenge end week treatment phase hba c measure end week treatment phase result formulation glipizide yield similar mean hba c value however mean fast plasma glucose fpg level significantly low glipizide gits treatment immediate release glipizide end week vs mmol l p lt end week treatment phase vs mmol l p lt fast insulin c peptide level low mg glipizide gits vs immediate release glipizide glucose response sustacal similar formulation glipizide however serum insulin p lt c peptide response p lt low glipizide gits immediate release glipizide treatment end week treatment phase mean plasma glipizide concentration stable end week concentration increase proportionately dose daily glipizide gits provide effective mean glipizide concentration gt ng ml h dose even low mg dose level formulation well tolerate conclusion glipizide gits significantly effective immediate release glipizide reduce fpg level formulation reduce postprandial plasma glucose level equally however glipizide gits exert control presence low plasma glipizide concentration addition significantly low insulin c peptide level suggest glipizide gits improves insulin sensitivity,Berelowitz M,1994,Diabetes Care,https://doi.org/10.2337/diacare.17.12.1460,7882817,Berelowitz M; Fischette C; Cefalu W; Schade DS; Sutfin T; Kourides IA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D000368: Aged; D001786: Blood Glucose; D002096: C-Peptide; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005913: Glipizide; D006442: Glycated Hemoglobin; D006801: Humans; D007328: Insulin; D008297: Male; D008875: Middle Aged; D011863: Radioimmunoassay",,,https://openalex.org/W2169458640,135,16,1,2250,387,14,en,en
false,relation abnormal composition lipoprotein hba c level non insulin dependent diabetes,plasma lipid vldl hdl composition study control group non diabetic subject male middle age patient non insulin dependent diabetes treat oral hypoglycemic agent glibenclamide weight maintain diet data diabetic separate base haemoglobin c less great vldl composition abnormality frequent diabetic patient hba c vldl cholesterol vldl triglycerides vldl phospholipids high diabetic whereas vldl apo b increase diabetic hba c apo cii apo ciii level also apo cii apo ciii ratio also reduce diabetic patient hba c level increase apo e apo e apo c ratio also see hyperglycemic diabetic hba c level contrast apo cii apo ciii level also apo cii apo ciii ratio remain unaltered diabetic patient less hba c level patient increase apo e level find apo e apo c ratio remain unaltered diabetic patient show increase hdl triglycerides triglyceride total cholesterol ratio respect control decrease hdl apo ai also see group diabetic hdl apo ai hdl apo aii ratio differ control,Sánchez-Cabezudo M,1994,Rev Esp Fisiol,,7886271,Sánchez-Cabezudo M; Ródenas S; Cuesta C,article,D016428: Journal Article,"D001053: Apolipoproteins; D001786: Blood Glucose; D015992: Body Mass Index; D002784: Cholesterol; D003131: Combined Modality Therapy; D003924: Diabetes Mellitus, Type 2; D006442: Glycated Hemoglobin; D006801: Humans; D008019: Life Style; D008074: Lipoproteins; D008075: Lipoproteins, HDL; D008079: Lipoproteins, VLDL; D008297: Male; D008875: Middle Aged; D010743: Phospholipids; D012907: Smoking; D014280: Triglycerides",,,https://openalex.org/W2411094038,99,14,1,1359,239,10,en,en
false,antihyperglycaemic efficacy response prediction dose response relation treatment metformin sulphonylurea alone primary combination,short term week antihyperglycaemic efficacy metformin glibenclamide g primary combination mg assess double blind study include unselected patient type diabetes patient diet failure randomize g mg dose titrate fast blood glucose concentration fbg mmol target use six dose level first three comprise increase monotherapy g low dose primary combination mgl second three add therapy g g primary combination therapy escalate high dose mgh success rate high mgl monotherapy difference achieve acceptable control fbg mmol versus confidence interval p drug combine slightly great fbg reduction p observe low dosage p response could predict body weight depend upon initial fbg p meal stimulated c peptide p fbg decline progressively increase dos metformin whereas glibenclamide exert effect low dose primary combination therapy metformin sulphonylurea may clinically useful,Hermann LS,1994,Diabet Med,https://doi.org/10.1111/j.1464-5491.1994.tb00253.x,7895460,Hermann LS; Scherstén B; Melander A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004359: Drug Therapy, Combination; D005260: Female; D005905: Glyburide; D006801: Humans; D006943: Hyperglycemia; D008297: Male; D008687: Metformin; D008875: Middle Aged",,,https://openalex.org/W2166640752,156,20,1,1289,260,9,en,en
false,glibenclamide v gliclazide type diabetes elderly,objective study compare effect two sulphonylureas frequency hypoglycaemic event glycaemic control elderly patient type diabetes twenty two untreated elderly patient treat glibenclamide gliclazide randomized double blind fashion prior treatment biochemical profile oral glucose tolerance test h hyperglycaemic glucose clamp glucose mmol zs baseline perform patient see regularly month assess glycaemic control frequency hypoglycaemic reaction hyperglycaemic clamp study oral glucose tolerance test repeat month area curve oral glucose tolerance test glibenclamide gliclazide mmol p n haemoglobin c glibenclamide gliclazide p n similar month hypoglycaemic reaction significantly frequent glibenclamide gliclazide v p insulin sensitivity index ml kg min pmol increase significantly glibenclamide gliclazide glibenclamide baseline vs month p gliclazide baseline vs month p n conclude glycaemic control equivalent two drug incidence hypoglycaemic reaction significantly great glibenclamide probably drug increase insulin sensitivity great degree,Tessier D,1994,Diabet Med,https://doi.org/10.1111/j.1464-5491.1994.tb00256.x,7895463,Tessier D; Dawson K; Tétrault JP; Bravo G; Meneilly GS,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005907: Gliclazide; D005905: Glyburide; D006801: Humans; D007003: Hypoglycemia; D008297: Male",,,https://openalex.org/W1972654341,61,10,1,1574,302,9,en,en
false,comparative study insulin glyburide versus glyburide insulin chronic control patient type diabetes,order know usefulness combined treatment gliburide nph insulin patient well control type ii diabetes mellitus study patient randomly divide three group group receive gliburide group ii insulin group iii gliburide insulin glucose fast glycosylated haemoglobin c peptide level determine five month statistical data process variance analysis perform initial final glucose determination group mg mg respectively p group ii mg mg p group iii mg mg p glycosylated haemoglobin determination group p group ii p group iii p c peptide group p group ii p group iii p significant statistical difference conclude combined treatment show effective superior order control diabetic patient useful therapeutic alternative well select patient,Cortes Aguirre H,1993,Gac Med Mex,,7926425,Cortes Aguirre H; Espinosa López FR; Angulo Cervera JA; Díaz Torres J,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000704: Analysis of Variance; D001786: Blood Glucose; D002908: Chronic Disease; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007328: Insulin; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2398585931,131,23,1,1216,267,7,en,en
true,bedtime dosing glyburide treatment type ii diabetes mellitus,suppression nocturnal hepatic glucose production key treatment non insulin dependent diabetes mellitus niddm article author compare effectiveness dose glyburide bedtime versus morning glycemic control patient niddm suboptimal control placebo controlled double blind crossover trial patient niddm suboptimal control chronic glyburide treatment fulfil entry criterion randomize receive one two regimen glyburide bedtime placebo morning placebo bedtime glyburide morning month regimen patient cross treatment complete additional month period baseline assessment fast blood sugar history physical exam compliance assessment perform monthly hbalc measure bimonthly sustacal tolerance test perform end month treatment period initial month comparison fasting blood sugar concentration decrease bedtime ingesters rise morning patient change statistically significant hbalc decrease significantly morning group remain unchanged bedtime group end month nighttime dose result good home glucose monitoring value fast blood sugar result sustacal tolerance profile difference statistically significant hypoglycemia observe monitored data collect bedtime dosing glyburide result measurable improvement fast blood sugar carbohydrate tolerance curve degree justify general recommendation technique patient niddm secondary failure oral agent,Hennessey JV,1994,Am J Med Sci,https://doi.org/10.1097/00000441-199430840-00004,7942982,Hennessey JV; Bustamante MA; Teter ML; Markert RJ; McDonald SD,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D001786: Blood Glucose; D002940: Circadian Rhythm; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005215: Fasting; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D008297: Male; D008875: Middle Aged; D010919: Placebos",,,https://openalex.org/W1978409184,74,12,1,1799,294,12,en,en
false,comparative dose related time action profile glibenclamide new non sulphonylurea drug ag ee zw euglycaemic clamp healthy subject,insulin glucose response glibenclamide study comparison novel non sulphonylurea drug ag mean euglycaemic clamp technique nine fast male subject connect biostator mg glibenclamide mg ag give blood glucose concentration clamp basal value glucose infusion rate register h administration tablet maximal glucose infusion rate glibenclamide high compare ag vs mg v mg v mg respectively reach h dos glibenclamide area glucose infusion curve maximal incremental serum insulin response high compare ag low medium high dos drug test however linear dose relationship obtain drug glucose infusion rate plot area insulin curve fact drug equipotent molecular weight basis hypoglycaemic index drug integrate glucose infusion rate divide integrated insulin release express per mumol drug reveal dose dependent parallel inverse curvilinear relation increase dos methodological approach allow u quantify compare metabolic effect oral hypoglycaemic agent standardised experimental condition,Ampudia-Blasco FJ,1994,Diabetologia,https://doi.org/10.1007/bf00417695,7958542,Ampudia-Blasco FJ; Heinemann L; Bender R; Schmidt A; Heise T; Berger M; Starke AA,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D001786: Blood Glucose; D002219: Carbamates; D004305: Dose-Response Relationship, Drug; D005947: Glucose; D015309: Glucose Clamp Technique; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D008297: Male; D010880: Piperidines; D013997: Time Factors",,,https://openalex.org/W2092132782,155,22,1,1450,255,9,en,en
false,prolong response glibenclamide niddm patient normoglycemic state,,Raz I,1994,Isr J Med Sci,,7960692,Raz I; Gilhar D; Hoffman A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001682: Biological Availability; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D005215: Fasting; D005260: Female; D005905: Glyburide; D006801: Humans; D006943: Hyperglycemia; D007408: Intestinal Absorption; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2408860431,79,12,1,0,0,0,en,
true,hypoglycemic activity glyburide glibenclamide metabolites human,assess hypoglycemic effect insulin releasing effect main glyburide glibenclamide metabolites trans hydroxy glibenclamide cis hydroxy glibenclamide humans eight healthy subject participate placebo controlled randomize single blind crossover study five single dose test month apart mg glibenclamide gb orally mg gb intravenously mg intravenously mg intravenously placebo intravenously fasting state standardized meal give h medication blood glucose level measure glucose oxidase method serum insulin concentration analyze specific immunoassay blood glucose level first h significantly lower gb also mean se blood glucose reduction versus placebo express percent area curve auc h intravenous gb gb orally serum insulin level significantly increase gb well two main metabolite glyburide glibenclamide hypoglycemic effect human due increased insulin secretion,Rydberg T,1994,Diabetes Care,https://doi.org/10.2337/diacare.17.9.1026,7988301,Rydberg T; Jönsson A; Røder M; Melander A,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D001786: Blood Glucose; D005260: Female; D005905: Glyburide; D006801: Humans; D007003: Hypoglycemia; D007275: Injections, Intravenous; D007328: Insulin; D008297: Male; D016037: Single-Blind Method",,,https://openalex.org/W1969535782,72,10,1,1277,235,6,en,en
false,effect hyperglycaemia absorption glibenclamide patient non insulin dependent diabetes mellitus,study absorption glibenclamide mg single morning dose patient non insulin dependent diabetes mellitus compare normoglycaemic hyperglycaemic state maximal glibenclamide plasma concentration significantly high normoglycaemic hyperglycaemic state vs mg l peak concentration attain faster normoglycaemia hyperglycaemia vs h conclude absorption glibenclamide two state different,Hoffman A,1994,Eur J Clin Pharmacol,https://doi.org/10.1007/bf00193478,7988624,Hoffman A; Fischer Y; Gilhar D; Raz I,article,D016428: Journal Article,"D000328: Adult; D000368: Aged; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006801: Humans; D006943: Hyperglycemia; D007408: Intestinal Absorption; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2025391735,120,15,1,526,83,3,en,en
false,effect glipizide treatment postprandial lipaemia patient niddm,primary goal present study examine effect improved glycaemic control associate glipizide treatment postprandial lipaemia non insulin dependent diabetic patient metabolism triglyceride rich lipoprotein intestinal origin assess measure retinyl palmitate content plasma svedberg flotation index sf sf lipoprotein fraction fast plasma glucose concentration vs mmol l glycated haemoglobin level vs daylong plasma glucose concentration significantly low glipizide treatment p improvement glycaemic control associate increase insulin mediated glucose uptake p plasma post heparin lipoprotein hepatic lipolytic activity p fast plasma triglyceride vs mmol l postprandial triglyceride concentration p low follow glipizide treatment associate significant fall retinyl palmitate content three lipoprotein fraction p substantial decrease see sf fraction data indicate glipizide induced improvement glycaemic control associate change metabolism triglyceride rich lipoprotein intestinal origin would anticipate reduce risk coronary heart disease non insulin dependent diabetic patient,Jeppesen J,1994,Diabetologia,https://doi.org/10.1007/bf00404335,7988780,Jeppesen J; Zhou MY; Chen YD; Reaven GM,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D001786: Blood Glucose; D002784: Cholesterol; D002940: Circadian Rhythm; D003924: Diabetes Mellitus, Type 2; D004224: Diterpenes; D004435: Eating; D005230: Fatty Acids, Nonesterified; D005260: Female; D005913: Glipizide; D006442: Glycated Hemoglobin; D006801: Humans; D008049: Lipase; D008071: Lipoprotein Lipase; D008074: Lipoproteins; D008099: Liver; D008297: Male; D008875: Middle Aged; D012016: Reference Values; D000084562: Retinyl Esters; D014280: Triglycerides; D014801: Vitamin A",,,https://openalex.org/W1997129422,77,11,1,1471,229,6,en,en
false,metabolic clearance rate insulin type diabetic patient treat combined insulin sulfonylurea therapy,metabolic clearance rate insulin mcri non obese type diabetic patient treat either insulin alone combine insulin plus sulfonylurea therapy investigate classical hour euglycaemic hyperinsulinaemic glucose clamp use artificial pancreas perform randomized order two week period treatment either subcutaneous injection insulin alone insulin plus oral administration sulfonylurea compound glipizide dose x mg day mcri calculate know constant insulin infusion rate u kg h measure basal steady state plasma free insulin c peptide level test perform end period treatment insulin plus glipizide min ingestion last dose mg glipizide plasma c peptide level significantly increase steady state free insulin level tend slightly high whereas metabolic clearance rate glucose affect mcri significantly reduce glipizide ml kg min p result demonstrate sulfonylurea glipizide decrease mcri effect may play role hypoglycemic action sulfonylurea,Castillo MJ,1994,Rev Esp Fisiol,,7991936,Castillo MJ; Scheen AJ; Lefebvre PJ,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D005260: Female; D005913: Glipizide; D015309: Glucose Clamp Technique; D006801: Humans; D007328: Insulin; D008297: Male; D008657: Metabolic Clearance Rate; D008875: Middle Aged",,,https://openalex.org/W156535694,119,18,1,1282,210,7,en,en
true,sulfonylurea induce cholesterol accumulation cultured human intimal cell macrophage,use primary culture human smooth muscle intimal cell mouse peritoneal macrophage demonstrate oral hypoglycemic agent sulfonylurea derivative concentration mol l cause significant intracellular total cholesterol accumulation vitro atherogenic effect confirm ex vivo model serum type diabetic patient take sulfonylurea administration acquire ability induce cholesterol accumulation cultured cell enhanced atherogenic effect patient serum observe next h follow treatment correspond well pharmacokinetic characteristic tested drug result suggest sulfonylurea may exert direct atherogenic action level arterial cell increase intracellular cholesterol content,Sobenin IA,1994,Atherosclerosis,https://doi.org/10.1016/0021-9150(94)90045-0,8003091,Sobenin IA; Maksumova MA; Slavina ES; Balabolkin MI; Orekhov AN,article,D016428: Journal Article,"D000328: Adult; D000818: Animals; D002478: Cells, Cultured; D002784: Cholesterol; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D005907: Gliclazide; D005913: Glipizide; D005905: Glyburide; D006801: Humans; D017737: Macrophages, Peritoneal; D008297: Male; D051379: Mice; D008807: Mice, Inbred BALB C; D008875: Middle Aged; D009131: Muscle, Smooth, Vascular; D013453: Sulfonylurea Compounds; D017539: Tunica Intima",,,https://openalex.org/W2024455394,93,11,1,852,139,5,en,en
false,effectiveness tolerance long term acarbose therapy diabetic patient threatened secondary failure sulfonylurea drug treatment,efficacy tolerability acarbose study type diabetic patient poorly control diet sulfonylureas acarbose give addition sulfonylureas single blind placebo controlled study three time three month acarbose placebo acarbose beginning study every three month body weight hba c biochemical hematological safety parameter measure patient control mid morning urine glucose two four time daily blood glucose concentration memory glucometer diabetic control improve significantly hba c beginning three month acarbose p three month placebo p three month acarbose p thus effect acarbose alone account respectively whereas effect teaching diet special diabetes unit difference study placebo account hba c home monitor blood urine glucose value improve postprandial blood glucose concentration postprandial difference mean blood glucose concentration glycosuria decrease acarbose treatment comparison placebo preprandial blood glucose concentration breakfast supper influence acarbose hematological biochemical safety parameter well blood pressure heart rate unchanged meteorism flatulence typical side effect decrease treatment acarbose safe effective adjunct treatment type diabetic patient uncontrolled diet sulfonylurea alone,Domke A,1994,Med Klin (Munich),,8015532,Domke A; Willms B,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D020909: Acarbose; D001786: Blood Glucose; D003131: Combined Modality Therapy; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D004305: Dose-Response Relationship, Drug; D004359: Drug Therapy, Combination; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D016037: Single-Blind Method; D013453: Sulfonylurea Compounds; D014312: Trisaccharides",,,https://openalex.org/W2396533554,146,21,1,1715,288,11,en,en
false,short term effect felodipine hypertensive type ii diabetic male sulfonylurea treatment,abstract objective study effect blood pressure glucose homeostasis felodipine calcium antagonist design double blind randomize cross study compare felodipine er placebo setting university centre diabetic care malm sweden subject seventeen hypertensive type ii diabetic male oral sulfonylurea glibenclamide treatment intervention four week treatment period separate week wash period felodipine mg daily give main outcome measure blood pressure heart rate hba c response oral glucose tolerance test glucose insulin c peptide measure randomization end double blind treatment period result blood pressure significantly reduce felodipine treatment heart rate slightly increase felodipine influence insulin c peptide level significant change glucose level increase hba c conclusion study demonstrate felodipine effective agent type ii diabetic patient glibenclamide treatment effect hba c noteworthy even clinical significance short term control long term study diabetic patient need fully evaluate antihypertensive agent,Kjellström T,1994,J Intern Med,https://doi.org/10.1111/j.1365-2796.1994.tb01119.x,8021573,Kjellström T; Blychert E; Lindgärde F,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D001786: Blood Glucose; D001794: Blood Pressure; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D015736: Felodipine; D006339: Heart Rate; D006441: Hemoglobin A; D006801: Humans; D006973: Hypertension; D007328: Insulin; D008297: Male; D008875: Middle Aged; D013453: Sulfonylurea Compounds; D013997: Time Factors",,,https://openalex.org/W2009674481,97,13,1,1299,211,23,en,en
false,use glipizide combine intensive insulin treatment induction remission new onset adult type diabetes,determine glipizide could enhance remission induction new onset type diabetes compare intensive insulin treatment alone patient type diabetes intensively treat open randomize trial subcutaneous injection one month insulin randomly either discontinue group insulin discontinue glipizide begin group b three patient group group b p undergo insulin free remission month respectively p n mean blood glucose level insulin treatment low patient enter remission mg dl versus mg dl p c peptide level perform week insulin treatment patient examine mean stimulate c peptide level week pm ml incrreased compare time pm ml p patient enter remission high week stimulate value pm ml compare time value pm ml p whereas remission patient mean c peptide level remain similar week data indicate insulin treatment plus glipizide induce high rate remission compare intensive insulin treatment alone b intensity initial metabolic control may important determinant remission induction c endogenous insulin secretion associate remission induction suggest glipizide alters insulin sensitivity immunomodulatory context new onset type diabetes,Selam JL,1993,Autoimmunity,https://doi.org/10.3109/08916939309014647,8025207,Selam JL; Woertz L; Lozano J; Robinson M; Chan E; Charles MA,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D017668: Age of Onset; D000465: Algorithms; D001786: Blood Glucose; D002096: C-Peptide; D003131: Combined Modality Therapy; D003922: Diabetes Mellitus, Type 1; D004359: Drug Therapy, Combination; D005260: Female; D005913: Glipizide; D006442: Glycated Hemoglobin; D006801: Humans; D007279: Injections, Subcutaneous; D007328: Insulin; D008297: Male; D012074: Remission Induction; D015430: Weight Gain",,,https://openalex.org/W2044253592,129,21,1,1588,301,8,en,en
false,effect sulphonylurea therapy plasma insulin intact split proinsulin subject type diabetes mellitus,study undertake clarify effect sulphonylurea therapy beta cell function subject newly diagnose type diabetes mellitus plasma glucose insulin intact split proinsulin measure diagnostic ogtt week conventional diet subject fast glucose mmol n commence sulphonylurea therapy diagnosis sulphonylurea require group hyperglycaemic p less obese p insulin deficient low min insulin p diet group follow dietary intervention sulphonylurea group weight remain unchanged reduction fast glucose p fast insulin intact proinsulin split proinsulin remain unchanged week sulphonylurea therapy weight gain kg p reduction fast glucose p fast insulin intact proinsulin increase p split proinsulin remain unchanged significant increase fasting insulin glucose ratio p intact split proinsulin ratio p final fasting glucose follow sulphonylurea therapy positively correlate initial intact split proinsulin fast glucose follow dietary treatment clear work sulphonylureas complex effect beta cell physiology well stimulate release insulin increase release intact proinsulin split proinsulin hence increase intact split proinsulin ratio,Davies MJ,1994,Diabet Med,https://doi.org/10.1111/j.1464-5491.1994.tb00274.x,8033529,Davies MJ; Metcalfe J; Day JL; Grenfell A; Hales CN; Gray IP,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D005215: Fasting; D005260: Female; D005951: Glucose Tolerance Test; D005905: Glyburide; D006801: Humans; D007328: Insulin; D008297: Male; D008875: Middle Aged; D011384: Proinsulin; D011498: Protein Precursors",,,https://openalex.org/W1967644594,126,20,1,1715,330,11,en,en
false,effect glipizide glucose metabolism muscle content insulin regulatable glucose transporter glut glycogen synthase activity hyperglycaemia type diabetic patient,examine whether sulphonylureas influence hyperglycaemia induced glucose disposal suppression hepatic glucose production hgp type diabetes mellitus min hyperglycaemic plasma glucose mmol l clamp concomitant somatostatin infusion use eight type diabetic patient week glipizide gz therapy clamp small replacement dose insulin give mu kg per min isotopically determine glucose induced glucose uptake similar gz administration lead improve glycaemic control basal plasma glucose vs mmol l p glucose induced suppression hgp however pronounced gz treatment vs mg kg per min p follow gz treatment hyperglycaemia fail stimulate glycogen synthase activity moreover gz result significant increase immunoreactive abundance insulin regulatable glucose transport protein glut p conclusion result suggest gz therapy type diabetic patient enhance hepatic sensitivity hyperglycaemia glucose induced glucose uptake remain unaffected addition gz tends normalize activity glycogen synthase increase content glut protein skeletal muscle,Schmitz O,1994,Acta Diabetol,https://doi.org/10.1007/bf00580757,8043894,Schmitz O; Lund S; Bak JF; Orskov L; Andersen PH; Møller N; Rasmussen O; Christiansen JS; Pedersen O,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001706: Biopsy; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D005230: Fatty Acids, Nonesterified; D005260: Female; D005913: Glipizide; D005934: Glucagon; D005947: Glucose; D015309: Glucose Clamp Technique; D051275: Glucose Transporter Type 4; D006006: Glycogen Synthase; D006801: Humans; D006943: Hyperglycemia; D008297: Male; D008875: Middle Aged; D009004: Monosaccharide Transport Proteins; D009124: Muscle Proteins; D009132: Muscles",,,https://openalex.org/W2081264581,198,29,1,1354,231,8,en,en
false,ischemic preconditioning coronary angioplasty prevent glibenclamide selective atp sensitive k channel blocker,brief episode ischemia render heart resistant subsequent ischemia phenomenon call ischemic preconditioning animal specie myocardial preconditioning appear due activation atp sensitive k katp channel role play katp channel precondition human remains unknown aim study establish whether glibenclamide selective katp channel blocker abolish ischemic preconditioning observe human coronary angioplasty follow repeat balloon inflations twenty consecutive patient undergo one vessel coronary angioplasty randomize receive mg oral glibenclamide placebo sixty minute glibenclamide placebo administration patient give infusion dextrose ml min correct glucose plasma level respectively infusion saline infusion rate thirty minute beginning infusion patient group underwent coronary angioplasty mean value sd st segment shift surface lead ecg intracoronary ecg measure end first second balloon inflation minute long glibenclamide treated patient mean st segment shift second balloon inflation similar observe first inflation versus mm p n severity cardiac pain great versus mm scale p conversely placebo treated patient mean st segment shift second inflation less first inflation versus mm p severity cardiac pain versus mm p blood glucose level significantly reduce minute glibenclamide compare baseline versus mg ml p glibenclamide group however coronary angioplasty blood glucose level increase mg ml value similar find placebo group mg ml p n human ischemic preconditioning brief repeat coronary occlusion completely abolish pretreatment glibenclamide thus suggest mainly mediate katp channel,Tomai F,1994,Circulation,https://doi.org/10.1161/01.cir.90.2.700,8044938,Tomai F; Crea F; Gaspardone A; Versaci F; De Paulis R; Penta de Peppo A; Chiariello L; Gioffrè PA,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000255: Adenosine Triphosphate; D015906: Angioplasty, Balloon, Coronary; D001786: Blood Glucose; D002121: Calcium Channel Blockers; D015220: Calcium Channels; D003326: Coronary Circulation; D004562: Electrocardiography; D005260: Female; D005905: Glyburide; D006801: Humans; D008297: Male; D008875: Middle Aged; D008991: Monitoring, Physiologic; D017202: Myocardial Ischemia; D016037: Single-Blind Method",,,https://openalex.org/W2002991383,129,17,1,2328,423,10,en,en
false,alcohol tolerance patient non insulin dependent type diabetes treat sulphonylurea derivative,oral ethanol load test g kg body mass give solution carry group patients non insulin dependent type diabetes day treatment one following sulphonylurea derivative tolbutamide cas chlorpropamide cas daily morning glibornuride cas glibenclamide cas glipizide cas response alcohol facial flush heart rate blood pressure compare blood concentration ethanol acetaldehyde pyruvate lactate hydrocarbonates well blood ph po pco determine fast state hour alcohol ingestion patient family history diabetes presence degree vascular complication register evident flush phenomenon observe patient treat chlorpropamide treated tolbutamide treated glibenclamide one receiving glibornuride none treat glipizide drug cause great rise blood ethanol acetaldehyde level relation control test difference reach statistical significance group receive chlorpropamide moreover patient pool positive thermographic response also significantly high blood level ethanol acetaldehyde second test ratio acetaldehyde ethanol concentration blood mumol mmol significantly change group indicate parallel impairment step ethanol metabolism abstract truncate word,Lao B,1994,Arzneimittelforschung,,8053971,Lao B; Czyzyk A; Szutowski M; Szczepanik Z,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000079: Acetaldehyde; D000328: Adult; D000368: Aged; D001784: Blood Gas Analysis; D001786: Blood Glucose; D001833: Body Temperature Regulation; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D000431: Ethanol; D005260: Female; D005483: Flushing; D006439: Hemodynamics; D006801: Humans; D007004: Hypoglycemic Agents; D007773: Lactates; D019344: Lactic Acid; D008297: Male; D008875: Middle Aged; D011773: Pyruvates; D019289: Pyruvic Acid; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2417152855,114,16,1,1675,293,9,en,en
false,metabolic effect metformin addition chronic glibenclamide treatment type diabetes,randomized double blind cross study addition metformin chronic glibenclamide treatment assess conventionally plasma glucose profile hba c measurement euglycaemic hyperinsulinaemic glucose clamp ten non obese body mass index se kg type diabetic patient poor metabolic control metformin mg twice day placebo add randomized sequence week usual sulphonylurea treatment glibenclamide mg three time day meal last day administration period euglycaemic glucose mmol l hyperinsulinaemic insulin pmol l clamp perform together study insulin binding circulate monocyte metformin reduce fast glucose level vs mmol l p mean daily plasma glucose concentration mmol l p hba c vs p variation register fast plasma insulin body weight significant reduction basal hepatic glucose production vs mumol kg min p together increase glucose utilization clamp vs mumol kg min p find metformin whereas residual glucose production insulin infusion change insulin bind circulate monocyte high metformin vs p lipaemic profile show reduction triglyceride vs mmol l p increase hdl cholesterol vs mmol l p without variation total cholesterol finding offer evidence metabolic control improve biguanide addition sulphonylurea treatment support hypothesis biguanides improve insulin sensitivity hepatic peripheral muscular level well triglyceride metabolism,Marena S,1994,Diabete Metab,,8056129,Marena S; Tagliaferro V; Montegrosso G; Pagano A; Scaglione L; Pagano G,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001786: Blood Glucose; D002784: Cholesterol; D008076: Cholesterol, HDL; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D015309: Glucose Clamp Technique; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D014280: Triglycerides",,,https://openalex.org/W2462205608,94,14,1,2043,380,8,en,en
true,long term randomize comparative study insulin versus sulfonylurea therapy type diabetes,study effect insulin sulfonylurea su therapy glycaemic control insulin resistance cardiovascular risk factor type diabetic subjects prospective parallel randomize control long term study outpatient clinic tertiary referral centre thirty six type diabetic subject treat diet su age year duration diabetes years individually adjust dos insulin glibenclamide glycosylated haemoglobin hba c insulin resistance euglycaemic glucose clamp level lipid lipoprotein blood pressure glycaemic control improve insulin treatment deteriorate su hba c level differ significantly group month therapy mean sem vs p body mass index increase significantly insulin treatment kg p increase result increase lean body mass total glucose disposal rate show small increase insulin group level triglyceride apolipoprotein b significantly reduce insulin treatment mmol l p g l p insulin prevent reduction level high density lipoprotein hdl cholesterol apolipoprotein increase lp lipoprotein observe su group blood pressure level change therapy insulin therapy superior su treatment achieve good metabolic control despite modest improvement cardiovascular risk factor insulin treated group significant difference observe group year treatment,Birkeland KI,1994,J Intern Med,https://doi.org/10.1111/j.1365-2796.1994.tb00801.x,8077888,Birkeland KI; Hanssen KF; Urdal P; Berg K; Vaaler S,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001794: Blood Pressure; D003924: Diabetes Mellitus, Type 2; D005260: Female; D015309: Glucose Clamp Technique; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007328: Insulin; D007333: Insulin Resistance; D008055: Lipids; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies",,,https://openalex.org/W2013936522,100,16,1,1755,308,6,en,en
true,efficacy week monotnerapy acarbose glibenclamide placebo niddm patient essen study,compare different therapeutic principle alpha glucosidase inhibitor sulphonylureas first line treatment non insulin dependent diabetes mellitus niddm patient dietary failure ninety six niddm patient year age body mass index bmi insufficiently treat diet alone hba c randomize three group treat week acarbose glibenclamide placebo efficacy base fast blood glucose bg bg h ingestion standard breakfast postprandial serum insulin postprandial insulin increase hba c tolerability base subjective symptom laboratory value investigate every week efficacy evaluation valid patients test drug dose follow mg acarbose three time day placebo tablet three time day mg glibenclamide tablet dose mean dose mg day compare placebo drug show mean efficacy fast bg mm acarbose mm glibenclamide h postprandial bg mm acarbose mm glibenclamide hba c acarbose glibenclamide show marked difference h postprandial insulin value pm acarbose pm glibenclamide mean relative insulin increase h postprandial placebo group acarbose group glibenclamide group change body weight could observe adverse event see placebo acarbose lead mild moderate intestinal symptom patient glibenclamide lead hypoglycemia could solve dose reduction patient dropout occur treatment groups acarbose glibenclamide effective drug monotherapy niddm patient diet alone fail postprandial insulin increase show associate increase risk cardiovascular disease acarbose lower pp increase may superior glibenclamide elevate postprandial insulin increase,Hoffmann J,1994,Diabetes Care,https://doi.org/10.2337/diacare.17.6.561,8082525,Hoffmann J; Spengler M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D020909: Acarbose; D000328: Adult; D000368: Aged; D001786: Blood Glucose; D002784: Cholesterol; D008076: Cholesterol, HDL; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D004040: Dietary Carbohydrates; D002149: Energy Intake; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006029: Glycosuria; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D010919: Placebos; D014280: Triglycerides; D014312: Trisaccharides",,,https://openalex.org/W2013843275,107,18,1,2126,389,11,en,en
true,diabetes control elderly randomized comparative study glyburide versus glipizide non insulin dependent diabetes mellitus,study seek compare efficacy safety glyburide glipizide elderly patient well controlled non insulin dependent diabetes mellitus niddm one hundred forty five patient age year niddm control least month oral sulfonylurea therapy enrol washout phase patient randomize receive glyburide mg day glipizide mg day week titration phase dos adjust accord prescribe guideline patient achieve glycemic control fast plasma glucose mmol l mg dl two consecutive occasion enter maintenance phase total treatment period month hypoglycemia define fasting plasma glucose mmol l mg dl random plasma glucose mmol l mg dl associate sign symptom patient glyburide glipizide group achieve satisfactory glycemic control significant difference group fast plasma glucose hemoglobin c level time note mean dose glyburide mg day approximately half glipizide mg day end maintenance period p regimen well tolerate associate similarly low incidence hypoglycemia conclude glyburide glipizide suitable treatment niddm properly select elderly patient,Rosenstock J,1993,Clin Ther,,8111800,Rosenstock J; Corrao PJ; Goldberg RB; Kilo C,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005913: Glipizide; D005905: Glyburide; D006801: Humans; D008297: Male; D016312: Treatment Refusal",,,https://openalex.org/W69384991,138,20,1,1513,274,10,en,en
true,efficacy safety gliclazide treatment non insulin dependent diabetes mellitus canadian multicenter study,postmarketing study involve office practice provide large body clinical experience date canada second generation sulfonylurea gliclazide treatment non insulin dependent diabetes mellitus niddm study focus efficacy safety niddm patient subject include patient whose disease control diet alone diet plus antidiabetic drug dose gliclazide mg day mg day patient treat month monthly evaluation fasting hour blood glucose glycated hemoglobin level measure study period value show significant decrease p total cholesterol triglyceride level also decrease significantly study p adverse effect record patient lead withdrawal study hypoglycemia symptom less frequently encounter gliclazide previous treatment p gliclazide find safe well tolerate majority patient result study appear confirm establish efficacy gliclazide treat niddm,Mailhot J,1993,Clin Ther,,8111803,Mailhot J,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001786: Blood Glucose; D002170: Canada; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D005260: Female; D005907: Gliclazide; D006801: Humans; D007003: Hypoglycemia; D008297: Male; D008875: Middle Aged; D011358: Product Surveillance, Postmarketing; D013997: Time Factors",,,https://openalex.org/W2416131105,124,18,1,1203,209,11,en,en
false,effect carbohydrase inhibitor miglitol sulfonylurea treated niddm patient,objective examine effect carbohydrase inhibitor miglitol bay metabolic profile non insulin dependent diabetes mellitus niddm patient suboptimally control maximal daily dos sulfonylurea sfu agent research design method multicenter double blind randomize placebo controlled week clinical trial six week single blind placebo lead run period niddm volunteer fast plasma glucose fpg mg dl hemoglobin c hba c least week treatment sfu maximal dose stratify baseline hba c randomly assign within stratum placebo n mg miglitol time day n mg miglitol time day n efficacy assess hba c fpg insulin lipid concentration plasma glucose serum insulin response standard meal result mg miglitol treatment group mean change baseline hba c placebo value subtract respectively highly significant p case mean peak plasma glucose level standard test meal comparably lower mg dl mg miglitol dose mg dl mg miglitol dose compare placebo p associated reduction integrated serum insulin response p lt significant drug associated change fpg insulin cholesterol level note fast triglyceride level lower significantly mg miglitol dose miglitol side effect limit flatulence loose stool abdominal discomfort dose related rapidly resolve drug discontinuation lead withdrawal study patient take mg miglitol respectively conclusion miglitol may indicate effective adjuvant therapy niddm patient suboptimal metabolic control despite conventional treatment diet maximal daily dos sfu dose mg miglitol time day may preferable mg miglitol time day comparable efficacy substantially reduce side effect,Johnston PS,1994,Diabetes Care,https://doi.org/10.2337/diacare.17.1.20,8112185,Johnston PS; Coniff RF; Hoogwerf BJ; Santiago JV; Pi-Sunyer FX; Krol A,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D017485: 1-Deoxynojirimycin; D015415: Biomarkers; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005260: Female; D005944: Glucosamine; D006442: Glycated Hemoglobin; D065089: Glycoside Hydrolase Inhibitors; D006801: Humans; D007004: Hypoglycemic Agents; D050112: Imino Pyranoses; D007328: Insulin; D008055: Lipids; D008297: Male; D008875: Middle Aged; D013997: Time Factors",,,https://openalex.org/W2018001558,85,10,1,2252,422,10,en,en
false,effect glucosidase inhibitor intestinal fermentation faecal lipid diabetic patient,eight non insulin dependent diabetes mellitus patient oral hypoglycaemic agent effective treat alpha glucosidase inhibitor ao mg day month month treatment statistically significant decrease blood glucose level h postprandially h blood glucose level also significantly reduce month treatment insulin hba c level month treatment low administration faecal weight frequency bowel movement ratio hydroxy fatty acid total fatty acid faecal short chain carboxylic acid content increase significantly treatment initially hard stool become normal soft although actual diarrhoea develop faecal bile acid excretion ratio primary bile acid total bile acid increase significantly month show recovery towards pretreatment level month treatment distinct change neutral sterol fatty acid excretion breath hydrogen excretion show slight increase treatment result suggest intestinal fermentation promote intestinal transit time shorten ao administration,Nakamura T,1993,J Int Med Res,https://doi.org/10.1177/030006059302100504,8112483,Nakamura T; Takebe K; Kudoh K; Terada A; Tandoh Y; Arai Y; Yamada N; Ishii M; Kikuchi H,article,D016428: Journal Article,"D000328: Adult; D000368: Aged; D001786: Blood Glucose; D003511: Cyclohexanols; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D004435: Eating; D002149: Energy Intake; D005243: Feces; D005260: Female; D005285: Fermentation; D005905: Glyburide; D006442: Glycated Hemoglobin; D065089: Glycoside Hydrolase Inhibitors; D006801: Humans; D007328: Insulin; D050356: Lipid Metabolism; D008297: Male; D008875: Middle Aged; D017211: Treatment Failure",,,https://openalex.org/W2411167413,102,14,1,1303,215,10,en,en
false,management diabetes general practice current requirement oral antidiabetic insulin therapy,oral antidiabetic agent continue play important role treatment type diabetes decisive importance timing use together knowledge specific property acarbose need initiate low slowly increase dose note fact virtually systemic side effect metformin reduces plasma glucose level without induce hyperinsulinemia carry virtually risk lactic acidosis glibenclamide use either alone treat type diabetes combination oral antidiabetic insulin today intensified insulin therapy represent optimal standard insulin replacement permit meal oriented injection normal insulin use longer acting insulin overnight form treatment facilitate possibility plasma glucose selfmonitoring use injection aid pen intensified treatment initiate time type diabetes diagnose case particularly instable metabolic situation neuropathy may become necessary use insulin pump,Mehnert H,1994,Fortschr Med,,8200602,Mehnert H,article,D004740: English Abstract; D016428: Journal Article; D016454: Review,"D003922: Diabetes Mellitus, Type 1; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin",,,https://openalex.org/W2418876834,110,20,2,1123,191,10,en,en
true,continuous versus intermittent sulphonylurea therapy non insulin dependent diabetes mellitus,although year since discovery hypoglycaemic effect sulphonylureas molecular basis effect still fully understood suggest long term sulphonylurea therapy may desensitise pancreatic beta cells drug effect intermittent sulphonylurea therapy may best approach maintain effectiveness randomised double blind study carry attempt answer question whether intermittent sulphonylurea therapy effective continuous administration responder oral glibenclamide glyburide go receive continuous intermittent treatment glibenclamide week placebo week week glycaemic control maintain continuous treatment group however glucose level deteriorate intermittent treatment group suggest merit intermittent sulphonylurea treatment strategy investigate include administration alternate day basis short period drug e g week underlying question optimal glycaemic control sulphonylureas warrant definitive answer,Grunberger G,1993,Drug Saf,https://doi.org/10.2165/00002018-199309040-00002,8260118,Grunberger G,article,D016428: Journal Article; D016454: Review,"D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D006801: Humans; D007004: Hypoglycemic Agents; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2085528654,95,9,1,1189,188,9,en,en
true,efficacy safety reformulate micronized glyburide tablet patient non insulin dependent diabetes mellitus multicenter double blind randomize trial,subject patient men woman non insulin dependent diabetes mellitus age year least week prior study subject take mg tablet original nonmicronized glyburide micronase tablet dos mg daily double blind week study subject randomly assign continue receive mg tablet original glyburide substitute mg tablet reformulate micronized glyburide glynase prestab tablet original tablet glyburide tablet reformulate improve bioavailability baseline mean fast serum glucose level group take reformulate original glyburide mg dl respectively study end point respective serum glucose level mg dl difference group significant group however end point glucose level significantly high baseline level baseline hemoglobin c level group take reformulate original glyburide study end point hemoglobin c level improve slightly group respectively difference within group end point significant group difference baseline end point find mean level postprandial serum glucose fast c peptide postprandial c peptide medical event experience subject two group similar nature number change laboratory test result vital sign weight clinically meaningful abstract truncate word,Carlson RF,1993,Clin Ther,,8269445,Carlson RF; Isley WL; Ogrinc FG; Klobucar TR,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001786: Blood Glucose; D002626: Chemistry, Pharmaceutical; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D008297: Male; D008875: Middle Aged; D013607: Tablets",,,https://openalex.org/W97458023,170,24,1,1672,294,12,en,en
false,effect gliclazide plasma lipid pancreatic beta cell function non insulin dependent diabetes mellitus,eighteen patient non insulin dependent diabetes mellitus niddm newly diagnose oral hypoglycemic agent discontinue month study evaluate effect gliclazide glycemic control plasma lipid beta cell function mean fasting plasma glucose vs mg dl p postprandial plasma glucose vs mg dl p hba c vs p decrease significantly months gliclazide treatment beta cell function show significant increase fast serum c peptide vs ng ml p insignificant increment serum c peptide glucagon stimulation vs ng ml p case initial serum cholesterol mg dl serum cholesterol decrease significantly vs mg dl p however ldl cholesterol vs mg p hdl cholesterol vs mg p show insignificant decrease gliclazide therapy patient hypertriglyceridemia serum triglyceride decrease vs mg dl p statistically significant finding suggest hyperglycemia fast serum c peptide level hypercholesteremia significantly improve month period gliclazide therapy niddm patient,Chen KW,1993,Changgeng Yi Xue Za Zhi,,8313208,Chen KW; Juang JH; Huang HS; Lin JD; Huang BY; Huang MJ,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005907: Gliclazide; D006801: Humans; D007515: Islets of Langerhans; D008055: Lipids; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2419401235,115,16,1,1467,287,7,en,en
false,prevention complication non insulin dependent diabetes mellitus niddm,expect number patient diabetes mellitus increase near future high rate microvascular macrovascular complication develop patient place even high burden healthcare system several pathophysiological factor involve development complication among hyperglycaemia per se consequent formation advanced glycation end products age intracellular accumulation sorbitol addition hypertension dyslipidaemia also play important role especially development coronary heart disease stroke major therapeutic goal patient non insulin dependent diabetes mellitus niddm reduce obesity normalise lipid disturbance increase blood pressure order improve well patient reduce risk development late diabetic complication often pharmacological treatment hyperglycaemia necessary case sulphonylureas metformin alpha glucosidase inhibitor acarbose insulin may employ believe medical intervention effect improve metabolic control reduce incidence severity diabetic complication especially consider toxic effect glucose accumulation age consequence raise tissue glucose level concept also base extrapolation finding diabetes control complication trial intensive glycaemic control iddm prevent progression least microvascular complication like retinopathy nephropathy however long term study niddm patient show treatment oral antihyperglycaemic agent help postpone prevent complication expect uk prospective diabetes study show whether good metabolic control either oral antihyperglycaemics insulin indeed improve outcome several study aim specific risk factor intervention hypertension hyperlipidaemia lipid oxidation niddm patient currently ongoing,Wolffenbuttel BH,1995,Drugs,https://doi.org/10.2165/00003495-199550020-00006,8521759,Wolffenbuttel BH; van Haeften TW,article,D016428: Journal Article; D016454: Review,"D020909: Acarbose; D000449: Aldehyde Reductase; D001645: Biguanides; D003924: Diabetes Mellitus, Type 2; D005947: Glucose; D006146: Guanidines; D006801: Humans; D006943: Hyperglycemia; D006973: Hypertension; D007004: Hypoglycemic Agents; D007328: Insulin; D008055: Lipids; D011446: Prospective Studies; D016032: Randomized Controlled Trials as Topic; D013453: Sulfonylurea Compounds; D013844: Thiazoles; D045162: Thiazolidinediones; D014312: Trisaccharides; D006113: United Kingdom",,,https://openalex.org/W2111587709,78,10,1,2157,339,11,en,en
false,comparison acarbose metformin insulin treatment type diabetic patient secondary failure sulfonylurea treatment,purpose study determine suitable treatment type non insulin dependent diabetic patient secondary failure sulfonylureas sfs four month comparative study type diabetic patient give sfs allocate three treatment group n f hbalc receive iu kg body weight bw insulin zn p b n f hbalc sfs plus mg day metformin c n f hbalc sfs plus acarbose x mg daily modification hbalc bw blood pressure bp lipoprotein profile insulin sensitivity evaluate hbalc decrease three group b c p b v c p bw increase group decrease group bp decrease statistically group b hdl cholesterol increase vs mmol l p triglyceride level decrease vs mmol l p group significant change studied parameter conclude type diabetic patient give sfs insulin metformin plus sfs provide good glycaemic control acarbose plus sfs metformin combine sfs offer advantage control bw bp,Calle-Pascual AL,1995,Diabete Metab,,8529760,Calle-Pascual AL; Garcia-Honduvilla J; Martin-Alvarez PJ; Vara E; Calle JR; Munguira ME; Marañes JP,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D020909: Acarbose; D000368: Aged; D001786: Blood Glucose; D001794: Blood Pressure; D015992: Body Mass Index; D001835: Body Weight; D002784: Cholesterol; D008076: Cholesterol, HDL; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005951: Glucose Tolerance Test; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D013453: Sulfonylurea Compounds; D017211: Treatment Failure; D014280: Triglycerides; D014312: Trisaccharides",,,https://openalex.org/W2260744210,139,21,1,1368,300,9,en,en
true,united kingdom prospective diabetes study year update randomize control trial effect improved metabolic control complication non insulin dependent diabetes mellitus,report progress year follow study design determine whether improved glucose control patient newly diagnose non insulin dependent diabetes mellitus niddm effective reduce incidence clinical complications multicenter randomize control trial different therapy niddm initial diet therapy asymptomatic patient remain hyperglycemic fast plasma glucose level mmol l assign either conventional therapy policy primarily diet alone intensive therapy policy aim fast plasma glucose level less mmol l assignment primary therapy sulfonylurea insulin increase insulin supply metformin enhance insulin sensitivity three mode pharmacologic therapy intensively treated group sulfonylurea insulin metformin similar efficacy reduce fasting plasma glucose glycated hemoglobin level year patient assign intensive therapy sulfonylurea insulin low fasting plasma glucose level median mmol l respectively patient assign conventional therapy regardless assigned therapy however fasting plasma glucose hemoglobin c level increase maintain near normal glycemia general feasible even insulin therapy achieve therapeutic goal near normal glycemia difficulty treat mark hyperglycemia risk hypoglycemic episode nine year diagnosis diabetes patient diabetes related clinical end point macrovascular complication microvascular complication report publish median duration randomization year range year power level significance detect whether obtained improvement glucose control cause decrease increase incidence major complication whether specific therapy advantageous disadvantageous,Turner R,1996,Ann Intern Med,https://doi.org/10.7326/0003-4819-124-1_part_2-199601011-00011,8554206,Turner R; Cull C; Holman R,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D001786: Blood Glucose; D001835: Body Weight; D003131: Combined Modality Therapy; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D005215: Fasting; D005260: Female; D005500: Follow-Up Studies; D006442: Glycated Hemoglobin; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007515: Islets of Langerhans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D006113: United Kingdom",,,https://openalex.org/W2007914298,199,29,1,2141,355,6,en,en
false,diet diabetes elderly,article draw attention unique aspect diabetes mellitus elderly outline principle management diabetes age group emphasis diet therapy implication diabetes control complication trial elderly person diabetes also briefly discuss new nutrition recommendation american diabetes association summarize evolving enhance role dietitian management diabetes highlight,Fonseca V,1995,Clin Geriatr Med,https://doi.org/10.1016/s0749-0690(18)30260-x,8556690,Fonseca V; Wall J,article,D016428: Journal Article; D016454: Review,"D000368: Aged; D003920: Diabetes Mellitus; D004038: Diet, Reducing; D005260: Female; D006801: Humans; D008297: Male",,,https://openalex.org/W270600627,32,6,1,507,82,3,en,en
false,metabolic benefit derive chronic vitamin c supplementation aged non insulin dependent diabetic,study investigate metabolic benefit derive chronic pharmacological vitamin c administration aged non insulin dependent type ii diabetic patients forty type ii diabetic patient age year underwent placebo vitamin c g twice daily administration double blind randomize cross fashion patient treat oral hypoglycaemic agent continue throughout study baseline observation treatment period last month separate day wash period patients antropometric data unchanged throughout study chronic vitamin c administration v placebo associate significant decline fast plasma free radical v p insulin v pmol l p total v mmol l p ldl cholesterol v mmol l p triglyceride v mmol l p level patient chronic vitamin c administration improve whole body glucose disposal nonoxidative glucose metabolism percent increase plasma vitamin c level correlate percent decline plasma ldl cholesterol r p insulin level r p finally percent increase plasma vitamin c level correlate percent decline plasma free radical increase gsh levels chronic vitamin c administration beneficial effect upon glucose lipid metabolism aged non insulin dependent type ii diabetic patient,Paolisso G,1995,J Am Coll Nutr,https://doi.org/10.1080/07315724.1995.10718526,8568117,Paolisso G; Balbi V; Volpe C; Varricchio G; Gambardella A; Saccomanno F; Ammendola S; Varricchio M; D'Onofrio F,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D001205: Ascorbic Acid; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D005527: Food, Fortified; D005947: Glucose; D015309: Glucose Clamp Technique; D006442: Glycated Hemoglobin; D006801: Humans; D007328: Insulin; D008055: Lipids; D008297: Male",,,https://openalex.org/W1969539304,107,14,1,1593,286,7,en,en
false,response truncated glucagon like peptide gastric inhibitory polypeptide glucose ingestion non insulin dependent diabetes mellitus,gastric inhibitory polypeptide tgip truncate glucagon like peptide glp potent gastrointestinal insulinotropic factor incretin release meal ingestion glucose man animal investigate whether sulfonylurea su affect secretion incretin modulation plasma gip tglp level follow glucose ingestion non insulin dependent diabetic type patient without su therapy study g oral glucose tolerance test ogtt carry healthy subject control patient non obese type treat diet alone niddm diet su glibenclamide mg gliclazide mg day niddm su plasma gip measure radioimmunoassay ria r antibody glp measure ria n terminal directed antiserum r glp nt c terminal directed antiserum r glp ct follow ogtt plasma glucose gip glp nt glp ct type patient increase markedly control despite low response insulin however significant difference plasma level peptide niddm diet niddm su group therefore unlikely su involve high response gip glp ogtt type patient,Fukase N,1995,Acta Diabetol,https://doi.org/10.1007/bf00838486,8590785,Fukase N; Manaka H; Sugiyama K; Takahashi H; Igarashi M; Daimon M; Yamatani K; Tominaga M; Sasaki H,article,D016428: Journal Article,"D000284: Administration, Oral; D000328: Adult; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005749: Gastric Inhibitory Polypeptide; D005934: Glucagon; D052216: Glucagon-Like Peptide 1; D005947: Glucose; D006801: Humans; D007328: Insulin; D008297: Male; D010446: Peptide Fragments; D011498: Protein Precursors; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2942484181,144,17,1,1330,244,7,en,en
false,randomize study glibenclamide versus traditional chinese treatment type diabetic patient chinese french scientific committee study diabetes,purpose study evaluate efficacy traditional chinese treatment tct base three plant association sulfonylurea glibenclamide mg x x factorial design adopt multicentre randomize double blind trial involve group placebo p tct p glibenclamide b p tct verum glibenclamide c verum tct p glibenclamide verum tct verum glibenclamide patient include type diabetic outpatient year age treat diet alone oral anti diabetic drug endpoint criterion evaluate hba blood glucose plasma insulin fasting h test meal visit clinical examination perform questionnaire side effect associate symptom complete dose reduce half case hypoglycaemia patient recruit centre shanghai shanghai beijing canton chengdu randomize treatment group b c respectively eleven patient withdraw administrative reason patient treat glibenclamide significant increase weight insulinaemia observe together significant decrease blood glucose value receive tct blood glucose value significantly decrease h test meal synergistic effect blood glucose observe treatment give hypoglycaemia occur patient two verum glibenclamide group first multicentre control trial show chinese plant test well tolerated effective type diabetes indicate significant synergistic effect association sulfonylurea,Vray M,1995,Diabete Metab,,8593925,Vray M; Attali JR,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D005905: Glyburide; D006801: Humans; D008297: Male; D008516: Medicine, Chinese Traditional; D008875: Middle Aged; D011446: Prospective Studies",,,https://openalex.org/W53995963,162,23,2,1783,344,12,en,en
false,activity superoxide dismutase erythrocyte leukocyte level zinc copper blood patient diabetes effect diabetic treatment examined parameter,purpose present work assess relationship leukocyte erythrocyte superoxide dismutase activity cofactor concentration e zinc copper plasma erythrocyte diabetic patient treatment variability patient include study person control group patient divide group niddm iddm patient niddm divide subgroup depend treatment insulin gliclazide dietary treat group assess follow parameter leucocyte erythrocyte sod activity accord method misra fridovich zinc copper concentration plasma erythrocyte measure flame absorption spectrophotometry statistical analysis perform use crisp program leukocyte erythrocyte superoxide dismutase activity significantly lower diabetes mellitus diabetic patient type type ii healthy people close correlation sod activity cofactor e zinc copper erythrocyte concentration insulin gliclazide treatment increase sod activity delay late diabetic complication,Zbrońska H,1995,Pol Arch Med Wewn,,8596760,Zbrońska H; Grzeszczak W; Jendryczko A; Zbroński R; Kuźniewicz R,article,D004740: English Abstract; D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D002648: Child; D003300: Copper; D003920: Diabetes Mellitus; D003927: Diet, Diabetic; D004912: Erythrocytes; D005260: Female; D005907: Gliclazide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007962: Leukocytes; D008297: Male; D008875: Middle Aged; D013482: Superoxide Dismutase; D015032: Zinc",,,https://openalex.org/W2419651939,184,31,2,1229,205,14,en,en
false,endocrinology,,Watts NB,1996,JAMA,,8642720,Watts NB; Blevins LS,article,D016428: Journal Article,D001862: Bone Resorption; D004704: Endocrinology; D006111: Graves Disease; D006801: Humans; D006961: Hyperparathyroidism; D007004: Hypoglycemic Agents; D008687: Metformin; D010024: Osteoporosis; D014481: United States,,,https://openalex.org/W4298077127,14,2,1,0,0,0,en,
false,metformin new treatment option non insulin dependent diabetes mellitus,metformin biguanide use alone combination sulfonylurea insulin treatment non insulin dependent diabetes mellitus niddm since biguanides increase pancreatic insulin secretion refer antihyperglycemic agent oppose hypoglycemic agent biguanides reduce hyperglycemia increase insulin sensitivity decrease glucose absorption inhibit hepatic gluconeogenesis advantage metformin include achieve glycemic control without exacerbate weight gain hyperinsulinemia beneficially affect serum cholesterol concentration although metformin potential cause lactic acidosis incidence significantly low compare phenformin risk factor lactic acidosis include renal serum creatinine mg dl cardiovascular pulmonary hepatic disease metformin temporarily discontinue prior surgery administration radiologic intravenous contrast patient sepsis severe gastrointestinal disease trauma acute cardiovascular event,Goo AK,1996,J Fam Pract,,8656173,Goo AK; Carson DS; Bjelajac A,article,D016428: Journal Article; D016454: Review,"D001645: Biguanides; D003924: Diabetes Mellitus, Type 2; D004347: Drug Interactions; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008687: Metformin; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2402923412,78,11,1,1102,160,7,en,en
false,clinical usefulness serum anhydroglucitol monitor glycaemic control,evaluate prospectively clinical value measure serum concentration anhydroglucitol ag monitor glycaemia patient newly diagnose non insulin dependent diabetes mellitus niddm measure serum ag patients patient group start continuously receive oral hypoglycaemic agent least week patient group b give agent week stop take least week patient follow additional week serum ag fructosamine glycated haemoglobin hba c self monitoring blood glucose monitor every day weeks sudden worsening glycaemia occur within week entail withdrawal oral treatment ag accurately detect slight change glycaemia whereas hba c fructosamine fail detect although change detect measurement fast plasma glucose fpg concentration fpg less sensitive ag patient near normoglycaemia hba c precede week show low concentration ag micrograms ml manifest high mean daily plasma glucose concentration even though hba c measurement suggest good control glycaemia result ag correlate strongly fpg r mean daily plasma glucose r estimate day estimaoffted precede week fall spearman correlation coefficient preceding time interval ag accurately detect slight change glycaemia without delay suitable use monitoring strict control glycaemia important clinical goal,Yamanouchi T,1996,Lancet,https://doi.org/10.1016/s0140-6736(96)90672-8,8684103,Yamanouchi T; Ogata N; Tagaya T; Kawasaki T; Sekino N; Funato H; Akaoka L; Miyashita H,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D015415: Biomarkers; D001786: Blood Glucose; D003847: Deoxyglucose; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D005069: Evaluation Studies as Topic; D005260: Female; D005500: Follow-Up Studies; D005907: Gliclazide; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007536: Isomerism; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012680: Sensitivity and Specificity; D013997: Time Factors",,,https://openalex.org/W2067519102,80,9,1,1775,310,7,en,en
false,drug induced asterixis amplify relative hypoglycemia,year old man chronic paranoid hallucinatoric psychosis transient episode marked paranoid delusion auditory hallucination without confusion shakiness upper extremity tachycardia sweating emg perform surface electrode reveal many silent period postural active muscle maximum duration blood glucose mg dl time blood glucose mg dl emg reveal silent period postural active muscle maximal duration patient note vibration outstretched hand drug induced asterixis clozapine benperidol amplify relative hypoglycemia therefore assume symptom disappear oral antidiabetic reduce,Poersch M,1996,Nervenarzt,,8684512,Poersch M; Hufnagel A; Smolenski C,article,D002363: Case Reports; D004740: English Abstract; D016428: Journal Article,"D014150: Antipsychotic Agents; D003024: Clozapine; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004359: Drug Therapy, Combination; D004576: Electromyography; D005207: Fasciculation; D005905: Glyburide; D006212: Hallucinations; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D009046: Motor Neurons; D018482: Muscle, Skeletal; D009207: Myoclonus; D009460: Neurologic Examination; D010259: Paranoid Disorders; D014202: Tremor",,,https://openalex.org/W2460381333,60,9,1,760,117,4,en,en
false,unchanged gene expression glycogen synthase muscle patient niddm follow sulphonylurea induced improvement glycaemic control,previously show mrna expression muscle glycogen synthase decrease non insulin dependent diabetic niddm patient objective present protocol examine whether gene expression muscle glycogen synthase niddm affect chronic sulphonylurea treatment ten obese patient niddm study week treatment weight maintaining diet combination sulphonylurea gliclazide gliclazide treatment associate significant reduction hba c p fast plasma glucose p well enhance beta cell response oral glucose load euglycaemic hyperinsulinaemic clamp mu x kg x min combination indirect calorimetry p increase whole body insulin stimulated glucose disposal rate predominantly due increase non oxidative glucose metabolism p demonstrate teh gliclazide treated patient compare pre treatment value biopsy obtain vastus lateralis muscle insulin infusion half maximal activation glycogen synthase achieve significantly low concentration allosteric activator glucose phosphate p however despite significant increase insulin stimulated non oxidative glucose metabolism muscle glycogen synthase activation gliclazide treated patient change find level glycogen synthase mrna immunoreactive protein muscle conclusion improve blood glucose control gliclazide treated obese niddm patient impact gene expression muscle glycogen synthase,Vestergaard H,1995,Diabetologia,https://doi.org/10.1007/bf00422374,8690177,Vestergaard H; Lund S; Bjørbaek C; Pedersen O,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000818: Animals; D001483: Base Sequence; D001706: Biopsy; D001786: Blood Glucose; D002096: C-Peptide; D017931: DNA Primers; D018076: DNA, Complementary; D003924: Diabetes Mellitus, Type 2; D005260: Female; D015870: Gene Expression; D005907: Gliclazide; D005914: Globins; D015309: Glucose Clamp Technique; D005951: Glucose Tolerance Test; D006006: Glycogen Synthase; D006801: Humans; D006946: Hyperinsulinism; D007004: Hypoglycemic Agents; D007262: Infusions, Intravenous; D007328: Insulin; D008297: Male; D008875: Middle Aged; D008969: Molecular Sequence Data; D018482: Muscle, Skeletal; D016133: Polymerase Chain Reaction; D012333: RNA, Messenger; D011817: Rabbits",,,https://openalex.org/W2050310915,146,18,1,1665,253,7,en,en
false,efficacy combination therapy insulin oral hypoglycemic agent patient type ii diabetes year period,abstract retrospective study author assess efficacy combined insulin oral hypoglycemic agent ohas control glycemic level well lipid level insulin requirement patient type diabetes mellitus year period thirty two patient secondary failure oha group sixteen patient group take high dos insulin alone overall patient respond combination therapy insulin month response define decrease hemoglobin ale month patient continue respond regimen significant difference see patient total cholesterol triglyceride level responder nonresponders group year combination oha insulin therapy patient show reduction daily insulin dose,Mozersky RP,1996,J Am Osteopath Assoc,https://doi.org/10.7556/jaoa.1996.96.6.346,8690621,Mozersky RP; Patel H; Bahl VK; Bahl S; Mook W,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008055: Lipids; D008297: Male; D008875: Middle Aged; D012189: Retrospective Studies; D016896: Treatment Outcome",,,https://openalex.org/W180141447,130,20,1,939,173,8,en,en
false,effect troglitazone new hypoglycemic agent patient niddm poorly control diet therapy,objective investigate clinical efficacy troglitazone newly develop oral hypoglycemic agent patient niddm research design method niddm patient year age whose glycemic control diet judge stable judge unsatisfactory fast plasma glucose fpg mmol l enter multicenter double blind study parallel group study randomly allocate two group troglitazone group group mg day p placebo group p group treat test drug week result evaluate efficacy patient group patient p group significant difference baseline characteristic p group group fpg hba c decrease significantly treatment versus fpg vs mmol l p lt hba c v p lt fpg hba c change treatment p group versus fpg vs mmol l hba c vs patient group classify responder serum triglyceride level also decrease group p group body weight increase slightly group difference change blood pressure two group serious adverse event occur either group conclusion troglitazone mg day decrease fpg hba c significantly niddm patient fail respond diet therapy troglitazone develop drug enhance insulin action useful hypoglycemic agent treatment niddm,Iwamoto Y,1996,Diabetes Care,https://doi.org/10.2337/diacare.19.2.151,8718436,Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001794: Blood Pressure; D001835: Body Weight; D002784: Cholesterol; D002839: Chromans; D003924: Diabetes Mellitus, Type 2; D003927: Diet, Diabetic; D004311: Double-Blind Method; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D010919: Placebos; D013844: Thiazoles; D045162: Thiazolidinediones; D014280: Triglycerides; D000077288: Troglitazone",,,https://openalex.org/W2080744024,106,17,1,1748,356,15,en,en
false,metformin noninsulin dependent diabetes mellitus,metformin oral antihyperglycemic agent approve food drug administration treatment noninsulin dependent diabetes mellitus differ sulfonylurea enhance insulin secretion normally produce hypoglycemia metformin act decrease preprandial postprandial blood glucose concentration increase skeletal muscle uptake glucose decrease gluconeogenesis decrease absorption glucose addition metformin maximum dosage sulfonylurea may synergistically improve glucose control drug may offer potential benefit weight loss minimal weight gain improve blood flow patient peripheral vascular disease reduction tissue plasminogen activator inhibitor improve lipid profile relatively safe take appropriately common side effect gastrointestinal nausea diarrhea anorexia metallic taste vitamin b malabsorption lactic acidosis may also occur rare metformin avoid patient contraindication use careful monitoring agent may consider initial treatment obese patient fail dietary measure whose disease refractory maximum dosage sulfonylurea tolerate,Lee AJ,1996,Pharmacotherapy,,8726592,Lee AJ,article,D016428: Journal Article; D016454: Review,"D001835: Body Weight; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D006801: Humans; D006937: Hypercholesterolemia; D007004: Hypoglycemic Agents; D008687: Metformin",,,,52,6,1,1348,218,9,en,en
false,high carbohydrate diet different effect niddm patient treat diet alone hypoglycemic drug,compare effect nigh carbohydrate diet blood glucose plasma lipid niddm patient either mild severe glucose intolerance crossover design day intervention diet use eighteen patient separate two group basis hypoglycemic treatment diet n diet plus glibenclamide n assign day treatment high carbohydrate low fiber diet contain energy carbohydrate fat low carbohydrate low fiber diet energy carbohydrate fat cross diet days high carbohydrate diet produce significant increase postprandial blood glucose patient glibenclamide vs mmol l p difference record group diet alone vs mmol l postprandial insulin level significantly high high carbohydrate diet group diet along vs pmol l p significant difference observe group vs pmol l high carbohydrate diet also induce significant increase fast plasma triglyceride concentration group vs mmol l p vs mmol l p difference observe fast plasma cholesterol hdl effect high carbohydrate diet blood glucose control niddm patient differ accord severity glucose intolerance,Parillo M,1996,Diabetes Care,https://doi.org/10.2337/diacare.19.5.498,8732716,Parillo M; Giacco R; Ciardullo AV; Rivellese AA; Riccardi G,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D015415: Biomarkers; D001786: Blood Glucose; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004040: Dietary Carbohydrates; D004041: Dietary Fats; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008875: Middle Aged",,,https://openalex.org/W2067916345,117,18,1,1581,286,4,en,en
false,daytime glibenclamide bedtime nph insulin compare intensive insulin treatment secondary sulphonylurea failure year follow,aim study compare metabolic effect combination daytime glibenclamide even nph insulin intensive insulin treatment rapid act insulin meal nph insulin bedtime patient exhibit secondary failure sulphonylurea treatment thirty nine mildly obese niddm patient bmi randomize week intensive insulin treatment either combination treatment ct n continue intensive insulin treatment n difference two group age diabetes duration bmi hba c basal glucagon stimulate c peptide patient follow year finding analyse intent treat basis two patient ct group exclude month respectively due unacceptably high postprandial glucose value significant difference hba c ct group month n v n p month n v n initial intensive insulin treatment bmi constant ct group increase significantly month group conclude treatment associate marked long term improvement glycaemic control intensive insulin treatment lead pronounced weight increase long run might negative effect overall metabolic control therefore combination treatment together intensified education dietary advice regard initial treatment choice oral agent failure moderately obese niddm patient,Clauson P,1996,Diabet Med,https://doi.org/10.1002/(sici)1096-9136(199605)13:5<471::aid-dia103>3.0.co;2-t,8737030,Clauson P; Karlander S; Steen L; Efendic S,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000419: Albuminuria; D000704: Analysis of Variance; D001786: Blood Glucose; D015992: Body Mass Index; D002096: C-Peptide; D002784: Cholesterol; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007336: Insulin, Isophane; D061389: Insulin, Regular, Pork; D008297: Male; D008687: Metformin; D008875: Middle Aged; D013453: Sulfonylurea Compounds; D017211: Treatment Failure; D014280: Triglycerides",,,https://openalex.org/W2068668933,140,19,1,1701,325,10,en,en
true,sulphonylurea treatment niddm patient cardiovascular disease mixed blessing,non insulin dependent diabetic niddm patient show high incidence cardiovascular disease great risk recurrent myocardial infarction less favourable clinical outcome non diabetic patient majority niddm patient treat sulphonylurea su derivative university group diabetes program conclude tolbutamide treatment cause increased cardiovascular mortality study lead curtailment oral antidiabetic treatment usa receive scepticism europe later criticism methodology reduce impact study however question safety su niddm patient cardiovascular disease opened face new experimental data heart vascular tissue prerequisite su action e su receptor atp dependent k k atp channel channel play important role protection myocardium ischaemia reperfusion damage closure su could lead amplified ischaemic damage review evidence animal human study deleterious su effect ischaemia induced myocardial damage either direct action diminish cardioprotective preconditioning closure k atp channel su lead reduction post infarct arrhythmia drug also claim improve various atherosclerosis risk factor evidence beneficial effect su also review look major difficulty hamper transfer information experimental study clinical decision making affinity su heart k atp channel order magnitude low beta cell channel reasonable expect vivo cardiac effect therapeutic pancreatic su dos b study utilized high dos acutely administer su effect similar chronic steady state su treated diabetic patient c convince su effect demonstrate acutely induce ischaemia acutely administer drug effect persist clinical situation gradually progressive ischaemia ischaemia modification k atp channel activity induce complex event opposing effect net result su action different su derivative lead different outcome e chronic hence clinically relevant situation direct deleterious beneficial su effect separate beneficial effect mediate metabolic action drug large prospective clinical study make use advanced technology assessment cardiovascular function answer question million niddm patient treat su derivative many age group cardiovascular risk extremely high question whether su derivative beneficial deleterious patient must finally settle unequivocally,Leibowitz G,1996,Diabetologia,https://doi.org/10.1007/bf00403296,8739909,Leibowitz G; Cerasi E,article,D016428: Journal Article; D016454: Review,"D018528: ATP-Binding Cassette Transporters; D000818: Animals; D002318: Cardiovascular Diseases; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D006801: Humans; D007004: Hypoglycemic Agents; D017202: Myocardial Ischemia; D015221: Potassium Channels; D024661: Potassium Channels, Inwardly Rectifying; D011955: Receptors, Drug; D013453: Sulfonylurea Compounds; D064233: Sulfonylurea Receptors",,,https://openalex.org/W2062947421,88,13,1,2967,490,18,en,en
false,circulate catecholamine metabolic effect captopril niddm patient,objective evaluate effect captopril circulate catecholamine level niddm patient possible relationship captopril related change circulate catecholamine level insulin sensitivity research design method fourteen nonobese normotensive niddm men age year undergo h euglycemic hyperinsulinemic clamp mu min baseline evaluation insulin sensitivity follow random assignment patient either captopril placebo treatment accord crossover double blind design euglycemic hyperinsulinemic clamp study repeat patient placebo captopril treatment plasma norepinephrine ne epinephrine e level assess clamp result result data show plasma catecholamine level increase baseline euglycemic hyperinsulinemic clamp ne time vs time min p lt e time vs time min p lt captopril treatment significantly increase total glucose uptake mmol kg min p lt reduced baseline plasma ne p lt e p lt level however magnitude ne time vs time min p lt e time vs time min p lt increment euglycemic hyperinsulinemia affect drug percentage change ratio total body glucose uptake circulate insulin level correspond decrement baseline plasma e level captopril therapy negatively correlate r p lt conclusion reduction circulate catecholamine could contribute least part captopril related amelioration insulin sensitivity,De Mattia G,1996,Diabetes Care,https://doi.org/10.2337/diacare.19.3.226,8742566,De Mattia G; Ferri C; Laurenti O; Cassone-Faldetta M; Piccoli A; Santucci A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000806: Angiotensin-Converting Enzyme Inhibitors; D001786: Blood Glucose; D002216: Captopril; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004837: Epinephrine; D015309: Glucose Clamp Technique; D006801: Humans; D007262: Infusions, Intravenous; D007328: Insulin; D008297: Male; D009638: Norepinephrine",,,https://openalex.org/W2007549123,79,10,1,1848,351,10,en,en
false,comparison acarbose versus metformin adjuvant therapy sulfonylurea treated niddm patient,compare effect acarbose metformin treatment use adjunct sulfonylurea agent treatment niddm adequately control use sulfonylurea agent alone poorly control female niddm patient sulfonylurea treatment randomly select outpatient diabetic clinic study week receive either acarbose mg daily metformin mg daily addition sulfonylurea crossover design use week washout period treatment efficacy drug regimen assess measure level glycosylated hemoglobin fast h postprandial blood glucose ppbg level cholesterol triglyceride fibrinogen level week therapy metabolic parameter measure initiation either treatment regimen similar mean fasting h postprandial glucose level reduce moderately end week combination treatment p although fasting h postprandial plasma insulin c peptide fibrinogen level end week treatment period low obtain beginning study difference value statistically significant cholesterol level remain unchanged h ppbg level group use acarbose plus sulfonylurea low level achieve group use metformin plus sulfonylurea vs mmol l respectively p difference pre posttreatment level h ppbg level arm study statistically significant delta acarbose vs delta metformin p specific drug associated side effect observe patient acarbose patient metformin acarbose metformin use effective adjuvant therapy sulfonylurea agent niddm patient poorly control sulfonylurea agent alone,Bayraktar M,1996,Diabetes Care,https://doi.org/10.2337/diacare.19.3.252,8742572,Bayraktar M; Van Thiel DH; Adalar N,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D020909: Acarbose; D000328: Adult; D001786: Blood Glucose; D002096: C-Peptide; D002784: Cholesterol; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008687: Metformin; D008875: Middle Aged; D013453: Sulfonylurea Compounds; D014280: Triglycerides; D014312: Trisaccharides",,,https://openalex.org/W2027615758,103,14,1,2018,342,9,en,en
false,new traditional treatment glycemia niddm,,Bloomgarden ZT,1996,Diabetes Care,https://doi.org/10.2337/diacare.19.3.295,8742586,Bloomgarden ZT,article,D016423: Congress,"D000818: Animals; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D015316: Genetic Therapy; D051275: Glucose Transporter Type 4; D006801: Humans; D007004: Hypoglycemic Agents; D051379: Mice; D008822: Mice, Transgenic; D009004: Monosaccharide Transport Proteins; D009124: Muscle Proteins; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2320464786,50,8,1,0,0,0,en,
true,novel mechanism glipizide sulfonylurea action decrease metabolic clearance rate insulin,examine whether sulfonylureas inhibit metabolic clearance rate mcr insulin healthy young subject participate two experiment first protocol n h oral glucose load perform without mg glipizide give min glucose ingestion total insulin response great without glipizide vs microu ml p however total c peptide response virtually identical vs nmol l study second protocol n mcr insulin measure h euglycemic insulin clamp perform without glipizide study glipizide subject ingest mg glipizide min steady state plasma insulin concentration th h e h glipizide ingestion significantly high nd h e glipizide ingestion vs microu ml p addition glucose uptake th h great vs mg kg min mcr insulin reduce vs ml min p conclude glipizide augments plasma insulin level enhance secretion decrease mcr insulin,Barzilai N,1995,Acta Diabetol,https://doi.org/10.1007/bf00576262,8750768,Barzilai N; Groop PH; Groop L; DeFronzo RA,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D002096: C-Peptide; D005260: Female; D005913: Glipizide; D005947: Glucose; D015309: Glucose Clamp Technique; D006801: Humans; D007004: Hypoglycemic Agents; D007262: Infusions, Intravenous; D007328: Insulin; D007700: Kinetics; D008297: Male; D008657: Metabolic Clearance Rate",,,https://openalex.org/W2092585967,97,14,1,1288,260,9,en,en
false,effect physical exercise glycemia healthy subject follow administration glimepiride,sulfonylurea predispose hypoglycaemia exercise hypoglycaemic effect novel sulfonylurea glimepiride g ca male healthy volunteer condition subject expose three experimental situation administration mg g rest administration mg g min bicycle ergometry e work load adjust heart rate bpm placebo p bicycle ergometry mention precede follow min physical rest base line glycaemia comparable pe mg dl gr mg dl ge mg dl fell gr mg dl min ge glycaemia cease decline min exercise rise thereafter reach value comparable pe min vs mg dl serum insulin concentration rise exercise follow administration g microu ml auc period min administration ge microu ml min gr microu ml min fell pe microu ml microu ml p vs ge gr ge serum insulin concentration fell microu ml end exercise thereafter auc period min administration microu ml min whereas remain microu ml gr microu ml min p vs ge conclusion exercise blunts hypoglycaemic effect glimepiride healthy individual,Gudat U,1996,Arzneimittelforschung,,8767351,Gudat U; Heinemann L,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D001786: Blood Glucose; D002096: C-Peptide; D015444: Exercise; D005080: Exercise Test; D005260: Female; D005934: Glucagon; D006339: Heart Rate; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007773: Lactates; D019344: Lactic Acid; D008297: Male; D013453: Sulfonylurea Compounds,,,https://openalex.org/W2410541868,107,18,1,1509,299,9,en,en
true,effect aspirin ibuprofen pharmacokinetics pharmacodynamics glyburide healthy subject,objective determine effect aspirin ibuprofen pharmacokinetics pharmacodynamics glyburide healthy volunteer design single center randomize two way crossover design follow initial baseline evaluation phase setting outpatient university based ambulatory care facility patient sixteen healthy nonsmoking men age year intervention three phase consist six treatment phase begin treatment baseline oral glucose tolerance test gtt follow treatment b glyburide mg plus gtt two phase administer crossover design phase consist administration aspirin mg qid day day gtt administer treatment c day glyburide mg plus gtt administer treatment e phase consist administration ibuprofen mg qid day gtt day treatment glyburide mg plus gtt day treatment f main outcome measure serum glyburide concentration treatment well glucose insulin ibuprofen salicylate serum concentration glyburide free fraction result aspirin administration result increase mean total glyburide oral clearance increase glyburide free fraction ibuprofen administration result slight increase mean glyburide free fraction significant change glyburide pharmacokinetic parameter observe insulin concentration increase glyburide plus aspirin treatment conflict result observe glucose parameter conclusion potential glyburide aspirin interaction result transient hypoglycemia consider diabetic patient receive glyburide therapy,Kubacka RT,1996,Ann Pharmacother,https://doi.org/10.1177/106002809603000103,8773160,Kubacka RT; Antal EJ; Juhl RP; Welshman IR,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000894: Anti-Inflammatory Agents, Non-Steroidal; D001241: Aspirin; D001786: Blood Glucose; D018592: Cross-Over Studies; D004347: Drug Interactions; D005951: Glucose Tolerance Test; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007052: Ibuprofen; D007328: Insulin; D008297: Male",,,https://openalex.org/W2157223833,110,15,1,1796,310,16,en,en
false,american diabetes association postgraduate course treatment prevention diabetes,,Bloomgarden ZT,1996,Diabetes Care,https://doi.org/10.2337/diacare.19.7.784,8799649,Bloomgarden ZT,article,D016423: Congress,"D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D019468: Disease Management; D004502: Education, Medical, Continuing; D006266: Health Education; D006801: Humans; D007328: Insulin; D008329: Managed Care Programs; D012955: Societies, Medical; D014481: United States",,,https://openalex.org/W2048458604,93,13,1,0,0,0,en,
true,dose response study glimepiride patient niddm previously receive sulfonylurea agent,assess efficacy safety dose response relationship glimepiride patient niddm day placebo washout period patient randomize receive either placebo glimepiride mg daily fast plasma glucose fpg h postprandial glucose ppg hba c measure predetermined interval washout period week study adverse event tabulated patient visit reduction baseline fpg great glimepiride group placebo group p change baseline endpoint mg glimepiride exceed placebo p mmol l respectively fpg percentage point respectively hba c mmol l respectively h ppg great reduction parameter observe mg mg p indicate dose response relationship patient baseline hba c level assess patient receive mg glimepiride hba c value endpoint compare patient receive mg glimepiride favorable safety profile glimepiride mg dos effective well tolerate although mg daily dos significantly potent mg dose three dos yield clinical improvement mg dose control hba c value great number patient high baseline hba c level mg dose high dose might beneficial patient difficult treat,Goldberg RB,1996,Diabetes Care,https://doi.org/10.2337/diacare.19.8.849,8842603,Goldberg RB; Holvey SM; Schneider J,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005215: Fasting; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D010919: Placebos; D019518: Postprandial Period; D013453: Sulfonylurea Compounds; D016312: Treatment Refusal",,,https://openalex.org/W2090610606,108,15,1,1626,313,8,en,en
false,glucagon like peptide enhance insulinotropic effect glibenclamide niddm patient perfused rat pancreas,investigate acute effect glibenclamide glucagon like peptide glp combination perfused isolated rat pancreas patient secondary failure sulfonylureas rat islet perfuse nmol l glp combination mumol l glibenclamide human experiment glp pmol kg min give continuous infusion min glibenclamide mg administer orally eight patient participate study age year bmi kg mean se subject blood glucose first normalize insulin infusion administer artificial pancreas biostator glp increase insulinotropic effect glibenclamide fourfold perfused rat pancreas human experiment treatment glp alone combination glibenclamide significantly decrease basal glucose level vs mmol l p glibenclamide glucose concentration remain unchanged glp markedly decrease total integrated glucose response meal vs mmol l min area curve auc min p whereas glibenclamide effect mmol l min auc min n combined treatment far enhance glucose lower effect glp mmol l min auc min p glp glibenclamide combine treat stimulated meal induced insulin release reflect insulinogenic index control glp p glibenclamide p combination p glp inhibited basal postprandial glucagon response use paracetamol marker gastric empty rate test meal treatment glp decrease gastric empty min approximately compare control subject p acute experiment overweight patient niddm glp exert marked antidiabetogenic action basal postprandial state peptide stimulate insulin suppress basal glucagon release prolong gastric emptying glucose lowering effect glp far enhance glibenclamide action may least partially account synergistic effect two compound insulin release glibenclamide per se enhance postprandial basal insulin release exert less pronounced antidiabetogenic effect compare glp,Gutniak MK,1996,Diabetes Care,https://doi.org/10.2337/diacare.19.8.857,8842604,Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000704: Analysis of Variance; D000818: Animals; D003924: Diabetes Mellitus, Type 2; D004357: Drug Synergism; D004359: Drug Therapy, Combination; D005746: Gastric Emptying; D005934: Glucagon; D052216: Glucagon-Like Peptide 1; D004763: Glucagon-Like Peptides; D005905: Glyburide; D006801: Humans; D066298: In Vitro Techniques; D007262: Infusions, Intravenous; D007328: Insulin; D000078790: Insulin Secretion; D007515: Islets of Langerhans; D008875: Middle Aged; D010446: Peptide Fragments; D010477: Perfusion; D011498: Protein Precursors; D051381: Rats; D017207: Rats, Sprague-Dawley; D017211: Treatment Failure",,,https://openalex.org/W2078387216,126,18,1,2524,456,18,en,en
false,effect glipizide gastrointestinal therapeutic system islet cell hormonal response test meal niddm,objective determine whether abnormal glucagon amylin secretion niddm secondary hyperglycemia relative hypoinsulinemia research design method total patient niddm study treatment glipizide gastrointestinal therapeutic system git randomized double blind placebo controlled fashion subject randomize glipizide gits arm randomize placebo arm study serum glucose insulin c peptide plasma glucagon plasma amylin concentration measure fasting postprandial post sustacal ingestion condition sustacal challenge perform baseline week treatment either glipizide git placebo result glipizide git treatment result significant reduction hyperglycemia increase insulin c peptide secretion hyperglucagonemia ameliorate amylin secretion alter glipizide git treatment placebo treated patient show significant change parameter measure conclusion glipizide git treatment fail ameliorate hyperglucagonemia niddm alter amylin secretion even though increase insulin secretion significantly ameliorate hyperglycemia observation suggest niddm related abnormality islet cell hormonal response result change inherent islet cell may independent hyperglycemia relative hypoinsulinemia,Mooradian AD,1996,Diabetes Care,https://doi.org/10.2337/diacare.19.8.883,8842609,Mooradian AD; Albert SG; Bernbaum M; Plummer S,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000682: Amyloid; D001786: Blood Glucose; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004435: Eating; D005215: Fasting; D005260: Female; D005913: Glipizide; D005934: Glucagon; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D058228: Islet Amyloid Polypeptide; D008297: Male; D008875: Middle Aged; D010919: Placebos; D019518: Postprandial Period; D016037: Single-Blind Method",,,https://openalex.org/W2086582539,116,18,1,1550,236,10,en,en
false,uniform diurnal blood glucose control reduction daily insulin dosage addition glibenclamide insulin type diabetes mellitus role enhanced insulin sensitivity,combination therapy insulin sulphonylurea gain acceptance management subject type non insulin dependent diabetes mellitus however role management type insulin dependent diabetes mellitus remain controversial study effect combination therapy insulin glibenclamide metabolic control daily insulin dosage insulin sensitivity assess subject type diabetes mellitus ten men type diabetes mellitus participate randomized double blind crossover clinical trial three treatment regimen namely insulin alone insulin placebo insulin glibenclamide last month combination therapy induce reduction daily insulin dosage uniform blood glucose control reflect low average h blood glucose level small difference mean preprandial h postprandial blood glucose concentration decrease h urine glucose excretion decline number hypoglycaemic event improve insulin sensitivity express rapid plasma glucose disappearance rate without significant alteration fast plasma glucagon h postprandial serum c peptide level compare treatment either insulin alone insulin placebo therefore apparent addition glibenclamide insulin reduces daily insulin dosage render great uniformity diurnal blood glucose control probably secondary enhancement insulin sensitivity,Kabadi UM,1995,Diabet Med,https://doi.org/10.1111/j.1464-5491.1995.tb00390.x,8846678,Kabadi UM; McCoy S; Birkenholz M; Kabadi M,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001786: Blood Glucose; D001835: Body Weight; D002096: C-Peptide; D002784: Cholesterol; D002940: Circadian Rhythm; D018592: Cross-Over Studies; D003922: Diabetes Mellitus, Type 1; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005934: Glucagon; D005905: Glyburide; D006442: Glycated Hemoglobin; D006029: Glycosuria; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D010919: Placebos; D014280: Triglycerides",,,https://openalex.org/W2141217393,188,30,1,1570,267,6,en,en
true,effect obesity pharmacokinetics pharmacodynamics glipizide patient non insulin dependent diabetes mellitus,summary pharmacokinetics pharmacodynamics glipizide evaluate patient non insulin dependent diabetes mellitus niddm group consist obese subject seven woman five men mean sd age year total body weight tbw kg percentage ibw ideal body weight eight nonobese subject two woman six men age year tbw kg percentage ibw week antidiabetic drug free period patient start glipizide therapy week glipizide dosage titrate achieve specify therapeutic goal maximum daily dose mg glipizide pharmacokinetics assess serum concentration obtain h pharmacokinetic evaluation perform first mg dose sd week chronic therapy cd glipizide pharmacodynamics evaluate serum glucose insulin c peptide response sustacal tolerance test baseline sd cd statistically significant difference sd pharmacokinetic parameter tmax vs h cmax vs g l area curve extrapolate infinity auci vs g h l oral clearance bioavailability cl f vs l h volume distribution bioavailability v f vs l vs h observe obese nonobese group respectively pharmacokinetic parameter assess cd condition also closely match two group difference glucose response sustacal challenge baseline sd cd auco glucose baseline vs sd vs cd vs mm h note obese nonobese group respectively however glucose concentration increase decrease small extent sd obese compare nonobese subject mean fast serum insulin c peptide concentration statistically different two group however obese subject exhibit high fasting insulin vs pm week evaluation c peptide concentration vs nm sd compare nonobese group small percentage increase c peptide response sustacal challenge observe obese compare nonobese subject baseline vs sd vs cd vs summary influence obesity glipizide pharmacokinetics appear little clinical significance observed difference pharmacodynamics require evaluation,Jaber LA,1996,Ther Drug Monit,https://doi.org/10.1097/00007691-199602000-00002,8848822,Jaber LA; Ducharme MP; Halapy H,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D001682: Biological Availability; D001786: Blood Glucose; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005913: Glipizide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D009765: Obesity; D012189: Retrospective Studies",,,https://openalex.org/W2021512930,137,17,1,2790,550,14,en,en
true,pharmacokinetics oral antihyperglycaemic agent patient renal insufficiency,paper review effect renal insufficiency pharmacokinetics oral antidiabetic drug group drug currently available treatment non insulin dependent diabetes mellitus niddm sulphonylureas metformin general well tolerated generally safe patient chronic renal insufficiency however care must exercise use many drug accumulation either active drug active metabolite lead serious adverse effect hypoglycaemia metformin lactic acidosis sulphonylurea drug great less degree metabolise liver variety active inactive compound general excrete kidney addition vary amount parent compound may depend renal elimination result sulphonylurea drug tolazamide acetohexamide chlorpropamide glibenclamide glyburide likely cause significant hypoglycaemia metabolism drug compare commonly prescribe sulphonylureas lead accumulation either parent drug active metabolite presence renal insufficiency tolbutamide glipizide gliclazide gliquidone much less likely cause hypoglycaemia metabolite either inactive minimal hypoglycaemic potency metformin dependent renal excretion significantly metabolise result caution require treat patient renal insufficiency metformin accumulation occur danger lactic acidosis although correlation creatinine clearance clcr total oral clearance drug weak correlation clcr renal clearance clr metformin clear renal insufficiency associate case metformin induced lactic acidosis reason clinician general would regard raise plasma creatinine contraindication metformin treatment acarbose alpha glucosidase inhibitor relatively new agent treat niddm likely safe patient impaired renal function drug significantly absorb gut data subject lack,Harrower AD,1996,Clin Pharmacokinet,https://doi.org/10.2165/00003088-199631020-00003,8853933,Harrower AD,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,"D020909: Acarbose; D000284: Administration, Oral; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D008687: Metformin; D051437: Renal Insufficiency; D013453: Sulfonylurea Compounds; D014312: Trisaccharides",,,https://openalex.org/W2089225574,87,10,1,2281,388,12,en,en
false,effect troglitazone insulin sensitivity pancreatic cell function woman high risk niddm,conduct randomize placebo controlled study determine effect thiazolidinedione compound troglitazone whole body insulin sensitivity si pancreatic cell function glucose tolerance latino woman impaired glucose tolerance igt history gestational diabetes mellitus gdm characteristic carry risk develop niddm within year baseline oral ogtt intravenous ivgtt glucose tolerance testing subject assign take placebo mg troglitazone daily week subject per treatment group ogtt ivgtt repeat th week treatment five subject fail complete trial personal reason medication compliance average remain subject none experience serious adverse event si calculate minimal model analysis ivgtt result change week placebo administration increase basal treatment mg troglitazone respectively p among group troglitazone administration also associate dose dependent reduction total insulin area ivgtts highly significant p lt reduction ogtts approach statistical significance p glucose tolerance improve slightly group magnitude change differ significantly among group whether assess number subject continue manifest igt week p among group change total glucose area ogtts p change fractional glucose disappearance rate ivgtts p among woman receive troglitazone great improvement si occur woman high diastolic blood pressure best ivgtt insulin response baseline testing finding indicate troglitazone improve whole body insulin sensitivity lower circulate insulin concentration woman prior gdm high risk niddm lack improvement glucose tolerance despite improved insulin sensitivity may manifestation cell defect predispose woman niddm overall pattern response troglitazone high risk patient indicate drug ideal agent test whether amelioration insulin resistance delay prevent diabetes woman limited cell reserve,Berkowitz K,1996,Diabetes,https://doi.org/10.2337/diab.45.11.1572,8866563,Berkowitz K; Peters R; Kjos SL; Goico J; Marroquin A; Dunn ME; Xiang A; Azen S; Buchanan TA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D001786: Blood Glucose; D001794: Blood Pressure; D015992: Body Mass Index; D002140: California; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D002839: Chromans; D003924: Diabetes Mellitus, Type 2; D016640: Diabetes, Gestational; D004305: Dose-Response Relationship, Drug; D005230: Fatty Acids, Nonesterified; D005260: Female; D018149: Glucose Intolerance; D005951: Glucose Tolerance Test; D006630: Hispanic or Latino; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D007515: Islets of Langerhans; D010919: Placebos; D011247: Pregnancy; D018570: Risk Assessment; D012307: Risk Factors; D013844: Thiazoles; D045162: Thiazolidinediones; D014044: Tolbutamide; D014280: Triglycerides; D000077288: Troglitazone",,,https://openalex.org/W2053990917,108,17,1,2552,455,11,en,en
false,effect metabolic control second generation sulfonylurea drug patient niddm secondary failure first generation agent,literature contain data examine result therapy second generation sulfonylurea drug subject non insulin dependent diabetes mellitus niddm onset secondary failure first generation agent present study undertake assess efficacy therapy second generation sulfonylurea subject niddm follow secondary failure first generation agents study include subject niddm manifest secondary failure first generation sulfonylurea therapy subject underwent therapy second generation sulfonylurea glipizide subject treat glyburide drug administer maximum daily dosage initiation second generation sulfonylurea agent end month metabolic control assess determination fast plasma glucose glycosylated hemoglobin hba c lipid profile fasting plasma glucose hba c level mg dl respectively initiation glipizide significantly change follow therapy fast plasma glucose mg dl hba c similarly significant alteration note metabolic value glyburide group glyburide therapy fast plasma glucose mg dl hba c glyburide therapy fast plasma glucose mg dl hba c lipid also significantly alter follow therapy either glipizide glyburide finally subject fast plasma glucose hba c mg dl respectively treatment first generation drug change significantly follow therapy second generation agent fast plasma glucose mg dl hba c p value comparisons treatment second generation sulfonylurea agent patient niddm follow onset secondary failure first generation sulfonylurea drug achieve good metabolic control treatment first generation agent,Sami T,1996,J Fam Pract,,8874372,Sami T; Kabadi UM; Moshiri S,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001786: Blood Glucose; D001835: Body Weight; D002784: Cholesterol; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D008297: Male; D008875: Middle Aged; D013453: Sulfonylurea Compounds; D017211: Treatment Failure; D014280: Triglycerides",,,https://openalex.org/W1434738,146,20,1,2155,352,8,en,en
false,conference report renal disease metformin adipocyte,,Bloomgarden ZT,1996,Diabetes Care,https://doi.org/10.2337/diacare.19.9.1038,8875112,Bloomgarden ZT,article,D016423: Congress,"D017667: Adipocytes; D000818: Animals; D003920: Diabetes Mellitus; D003922: Diabetes Mellitus, Type 1; D003924: Diabetes Mellitus, Type 2; D003928: Diabetic Nephropathies; D017127: Glycation End Products, Advanced; D006031: Glycosylation; D006801: Humans; D007004: Hypoglycemic Agents; D007676: Kidney Failure, Chronic; D020738: Leptin; D008687: Metformin; D051379: Mice; D008817: Mice, Mutant Strains; D008820: Mice, Obese; D009765: Obesity; D014176: Protein Biosynthesis; D011506: Proteins",,,https://openalex.org/W2330150790,62,11,1,0,0,0,en,
true,influence multiple dosing age pharmacokinetics pharmacodynamics glipizide patient type ii diabetes mellitus,study objective determine pharmacokinetics pharmacodynamics glipizide single dose week dose patient type ii diabetes mellitus evaluate influence age design comparison single multiple dos glipizide set university affiliated outpatient internal medicine clinic diabetes care unit patient twenty patient men woman mean age yr type ii diabetes mellitus currently receive oral hypoglycemic agent hyperglycemic diet intervention hour pharmacokinetic evaluation glipizide assess mg dose start therapy week therapy pharmacokinetic parameter assess use compartmental population analysis technique glipizide pharmacodynamic evaluation assess serum glucose insulin c peptide response hour sustacal tolerance test perform baseline institute glipizide therapy first mg dose week therapy glipizide dosage titrate targeted goal fast plasma glucose mmol l less reach maximum daily dos mg measurement main result significant difference time peak concentration apparent volume distribution central peripheral compartment apparent oral clearance central compartment distributional clearance central peripheral compartment terminal elimination half life observe single dose long term dosing mean sd terminal elimination half lives hour single dose week respectively fast plasma glucose concentration decrease mmol l first dose glipizide mmol l week treatment value area serum concentration time curve zero hour glucose auc glucose significantly reduce week baseline week mmol l hr glipizide provoke increase serum insulin c peptide concentration auc insulin baseline single dose long term dose pmol l hr significant change insulin response observe single multiple dos age related difference pharmacokinetic parameter pharmacodynamic response glipizide observe conclusion long term dosing age little effect pharmacokinetic profile glipizide addition glipizide stimulates insulin secretion similar extent follow glucose challenge single dose long term administration,Jaber LA,1996,Pharmacotherapy,,8888072,Jaber LA; Ducharme MP; Edwards DJ; Slaughter RL; Grunberger G,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000367: Age Factors; D000368: Aged; D019540: Area Under Curve; D001682: Biological Availability; D001786: Blood Glucose; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005913: Glipizide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008657: Metabolic Clearance Rate; D008875: Middle Aged",,,https://openalex.org/W1567093432,141,21,1,2714,447,23,en,en
false,review safety efficacy acarbose diabetes mellitus,acarbose novel oral anti hyperglycemic agent approve treatment noninsulin dependent diabetes mellitus inhibit alpha glucosidases small intestine action delay digestion absorption complex carbohydrate subsequently small rise postprandial plasma glucose level overall decrease glycosylated hemoglobin potential advantage acarbose include great effectiveness control postprandial hyperglycemia low risk hypoglycemia possible delay initiate insulin therapy acarbose potentiate hypoglycemic effect sulfonylurea insulin associate weight gain hyperinsulinemia occur sulfonylurea insulin gastrointestinal adverse effect common acarbose may decrease continued treatment although rare elevated serum transaminase level report,Yee HS,1996,Pharmacotherapy,,8888075,Yee HS; Fong NT,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,"D020909: Acarbose; D000328: Adult; D002240: Carbohydrate Sequence; D002648: Child; D002986: Clinical Trials as Topic; D000075202: Contraindications; D003920: Diabetes Mellitus; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D004791: Enzyme Inhibitors; D005767: Gastrointestinal Diseases; D065089: Glycoside Hydrolase Inhibitors; D006801: Humans; D007004: Hypoglycemic Agents; D008969: Molecular Sequence Data; D014312: Trisaccharides",,,https://openalex.org/W2117299500,68,12,1,958,147,8,en,en
false,effect low dose tolbutamide combine glucosidase inhibitor non insulin dependent diabetes mellitus,effect add low dose sulphonylurea tolbutamide treatment patient non insulin dependent diabetes mellitus niddm investigate patient take mg tds glucosidase inhibitor orally week mg tds sulphonylurea tolbutamide last week period glycosylated haemoglobin level significantly reduce combined treatment period compare level treatment glucosidase inhibitor alone p although compare pretreatment level significant change postprandial blood glucose serum lipid level connective peptide immunoreactivities preliminary result indicate addition low dose tolbutamide recommend diet treatment glucosidase inhibitor may improve glucose metabolism without raise insulin secretion influence lipid metabolism,Okada S,1996,J Int Med Res,https://doi.org/10.1177/030006059602400505,8895047,Okada S; Ishii K; Hamada H; Tanokuchi S; Ichiki K; Ota Z,article,D016430: Clinical Trial; D016428: Journal Article,"D000368: Aged; D001786: Blood Glucose; D003238: Connective Tissue; D003924: Diabetes Mellitus, Type 2; D004791: Enzyme Inhibitors; D006442: Glycated Hemoglobin; D065089: Glycoside Hydrolase Inhibitors; D006801: Humans; D007004: Hypoglycemic Agents; D007150: Immunohistochemistry; D007294: Inositol; D008055: Lipids; D008875: Middle Aged; D010455: Peptides; D014044: Tolbutamide",,,https://openalex.org/W1922995903,128,18,1,951,155,5,en,en
false,metformin effect glucose lipid metabolism patient secondary failure sulfonylureas,objective compare result obtain metformin versus obtain dna recombinant insulin obese patient niddm suffer secondary failure sulfonylureas research design method conduct open prospective randomize comparative study comprise total patient select place two parallel group previously confirm subject secondary failure high dos sulfonylurea initial metformin dosage single mg tablet dosage increase two three tablet depend patient metabolic change initial dosage dna recombinant insulin u subcutaneously administer divide two portion two thirds around breakfast remain third p dinner dosage adjust base patient clinical metabolic response result initial average glucose value metformin group mg dl decrease end study mg dl insulin group figure go mg dl beginning study mg dl decrease correlate reduction glycosylated hemoglobin first group second well reduction triglyceride value mg dl mg dl respectively bmi blood pressure systolic mmhg diastolic mmhg total cholesterol level mg dl decrease metformin group conclusion metformin effective safe well tolerated treatment improve metabolic control favorably modifies secondary clinical alteration due insulin resistance arterial hypertension overweight hyperlipidemia obese patient niddm suffer secondary failure sulfonylurea,Fanghänel G,1996,Diabetes Care,https://doi.org/10.2337/diacare.19.11.1185,8908377,Fanghänel G; Sánchez-Reyes L; Trujillo C; Sotres D; Espinosa-Campos J,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D001786: Blood Glucose; D015992: Body Mass Index; D002096: C-Peptide; D002784: Cholesterol; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008055: Lipids; D008297: Male; D008687: Metformin; D008875: Middle Aged; D009765: Obesity; D011994: Recombinant Proteins; D012044: Regression Analysis; D013453: Sulfonylurea Compounds; D017211: Treatment Failure; D014280: Triglycerides",,,https://openalex.org/W2019146531,103,15,1,1965,340,11,en,en
true,glimepiride new daily sulfonylurea double blind placebo controlled study niddm patient,objective compare efficacy safety two daily dos new sulfonylurea glimepiride amaryl daily dose two divided dos patient niddm research design method previously treat niddm patient enter multicenter randomize double blind placebo controlled fixed dose study week placebo washout patient receive week course placebo glimepiride mg q mg b mg q mg b result fast plasma glucose fpg hba c value similar baseline treatment group placebo group fpg value increase mmol l baseline mmol l last evaluation endpoint p contrast fpg value four glimepiride group decrease range mmol l baseline range mmol l endpoint p within group change baseline p group change vs placebo baseline two hour postprandial plasma glucose ppg finding consistent fpg finding placebo group hba c value increase baseline endpoint p whereas hba c value glimepiride group baseline endpoint p within group change baseline p group change baseline meaningful difference glycemic variable daily dos mg twice daily dosing adverse event laboratory data demonstrate glimepiride favorable safety profile conclusion glimepiride effective well tolerated oral glucose lowering agent result study demonstrate maximum effectiveness achieve mg q glimepiride niddm subject,Rosenstock J,1996,Diabetes Care,https://doi.org/10.2337/diacare.19.11.1194,8908379,Rosenstock J; Samols E; Muchmore DB; Schneider J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D019518: Postprandial Period; D013453: Sulfonylurea Compounds; D013997: Time Factors",,,https://openalex.org/W1994860175,101,14,1,1810,332,13,en,en
false,american diabetes association annual meeting etiology type ii diabetes obesity treatment type ii diabetes,,Bloomgarden ZT,1996,Diabetes Care,https://doi.org/10.2337/diacare.19.11.1311,8908409,Bloomgarden ZT,article,D016423: Congress,"D000818: Animals; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006801: Humans; D006937: Hypercholesterolemia; D006973: Hypertension; D009765: Obesity; D011247: Pregnancy; D011254: Pregnancy in Diabetics; D012307: Risk Factors; D015431: Weight Loss",,,https://openalex.org/W2332951925,131,23,1,0,0,0,en,
false,acarbose role treatment diabetes mellitus,objective review clinical pharmacology acarbose alpha glucosidase inhibitor summarize role pharmacotherapy diabetes mellitus data source medline search identify relevant article include review bayer pharmaceutical study selection due large number clinical trial available specific criterion use narrow focus review randomize double blind placebo controlled parallel group study design minimum patient enrolled per treatment arm treatment duration day adherence food drug administration good clinical practice guideline data extraction clinical trial available december review preliminary trial unpublished report review data synthesis acarbose effective reduce postprandial hyperglycemia stimulate endogenous insulin secretion therefore cause hypoglycemia use monotherapy enhanced glycemic control achieve acarbose additive sulfonylurea lower postprandial serum glucose insulin concentration promote weight gain acarbose use first line therapy diet exercise use combination sulfonylurea lower hemoglobin lc concentration additional acarbose cure diabetes substitute diet exercise oral hypoglycemic agent insulin adverse effect gastrointestinal diminish start initial dosage mg tid depend patient response dosage increase maximum mg tid time conclusion acarbose unique mechanism action appear safe effective adjunctive agent diet exercise therapy sulfonylurea therapy treatment non insulin dependent diabetes mellitus,Campbell LK,1996,Ann Pharmacother,https://doi.org/10.1177/106002809603001110,8913408,Campbell LK; White JR; Campbell RK,article,D016428: Journal Article; D016454: Review,"D020909: Acarbose; D003924: Diabetes Mellitus, Type 2; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D016032: Randomized Controlled Trials as Topic; D014312: Trisaccharides",,,https://openalex.org/W2151898117,56,10,1,1944,336,14,en,en
false,comparison different insulin regimen elderly patient niddm,objective compare metabolic effect three different frequently use regimen insulin administration blood glucose control serum lipid cost associate treatment subject niddm poorly control oral antihyperglycemic agent research design method study elderly patient niddm age year bmi kg median time since diagnosis diabetes year range men woman poorly control despite diet maximal dos oral antihyperglycemic agent three insulin administration regimen compare month period patient randomize treatment two injection scheme regimen combination glibenclamide one injection nph insulin administer either bedtime regimen b breakfast regimen c insulin treatment mainly institute outpatient setting result month insulin treatment fast blood glucose total patient population decrease average mmol l p lt hba c fell p lt patient reach hba c level even two insulin injection daily hba c decrease combined treatment hba c fell regimen b regimen c comparable improvement measure glycemic control lipid lipoprotein observe different treatment regimen body weight increase moderate mean kg similar patient group one third patient start one insulin injection daily need second injection control glycemia one episode severe hypoglycemia observe combine insulin sulfonylurea treatment almost expensive twice daily administration insulin alone conclusion insulin treatment safely institute elderly patient niddm however difficult obtain optimal glycemic control insulin moderate beneficial effect serum lipoprotein although basis glycemic control weight gain preference treatment regimen discern twice daily insulin administration simple cost effective regimen,Wolffenbuttel BH,1996,Diabetes Care,https://doi.org/10.2337/diacare.19.12.1326,8941458,Wolffenbuttel BH; Sels JP; Rondas-Colbers GJ; Menheere PP; Nieuwenhuijzen Kruseman AC,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D016632: Apolipoprotein A-I; D001055: Apolipoproteins B; D001786: Blood Glucose; D002096: C-Peptide; D002784: Cholesterol; D008076: Cholesterol, HDL; D003365: Costs and Cost Analysis; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D005230: Fatty Acids, Nonesterified; D005260: Female; D019270: Fructosamine; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007515: Islets of Langerhans; D008055: Lipids; D017270: Lipoprotein(a); D008297: Male; D009426: Netherlands; D014280: Triglycerides",,,https://openalex.org/W1987371339,71,10,1,2400,446,14,en,en
false,new treatment patient type diabetes mellitus,summary subject type diabetes defect insulin secretion insulin resistance contribute development hyperglycaemia major goal treatment optimise blood glucose control normalise associate lipid disturbance elevate blood pressure pharmacologic treatment often necessary paper discuss new form oral treatment subject type diabetes include new sulphonylurea compound glimepiride amaryl bind different protein putative sulphonylurea receptor glibenclamide seem low risk hypoglycaemia new class drug insulin secretory capacity repaglinide novonorm lead compound phase iii clinical trial alpha glucosidase inhibitor reversibly inhibit alpha glucosidase enzyme small intestine delay cleavage oligo disaccharide monosaccharide lead delayed reduced blood glucose rise meal two compound development market ie miglitol acarbose glucobay another new class drug thiazolidine diones seem work enhance insulin action insulin sensitise effect lead compound troglitazone brl c involve effect insulin secretion drug also seem beneficially influence serum cholesterol triglyceride level oral antihyperglycaemic agent use limited period time patient diabetic state worsens insulin therapy start light two new form treatment require subcutaneous injection also discuss synthetic human amylin analogue ac pramlintide glucagon like peptide amide strong glucose dependent stimulator insulin secretion remain see whether compound develop far clinical use patient diabetes,Wolffenbuttel BH,1996,Postgrad Med J,https://doi.org/10.1136/pgmj.72.853.657,8944206,Wolffenbuttel BH; Graal MB,article,D016428: Journal Article; D016454: Review,"D000682: Amyloid; D003924: Diabetes Mellitus, Type 2; D005934: Glucagon; D052216: Glucagon-Like Peptide 1; D065089: Glycoside Hydrolase Inhibitors; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007333: Insulin Resistance; D000078790: Insulin Secretion; D058228: Islet Amyloid Polypeptide; D010446: Peptide Fragments; D011498: Protein Precursors; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2135084189,57,9,1,1989,336,15,en,en
true,uk prospective diabetes study,diabetes control complication study show improved blood glucose control would delay progress microvascular complication diabetes however patient non insulin dependent diabetes mellitus major morbidity mortality arises premature cardiovascular disease uncertain whether therapy aim improve diabetes control prevent cardiovascular complication whether available therapy sulphonylurea biguanides insulin may even long term deleterious side effects uk prospective diabetes study start evaluate whether long term therapy improve glucose control would advantageous clinical practice study demonstrate difficult maintain improved glucose control progressive cell dysfunction study also evaluate whether improve control hypertension would advantageous progress study summarize result expect publish,Turner RC,1996,Ann Med,https://doi.org/10.3109/07853899608999105,8949976,Turner RC; Holman RR,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000368: Aged; D002318: Cardiovascular Diseases; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D006801: Humans; D006973: Hypertension; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D007515: Islets of Langerhans; D008687: Metformin; D008875: Middle Aged; D009765: Obesity; D011446: Prospective Studies; D011788: Quality of Life; D012307: Risk Factors; D013453: Sulfonylurea Compounds; D006113: United Kingdom; D015430: Weight Gain",,,https://openalex.org/W1994466416,33,5,1,1021,154,8,en,en
true,pharmacokinetics safety glimepiride clinically effective dos diabetic patient renal impairment,pharmacokinetics efficacy safety glimepiride investigate single multiple dose open study patient non insulin dependent diabetes mellitus renal impairment initial creatinine clearance ml min patient divide three group creatinine clearance ml min ml min ml min fifteen fast patient receive single dose mg glimepiride serial blood urine sample take h pharmacokinetic efficacy analysis patient receive glimepiride month period initial dose mg glimepiride adjust within range mg achieve good glucose control pharmacokinetic evaluation day month mean relative total clearance mean volume distribution single ml min litre respectively creatinine clearance ml min multiple dos glimepiride increase proportion degree renal impairment ml min litre respectively creatinine clearance ml min single dose whereas terminal halflife mean time remain unchanged lower relative total clearance renal clearance glimepiride metabolite correlate significantly low creatinine clearance value patient require mg glimepiride stabilize fasting blood glucose glimepiride well tolerated drug related adverse event conclusion glimepiride safe effective clearly definable pharmacokinetics diabetic patient renal impairment increased plasma elimination glimepiride decrease kidney function explainable basis altered protein bind increase unbound drug,Rosenkranz B,1996,Diabetologia,https://doi.org/10.1007/s001250050624,8960852,Rosenkranz B; Profozic V; Metelko Z; Mrzljak V; Lange C; Malerczyk V,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D000368: Aged; D015331: Cohort Studies; D003404: Creatinine; D003924: Diabetes Mellitus, Type 2; D003928: Diabetic Nephropathies; D005260: Female; D006207: Half-Life; D006801: Humans; D007004: Hypoglycemic Agents; D007668: Kidney; D008297: Male; D008875: Middle Aged; D012044: Regression Analysis; D012449: Safety; D013453: Sulfonylurea Compounds; D013997: Time Factors",,,https://openalex.org/W2044398229,115,15,1,1841,299,11,en,en
true,niddm rapid progressive disease result long term randomise comparative study insulin sulphonylurea treatment,objective present study assess relative efficacy insulin glibenclamide treatment non insulin dependent diabetes mellitus niddm month perform randomise control trial allocate patient treat diet oral antihyperglycaemic agent treatment glibenclamide insulin achieve hbalc level include subject establish niddm year duration mean hbalc level significantly reduce patient allocate insulin treatment start p year change significantly thereafter throughout study period mean hbalc level increase study patient allocate glibenclamide treatment patient switch insulin treatment due increase hyperglycaemia hbalc mean body weight increase subject allocate insulin kg study period conclusion insulin effective glibenclamide treatment obtain control hyperglycaemia patient improve glycaemic control deteriorate month insulin treated group two third patient allocate glibenclamide treatment give insulin due inadequate glycaemic control,Birkeland KI,1996,Diabetologia,https://doi.org/10.1007/s001250050626,8960854,Birkeland KI; Rishaug U; Hanssen KF; Vaaler S,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001786: Blood Glucose; D001835: Body Weight; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008055: Lipids; D008297: Male; D008875: Middle Aged; D013453: Sulfonylurea Compounds; D013997: Time Factors",,,https://openalex.org/W1974501150,128,20,1,1362,232,8,en,en
false,blockade katp channel glibenclamide abolish precondition demand ischemia,patient coronary artery disease cad clinical evidence short term adaptation ischemia manifestation adaptation occurrence angina pectoris exertion disappear exertion continue sometimes term warm phenomenon mcalpin r kattus adaptation exercise angina pectoris electrocardiogram treadmill walk coronary angiographic finding circulation crossref scopus google scholar adaptation also describe experimental condition include increase exercise time onset angina second exercise treadmill test ett shortly follow initial ett increase tolerance atrial pacing initial warm pacing episode mcalpin r kattus adaptation exercise angina pectoris electrocardiogram treadmill walk coronary angiographic finding circulation crossref scopus google scholar williams bass gewirtz h adaptation stress tachycardia patient coronary artery disease insight mechanism warm phenomenon circulation crossref pubmed scopus google scholar observation may reflect ischemic preconditioning brief ischemic episode protects subsequent ischemic episode van winkle chien g wolff r soifer b kuzume k davis r cardioprotection provide adenosine receptor activation abolish blockade katp channel j physiol h h google scholar kloner r yellon ischemic precondition occur patient j coll cardiol abstract full text pdf pubmed scopus google scholar liu g thornton j vanwinkle dm stanley awh olsson ra downey jm protection infarction afford precondition mediate adenosine receptor rabbit heart circulation crossref pubmed scopus google scholar deutsch e berger kussmaul kg hirshfeld jw herrmann hc laskey wk adaptation ischemia percutaneous transluminal coronary angioplasty circulation crossref pubmed scopus google scholar whereas role opening adenosine triphosphate atp dependent potassium channel katp channel preconditioning suggest study show blockade katp channel use glibenclamide limit effect precondition animal adaptive response coronary artery occlusion man kloner r yellon ischemic precondition occur patient j coll cardiol abstract full text pdf pubmed scopus google scholar tomai f crey f gaspardone ischemic preconditioning coronary angioplasty prevent glibenclamide selective atp sensitive k channel blocker circulation crossref pubmed scopus google scholar carmeliet e storm l vereecke j atp ddependent k dchannel zipes jalife j cardiac electrophysiology cell bedside wb saunders philadelphia google scholar speechly dick grover gj yellon dm ischemic preconditioning human involve protein kinase c atp dependent k channel circ crossref pubmed scopus google scholar experiment evaluate role katp channel short term adaptation demand ischemia therefore purpose study test hypothesis opening katp channel mechanism adaptation demand ischemia sequential ett atrial pacing patient coronary artery disease,Correa SD,1997,Am J Cardiol,https://doi.org/10.1016/s0002-9149(96)00681-9,9024742,Correa SD; Schaefer S,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000222: Adaptation, Physiological; D000255: Adenosine Triphosphate; D000368: Aged; D002304: Cardiac Pacing, Artificial; D004311: Double-Blind Method; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D015221: Potassium Channels",,,https://openalex.org/W2101122893,100,13,1,3730,661,28,en,en
false,comparative study efficiency ultralente insulin nph insulin combine sulfonylurea type diabetes patient secondary tolerance sulfonylurea possible selection criterion,treatment niddm patient secondary failure sulfonylurea still debated problem study compare niddm patient secondary failure glyburide effect add single low dose bed time either nph ultralent insulin injection u kg previously ineffective sulfonylurea treatment nph ultralent insulin therapy demonstrate effective ameliorate metabolic control niddm patient secondary failure sulfonylurea however addition bed time ultralent insulin cause great significant decrease post prandial plasma glucose contrast average fasting plasma glucose decrease significantly great nph insulin administration result indicate niddm patient secondary failure glyburide bed time ultralent insulin administration good tool improve post prandial plasma glucose,Sangiorgio L,1996,Minerva Endocrinol,,9026680,Sangiorgio L; Rabuazzo MA; Cordaro G; Grasso G; Condorelli L; Lunetta M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D001786: Blood Glucose; D002096: C-Peptide; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D004361: Drug Tolerance; D004435: Eating; D005215: Fasting; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007336: Insulin, Isophane; D049528: Insulin, Long-Acting; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome",,,https://openalex.org/W2416495162,201,31,2,942,147,6,en,en
false,eprosartan angiotensin ii receptor antagonist affect pharmacodynamics glyburide patient type ii diabetes mellitus,potential eprosartan nonbiphenyl tetrazole angiotensin ii receptor antagonist affect hour plasma glucose profile type ii diabetic patient treat glyburide investigate randomized placebo controlled double blind eprosartan placebo phase two period period balanced crossover study patient receive stable oral dose mg day glyburide least day first dose double blind study medication administer patient randomize receive either mg oral dos eprosartan twice daily match oral placebo dos concomitantly glyburide day treatment period minimum washout period day patient cross alternate treatment serial sample measure glucose concentration plasma collect hour period day administration eprosartan placebo day mean glucose concentration comparable treatment group administration eprosartan placebo point estimate confidence interval ratio average mean hour plasma glucose concentration eprosartan glyburide placebo glyburide day administration eprosartan significantly alter hour plasma glucose profile patient type ii diabetes mellitus previously stabilize glyburide,Martin DE,1997,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1997.tb04774.x,9055142,Martin DE; DeCherney GS; Ilson BE; Jones BA; Boike SC; Freed MI; Jorkasky DK,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000179: Acrylates; D057911: Angiotensin Receptor Antagonists; D000959: Antihypertensive Agents; D001786: Blood Glucose; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004347: Drug Interactions; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007093: Imidazoles; D008297: Male; D008875: Middle Aged; D013546: Sweating; D013876: Thiophenes",,,https://openalex.org/W1983738034,143,22,1,1460,235,8,en,en
false,short term effect continuous subcutaneous insulin infusion treatment insulin secretion non insulin dependent overweight patient poor glycaemic control despite maximal oral anti diabetic treatment,difficult treat obese non insulin dependent diabetic patient nidds whose glycaemic control remain poor despite maximal oral antidiabetic therapy study effect continuous subcutaneous insulin infusion csii associate low calorie diet metformin mg day glycaemic control basal stimulate insulin secretion series overweight nidd csii csii withdrawal patient treat day mean amount iu kg day glycaemic control good day csii remain good fast postprandial plasma c peptide level decrease significantly fast c peptide similar postprandial c peptide significantly high molar fasting postprandial plasma c peptide glycaemia ratio increase significantly glucagon injection molar delta c peptide glycaemia ratio significantly increase even high significant correlation fast postprandial c peptide level glucagon induced c peptide peak fasting postprandial c peptide level weight change correlate significantly molar fasting c peptide glycaemia ratio twenty nine patient ratio x lose weight length csii treatment correlate weight change biological parameter study show csii moderate amount insulin associate low calorie diet metformin provide rapid glycaemic control lead weight loss maintain regulation insulin secretion seem improve insulin secretion sensitivity result obtain day,Valensi P,1997,Diabetes Metab,,9059766,Valensi P; Moura I; Le Magoarou M; Pariès J; Perret G; Attali JR,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000279: Administration, Cutaneous; D000284: Administration, Oral; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001786: Blood Glucose; D001835: Body Weight; D002096: C-Peptide; D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006801: Humans; D007263: Infusions, Parenteral; D007328: Insulin; D000078790: Insulin Secretion; D008297: Male; D008875: Middle Aged; D009765: Obesity; D012636: Secretory Rate; D013997: Time Factors",,,https://openalex.org/W2401965127,212,25,1,1855,326,14,en,en
false,study potential effect sertraline pharmacokinetics protein binding tolbutamide,effect selective serotonin reuptake inhibitor ssri sertraline mg day metabolism intravenously administer tolbutamide examine randomised nonblinded parallel group study healthy male volunteer small statistically significant decrease clearance tolbutamide patient receive maximum recommend dosage sertraline terminal elimination rate constant also significantly reduce correspond increase terminal elimination half life hour decrease clearance associate significant change plasma protein binding apparent volume distribution tolbutamide suggest change tolbutamide clearance may due slight inhibition cytochrome p cyp isoenzyme cyp c sertraline administer maximum recommended dosage however small change volume distribution plasma binding tolbutamide sertraline treatment indicate minimal interaction sertraline tolbutamide,Tremaine LM,1997,Clin Pharmacokinet,https://doi.org/10.2165/00003088-199700321-00005,9068933,Tremaine LM; Wilner KD; Preskorn SH,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D015057: 1-Naphthylamine; D000293: Adolescent; D000328: Adult; D000928: Antidepressive Agents; D001189: Aryl Hydrocarbon Hydroxylases; D001798: Blood Proteins; D065729: Cytochrome P-450 CYP2C9; D065607: Cytochrome P-450 Enzyme Inhibitors; D004357: Drug Synergism; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D006899: Mixed Function Oxygenases; D011485: Protein Binding; D017367: Selective Serotonin Reuptake Inhibitors; D020280: Sertraline; D039181: Steroid 16-alpha-Hydroxylase; D013250: Steroid Hydroxylases; D014044: Tolbutamide,,,https://openalex.org/W1993311073,104,16,1,1127,178,6,en,en
false,increased complication noninsulin dependent diabetic patient treat insulin versus oral hypoglycemic agent population study,cross sectional population study perform cohort non insulin dependent diabetes mellitus niddm patient reside great denver metropolitan region purpose evaluate relationship insulin oral hypoglycemic agent ohas regard metabolic control diabetic complication mean glycosylated hemoglobin patient treat insulin versus p oha difference fast blood sugar insulin treated group mg dl versus oha treated group mg dl statistically significant categorical increase urinary albumin excretion associate positively within insulin versus oha therapy p patient treat insulin therapy high frequency peripheral vascular disease insulin therapy oha therapy p neuropathy insulin therapy oha therapy p retinopathy insulin therapy oha therapy p frequency cardiovascular disease equivalent two group versus protocol correct diabetes duration glycosylated hemoglobin gender multivariate model use insulin still relate significantly increase urinary albumin excretion p retinopathy p neuropathy p subgroup individual diabetes duration year n insulin treatment n oha treatment frequency neuropathy still significantly high insulin group vs p retinopathy vs p overt albuminuria also significant insulin treated patient p summary niddm patient treat insulin nephropathy retinopathy neuropathy niddm patient treat oha independent duration diabetes fast blood glucose glycosylated hemoglobin age blood pressure level result niddm patient may due contribution bad blood glucose control early stage patient diabetes mitogenic atherogenic thrombogenic vascular permeability effect insulin,Savage S,1997,Proc Assoc Am Physicians,,9069587,Savage S; Estacio RO; Jeffers B; Schrier RW,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000284: Administration, Oral; D000368: Aged; D000419: Albuminuria; D001786: Blood Glucose; D015331: Cohort Studies; D003430: Cross-Sectional Studies; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D003928: Diabetic Nephropathies; D003929: Diabetic Neuropathies; D003930: Diabetic Retinopathy; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies",,,https://openalex.org/W67545546,139,18,1,2245,435,12,en,en
false,drug interaction rifampicin glibenclamide,rifampicin potent inducer hepatic microsomal enzyme system however drug show cause clinically important interaction many drug study design test interaction rifampicin oral hypoglycaemic agent glibenclamide twenty nine well controlled diabetic patient combination therapy diet glibenclamide willing participate trial receive daily dose mg body weight kg mg body weight kg rifampicin days significant p worsening fast post prandial blood sugar administration rifampicin dose modification glibenclamide require patient diabetes become uncontrolled blood sugar normalize day stop rifampicin patients rifampicin glibenclamide interact therefore necessary dose modification make order achieve euglycaemia two drug give together,Surekha V,1997,Natl Med J India,,9069698,Surekha V; Peter JV; Jeyaseelan L; Cherian AM,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000904: Antibiotics, Antitubercular; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004347: Drug Interactions; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D012293: Rifampin",,,https://openalex.org/W101149224,47,7,1,1001,167,6,en,en
false,novel mody mutation hepatocyte nuclear factor gene evidence hyperexcitability pancreatic cells intravenous secretagogues glucose tolerant carrier p l mutation,one form maturity onset diabetes young mody result mutation hepatocyte nuclear factor hnf alpha gene locate chromosome q primary objective present study search genetic variation hnf alpha gene nine nonrelated danish caucasian subject mody direct sequencing cod region intron exon boundary hnf alpha gene reveal novel previously report missense mutation novel frameshift mutation five nine mody subject five mutation find neither niddm patient control subject one glucose tolerant lean male p l missense mutation relative cause mody undergo oral glucose tolerance test ogtt tolbutamide modify frequently sample intravenous glucose tolerance test glucagon test examine possible early beta cell abnormality low insulin secretion rate ogtt twofold increase pancreatic beta cell response intravenous glucose fold increase beta cell response either intravenous tolbutamide intravenous glucagon load conclusion mutation hnf alpha gene common danish caucasian mody patient early stage pathogenesis mody cause p l mutation may characterize hyperexcitability beta cells intravenous secretagogues,Hansen T,1997,Diabetes,https://doi.org/10.2337/diab.46.4.726,9075819,Hansen T; Eiberg H; Rouard M; Vaxillaire M; Møller AM; Rasmussen SK; Fridberg M; Urhammer SA; Holst JJ; Almind K; Echwald SM; Hansen L; Bell GI; Pedersen O,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D001786: Blood Glucose; D004268: DNA-Binding Proteins; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005951: Glucose Tolerance Test; D051537: Hepatocyte Nuclear Factor 1; D051538: Hepatocyte Nuclear Factor 1-alpha; D051539: Hepatocyte Nuclear Factor 1-beta; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D009154: Mutation; D009687: Nuclear Proteins; D010375: Pedigree; D014044: Tolbutamide; D014157: Transcription Factors",,,https://openalex.org/W2114076638,197,28,1,1439,240,7,en,en
false,sulfonylurea treatment prevents recurrence hyperglycemia obese african american patient history hyperglycemic crisis,objective many newly diagnose obese african american patient history severe hyperglycemia diabetic ketoacidosis dka able discontinue pharmacological treatment continued good metabolic control however many individual relapse hyperglycemia within year patient compare effect low dose sulfonylurea dietary therapy prevention recurrence hyperglycemia research design method conduct intention treat study obese newly diagnose diabetic patient dka severe hyperglycemia discontinuation insulin seven patient dka seven patient hyperglycemia manage diet glyburide mg day whereas patient follow diet alone patient pancreatic insulin reserve documented day resolution hyperglycemic crisis within week discontinuation insulin recurrence hyperglycemia define fast blood glucose gt mmol l mg dl random blood glucose gt mmol l mg dl two consecutive determination hba c gt result treatment group comparable age sex duration diabetes month insulin therapy bmi glucose hba c presentation acute c peptide response glucagon obese dka patient low patient hyperglycemia p lt response comparable discontinuation insulin sulfonylurea treatment significantly reduce recurrence hyperglycemia obese dka obese hyperglycemic patient p median follow month hyperglycemia recur six dka patient five hyperglycemia patient treat diet alone compare one seven dka one seven hyperglycemia patient treat glyburide readmission metabolic decompensation occur four patient treat diet none patient treat diet glyburide conclusion low dose sulfonylurea therapy prevents recurrence hyperglycemia newly diagnose obese african american patient history hyperglycemic crisis,Umpierrez GE,1997,Diabetes Care,https://doi.org/10.2337/diacare.20.4.479,9096964,Umpierrez GE; Clark WS; Steen MT,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001741: Black or African American; D044383: Black People; D001786: Blood Glucose; D002096: C-Peptide; D003131: Combined Modality Therapy; D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D016883: Diabetic Ketoacidosis; D003927: Diet, Diabetic; D005260: Female; D005845: Georgia; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D007515: Islets of Langerhans; D008297: Male; D008875: Middle Aged; D009765: Obesity; D012008: Recurrence",,,https://openalex.org/W2059590461,133,16,1,2230,382,13,en,en
true,efficacy safety dose response characteristic glipizide gastrointestinal therapeutic system glycemic control insulin secretion niddm result two multicenter randomize placebo controlled clinical trial,investigate efficacy safety dose response characteristic extended release preparation glipizide use gastrointestinal therapeutic system git plasma glucose glycosylated hemoglobin hba c insulin secretion liquid mixed meal niddm patients two prospective randomize double blind placebo controlled multicenter clinical trial perform site patient niddm aged year bmi kg know diabetes duration year study clinical trial duration week week washout week single blind placebo phase week titration fix dose week maintenance phase assigned dose first trial daily dos mg glipizide git compare placebo patient second trial dos mg glipizide git compare placebo patient hba c fast plasma glucose fpg insulin c peptide glipizide level determine regular interval throughout study postprandial plasma glucose ppg insulin c peptide also determine h mixed meal sustacal dos glipizide git trial produce significant reduction placebo fpg range mg dl hba c range pharmacodynamic analysis indicate significant relationship plasma glipizide concentration reduction fpg hba c dose range mg maximal efficacy achieve dose mg fpg mg hba c ppg level significantly low postprandial insulin c peptide level significantly high patient treat glipizide git compare placebo percent reduction fpg comparable across patient diverse demographic clinical characteristic include entry fpg mg dl result great absolute decrease fpg hba c patient severe hyperglycemia despite forced titration randomly assign dose patient study discontinue therapy hypoglycemia glipizide git alter lipid level produce weight gain daily glipizide git lower hba c fpg ppg dose range mg maximally effective mg use hba c mg use fpg base pharmacokinetic pharmacodynamic relationship maintain effectiveness poorly control patient entry fpg mg dl safe well tolerate wide variety patient niddm produce weight gain adversely affect lipid,Simonson DC,1997,Diabetes Care,https://doi.org/10.2337/diacare.20.4.597,9096986,Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001786: Blood Glucose; D002096: C-Peptide; D003692: Delayed-Action Preparations; D003924: Diabetes Mellitus, Type 2; D004064: Digestive System; D004305: Dose-Response Relationship, Drug; D005215: Fasting; D005260: Female; D005913: Glipizide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D000078790: Insulin Secretion; D008297: Male; D008875: Middle Aged; D010919: Placebos; D016037: Single-Blind Method; D013997: Time Factors",,,https://openalex.org/W2061936289,227,31,1,2717,504,11,en,en
false,duration action pharmacokinetics oral antidiabetic drug gliquidone patient non insulin dependent type diabetes mellitus,duration action pharmacokinetics gliquidone cyclohexyl dihydro methoxy dimethyl dioxo h isochinolyl ethyl phenyl sulfonyl urea ar df se cas glurenorm beglynor investigate patient non insulin dependent type diabetes mellitus h single blinded cross design vs placebo one mg tablet gliquidone administer min breakfast concomitant measurement glucose insulin gliquidone plasma level subject determine new specific liquid chromatographic hplc assay method fluorescence detection pharmacokinetic parameter calculate follow gliquidone administration mean plasma glucose profile responder low placebo p p represent duration blood sugar lowering effect h insulin value raise peak high shortly meal subsequently insulin level return approximately level obtain placebo postprandial phase plasma concentration gliquidone show pronounced interindividual variability mean maximum concentration plasma cmax microgram ml range micrograms ml coefficient variation cv median time reach maximum plasma concentration tmax h range h area plasma concentration time curve zero time infinity auc infinity mean terminal elimination half lives beta compute patient n exhibit least five plasma level limit quantitation terminal log linear phase use two compartment model mean auc infinity micrograms h ml range micrograms h ml cv dominant half life alpha derive therapeutically relevant plasma level gliquidone ng ml approximately h range h cv mean terminal half life beta approximately h range h cv pharmacodynamic behavior well pharmacokinetic parameter deduce gliquidone belongs class short acting sulfonylurea use antidiabetic therapy,von Nicolai H,1997,Arzneimittelforschung,,9105542,von Nicolai H; Brickl R; Eschey H; Greischel A; Heinzel G; König E; Limmer J; Rupprecht E,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D019540: Area Under Curve; D001786: Blood Glucose; D002138: Calibration; D002851: Chromatography, High Pressure Liquid; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006207: Half-Life; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D011786: Quality Control; D016037: Single-Blind Method; D013050: Spectrometry, Fluorescence; D013453: Sulfonylurea Compounds",,,https://openalex.org/W1660847917,147,22,1,2349,417,10,en,en
false,metformin hydrochloride antihyperglycemic agent,pharmacology pharmacokinetics clinical efficacy adverse effect drug interaction dosage administration metformin hydrochloride review metformin antihyperglycemic agent lower blood glucose concentration without cause hypoglycemia propose mechanism action include decrease intestinal absorption glucose increase glucose uptake blood tissue decrease glucose production liver decrease insulin requirement glucose disposal metformin slowly absorb small intestine undergo hepatic metabolism half life five hour major route elimination renal drug contraindicate patient impaired renal function double blind placebo controlled trial metformin show efficacy treatment non insulin dependent diabetes mellitus niddm drug effective sulfonylurea patient diabetes nonobese obese whose diabetes uncontrolled diet alone metformin may useful addon therapy obese patient diabetes uncontrolled sulfonylurea diet lipid profile may favorably influence common adverse effect gastrointestinal rare potentially fatal adverse effect lactic acidosis metformin potential interact cationic drug eliminate renal tubular pathway usual effective dosage g day orally two three divide dos metformin hydrochloride effective alternative sulfonylureas obese non obese patient niddm diet alone achieve glycemic control may useful addon therapy patient whose diabetes respond adequately sulfonylureas plus dietary measure,Klepser TB,1997,Am J Health Syst Pharm,https://doi.org/10.1093/ajhp/54.8.893,9114921,Klepser TB; Kelly MW,article,D016428: Journal Article; D016454: Review,"D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D004347: Drug Interactions; D005260: Female; D005947: Glucose; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin",,,https://openalex.org/W2345930727,51,6,1,1799,285,15,en,en
true,efficacy safety miglitol therapy compare glibenclamide patient niddm inadequately control diet alone,compare therapeutic effect alpha glucosidase inhibitor miglitol bay sulfonylurea glibenclamide placebo parameter metabolic control safety patient niddm inadequately control diet alone week placebo run period patient center country randomize double blind manner miglitol mg follow mg glibenclamide mg q b placebo week efficacy criterion change baseline hba c fast postprandial blood glucose insulin level body weight serum triglycerides efficacy assess patient complete full protocol result similar obtain patient fulfil validity criterion analysis compare placebo mean baseline adjusted hba c decrease p p miglitol glibenclamide treatment group respectively blood glucose decrease slightly fasting state considerably postprandial state treatment group placebo group fast insulin level increase slightly n treatment group however postprandial insulin level decrease miglitol increase markedly glibenclamide p treatment group gastrointestinal side effect flatulence diarrhea occur mostly miglitol treated patient glibenclamide treated patient symptom suggestive hypoglycemia miglitol monotherapy effective safe niddm patient compare glibenclamide reduce hba c less effectively cause gastrointestinal side effect hand glibenclamide unlike miglitol tend cause hypoglycemia hyperinsulinemia weight gain desirable patient niddm,Segal P,1997,Diabetes Care,https://doi.org/10.2337/diacare.20.5.687,9135927,Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D017485: 1-Deoxynojirimycin; D000328: Adult; D000368: Aged; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D003967: Diarrhea; D003927: Diet, Diabetic; D004311: Double-Blind Method; D004791: Enzyme Inhibitors; D005215: Fasting; D005260: Female; D005414: Flatulence; D005944: Glucosamine; D005905: Glyburide; D006442: Glycated Hemoglobin; D065089: Glycoside Hydrolase Inhibitors; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D050112: Imino Pyranoses; D008297: Male; D008875: Middle Aged; D010919: Placebos; D019518: Postprandial Period",,,https://openalex.org/W1980062765,132,19,1,1893,318,10,en,en
false,comparative effect glibenclamide metformin ambulatory blood pressure cardiovascular reactivity niddm,compare effect chronic glibenclamide metformin therapy blood pressure bp cardiovascular responsiveness patient niddm fourteen patient niddm receive metformin glibenclamide month double blind randomize crossover study end treatment period patient test forearm vascular responsiveness intrabrachial arterial infusion diazoxide atp sensitive potassium channel opener acetylcholine sodium nitroprusside norepinephrine bp response intravenous infusion ne angiotensin ii bp response cold pressor test isometric exercise h ambulatory bp monitoring metformin glibenclamide produce similar glycemic control mean h bps differ two group mean h heart rate significantly low bpm vs bpm glibenclamide therapy metformin plasma norepinephrine level significantly high glibenclamide vs mmol l p systolic bp response intravenous norepinephrine angiotensin ii significantly high glibenclamide metformin p p respectively systolic bp response cold pressor test appear high glibenclamide metformin difference quite achieve statistical significance p baseline forearm vascular resistance differ two drug forearm vascular resistance response diazoxide acetylcholine sodium nitroprusside norepinephrine differ glibenclamide therapy accompany great systolic bp response norepinephrine angiotensin ii high plasma norepinephrine level occur metformin therapy low heart rate glibenclamide therapy despite evidence great sympathetic activity suggest glibenclamide may negative chronotropic effect,Sundaresan P,1997,Diabetes Care,https://doi.org/10.2337/diacare.20.5.692,9135928,Sundaresan P; Lykos D; Daher A; Diamond T; Morris R; Howes LG,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000109: Acetylcholine; D000328: Adult; D000368: Aged; D000804: Angiotensin II; D001786: Blood Glucose; D001794: Blood Pressure; D002784: Cholesterol; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D003981: Diazoxide; D004311: Double-Blind Method; D005260: Female; D005542: Forearm; D005905: Glyburide; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D007004: Hypoglycemic Agents; D007261: Infusions, Intra-Arterial; D008074: Lipoproteins; D008297: Male; D008687: Metformin; D008875: Middle Aged; D009599: Nitroprusside; D009638: Norepinephrine; D012039: Regional Blood Flow; D014655: Vascular Resistance",,,https://openalex.org/W2052410736,118,15,1,1944,307,7,en,en
false,oral antihyperglycaemics,non insulin dependent diabetes mellitus niddm increase incidence population country age multiple pathology common elderly cardiovascular disease usually present diagnosis patient develop niddm age year may live long enough develop microvascular complication others frail multiple pathology may require treatment prevent symptomatic hyperglycaemia dehydration whilst avoid hypoglycaemia goal management niddm elderly people prevention complication relief symptom treatment must tailor individual expectation review regularly change circumstance age dietary measure fail control glucose level antihyperglycaemic sulphonylureas frequently prescribed form treatment however concern potential drug cause hypoglycaemia limit choice second generation sulphonylureas agent preserve first phase insulin release non biologically active metabolite promptly eliminate biguanide agent metformin also appropriate elderly obese patient niddm renal liver cardiac failure combination sulphonylurea metformin effective patient insulin would otherwise require novel compound acarbose thiazolinediones may also useful treatment old diabetic patient,Jennings PE,1997,Drugs Aging,https://doi.org/10.2165/00002512-199710050-00001,9143853,Jennings PE,article,D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D000368: Aged; D000375: Aging; D001645: Biguanides; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D015507: Drugs, Investigational; D004791: Enzyme Inhibitors; D005959: Glucosidases; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008017: Life Expectancy; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2044968441,24,2,1,1524,240,11,en,en
false,concentration effect relation glibenclamide active metabolite man modelling pharmacokinetics pharmacodynamics,main purpose paper describe relationship serum concentration glibenclamide main metabolite effect blood glucose level clinically relevant parameter assess diabetes serum concentration blood glucose lower effect express percent blood glucose reduction v placebo glibenclamide gb active metabolite trans hydroxy cis hydroxy glibenclamide analyse eight healthy subject participate placebo controlled randomize single blind crossover study use intravenous administration compound well oral administration gb plots blood glucose reduction v log serum concentration demonstrate counter clockwise hysteresis parent drug metabolite effect compartment link appropriate pharmacokinetic model pharmacokinetic pharmacodynamic modelling use fit pharmacokinetics gb route metabolite individual base individual concentration time profile pk pd model apply effect data simultaneously increase steady state serum concentration effect maximal cess find sequence ng ml ng ml gb ng ml correspond interindividual variability express cv elimination rate constant effect site keo estimate increase order h cv h cv gb h cv correspond equilibration half lives effect site keo hl h h h estimate emax values obtain gb cv cv cv respectively conclude two major metabolite gb hypoglycaemic man may high activity low concentration may longer effect duration parent drug,Rydberg T,1997,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.1997.00571.x,9146849,Rydberg T; Jönsson A; Karlsson MO; Melander A,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000704: Analysis of Variance; D001786: Blood Glucose; D003198: Computer Simulation; D018592: Cross-Over Studies; D004305: Dose-Response Relationship, Drug; D005905: Glyburide; D006207: Half-Life; D006801: Humans; D007004: Hypoglycemic Agents; D007275: Injections, Intravenous; D007328: Insulin; D008297: Male; D008956: Models, Chemical; D016037: Single-Blind Method; D013237: Stereoisomerism",,,https://openalex.org/W2054666475,133,16,1,1991,370,7,en,en
false,treatment non insulin dependent diabetes mellitus metformin,metformin alleviate hyperglycemia non insulin dependent diabetes mellitus niddm inhibit hepatic glucose production improve peripheral insulin sensitivity contrast sulfonylureas metformin stimulate insulin secretion promote weight gain exacerbate hyperinsulinemia cause hypoglycemia also favorably affect serum lipids comprehensive review medical literature present conduct use key word metformin non insulin dependent diabetes mellitus metformin monotherapy superior placebo comparable sulfonylureas reduce fast plasma glucose glycosylated hemoglobin level patient niddm uncontrolled diet metformin sulfonylurea however diverse effect body weight fast plasma insulin level weight insulin level remain unchanged decrease metformin increase sulfonylurea patient secondary sulfonylurea failure combination metformin sulfonylurea synergistically improve glycemic control well either drug alone comparable insulin plus sulfonylurea hyperglycemia uncontrolled insulin secondary sulfonylurea failure limited data suggest efficacy metformin plus insulin mild transient self limited gastrointestinal side effect sometimes occur minimize gradually increase dos take metformin food risk metformin associated lactic acidosis low prescribing guideline adhere potential adverse drug interaction include hypoglycemia concurrent sulfonylurea therapy elevate metformin plasma concentration metformin take concomitantly cimetidine metformin use safely effectively first line monotherapy niddm combination sulfonylurea monotherapy either agent fail particularly suitable weight gain hyperlipidemia hypoglycemia clinically important issue,Guthrie R,1997,J Am Board Fam Pract,,9159660,Guthrie R,article,D016428: Journal Article; D016454: Review,"D000140: Acidosis, Lactic; D003924: Diabetes Mellitus, Type 2; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008687: Metformin",,,https://openalex.org/W1831980957,68,8,1,2040,294,11,en,en
false,effect combination therapy troglitazone sulphonylureas patient type diabetes poorly control sulphonylurea therapy alone,clinical efficacy troglitazone new oral hypoglycaemic agent investigate type diabetes combination sulphonylureas two hundred ninety one patient type diabetes age year whose previous glycaemic control sulphonylureas judge stable unsatisfactory fast plasma glucose fpg mmol l randomly allocate troglitazone treatment group troglitazone group n placebo treatment group placebo group n treat test drug week combination dose sulphonylureas trial one hundred twenty two patient receive troglitazone patient receive placebo evaluate efficacy baseline characteristic differ significantly two group troglitazone group fpg hba c decrease significantly treatment v fpg mmol l v mmol l p hba c v p fpg hba c change treatment placebo group v fpg mmol l v mmol l hba c v serum total cholesterol hdl cholesterol change either group however serum triglyceride significantly decrease troglitazone group serious adverse event occur either group conclusion troglitazone mg day significant hypoglycaemic effect combination sulphonylureas without serious adverse event troglitazone develop insulin action enhancer useful hypoglycaemic agent treatment patient type diabetes well control sulphonylureas alone,Iwamoto Y,1996,Diabet Med,https://doi.org/10.1002/(sici)1096-9136(199604)13:4<365::aid-dia19>3.0.co;2-m,9162613,Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001786: Blood Glucose; D002839: Chromans; D003710: Demography; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D006801: Humans; D007004: Hypoglycemic Agents; D008055: Lipids; D008875: Middle Aged; D013453: Sulfonylurea Compounds; D013844: Thiazoles; D045162: Thiazolidinediones; D016896: Treatment Outcome; D000077288: Troglitazone",,,https://openalex.org/W1985317064,155,22,1,1759,326,11,en,en
true,glipizide gits increase hypoglycemic effect mild exercise fast niddm,objective study compare effect mild exercise fast plasma glucose concentration subject niddm treat extended release glipizide subject take oral hypoglycemic agent research design method twenty five moderately obese subject niddm randomize treatment extended release glipizide placebo week treatment fast overnight take study drug omit breakfast exercise treadmill min glucose insulin c peptide concentration measure exercise result fasting exercise day fast glucose concentration low vs mg dl p lt insulin c peptide concentration higher extended release glipizide group decrement glucose fast baseline modest equivalent two group vs mg dl end exercise vs mg dl h recovery subject hypoglycemic symptom conclusion chronic use extended release glipizide enhance hypoglycemic effect fast plus mild exercise people niddm routine lifestyle treatment niddm may continue ongoing use agent,Riddle MC,1997,Diabetes Care,https://doi.org/10.2337/diacare.20.6.992,9167112,Riddle MC; McDaniel PA; Tive LA,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D002096: C-Peptide; D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D015444: Exercise; D005080: Exercise Test; D005260: Female; D005913: Glipizide; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D009765: Obesity; D013997: Time Factors",,,https://openalex.org/W2016878819,97,14,1,1259,213,9,en,en
true,short term comparison versus twice daily administration glimepiride patient non insulin dependent diabetes mellitus,objective investigate metabolic effect frequency adverse event mg glimepiride new oral sulfonylurea give twice daily dosage patient non insulin dependent diabetes mellitus niddm research design method week study involve subject niddm subject randomize two group week group receive glimepiride mg twice daily group receive glimepiride mg daily week placebo washout period twice daily regimen cross second week treatment period subject hospitalize end placebo active treatment phase glucose concentration record time point hour period insulin c peptide concentration record time point period parameter calculate included fasting hour postprandial concentration glucose insulin c peptide result one hundred six patient randomize receive treatment complete entire study exist physiologic mechanism glucose control apparently unimpaired glimepiride treatment insulin concentration increase postprandial glucose peak subject fast twice daily regimen prove equally effective reduce concentration fasting postbreakfast postlunch postdinner plasma glucose twenty four hour mean glucose concentration show slightly great decrease baseline twice daily regimen difference regimen statistically significant clinically meaningful incidence adverse event glimepiride approximate obtain placebo group report one adverse event headache subject conclusion glimepiride equally effective whether administer twice daily glimepiride seem stimulate insulin production primarily meal plasma glucose concentration high control blood glucose throughout day,Sonnenberg GE,1997,Ann Pharmacother,https://doi.org/10.1177/106002809703100601,9184703,Sonnenberg GE; Garg DC; Weidler DJ; Dixon RM; Jaber LA; Bowen AJ; DeChemey GS; Mullican WS; Stonesifer LD,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D002096: C-Peptide; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D019518: Postprandial Period; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2131316918,136,15,1,2126,337,16,en,en
true,pharmacokinetics oral glyburide subject non insulin dependent diabetes mellitus renal failure,test hypothesis renal failure effect pharmacokinetics glyburide five subject non insulin dependent diabetes mellitus niddm end stage renal disease require hemodialysis four niddm subject normal renal function study day subject consume carbohydrate gram glucose insulin c peptide measure hour day subject receive mg glyburide measure plasma concentration hour day multiple dose mg glyburide daily begin day plasma concentration measure hour pharmacokinetics pharmacodynamics glyburide glucose insulin c peptide determine well daily fast blood glucose glucose area curve auc daily fast glucose level change either control hemodialysis subject mean serum glyburide blood level pharmacokinetics differ initial chronic glyburide administration niddm subject end stage renal disease treat hemodialysis compare control glyburide half life averaged hour control subject hour hemodialysis subject hemodialysis subject increase c peptide insulin auc chronic dosing renal failure affect pharmacokinetics mg oral glyburide,Brier ME,1997,Am J Kidney Dis,https://doi.org/10.1016/s0272-6386(97)90465-0,9186077,Brier ME; Bays H; Sloan R; Stalker DJ; Welshman I; Aronoff GR,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.","D000284: Administration, Oral; D000328: Adult; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007676: Kidney Failure, Chronic; D008297: Male; D008875: Middle Aged; D006435: Renal Dialysis; D013997: Time Factors",,,https://openalex.org/W1995315145,109,13,1,1365,230,11,en,en
false,general medicine update niddm prevention cad risk benefit hormone replacement therapy,,Sheffield JV,1997,Compr Ther,,9195119,Sheffield JV,article,D016428: Journal Article; D016454: Review,"D000368: Aged; D001943: Breast Neoplasms; D002318: Cardiovascular Diseases; D003327: Coronary Disease; D003924: Diabetes Mellitus, Type 2; D015914: Estrogen Replacement Therapy; D005260: Female; D006801: Humans; D008875: Middle Aged",,,https://openalex.org/W2402193924,101,19,1,0,0,0,en,
false,effect insulin treatment circulate islet amyloid polypeptide patient niddm,objective evaluate effect insulin treatment circulate islet amyloid polypeptide iapp twelve patient niddm secondary failure study oral agent switch insulin treatment fasting postprandial iapp concentration measure oral treatment insulin treatment patient postprandial concentration determine patient investigate fast postprandially fasting iapp concentration pmol l mean sem oral treatment rise min breakfast p insulin treatment hbalc decrease p plasma c peptide concentration significantly lower p close correlation use simple regression per cent change iapp concentration per cent change c peptide concentration period r p total patient material patient significant correlation use simple regression analysis per cent change iapp concentration per cent change c peptide concentration use measurement available r p data suggest secretion iapp lower endogenous insulin secretion lower administration exogenous insulin patient niddm thus iapp secretion pathogenetic role development beta cell failure niddm insulin treatment might delay deterioration john wiley son ltd,Lindström T,1997,Diabet Med,https://doi.org/10.1002/(sici)1096-9136(199706)14:6<472::aid-dia388>3.0.co;2-q,9212313,Lindström T; Leckström A; Westermark P; Arnqvist HJ,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000682: Amyloid; D001786: Blood Glucose; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D005215: Fasting; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D058228: Islet Amyloid Polypeptide; D016014: Linear Models; D008297: Male; D008875: Middle Aged; D015999: Multivariate Analysis",,,https://openalex.org/W2038357512,91,13,1,1574,286,11,en,en
true,glucose tolerance mortality include substudy tolbutamide treatment,mortality accord glucose tolerance study determine prognosis impaired glucose tolerance among person test community screen programme followed mortality end age sex adjusted mortality rate death per person years se normal glucose tolerance impair glucose tolerance diabetes world health organization criterion baseline age sex adjusted mortality rate due ischaemic heart disease death per person years respectively use criterion predate world health organization men abnormal glucose tolerance enter randomized clinical trial treat tolbutamide approximately year treat low mortality rate cause mortality rate ratio confidence interval ischaemic heart disease mortality rate ratio confidence interval receive tolbutamide thus mortality rate increase person impaired glucose tolerance diabetes small clinical trial suggest tolbutamide may beneficial men abnormal glucose tolerance diabetologia,Knowler WC,1997,Diabetologia,https://doi.org/10.1007/s001250050734,9222648,Knowler WC; Sartor G; Melander A; Scherstén B,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000367: Age Factors; D000368: Aged; D000369: Aged, 80 and over; D001786: Blood Glucose; D002423: Cause of Death; D016001: Confidence Intervals; D003920: Diabetes Mellitus; D005260: Female; D018149: Glucose Intolerance; D006801: Humans; D007004: Hypoglycemic Agents; D015994: Incidence; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D012727: Sex Characteristics; D012737: Sex Factors; D013997: Time Factors; D014044: Tolbutamide; D014944: World Health Organization",,,https://openalex.org/W1998705051,78,11,1,1356,237,7,en,en
false,beta cell response oral glimepiride administration follow hyperglycaemic clamp niddm patient,aim present study assess beta cell response glimepiride administer orally follow hyperglycaemic clamp niddm patient male age st dev year body mass index kg hbalc baseline placebo control study patient stable treatment second generation sulphonylurea least week prior randomization receive placebo p mg glimepiride g daily day mg prior hyperglycaemic clamp mmol l min precede v insulin infusion stablize fast blood glucose level mmol l clamp follow observation period h subject h next subject blood glucose plasma insulin c peptide proinsulin level measure regular interval determine effect glimepiride interaction change glycaemia plasma level beta cell product neither g p elicit first phase insulin response area plasma insulin curve h hyperglycaemic clamp v pmol h l g p clamp respectively p total area auc plasma insulin curve v pmol h l g p clamp total auc c peptide pmol h g p clamp respectively p total auc proinsulin versus pmol h l g p clamp respectively p five hour g p administration blood glucose level mmol g clamp v mmol l p clamp p number hypoglycaemic event blood glucose mmol l h observation period g clamp vs p clamp p n conclusion glimepiride stimulate second phase insulin proinsulin secretion lowering blood glucose level accompany commensurate inhibition insulin secretion study require compare new drug currently available oral hypoglycaemic agent respect glycaemic control risk hypoglycaemia john wiley son ltd,van der Wal PS,1997,Diabet Med,https://doi.org/10.1002/(sici)1096-9136(199707)14:7<556::aid-dia389>3.0.co;2-6,9223393,van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000368: Aged; D001786: Blood Glucose; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005934: Glucagon; D015309: Glucose Clamp Technique; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D007515: Islets of Langerhans; D008297: Male; D008875: Middle Aged; D004364: Pharmaceutical Preparations; D011384: Proinsulin; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2084671153,115,16,1,2255,476,16,en,en
false,treatment oral antidiabetic agent troglitazone improve beta cell response glucose subject impaired glucose tolerance,impaired glucose tolerance igt associate defect insulin secretion action carry high risk conversion non insulin dependent diabetes mellitus niddm troglitazone insulin sensitize agent reduces glucose concentration subject niddm igt know affect insulin secretion seek determine role beta cell function mediate improve glucose tolerance obese subject igt receive wk either mg daily troglitazone n placebo n randomized double blind design study measure baseline treatment glucose insulin response g oral glucose tolerance test insulin sensitivity index si assess frequently sample intravenous glucose tolerance test insulin secretion rate graded glucose infusion beta cell glucose sensing ability oscillatory glucose infusion troglitazone reduce integrate glucose insulin response oral glucose p p respectively si increase x min pm p average insulin secretion rate adjust si glucose interval mmol liter increase p ability beta cell entrain exogenous oscillatory glucose infusion evaluate analysis spectral power improve p significant change parameter demonstrate placebo group addition increase insulin sensitivity demonstrate troglitazone improve reduced beta cell response glucose characteristic subject igt appear important factor observed improvement glucose tolerance,Cavaghan MK,1997,J Clin Invest,https://doi.org/10.1172/jci119562,9239399,Cavaghan MK; Ehrmann DA; Byrne MM; Polonsky KS,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000284: Administration, Oral; D000328: Adult; D000818: Animals; D002839: Chromans; D004311: Double-Blind Method; D005260: Female; D005947: Glucose; D018149: Glucose Intolerance; D005951: Glucose Tolerance Test; D006168: Guinea Pigs; D006801: Humans; D007004: Hypoglycemic Agents; D007515: Islets of Langerhans; D008297: Male; D008875: Middle Aged; D013844: Thiazoles; D045162: Thiazolidinediones; D016896: Treatment Outcome; D000077288: Troglitazone",,,https://openalex.org/W2085390992,140,20,1,1768,320,11,en,en
true,influence bromfenac pharmacokinetics pharmacodynamic response glyburide diabetic subject,study objective assess effect bromfenac sodium nonnarcotic analgesic drug development pharmacokinetics pharmacodynamics glyburide patient type ii diabetes design randomize double blind placebo controlled multiple dose study two period crossover design patient eleven men one woman age yr whose diabetes responsive oral sulfonylurea therapy intervention placebo bromfenac mg give single oral dose times day first day study day patient receive alternative treatment least month study patient take usual single daily dose glyburide mg measurement main result bromfenac concentration measure high performance liquid chromatography ultraviolet detection glyburide concentration measure gas chromatography nitrogen phosphorus detection glycemia measure repeatedly day treatment pharmacokinetic analysis perform noncompartmental technique significant difference pharmacokinetics glyburide pharmacodynamic response serum glucose level observe placebo bromfenac intersubject variability concentration modest glyburide glucose cv less conclusion glyburide level change concomitant administration bromfenac,Boni JP,1997,Pharmacotherapy,,9250558,Boni JP; Cevallos WH; DeCleene S; Korth-Bradley JM,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000700: Analgesics; D019540: Area Under Curve; D001577: Benzophenones; D001682: Biological Availability; D001786: Blood Glucose; D001969: Bromobenzenes; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D005260: Female; D005905: Glyburide; D006207: Half-Life; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008657: Metabolic Clearance Rate; D008875: Middle Aged",,,https://openalex.org/W1935585629,114,15,1,1459,230,18,en,en
false,effect glibenclamide insulin release moderate high blood glucose level normal man,insulin release occur two phase sulphonylurea derivative may different potency stimulate first second phase insulin release study effect glibenclamide insulin secretion submaximally maximally stimulating blood glucose level primed hyperglycaemic glucose clamp twelve healthy male subject age mean sem year body mass index bmi kg study randomized double blind study design glibenclamide mg placebo take h hyperglycaemic clamp blood glucose mmol l first h mmol l next h hyperglycaemic clamp mmol l area insulin curve auc insulin mean sem min first phase different vs pmol l min without glibenclamide p however glibenclamide lead significantly large increase auc insulin min second phase vs pmol l min without glibenclamide respectively p true auc c peptide difference min significantly high auc c peptide min glibenclamide day p ratio mean glucose infusion rate divide mean plasma insulin concentration min measure insulin sensitivity change vs mol kg min pmol l without glibenclamide p hyperglycaemic clamp mmol l auc insulin min first phase different study day vs pmol l min without glibenclamide p auc insulin min second phase also show difference vs pmol l min without glibenclamide p auc c peptide min min slightly low glibenclamide study day p ratio min change vs mol kg min pmol l without glibenclamide p conclusion glibenclamide increase second phase insulin secretion submaximally stimulating blood glucose level without enhancement first phase insulin release additive effect insulin secretion maximally stimulate blood glucose level glibenclamide change insulin sensitivity acute experiment,Ligtenberg JJ,1997,Eur J Clin Invest,https://doi.org/10.1046/j.1365-2362.1997.1710716.x,9279533,Ligtenberg JJ; Venker CE; Sluiter WJ; Reitsma WD; Van Haeften TW,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D001786: Blood Glucose; D004311: Double-Blind Method; D005905: Glyburide; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male,,,https://openalex.org/W2123054466,98,16,1,2562,535,14,en,en
false,glibenclamide acarbose increase leptin concentration parallel change insulin subject niddm,hypothesize glibenclamide increase insulin level also increase leptin concentrations leptin hormone regulate weight mouse obese human leptin concentration increase suggest resistance effect hormone although short term infusion insulin hyperinsulinemiceuglycemic clamp increase leptin concentration effect oral antidiabetic agent leptin concentration unknown differ effect expect since glibenclamide act via stimulation insulin secretion whereas acarbose inhibit alpha glucosidases small intestine direct effect insulin level examine effect acarbose n glibenclamide n placebo n insulin leptin level h period week therapy observe significant diurnal variation leptin concentration inversely relate insulin level h follow usual diet neither placebo acarbose altered leptin concentration however glibenclamide increase leptin concentration parallel insulin level minor change body weight l week follow decrease placebo group change kg p acarbose change kg p increase glibenclamide group change kg p however individual subject gain weight increase leptin concentration diurnal variation leptin concentration preserve glibenclamide glibenclamide increase circadian leptin insulin concentration whereas acarbose observation may help explain weight gain subject treat glibenclamide stable weight treat acarbose long run,Haffner SM,1997,Diabetes Care,https://doi.org/10.2337/diacare.20.9.1430,9283792,Haffner SM; Hanefeld M; Fischer S; Fuçker K; Leonhardt W,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D020909: Acarbose; D000704: Analysis of Variance; D002940: Circadian Rhythm; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D020738: Leptin; D008297: Male; D008875: Middle Aged; D011506: Proteins; D014312: Trisaccharides",,,https://openalex.org/W1977757682,118,18,1,1820,301,12,en,en
false,pathophysiology type diabetes mode action therapeutic intervention,least million person diabetes mellitus united state half whose condition remain undiagnosed type diabetes type diabetes precede long period impaired glucose tolerance reversible metabolic state associate increased prevalence macrovascular complication thus time diagnosis long term complication develop almost one fourth patient susceptibility type diabetes require genetic likely polygenic acquire factor pathogenesis involve interplay progressive insulin resistance beta cell failure ideal treatment type diabetes reverse insulin resistance beta cell dysfunction treated patient prevent delay reverse long term complication current strategy aim amelioration insulin resistance diet exercise weight loss metformin troglitazone therapy augmentation insulin supply sulfonylurea insulin therapy limitation postprandial hyperglycemia acarbose therapy future therapies probably target insulin resistance use multifaceted approach hepatic glucose production use gluconeogenesis inhibitor excess nonesterified fatty acid production use lipolysis inhibitor fat oxidation use carnitine palmitoyltransferase ii inhibitor attempt also could make stimulate energy expenditure increase nonoxidative glucose disposal mean adrenoceptor agonist one promising strategy attack multiple pathophysiological process combine antidiabetic agent disparate mechanism action thus unprecedented resource drug therapy diabetes great opportunity innovative combination hop expand choice provide tool necessary efficient management type diabetes prevention long term complication arch intern med,Dagogo-Jack S,1997,Arch Intern Med,https://doi.org/10.1001/archinte.1997.00440370028004,9290539,Dagogo-Jack S; Santiago JV,article,D016428: Journal Article; D016454: Review,"D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005947: Glucose; D006801: Humans; D006943: Hyperglycemia; D007004: Hypoglycemic Agents; D008099: Liver",,,https://openalex.org/W2124095103,83,12,1,2017,329,13,en,en
false,monitoring metabolic control patient non insulin dependent diabetes mellitus oral hypoglycaemic agent value even blood glucose determination,monitoring metabolic control patient non insulin dependent type diabetes niddm usually base upon blood glucose assay morning overnight fast postprandial state breakfast lunch however schedule seek low blood glucose value especially evening conduct prospective study laboratory blood glucose profile g carbohydrate breakfast evening pm include consecutive niddm patient regularly follow clinic men age year diabetes duration year bmi kg treat sulphonylurea gliclazide alone mg h mean mg group n combination metformin mg h mg group n patient stable change dosage least month mean glycaemic control good group hba c group even blood glucose value low day patient group group mean even blood glucose level low p value group v mmol l group v value group group blood glucose value hypoglycaemic range observe hba c strongly correlate p whole group r r even blood glucose value r result indicate patient treat sulphonylurea gliclazide alone combination metformin low blood glucose value occur evening frequently morning therefore even blood glucose determination perform systematically course metabolic evaluation niddm patient oral hypoglycaemic agent john wiley son ltd,Guillausseau PJ,1997,Diabet Med,https://doi.org/10.1002/(sici)1096-9136(199709)14:9<798::aid-dia420>3.0.co;2-c,9300232,Guillausseau PJ,article,D003160: Comparative Study; D016428: Journal Article,"D000284: Administration, Oral; D000368: Aged; D001786: Blood Glucose; D002940: Circadian Rhythm; D015331: Cohort Studies; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005215: Fasting; D005260: Female; D005907: Gliclazide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008687: Metformin; D008875: Middle Aged; D019518: Postprandial Period; D011446: Prospective Studies",,,https://openalex.org/W2003524585,163,21,1,1997,443,13,en,en
false,relative hyperproinsulinemia niddm persists despite reduction hyperglycemia insulin sulfonylurea therapy,subject niddm increase plasma proinsulin concentration compare nondiabetic subject absolute term proportion circulate insulin like molecule remain uncertain whether reflect primary beta cell defect proinsulin processing secondary hyperglycemia address question assess effect reduce hyperglycemia relative hyperproinsulinemia subject niddm eight subject niddm underwent three week period randomized crossover design therapy diet alone sulfonylurea gliclazide insulin ultralente effect beta cell peptide concentration assessed fasting response hyperglycemic clamping response injection nonglucose secretogogue arginine compare measurement seven nondiabetic control subject sulfonylurea insulin therapy substantially reduce fast plasma glucose glycosylated hemoglobin hba e concentration compare diet therapy alone diabetic subject diet therapy relative hyperproinsulinemia assess relative c peptide concentration fast response hyperglycemic clamping arginine compare control subject neither sulfonylurea insulin therapy alter relative hyperproinsulinemia insulin therapy reduce fasting proinsulin concentration geometric mean sd range pmol l diet therapy pmol l p similar trend evident fast c peptide concentration reduction nmol l diet therapy nmol l p relative hyperproinsulinemia assess ratio fast proinsulin c peptide unchanged insulin similarly insulin therapy fail reduce ratio proinsulin c peptide concentration response hyperglycemic clamp acute incremental response arginine failure improve relative hyperproinsulinemia niddm despite significant reduction hyperglycemia exogenous insulin therapy support hypothesis relative hyperproinsulinemia niddm reflection primary beta cell defect rather secondary hyperglycemia,Rachman J,1997,Diabetes,https://doi.org/10.2337/diacare.46.10.1557,9313749,Rachman J; Levy JC; Barrow BA; Manley SE; Turner RC,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001120: Arginine; D001786: Blood Glucose; D002096: C-Peptide; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D005215: Fasting; D005907: Gliclazide; D015309: Glucose Clamp Technique; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008875: Middle Aged; D011384: Proinsulin",,,https://openalex.org/W1984186048,122,15,1,2286,361,12,en,en
false,insulin sulfonylurea therapy niddm patient effect lipoprotein metabolism different even similar blood glucose control,study evaluate effect insulin versus glibenclamide lipoprotein metabolism comparable level blood glucose control particular concentration distribution vldl subfractions lipolytic enzyme activity nine niddm men age year bmi kg mean se participate crossover study week washout period patient randomly assign month treatment period insulin glibenclamide thereafter patient cross treatment end period mean daily blood glucose mdbg hba c plasma lipid lipoprotein vldl ldl hdl lipoprotein subfractions vldl hdl hdl post heparin lipase activity lipoprotein lipase lpl hepatic lipase hl evaluate although glucose control similar end period mdbg vs mmol l hba c vs insulin versus glibenclamide insulin compare glibenclamide induce significant reduction plasma triglyceride vs mmoh p lt vldl triglyceride vs mg dl p lt vldl lipid concentration vs mg dl p lt increase hdl cholesterol vs mg dl p lt term vldl percentage subfraction distribution insulin decrease large subfractions vldl vs p lt increase small vldl vs p lt moreover hl activity significantly low insulin glibenclamide hl vs mu ml p lt conclusion compare glibenclamide insulin treatment independent variation glucose control able decrease significantly plasma triglyceride increase hdl cholesterol reduce concentration large vldl subfractions consequent redistribution profile,Romano G,1997,Diabetes,https://doi.org/10.2337/diacare.46.10.1601,9313756,Romano G; Patti L; Innelli F; Di Marino L; Annuzzi G; Iavicoli M; Coronel GA; Riccardi G; Rivellese AA,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D002784: Cholesterol; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D005215: Fasting; D005502: Food; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008074: Lipoproteins; D008075: Lipoproteins, HDL; D008077: Lipoproteins, LDL; D008079: Lipoproteins, VLDL; D008297: Male; D008875: Middle Aged; D014280: Triglycerides",,,https://openalex.org/W2126797308,144,22,1,2045,433,7,en,en
false,die stellung der biguanide der therapie des diabetes mellitus,background objective biguanides use treatment diabetes mellitus year due frequent occurrence lactic acidosis particularly patient serious contraindication biguanide therapy case non compliance dosage instruction buformin phenformin take market european country end seventy metformin continue allow since risk lactic acidosis time less phenformin buformin due different pharmacokinetic property substance plenty clinical experience gain metformin document large number reliable long term study finding metformin lower fast blood glucose level average postprandial blood glucose hba c bei metformin reduces raise plasma insulin level case metabolic syndrome much reduce insulin requirement type insulin treated diabetic well document effect various rheological parameter overweight type diabetic metformin show level hypoglycaemic effect important sulfonylurea derivative use europe active mechanism derivative however concentrate solely reduction blood glucose mechanism take account remain risk constellation involve insulin resistance biguanides similarly weight reduction lead reduction hyperinsulinaemia contrast exacerbate sulfonylurea particular exogenous insulin conclusion risk lactic acidosis probably eliminate entirely dosage instruction contraindication observe carefully cause neglect case limit renal function serum creatinine mg regard morbidity mortality lactic acidosis metformin therapy risky treatment sulfonylurea derivative glibenclamide take account incidence fatal hypoglycaemia latter,Haupt E,1997,Med Klin (Munich),https://doi.org/10.1007/bf03044916,9340472,Haupt E; Panten U,article,D016428: Journal Article; D016454: Review,"D001645: Biguanides; D001786: Blood Glucose; D000075202: Contraindications; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D007333: Insulin Resistance; D008687: Metformin",,,https://openalex.org/W49811413,64,10,1,2136,367,13,de,en
false,american diabetes association annual meeting type diabetes,,Bloomgarden ZT,1997,Diabetes Care,https://doi.org/10.2337/diacare.20.11.1791,9353625,Bloomgarden ZT,article,D016423: Congress; D016433: News,"D002839: Chromans; D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D006706: Homeostasis; D006801: Humans; D007004: Hypoglycemic Agents; D012955: Societies, Medical; D013844: Thiazoles; D045162: Thiazolidinediones; D000077288: Troglitazone; D014481: United States",,,https://openalex.org/W2093159285,67,11,1,0,0,0,en,
false,concomitant administration glucosidase inhibitor voglibose ao alter pharmacokinetics glibenclamide,objective voglibose new potent inhibitor alpha glucosidases use treatment diabetes mellitus increase gastro intestinal motility could thus affect absorption concurrently administer antidiabetic drug aim study investigate whether voglibose modifies pharmacokinetics glibenclamide widely use oral antidiabetic glibenclamide induced decrease fast serum glucose method twelve healthy male subject include double blind cross study receive single mg dose glibenclamide th day continuous administration either placebo reference voglibose mg test blood sample take determine pharmacokinetic characteristic glibenclamide test reference ratio evaluate accord bioequivalence criterion additional blood sample take measure serum glucose day result concentration time course glibenclamide concomitant voglibose administration similar placebo equivalence ratio test reference pharmacokinetic characteristic aucnorm geometric mean confidence interval cmax norm parameter within accepted range auc cmax thus fulfil equivalence criterion indicate effect voglibose glibenclamide kinetics glibenclamide induced decrease fast serum glucose concentration similarly independent placebo voglibose co administration conclusion voglibose interact glibenclamide pharmacokinetic level concomitant treatment well tolerate prove safe clinical use,Kleist P,1997,Eur J Clin Pharmacol,https://doi.org/10.1007/s002280050354,9403288,Kleist P; Ehrlich A; Suzuki Y; Timmer W; Wetzelsberger N; Lücker PW; Fuder H,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,D000328: Adult; D019540: Area Under Curve; D001786: Blood Glucose; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004347: Drug Interactions; D004791: Enzyme Inhibitors; D005905: Glyburide; D065089: Glycoside Hydrolase Inhibitors; D006801: Humans; D007004: Hypoglycemic Agents; D007294: Inositol; D008297: Male,,,https://openalex.org/W2030537348,129,18,1,1786,275,13,en,en
false,assist effect lithium hypoglycemic treatment patient diabetes,article report assist effect lithium hypoglycemic treatment patient diabetes thirty eight diabetic patient male female age yr noninsulin dependent diabetes mellitus niddm patient insulin dependent diabetes mellitus iddm patient recruit study fasting h postprandial blood glucose bg profile undertake three group patient diabetes short term treatment lithium carbonate group treat diet group ii oral hypoglycemic agent oha group iii insulin fast blood glucose fbg level h postprandial blood glucose h pbg level treatment lithium group fbg vs h pbg vs group ii fbg vs h pbg vs group iii fbg vs h pbg vs mmol l respectively fbg pbg three group decrease significantly lithium treatment except fbg group data suggest combine therapy lithium could improve glucose metabolism patient diabetes result suggest lithium assist hypoglycemic effect antidiabetic treatment,Hu M,1997,Biol Trace Elem Res,https://doi.org/10.1007/bf02783316,9404682,Hu M; Wu H; Chao C,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D003922: Diabetes Mellitus, Type 1; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D016651: Lithium Carbonate; D008297: Male; D008875: Middle Aged; D019518: Postprandial Period",,,https://openalex.org/W2007759381,80,11,1,1377,266,8,en,en
false,result placebo controlled study metabolic effect addition metformin sulfonylurea treated patient evidence central role adipose tissue,define metabolic effect metformin treatment niddm evaluate potential mechanism ability improve glycemic control sulfonylurea treated patient inadequate glycemic control treat metformin either placebo controlled open fashion measurement make fasting postprandial plasma glucose insulin free fatty acid ffa concentration glucose appearance disappearance rate measure overnight h glucose plasma ffa concentration min infusion period relatively low approximately pmol l insulin concentrations mean se hourly plasma glucose insulin ffa concentration similar treatment placebo group contrast mean hourly plasma glucose concentration significantly low p metformin treatment placebo controlled open label group mmol l respectively similarly day long hourly ffa level low p follow metformin placebo controlled open label group mumol l respectively plasma insulin concentration change treatment group overnight glucose turnover study indicate neither rate glucose appearance hepatic glucose production glucose disappearance change significantly treatment placebo metformin group plasma glucose concentration much low metformin treatment overnight glucose metabolic clearance rate significantly p low group finally plasma ffa concentration response low dosage insulin infusion mu min significantly low metformin compare placebo treated group p metformin treatment associate significantly low day long plasma glucose ffa concentration although overnight hepatic glucose production unchanged follow treatment metformin overnight glucose metabolic clearance rate significantly increase give finding suggest least part antihyperglycemic effect metformin due increase glucose uptake secondary decrease release ffa adipose tissue low circulate ffa concentration,Abbasi F,1997,Diabetes Care,https://doi.org/10.2337/diacare.20.12.1863,9405908,Abbasi F; Kamath V; Rizvi AA; Carantoni M; Chen YD; Reaven GM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000273: Adipose Tissue; D001786: Blood Glucose; D002940: Circadian Rhythm; D015331: Cohort Studies; D003924: Diabetes Mellitus, Type 2; D005230: Fatty Acids, Nonesterified; D005260: Female; D005913: Glipizide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D016037: Single-Blind Method; D013997: Time Factors",,,https://openalex.org/W1996837544,171,26,1,2345,380,10,en,en
true,prospective trial risk factor sulfonylurea induced hypoglycemia type diabetes mellitus,context retrospective study identify oral sulfonylurea age fast major risk factor hypoglycemia patient type diabetes sulfonylureas may withhold elderly patient concern hypoglycemia objective toevaluate hypoglycemic effect maximum dos oncedaily second generation sulfonylurea administer fast elderly patients design prospective randomize double blind clinical trial setting university new mexico general clinical research center patients fifty twosulfonylurea treated subject type diabetes mean sd age years interventions subjects randomly assign glyburide glipizide gastrointestinal therapeutic system git subject participate three hour fast study sequential administration week placebo week mg week mg assigned sulfonylurea main outcome measures occurrence hypoglycemia define plasma glucose level mmol l mg dl hormonal parameter final hour hour fast patient take sulfonylureas vs placebo results hypoglycemia observe fast studies plasma glucose level decrease nadir mmol l mg dl mg dose glyburide v mmol l mg dl placebo nadir mmol l mg dl mg dose glipizide git vs mmol l mg dl placebo serum insulin increase sulfonylurea study compare placebo p plasma glucose parameter differ sulfonylurea c peptide concentration increase glyburide group compare glipizide git mg study p concentrations epinephrine increase sulfonylurea study compare placebo p epinephrine secretion increase glucose concentration fell mean sd level mmol l mg dl mg study mmol l mg dl mg study conclusions fasting well tolerate among elderly patient type diabetes treat sulfonylureas older age consider contraindication sulfonylurea treatment diabetes stimulation epinephrine secretion normal elevate plasma glucose level appear primary mechanism protection hypoglycemia study,Burge MR,1998,JAMA,https://doi.org/10.1001/jama.279.2.137,9440664,Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000367: Age Factors; D000368: Aged; D000704: Analysis of Variance; D001774: Blood Chemical Analysis; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004837: Epinephrine; D005215: Fasting; D005260: Female; D005913: Glipizide; D005905: Glyburide; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D010455: Peptides; D011446: Prospective Studies; D012307: Risk Factors",,,https://openalex.org/W2034819488,101,14,1,2440,388,1,en,en
true,possible risk sulfonylurea treatment non insulin dependent diabetes mellitus coronary artery disease,,Mühlhauser I,1997,Diabetologia,https://doi.org/10.1007/s001250050855,9447960,Mühlhauser I; Sawicki PT; Berger M,article,D016422: Letter,"D003924: Diabetes Mellitus, Type 2; D006801: Humans; D009203: Myocardial Infarction; D012307: Risk Factors; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2060929081,118,15,1,0,0,0,en,
true,united kingdom prospective diabetes study year randomize control trial compare sulfonylurea insulin metformin therapy patient newly diagnose type diabetes could control diet therapy,articles february united kingdom prospective diabetes study year randomize control trial compare sulfonylurea insulin metformin therapy patient newly diagnose type diabetes could control diet therapyauthor article disclosure informationhttps doi org sectionsaboutfull textpdf toolsadd favoritesdownload citationstrack citationspermissions sharefacebooktwitterlinkedinredditemail abstractbackground uncertainty exist suitability oral hypoglycemic drug insulin therapy patient newly diagnose type diabetes objective assess compare response sulfonylurea insulin metformin year patient newly diagnose type diabetes disease could could control diet therapy alone design multicenter randomize control trial setting outpatient diabetes clinic hospital united kingdom intervention sulfonylurea chlorpropamide glyburide insulin metformin patient obese patients patient newly diagnose type diabetes could control diet hyperglycemic symptom fast plasma glucose level great mmol l initial month diet therapy primary diet failure group patient disease control diet therapy fast plasma glucose level mmol l hyperglycemic symptom receive diet therapy alone measurements fast plasma level glucose insulin hemoglobin c concentration body weight therapy required results compare diet controlled group primary diet failure group young less obese retinopathy low fast plasma insulin level reduce cell function year patient allocate insulin low fasting plasma glucose level patient allocate oral agent hemoglobin c concentration similar forty eight percent ci patient primary diet failure group maintain hemoglobin c concentration less year patient ci allocate ultralente insulin require additional short acting insulin patient ci allocate sulfonylurea require additional therapy metformin insulin control symptom maintain fast plasma glucose level less mmol l patient allocate insulin gain weight hypoglycemic attack patient allocate sulfonylurea obese patient allocate metformin gain least weight hypoglycemic attack therapy control achieve year worse primary diet failure group diet controlled group conclusions initial insulin therapy induce hypoglycemic reaction weight gain without necessarily provide well control may reasonable start oral agent change insulin goal glycemic level achieved references guideline good practice diagnosis treatment non insulin dependent diabetes mellitus report joint work party british diabetic association research unit royal college physician royal college general practitioner j r coll physicians lond google scholar consensus statement pharmacological treatment hyperglycemia niddm diabetes care suppl google scholar uk prospective diabetes study ukps viii study design progress performance diabetologia google scholar united kingdom prospective diabetes study ukps relative efficacy randomly allocate diet sulphonylurea insulin metformin patient newly diagnose non insulin dependent diabetes follow three year bmj google scholar phillips simpson rw holman rr turner rc simple rational twice daily insulin regime distinction basal meal insulin requirement q j med google scholar uk prospective diabetes study complication newly diagnose type diabetic patient association different clinical biochemical risk factor diabetes google scholar uk prospective diabetes study ukps xi biochemical risk factor type diabetic patient diagnosis compare age matched normal subject diabet med google scholar rudenski matthew dr levy jc turner rc understanding insulin resistance glucose resistance insulin resistance require model human diabetes metabolism google scholar matthew dr hosker jp rudenski naylor ba treacher df turner rc homeostasis model assessment insulin resistance cell function fast plasma glucose insulin concentration man diabetologia google scholar uk prospective diabetes study v characteristic newly present type diabetic patient estimate insulin sensitivity islet cell function multicentre study diabet med google scholar davis md hubbard ld trautman j klein r conference insulin pump therapy diabetes multicenter study effect microvascular disease study retinopathy methodology assessment classification fundus photograph diabetes suppl google scholar user manual statistical analysis system version cary nc sas institute google scholar harris mi undiagnosed niddm clinical public health issue diabetes care google scholar nabarro jd oral hypoglycaemic agent first thirty year j r coll physicians lond google scholar groop l schalin c franssila kallunki widen e ekstrand eriksson j characteristic non insulin dependent diabetic patient secondary failure oral antidiabetic therapy j med google scholar u k prospective diabetes study overview year therapy type ii diabetes progressive disease u k prospective diabetes study group diabetes google scholar university group diabetes program study effect hypoglycemic agent vascular complication patient adult onset diabetes v evaluation pheniformin therapy diabetes suppl google scholar kilo c miller jp williamson jr achilles heel university group diabetes program jama google scholar effect intensive treatment diabetes development progression long term complication insulin dependent diabetes mellitus diabetes control complication trial research group n engl j med google scholar turner r stratton horton v manley zimmet p mackay ir et al ukps autoantibody islet cell cytoplasm glutamic acid decarboxylase prediction insulin requirement type diabetes uk prospective diabetes study group lancet google scholar author article disclosure informationaffiliations acknowledgment author thank patient national health serviceand non national health service staff center cooperation grant support grant united kingdom medical research council british diabetic association united kingdom department health national eye institute u ey national institute diabetes digestive kidney disease r dk national institute health british heart foundation health promotion research trust clothworkers foundation charles wolfson charitable trust alan babette sainsbury trust oxford university medical research fund committee corresponding author united kingdom prospective diabetes study group diabetes research laboratory radcliffe infirmary woodstock road oxford ox united kingdom current author address drs wright cull holman turner united kingdom prospective diabetes study group diabetes research laboratory radcliffe infirmary woodstock road oxford ox united kingdom nextarticle advertisement figuresreferencesrelateddetails metric cite byreal world efficacy glucagon like peptide glp receptor agonist dulaglutide metabolic parameter japanese patient type diabetes retrospective longitudinal studydietary fiber intake relate skeletal muscle mass body fat mass muscle fat ratio among people type diabetes cross sectional studyk rperliche und psychische folgeerkrankungen bei diabetes mellitusmetformin improves skeletal muscle microvascular insulin resistance metabolic syndromerecommendations practical use metformin central pharmacological therapy type diabeteschoosing medication type diabetes weighting give cardiovascular risk reduction long term outcome add alpha glucosidase inhibitor insulin treated patient type diabetesa review metformin clinical significance side effectsprevalence incidence micro macro vascular complication diabetic population bangladesh retrospective cohort studyramadan fasting diabetes late evidence technological advancement updateramadan fast diabetes late evidence technological advancement updatehypoglycemia induces mitochondrial reactive oxygen specie production increase fatty acid oxidation promote retinal vascular permeability diabetic micethe age vasculature glucose tolerance hypoglycemia role serum response factorbioactive component salvia potential antidiabetic property reviewpersonalized diabetes management patient diabetes mellitus prefer discrete choice experimentthe association metformin treatment outcome type diabetes mellitus patient heart failure preserved ejection fraction retrospective studyimpacts early insulin treatment v glimepiride diabetic patient background metformin therapymetabolic control determinant among hiv infected type diabetes mellitus patient attend tertiary clinic botswanahypoglycaemia management primary care settingjapanese clinical practice guideline diabetes japanese clinical practice guideline diabetes metformin monotherapy adult type diabetes mellitusspotlight experience medicine unavailability access medicine challenge ncds ntds contrasting case insulin praziquantelefficacy safety empagliflozin add insulin japanese patient type diabetes randomized double blind placebo controlled trialpioglitazone exposure reduce risk cause mortality insulin treated patient type diabetes mellitusoral insulin updateeffect diabetes self management education glycemic control latino adult type diabetes systematic review meta analysisthe metformin paradoxtype ii diabetes mellitusdriver versus navigator causation biology case insulin fast glucoseall cause mortality insulin plus dipeptidyl peptidase inhibitor person type diabetesunderstanding glucoregulatory mechanism metformin type diabetes mellitusdiabetes education impact hypoglycemia outcome systematic review evidence gap literatureendocrine pharmacologysystemic effect periodontitis treatment patient type diabetes month single centre investigator masked randomise trialrelationship serum adipsin first phase glucose stimulated insulin secretion individual different glucose tolerancepharmacokinetics metformin patient gastrointestinal intolerancecardiovascular outcome dipeptidyl peptidase inhibitor patient type diabetes insulin therapyjapanese clinical practice guideline diabetes pharmacologic glycemic management type diabetes adultshigh glucose mediated tyrosine nitration pi kinase molecular switch survival apoptosis endothelial cellsjapanese clinical practice guideline diabetes mobile diabetes intervention study patient engagement impact blood glucose mixed method analysiscardiovascular safety non insulin pharmacotherapy type diabetesoral insulin delivery physiologic context reviewestimation insulin secretion glucose uptake tissue liver handling glucose use mathematical model glucose insulin homeostasis lean obese micerelationship hla haplotype bmi change japanese slowly progressive type diabetes patientsweight change initiation oral hypoglycemic monotherapy diabetes predicts year mortality observational studyanti diabetic medication make choice efficacy safety basal supported prandial glp receptor agonist therapyhypoglycemia diabetesefficacy safety insulin type diabetes meta analysis randomise control trialsefficacy safety canagliflozin combination insulin double blind randomize placebo controlled study japanese patient type diabetes mellitusaddition sulphonylurea metformin relevantly change body weight prospective observational cohort study zodiac importance multidisciplinary team management complex obesity patient diabetesdiabetes medication monotherapy metformin based combination therapy type diabetes systematic review meta analysisnisa maruthur md mhs eva tseng md mph susan hutfless phd lisa wilson scm catalina suarez cuervo md zackary berger md phd yue chu msph emmanuel iyoha mbchb mph jodi b segal md mph shari bolen md mphcombination therapy sglt inhibitor incretin based therapy treatment type diabetes mellitus effect mechanism actionefficacy safety sglt inhibitor luseogliflozin japanese patient type diabetes mellitus stratify accord baseline body mass index pool analysis data week phase iii trialss breast cancer focus metformin integrative metformin mimic medicine real natural optionshypoglycemiaantidiabetic property bioactive constituent therapeutic effect scoparia dulcissafety efficacy early clinical experience insulin degludec japanese people diabetes mellitus first year report japanpharmacogenetics individual response treatment hyperglycemia type diabetesevidence based practice guideline treatment diabetes japan cardiovascular risk diabetes mellitus complication disease antihyperglycemic medicationsa randomize controlled trial liraglutide versus insulin detemir plus sitagliptin effective switch intensive insulin therapy daily injection patient well controlled type diabetesdifferential cardiovascular outcome dipeptidyl peptidase inhibitor sulfonylurea pioglitazone therapy combination metformin type diabetes population based cohort studypharmacologic treatment type diabetescontrol cardiovascular risk factor revascularized patient diabetes subanalysis icp bypass studycontrol de factores de riesgo cardiovascular en pacientes diab ticos revascularizados un suban lisis del estudio icp bypassoral antihyperglycemic treatment option type diabetes mellitushypoglycemia carea combine analysis type diabetes genetic risk variant show discriminative value predict time first prescription glucose lowering drug danish patient screen detect type diabetesglucose lowering drug patient chronic kidney disease narrative review pharmacokinetic propertieseconomic impact therapeutic choice case incretinsinsulin glargine add therapy oral hypoglycaemic agent achieve target fast plasma glucose level type diabetes patient indian setupweight gain glucose lowering agentsglucose control non insulin therapiesage specific effectiveness safety newly initiate insulin therapy japanese patient uncontrolled diabetespersonalizing guideline diabetes management twilight dawn expert additive postprandial glucose lowering effect mitiglinide sitagliptin patient type diabetes mellitushypoglycaemia type diabetes elderly peoplecounterregulatory deficiency diabetespharmacoth rapie du diab te de type get people diabetes cyclingsafety efficacy sulfonylurea drug type diabetes mellituspharmacologic management type diabetesnoninsulin glucose lowering agent treatment patient dialysiskomorbidit tenhypoglycemia associated autonomic failure diabetesendocrine pharmacologyclinical application different cross reactivities anti insulin antibody insulin lispro evaluate endogenous insulin secretiondosage antihyperglycemic drug patient renal insufficiencyfuture detection monitoring diabetes may entail analysis cell function volume marker cell loss may assistthe glucose lowering effect pde inhibitor roflumilast roflumilast n oxide db db miceevolution insulin development focus key parametersthe semdsa guideline management type diabetes revise hypoglycaemia diabetesbaseline factor associate glycemic control weight loss exenatide twice daily add optimize insulin glargine patient type diabetesthe semdsa guideline management type diabetesindividuelle therapieziele bei diabetes und extremer adipositaseffective management hypoglycaemia diabetesevaluation perception insulin therapy among chinese patient type diabetes mellitussulfonylureas need introspect safety manage hypoglycaemiamedically minimise impact hypoglycaemia type diabetes reviewinsulin detemir attenuate food intake body weight gain fat mass gain diet induced obese sprague dawley ratsutilities disutilities attribute injectable treatment type diabetesclinical audit hypoglycaemic symptom type diabetic patient singhealth polyclinicscomparative effectiveness safety medication type diabetes update include new drug drug combinationswendy l bennett md mph nisa maruthur md mhs sonal singh md mph jodi b segal md mph lisa wilson scm ranee chatterjee md mph spyridon marinopoulos md mba milo puhan md phd padmini ranasinghe md mph lauren block md wanda k nicholson md mph susan hutfless mph phd eric b bass md mph shari bolen md mphtaking hypoglycaemia seriously diabetes dementia heart diseasehypoglycemiaa comparison intermediate long acting insulin people type diabetes start insulin observational database studyweight management type diabetes mellitushypoglycemia diabetesglycaemic goal patient type diabetes current status challenge recent advancesclinical analysis elderly patient elderly onset type diabetes mellitus china assessment appropriate therapypioglitazone use combination insulin prospective pioglitazone clinical trial macrovascular event study proactive expression characterization momordica chanrantia anti hyperglycaemic peptide escherichia colirisk fatal nonfatal lactic acidosis metformin use type diabetes mellitusepidemiology diabetic retinopathythe continuation oral medication initiation insulin therapy type diabetes review evidencesuccesses challenge insulin therapy type diabetes managed care settinginsulin resistance cell dysfunction conversion type diabetes multiethnic populationsimultaneous pancreas kidney transplantation type diabetesdiabetes medication body weighttransplantation type diabetesmyocardial infarction stroke early year diagnosis type diabetes risk factor relation self monitoring blood glucosepro con early use insulin management type diabetes clinical evaluationorlistat mg improves glycaemic control type diabetic patient without concurrent weight losscontinuous glucose monitoring system free living healthy subject result pilot studyactivation amp activated protein kinase metformin improves leave ventricular function survival heart failuredrug evaluation vildagliptin metformin single tablet combinationinsulin monotherapy versus combination insulin oral hypoglycaemic agent patient type diabetes mellitusdiabetes mellituseffect diabetes medication cardiovascular risk surrogate marker patient type diabeteseffect weight reducing agent glycaemic parameter progression type diabetes reviewsuboptimal glycaemic control primary care need intensification therapy recognise hypoglycemia still limit factor glycemic management diabetesinsulin use weight maintenance well controlled type diabetes prospective cohort studysafety efficacy glargine compare nph insulin treatment type diabetes meta analysis randomize control trialsgps approach insulin prescribe old patient qualitative studyinsulin may role play protect beta cell deterioration diabetes reply del parigi letter primary care physician insulin initiation multiple barrier lack knowledge impact therapeutic advance hypoglycaemia type diabetesbarriers obesity treatmentpharmacogenetics potential role treatment diabetes obesitytailoring diabetes self care intervention use old rural african american womenan audit diabetes management asian patient treat specialist diabcare asia studiestype diabetes mellitus evidence based approach practical managementanalisi di costo efficacia di exenatide versus insulina glargine nel trattamento dei pazienti diabetici di tipo fallimento secondario al doppio ipoglicemizzante oraleriesgo elevado de disfunci n lipoproteica en la diabetes mellitus tipo delayed initiation subcutaneous insulin therapy failure oral glucose lowering agent patient type diabetes population based analysis ukhypoglycemia type diabetesoral hypoglycemic agentssystematic review comparative effectiveness safety oral medication type diabetes mellitusshari bolen md mph leonard feldman md jason vassy md mph lisa wilson b scm hsin chieh yeh phd spyridon marinopoulos md mba crystal wiley md mph elizabeth selvin phd renee wilson eric b bass md mph frederick l brancati md mhskombinierte niere pankreas transplantationcontinuous glucose monitoring patient type diabetes premixed insulin treatment type diabetes analogue human short term economic impact body weight change among patient type diabetes treat antidiabetic agent analysis use claim laboratory medical record dataobesity nutrigenomics metabolic syndrome type diabetesinsulin therapy hypoglycemia type diabetes mellitusafter pregnancy complicate diabetes postpartum care educationa double blind randomize study compare effect continue continue rosiglitazone metformin therapy start insulin therapy people type diabetes lean patient type diabetes characteristic therapy challengethe use basal insulin nph compare pre mixed biphasic insulin patient type diabetes mellitusmetformin associated lactic acidosis burn patientsicherheitsaspekte oraler antidiabetikatype diabetes get good startthe place insulin secretagogues treatment type diabetes twenty first centuryhealthcare professional bias obese know problem weight change follow initiation new anti hyperglycaemic therapiescontemporary analysis secondary failure successful sulfonylurea therapyoptimal glucose control type diabetes mellitus guide family practitionerlong term efficacy metformin therapy nonobese individual type diabetesinsulin aspart reviewaccuracy continuous subcutaneous glucose monitoring glucoday type diabetic patient treat subcutaneous insulin infusion exercise low versus high intensityinsulin sensitivity oral glucose tolerance test relation parameter glucose metabolism endothelial function type diabetic subject metformin thiazolidinedioneefficacy conversion bedtime nph insulin morning insulin glargine type diabetic patient basal prandial insulin therapyinterventions improve diabetes self managementan evaluation well research report facilitate use finding practiceeffect cyp c genetic polymorphism efficacy pharmacokinetics glimepiride subject type diabetesthe place sulfonylurea therapy type diabetes mellituscost hypoglycemia patient type diabetes swedendevelopment validation economic assessment glycemic control long term effect diabetes eagle modelprevalence inadequate glycemic control among patient type diabetes united kingdom general practice research database series retrospective analysis data challenges strategy move patient injectable medicationsrisk fatal nonfatal lactic acidosis metformin use type diabetes mellitusnateglinide glibenclamide examination use respiratory quotient rq hypoglycemia type diabetestype diabetes dyslipidemia vascular risk rationale evidence correct lipid imbalanceeffect increase cost sharing oral hypoglycemic use five managed care organizationsthe economic quality life impact hypoglycemiabasic approach manage hyperglycemia nonendocrinologistblood pressure control risk stroke untreated treated hypertensive patient screen clinical practice result forlife studyislet autoantibody clinically diagnose type diabetes prevalence relationship metabolic control ukpds association middle aged mother father body mass index year old son waist circumference birth weight serum hepatic enzyme levelsevaluation drug therapy risk factor diabetic hypertensive study quality care provide diabetic clinic bahrain exercise metformin hypoglycaemia neglected entityhypoglycemia stable insulin treated veteran type diabeteslower within subject variability fast blood glucose reduced weight gain insulin detemir compare nph insulin patient type diabetesbarriers follow dietary recommendation type diabetesefficacy glimepiride patient poorly control insulin treated type diabetes mellitusinsulin sensitivity oral glucose tolerance test relation parameter glucose metabolism endothelial function type diabetic subject metformin thiazolidinedionepractical consideration guideline dose sulfonylurea monotherapy combination therapythe effect different nutritional feed postprandial glucose response healthy volunteer patient type ii diabetesachieving glycemic control type diabetes practical guide clinician oral hypoglycemicsthe diabetes continuity care scale development initial evaluation questionnaire measure continuity care patient perspective impact insulin glargine clinical humanistic outcome patient uncontrolled insulin oral agent office based naturalistic study systematic approach manage hypertension metabolic syndrome primary caremanagement type diabetes mellitus time paradigm shift effect liraglutide long acting glucagon like peptide derivative glycemic control body composition h energy expenditure patient type diabetesanalisi di costo efficacia della terapia combinata con pioglitazone nel trattamento del diabete mellito di tipo italiahypoglycemia type diabetesdiverse cause hypoglycemia associated autonomic failure diabetesserum adiponectin associate high density lipoprotein cholesterol triglyceride low density lipoprotein particle size young healthy mencombination therapy type diabetesa placebo controlled crossover study compare effect nateglinide glibenclamide postprandial hyperglycaemia hyperinsulinaemia patient type diabetesclinical evaluation continuous minimally invasive glucose flux sensor place ultrasonically permeate skinorlistateffects moderate weight loss orlistat insulin resistance regional adiposity fatty acid type diabetesinappropriate medication elderly patientsaddition biphasic insulin aspart rosiglitazone type diabetes mellitus poorly control glibenclamide monotherapyhypoglycemiaprevention treatment type diabetes mellitus child special emphasis american indian alaska native childrenc reactive protein young apparently healthy men association serum leptin qtc interval high density lipoprotein cholesterolcommon problem outpatient management patient diabetes age insulin analoguesrisk fatal nonfatal lactic acidosis metformin use type diabetes mellitusclinical evaluation obese patientthe management obese diabetic patienthypoglycemia diabetesaddressing dose frequency diabetes simple approach improve adherence therapy clinical outcomesassociation hypoglycemia cardiac ischemiainsulin hypoglycemic agentstherapie de diabetes mellituspharmacotherapy diabetes mellitus implication prevention treatment cardiovascular diseasetroglitazone discovery development novel therapy treatment type diabetes mellitusbiomarkers functional food obesity diabetesthe improve primary care african american diabetes ipcaad projectadherence oral hypoglycaemic agent prior insulin therapy type diabetesorlistat use type diabetesclinical efficacy orlistat therapy overweight obese patient insulin treated type diabetesyoung men high normal blood pressure low serum adiponectin small ldl size high elevated heart rate optimal blood pressurepromoting physical activity people type diabetesorlistat treatment type diabetes mellitusimproved postprandial glycemic control biphasic insulin aspart relative biphasic insulin lispro biphasic human insulin patient type diabeteshypoglycemia associated autonomic failure advanced type diabetescontinuous subcutaneous glucose monitoring diabetic patientstreatment type diabetes mellitus pharmacologic interventionobesity type diabetes mellitus treatment challengenegotiating barrier hypoglycemia diabeteseffect acarbose weight maintenance dietary weight loss obese subject hypoglycemia associated autonomic failure diabetesrevis da hiperglicemia p prandial e hipoglicemia controle diabetes mellitus papel da insulina lispro e suas pr misturas picos e valesmanagement type diabetesthe effect metformin body mass index glucose tolerance obese adolescent fast hyperinsulinemia family history type diabetesbasal insulin therapy type diabetesglucose induced insulin resistance phosphatidylinositol oh kinase akt pkb mediate hexosamine biosynthesis pathwayonce twice daily dosing rosiglitazone improve glycemic control patient type diabetesmonotherapy metformin improve hypoxia type diabetic patient abnormality cell function development progression type diabetesglukosenuevos enfoques terap uticos en la diabetes tipo effect metformin cardiovascular risk factor obese type diabetic patientsnon insulin dependent diabetes mellitus type secondary failure metformin glibenclamide treatmenthormone replacement therapy postmenopausal woman diabetes mellitusafferent signal regulate food intakeenergy metabolism substrate oxidative pattern type diabetic patient treat sulphonylurea alone combination metforminpostpartum care woman diabetesbarriers control blood glucose diabetes mellitusmedical cost manage care patient type diabetes mellituscurrent potential drug treatment obesitypharmacologic therapy type diabetes mellitusralph defronzo mdeffects metformin patient poorly control insulin treated type diabetes mellitus randomized double blind placebo controlled triallarissa avil santa md joyce sinding msn rn philip raskin mddiabetische nephropathieglucose control guideline current conceptseffect high carbohydrate versus high monounsaturatedfatty acid diet metabolic control diabetes hyperglycemic patientstherapie de diabetes mellitushypoglycemia type diabetes february volume issue page keywordsattentionblood plasmadietglucosehemoglobinhyperglycemiahypoglycemicsinsulinoverweighttype diabetes epublished august issue publish february copyright permissionscopyright american college physician right reserved pdf downloadloading,,1998,Ann Intern Med,https://doi.org/10.7326/0003-4819-128-3-199802010-00001,9454524,,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D003131: Combined Modality Therapy; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005500: Follow-Up Studies; D006442: Glycated Hemoglobin; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D009765: Obesity; D011446: Prospective Studies; D013223: Statistics as Topic; D013453: Sulfonylurea Compounds; D006113: United Kingdom",,,https://openalex.org/W36168761,235,38,1,34940,5190,123,en,en
false,pharmacokinetics hypoglycemic sulfonamide ozidia new concept,hypoglycaemic sulfonamide differ property vary clinical importance potency sulfonamide increase generation however potency compensate practice dose prescribed much small recent generation half life far important property effective action period correlate half life much longer action period short term sulfonamide h tolbutamide glipizide exceed h long term sulfonamide e g glibenclamide metabolism elimination reduce risk accumulation sulfonamide metabolise liver metabolite inactive except one glibenclamide function action period possibly intrinsic property sulfonamide others e g glibenclamide affect fast hepatic glucose production particularly increase early day non insulin dependent diabetic patient circadian drop insulin sensitivity dawn phenomenon finally chronic administration sulfonamide cause progressive desensitisation beta cell respond insulin secretion peak food intake condition indicate unuselessness sulfonamide fractionation contrary classic notion low risk hypoglycaemia meal skip ideal product would sulfonamide high potency ultra short half life capable maintain plasma concentration h might seem incompatible except continuous administration moreover would exert action relatively low level insulinaemia completely metabolisable glipizide osmotic oral form ozidia satisfy condition since potent sulfonamide quite short half life intestinal delivery h administration osmotic principle control fast glycaema well ordinary glipizide least well glibenclamide act hepatic glucose production compare glibenclamide advantage generation effect low level insulinaemia comparison normal glipizide allow identical control low postprandial inslinaemias proof powerful inductive effect insulin sensitivity,Selam JL,1997,Diabetes Metab,,9463023,Selam JL,article,D016428: Journal Article; D016454: Review,"D000284: Administration, Oral; D002940: Circadian Rhythm; D003924: Diabetes Mellitus, Type 2; D005913: Glipizide; D006801: Humans; D007004: Hypoglycemic Agents; D007515: Islets of Langerhans; D008099: Liver",,,https://openalex.org/W2396907897,71,13,1,2399,403,20,en,en
false,population pharmacokinetics glyburide patient well controlled diabetes,study objective investigate glyburide pharmacokinetics patient well controlled noninsulin dependent diabetes mellitus niddm test hypothesis intersubject variability glyburide dose due patient difference drug pharmacokinetics method prospective open label study set university affiliated internal medicine outpatient clinic patient fifty one patient niddm woman men mean age yr receive oral glyburide well controlled glycohemoglobin level intervention fast overnight patient ingest regular morning dose glyburide eat breakfast blood sample draw dose hour hour hour dose measurement main result serum glyburide assay high performance liquid chromatography pharmacokinetics nonmem glyburide clearance proportional weight great old patient yr conclusion variability glyburide dose primarily due intersubject difference drug pharmacokinetics,Tracewell WG,1998,Pharmacotherapy,,9469681,Tracewell WG; Stalker DJ; Maloley PA; Gallagher TF; Gwilt PR,article,D016428: Journal Article,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001682: Biological Availability; D015331: Cohort Studies; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008657: Metabolic Clearance Rate; D008875: Middle Aged; D011446: Prospective Studies",,,https://openalex.org/W1568874392,82,9,1,1146,185,16,en,en
false,treatment niddm youth,study present characteristic child female niddm require oral hypoglycemic agent oha therapy family history niddm present none islet cell antibody ica glutamic acid decarboxylase gad antibody tolbutamide drug choice glibenclamide introduce glycemic control obtain month tolbutamide therapy seven patient eventually required insulin therapy clin pediatr,Owada M,1998,Clin Pediatr (Phila),https://doi.org/10.1177/000992289803700209,9492120,Owada M; Nitadori Y; Kitagawa T,article,D002363: Case Reports; D016428: Journal Article,"D000293: Adolescent; D002648: Child; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007564: Japan; D008297: Male; D012572: School Health Services; D014044: Tolbutamide",,,https://openalex.org/W2110083541,27,5,1,496,92,7,en,en
false,molecular effect sulphonylurea agent circulate lymphocyte patient non insulin dependent diabetes mellitus,circulate lymphocyte niddm patient pyruvate dehydrogenase pdh major determinant glucose consumption oxidative pathway poorly active aim study examine whether sulphonylurea drug treatment revive pdh activity circulate lymphocyte niddm patients twenty normal weight individual niddm enrol study maintain glycaemic level close normal mean restrict diet longer successful proceed month treatment protocol consist mg gliclazide daily week twenty healthy subject match age body mass index gender enrol control group patient treatment well control test pdh activity circulating lymphocyte nine untreated patient nine healthy subject mention characteristic recruit assay pdh activity circulating lymphocyte exposure vitro gliclazide insulin gliclazide insulin combination gliclazide treated niddm patient pdh activity circulate lymphocyte recover vitro circulate lymphocyte untreated patient control insulin microu ml ineffective highly effective respectively raise enzyme activity gliclazide ng ml ineffective pdh group combination insulin microu ml group pdh active cell control expose insulin cell control gliclazide alone ng ml cause enzyme activation whereas ng ml cause inhibition cell patient ng ml effect ng ml raise enzyme activity basal level controls study suggest free gliclazide concentration determine recovery pdh activity circulate lymphocyte treated patient drug mediated enhanced insulin control pdh drug alone,Rabbone I,1998,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.1998.00680.x,9517374,Rabbone I; Piccinini M; Curto M; Mostert M; Gamba S; Mioletti S; Bruno R; Rinaudo MT,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005907: Gliclazide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008214: Lymphocytes; D008297: Male; D008875: Middle Aged; D011768: Pyruvate Dehydrogenase Complex",,,https://openalex.org/W1633802741,125,14,1,2079,370,9,en,en
false,long term treatment dual antithromboxane agent picotamide decrease microalbuminuria normotensive type diabetic patient,picotamide inhibits thromboxane synthetase act thromboxane antagonist receptor level investigate long term effect picotamide urinary albumin excretion uae rest induce exercise type diabetic patient normotensive microalbuminuria rest subject study mean age year bmi kg diabetes duration year hba c study randomized double blind placebo controlled trial patient randomly allocate receive year either picotamide mg tablets day placebo tablets day patient ask visit outpatient clinic month treatment time blood pressure microalbuminuria rest blood glucose serum creatinine serum picotamide creatinine clearance measure baseline month patient underwent submaximal physical exercise month picotamide baseline exercise induced microalbuminuria significantly decrease one third compare baseline placebo level drop month picotamide treatment placebo treatment uae rest exercise slightly increase compare baseline value effect picotamide occur without significant side effect change either blood pressure level glycometabolic control study first long term intervention trial type diabetes show antithromboxane agent able decrease microalbuminuria disease dual marker macro microangiopathy finding suggest important role thromboxane pathophysiology microalbuminuria diabetes moreover hypothesize antithromboxane agent may place treatment prevention macro microvascular complication type diabetic patient,Giustina A,1998,Diabetes,https://doi.org/10.2337/diabetes.47.3.423,9519749,Giustina A; Perini P; Desenzani P; Bossoni S; Ianniello P; Milani M; Davì G; Romanelli G,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000419: Albuminuria; D001794: Blood Pressure; D015331: Cohort Studies; D003924: Diabetes Mellitus, Type 2; D003928: Diabetic Nephropathies; D004311: Double-Blind Method; D015444: Exercise; D005260: Female; D005500: Follow-Up Studies; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D010795: Phthalic Acids; D010975: Platelet Aggregation Inhibitors; D013929: Thromboxane B2; D013997: Time Factors",,,https://openalex.org/W2128491499,135,17,1,1989,344,12,en,en
false,concentration effect relationship sulphonylureas,sulphonylureas remain mainstay oral therapy type non insulin dependent diabetes mellitus niddm stimulate insulin release pancreatic beta cell pharmacokinetic difference various sulphonylureas clinical importance term time onset action timing drug administration relation food intake magnitude duration glucose lowering effect risk serious hypoglycaemia recent study improved analytical sensitivity show elimination half life glibenclamide long previously think metabolite glibenclamide significant hypoglycaemic activity furthermore single dose study healthy volunteer use integrate pharmacokinetic pharmacodynamic model identify clear concentration effect relationship glibenclamide metabolite oral intravenous administration multiple dose condition kinetic dynamic relation identify shorter acting drug dosage give discontinuous sulphonylurea exposure however continuous exposure e sustain hour therapeutic concentration plasma evidence indicate development tolerance may cause downregulation beta cell sensitivity sophisticated concentration effect study appear become evident currently recommend maximum daily dos many sulphonylureas high,Melander A,1998,Clin Pharmacokinet,https://doi.org/10.2165/00003088-199834030-00001,9533980,Melander A; Donnelly R; Rydberg T,article,D016428: Journal Article; D016454: Review,"D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2056696280,64,8,1,1488,213,9,en,en
false,effect short period caloric restriction weight loss glycemic control type diabetes,objective determine whether intermittent low calorie diet vlcd improve weight loss glycemic control moderate caloric restriction alone research design method individual type diabetes n ideal body weight participate week behavioral weight control program subject randomize either standard behavioral therapy sbt group one two vlcd group sbt subject receive kcal day diet throughout vlcd group follow vlcd consecutive day week follow either intermittent vlcd therapy day week week day consecutive day every week day kcal day diet time result vlcd group lose weight sbt group week p although group differ fast plasma glucose fpg change week subject day group attain normal hba c compare sbt group p benefit independent effect weight loss best predictor overall change fpg hba c fpg response first week program conclusion periodic vlcds improve weight loss diabetic subject regimen intermittent day vlcd therapy seem particularly promising subject group attain normal hba c moreover glucose response week period diet therapy predict glycemic response week good predictor week response initial overall weight loss,Williams KV,1998,Diabetes Care,https://doi.org/10.2337/diacare.21.1.2,9538962,Williams KV; Mullen ML; Kelley DE; Wing RR,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000368: Aged; D001521: Behavior Therapy; D001786: Blood Glucose; D015992: Body Mass Index; D002784: Cholesterol; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D004038: Diet, Reducing; D002149: Energy Intake; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D008297: Male; D008875: Middle Aged; D009765: Obesity; D012044: Regression Analysis; D013997: Time Factors; D014280: Triglycerides; D015431: Weight Loss",,,https://openalex.org/W2003983465,105,18,1,1615,299,12,en,en
true,ukpds randomized trial efficacy early addition metformin sulfonylurea treated type diabetes,assess efficacy year addition metformin maximum sulfonylurea therapy type diabetes multicenter randomize open controlled trial conduct outpatient diabetes clinic u k hospital total subject already randomly allocate sulfonylurea therapy take maximum dos suboptimal glycemic control e raise fast plasma glucose fpg concentration mmol l significant hyperglycemic symptom main outcome measure include fpg glycated hemoglobin protocol defined mark hyperglycemia body weight blood pressure fast plasma lipid compliance hypoglycemia side effects addition metformin fpg concentration decrease mean ci mmol l year compare increase mmol l subject sulfonylurea alone p median fpg concentration year vs mmol l respectively p hba c value respectively p adjustment baseline bmi fpg concentration affect response therapy allocate sulfonylurea plus metformin developed protocol defined mark hyperglycemia compare allocate sulfonylurea alone p fast plasma lipid body weight blood pressure change significantly incidence hypoglycemic episode differ group sulfonylurea plus metformin sulfonylurea alone ns early addition metformin improve glycemic control patient suboptimal glycemic control take maximum sulfonylurea therapy irrespective obesity baseline fpg concentration,,1998,Diabetes Care,https://doi.org/10.2337/diacare.21.1.87,9538975,,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D001786: Blood Glucose; D001794: Blood Pressure; D002747: Chlorpropamide; D002784: Cholesterol; D002985: Clinical Protocols; D003924: Diabetes Mellitus, Type 2; D004359: Drug Therapy, Combination; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D010349: Patient Compliance; D013453: Sulfonylurea Compounds; D014280: Triglycerides; D006113: United Kingdom",,,https://openalex.org/W2786617581,111,18,1,1760,302,8,en,en
false,blood glucose lower effect exercise glibenclamide patient type diabetes mellitus,physical exercise associate fall serum insulin level whereas sulphonylurea administration increase insulin release date oppose effect exercise sulphonylurea administration systematically study type diabetic patient infrequently treat sulphonylureas study nine patient type diabetes mellitus subject four treatment random order separate day endurance exercise administration mg glibenclamide b give mg glibenclamide c placebo rest administration mg glibenclamide exercise placebo result small decrease glycaemia rest administration mg glibenclamide lead moderate steady fall blood glucose concentration glibenclamide administration exercise combine blood glucose concentration decline markedly serum insulin concentration show physiological decrease exercise placebo administration patient rest administration glibenclamide serum insulin level rise remain elevate exercise glibenclamide combine rise serum insulin level blunt insulin level fell exercise begin thus exercise attenuate glibenclamide induce increase serum insulin moderately hyperglycaemic type diabetic patient nevertheless exercise substantial hypoglycaemic effect glibenclamide treat type diabetic patient,Gudat U,1998,Diabet Med,https://doi.org/10.1002/(sici)1096-9136(199803)15:3<194::aid-dia546>3.0.co;2-2,9545119,Gudat U; Bungert S; Kemmer F; Heinemann L,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001786: Blood Glucose; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D015444: Exercise; D005934: Glucagon; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D019344: Lactic Acid; D008875: Middle Aged",,,https://openalex.org/W1997874887,106,16,1,1549,248,11,en,en
true,model cause mortality projection impact smoke cessation base nhefs nhanes epidemiologic follow study,model relate clinical risk factor subsequent mortality use simulate impact smoke cessation survivor function derive multivariate hazard regression fit data first national health nutrition examination survey nhanes epidemiologic followup study longitudinal survey representative sample u adult use project death causes validation test show hazard regression agree risk relationship report others project death baseline risk factor closely match observed mortality projection attribute death appropriate level important risk factor projection impact smoke cessation show number cumulative death would low year low years model produce realistic projection effect risk factor modification subsequent mortality adult comparison projection smoke cessation estimate risk attributable smoke publish center disease control prevention suggest cessation could capture benefit possible eliminate smoking,Russell LB,1998,Am J Public Health,https://doi.org/10.2105/ajph.88.4.630,9551006,Russell LB; Carson JL; Taylor WC; Milan E; Dey A; Jagannathan R,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.",D000368: Aged; D002423: Cause of Death; D005260: Female; D005500: Follow-Up Studies; D005544: Forecasting; D006801: Humans; D008297: Male; D008875: Middle Aged; D009026: Mortality; D015999: Multivariate Analysis; D009749: Nutrition Surveys; D016016: Proportional Hazards Models; D015203: Reproducibility of Results; D012307: Risk Factors; D012907: Smoking; D016540: Smoking Cessation; D000074606: Smoking Prevention; D014481: United States,,,https://openalex.org/W2040959518,136,22,2,1225,190,2,en,en
true,glimepiride,unlabelled glimepiride sulphonylurea agent stimulate insulin release pancreatic beta cells may act via extrapancreatic mechanism administer daily patient type non insulin dependent diabetes mellitus glycaemia control diet exercise alone may combine insulin patient secondary sulphonylurea failure great blood glucose lower effect glimepiride occur first hour dose glimepiride less severe effect cardiovascular variable glibenclamide glyburide pharmacokinetics mainly unaltered elderly patient renal liver disease drug interaction glimepiride document patient type diabetes glimepiride effective dosage range mg day although little difference efficacy dosage mg day glimepiride similar efficacy glibenclamide glipizide year study however glimepiride appear reduce blood glucose rapidly glipizide first week treatment glimepiride gliclazide compare patient good glycaemic control baseline week study note difference effect glimepiride plus insulin effective insulin plus placebo help patient secondary sulphonylurea failure reach fasting blood glucose target level mmol l although low insulin dosage rapid effect glycaemia see glimepiride although glimepiride monotherapy generally well tolerate hypoglycaemia occur patient treat year patient receive concomitant insulin month pool clinical trial data suggest glimepiride may low incidence hypoglycaemia glibenclamide particularly first month treatment dosage usually start mg day titrate glycaemic control week interval usual dosage range mg day maximum mg day uk mg day u conclusion glimepiride conveniently administer alternative sulphonylureas patient type diabetes mellitus well control diet alone possible tolerability advantage use combination oral antidiabetic drug require study glimepiride also report reduce exogenous insulin requirement patient secondary sulphonylurea failure administer combination insulin,Langtry HD,1998,Drugs,https://doi.org/10.2165/00003495-199855040-00007,9561345,Langtry HD; Balfour JA,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,"D001786: Blood Glucose; D018849: Controlled Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004338: Drug Combinations; D004347: Drug Interactions; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007515: Islets of Langerhans; D013453: Sulfonylurea Compounds; D014018: Tissue Distribution",,,https://openalex.org/W1973551179,11,1,1,2603,428,17,en,en
true,response intensive therapy step glipizide dose combination insulin type diabetes va feasibility study glycemic control complication va csdm,feasibility study va cooperative study glycemic control complication type diabetes va csdm prospectively study insulin requiring type diabetes patient randomize intensively treated arm standard treatment arm mean follow month glycemic response progressive sequential phase insulin treatment assess along incidence hypoglycemic reaction relative efficacy different dos glipizide combination fixed dos insulin five medical center participate half patient assign intensive treatment arm aim normal hba c level age patient year duration diabetes year bmi kg four step management technique use patient move next step operational goal meet phase even intermediate long acting insulin phase ii add day time glipizide phase iii two injection insulin alone phase iv multiple daily insulin injection home glucose monitoring measurement twice daily week hypoglycemic reaction home glucose monitor result record count treatment phases baseline hba c fast plus serum glucose mmol fast serum glucose fell near normal phase remain treatment phase hba c separation arm maintain course study intensive arm keep hba c level p decrease hba c occur one injection insulin alone phase add day time glipizide phase ii compare baseline hba c decrease far substitute two injection insulin alone twice insulin dose multiple daily injection result additional hba c fall compare baseline however two thirds patient still one two injection day end study change home glucose monitoring level parallel hba c increment number reported hypoglycemic reaction virtually either mild moderate character combination glipizide insulin phase ii significant effect obtain daily dos mg day significant additional benefit fourfold high daily dos hba c level upward trend dos mg day simple regime single injection insulin alone glipizide seem sufficient obtain clinically acceptable level hba c obese insulin requiring type diabetes patient decrease hba c demand multiple daily injection expense double insulin dose rate hypoglycemic event combination therapy dos glipizide mg day offer additional benefit,Abraira C,1998,Diabetes Care,https://doi.org/10.2337/diacare.21.4.574,9571345,Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.","D000328: Adult; D000368: Aged; D001786: Blood Glucose; D015190: Blood Glucose Self-Monitoring; D003924: Diabetes Mellitus, Type 2; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005215: Fasting; D005913: Glipizide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies",,,https://openalex.org/W2083008973,174,30,1,3022,549,16,en,en
false,beta cell deterioration determine onset rate progression secondary dietary failure type diabetes mellitus year follow belfast diet study,secondary failure plasma glucose control follow initial successful response diet therapy may due dietary indiscretion progression intrinsic diabetic condition report year prospective natural history study newly diagnose diabetic patient age year undertaken assess effect intensive dietary management patient transfer insulin oral hypoglycaemic therapy tolbutamide metformin predetermine criterion weight plasma glucose secondary failure diet therapy occur patient year patient year patient year patient remain diet alone death end study continuation diet alone associate low ongoing fast plasma glucose great beta cell function assess oral glucose tolerance test month increase age rate rise fast plasma glucose inversely relate duration successful dietary therapy mean weight remain constant group diet alone ongoing fall beta cell function assess homa model closely mirror progressive rise fast plasma glucose change mean insulin sensitivity group john wiley son ltd,Levy J,1998,Diabet Med,https://doi.org/10.1002/(sici)1096-9136(199804)15:4<290::aid-dia570>3.0.co;2-m,9585393,Levy J; Atkinson AB; Bell PM; McCance DR; Hadden DR,article,D016428: Journal Article,"D000328: Adult; D000368: Aged; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007515: Islets of Langerhans; D008297: Male; D008687: Metformin; D008875: Middle Aged; D009660: Northern Ireland; D013997: Time Factors; D014044: Tolbutamide; D017211: Treatment Failure",,,https://openalex.org/W2090582239,174,27,1,1325,229,7,en,en
true,ukpds sulphonylurea failure non insulin dependent diabetic patient six year,patient type non insulin dependent diabetes mellitus dm sulphonylurea therapy convert insulin progressively sulphonylureas fail rate failure feature fail poorly describe assess secondary failure rate sulphonylureas report response patient newly diagnose type dm randomly allocate therapy either chlorpropamide glibenclamide uk prospective diabetes study ukpds patient initially treat diet month fasting plasma glucose mmol l mean age sd year bmi sd kg median fasting plasma glucose quartile mmol l fasting plasma glucose subsequently rise mmol l develop hyperglycaemic symptom additional hypoglycaemic therapy give metformin ultratard insulin soluble insulin require year require additional therapy randomize glibenclamide require additional therapy year compare allocate chlorpropamide p sixty one per cent respectively patient fast plasma glucose mmol l mmol l mmol l mmol l randomization require additional therapy p initial year non obese subject bmi kg likely require additional therapy obese patient bmi kg vs year p model beta cell function show low function likely fail p thus sulphonylureas fail therapeutic agent rate dependent phenotype presentation perhaps agent use initially high failure rate find high glucose concentration young low beta cell reserve randomize glibenclamide compare chlorpropamide,Matthews DR,1998,Diabet Med,https://doi.org/10.1002/(sici)1096-9136(199804)15:4<297::aid-dia572>3.0.co;2-w,9585394,Matthews DR; Cull CA; Stratton IM; Holman RR; Turner RC,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D001786: Blood Glucose; D015992: Body Mass Index; D002747: Chlorpropamide; D003924: Diabetes Mellitus, Type 2; D005215: Fasting; D005260: Female; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007515: Islets of Langerhans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D017211: Treatment Failure; D006113: United Kingdom",,,https://openalex.org/W2013253832,89,12,1,2030,419,12,en,en
false,effect magnesium supplementation increase dos control type diabetes,hypomagnesemia occur patient type diabetes several study suggest association magnesium mg depletion insulin resistance reduction insulin secretion case purpose evaluate mg supplementation magnesium oxide mgo would improve metabolic control patient type diabetes study patient type diabetes men woman age year treat diet diet plus oral antidiabetic drug bahia federal university hospital brazil patient risk hypomagnesemia reduced renal function exclude study clinical randomized double blind placebo controlled trial patient receive either placebo mmol mgo mmol mgo daily elementary mg day mg concentration measure plasma mononuclear cell h urine sample fast blood glucose hba fructosamine use parameter metabolic control patient low plasma mg low intramononuclear mg level intracellular mg patient diabetes significantly low normal population blood donor vs micrograms mg total protein correlation find plasma intracellular mg concentration r p mg concentration glycemic control r p intracellular mg level low patient peripheral neuropathy without vs micrograms mg similar finding observe patient coronary disease vs micrograms mg placebo mmol mg group neither change plasma intracellular level improvement glycemic control observe replacement mmol mg tend increase plasma cellular urine mg cause significant fall mmol l fructosamine normal mmol l mg depletion common poorly control patient type diabetes especially neuropathy coronary disease prolonged use mg dos high usual need establish routine selective administration patient type diabetes improve control prevent chronic complication,de Lordes Lima M,1998,Diabetes Care,https://doi.org/10.2337/diacare.21.5.682,9589224,de Lordes Lima M; Cruz T; Pousada JC; Rodrigues LE; Barbosa K; Canguçu V,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001786: Blood Glucose; D015992: Body Mass Index; D001835: Body Weight; D003924: Diabetes Mellitus, Type 2; D019587: Dietary Supplements; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005215: Fasting; D005260: Female; D019270: Fructosamine; D005951: Glucose Tolerance Test; D006442: Glycated Hemoglobin; D006801: Humans; D006943: Hyperglycemia; D008274: Magnesium; D008297: Male; D008875: Middle Aged; D012016: Reference Values",,,https://openalex.org/W2118142139,93,15,1,2365,432,15,en,en
false,change amylin amylin like peptide concentration ana cell function response sulfonylurea insulin therapy niddm,objective amylin secretory peptide fi cells constituent peptide islet amyloid characteristic niddm change amylin secretion response therapy may influence rate production islet amyloid primary objective study determine whether therapy sulfonylurea basal insulin niddm would alter amylin secretion way might affect formation islet amyloid research design method randomized crossover design eight subject niddm underwent diree week period therapy diet alone sulfonylurea exogenous basal insulin evaluation amylin amylin like peptide alp glucose c peptide concentration fasting standard breakfast change cell function assess basal state homeostasis model assessment homa stimulated state hyperglycemic clamp seven nondiabetic control subject underwent meal profile hyperglycemic clamp result sulfonylurea insulin therapy reduce basal glucose concentration compare diet alone neither reduce increase postprandial glucose increment sulfonylurea insulin therapy increase basal assess homa sulfonylurea increase second phase c peptide response hyperglycemic clamp sulfonylurea increase time averaged mean postprandial amylin alp concentration compare diet alone geometric mean sd range amylin vs pmol p alp vs pmol p insulin therapy reduce basal alp concentration compare diet alone vs pmol p effect postprandial concentration amylin pmol alp pmol conclusion increase postprandial concentration constituent peptide islet amyloid sulfonylurea therapy might increase rate deposition islet amyloid thereby accelerate decline niddm compare diet therapy alone,Rachman J,1998,Diabetes Care,https://doi.org/10.2337/diacare.21.5.810,9589246,Rachman J; Payne MJ; Levy JC; Barrow BA; Holman RR; Turner RC,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000682: Amyloid; D001786: Blood Glucose; D002096: C-Peptide; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D005215: Fasting; D005260: Female; D005947: Glucose; D015309: Glucose Clamp Technique; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D058228: Islet Amyloid Polypeptide; D007515: Islets of Langerhans; D008297: Male; D008875: Middle Aged; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2082773022,133,20,1,2148,380,10,en,en
false,oxidative stress metabolic control non insulin dependent diabetes mellitus,aim study evaluate conjugated dienes subject non insulin dependent diabetes mellitus niddm metabolic control achieve good metabolic control addition dietary management oral hypoglycemic agent glibenclamide gliclazide metformin give patient human plasma low density lipoprotein ldl delipidised triglyceride ldl tg cholesterol ester ldl ce separate conjugate dienes ldl tg ldl ce subject niddm n normal glucose tolerance ngt n measure use second derivative uv absorption spectrum hypoglycemic agent lower substantially concentration ci trans c trans trans conjugate dienes ldl ce ldl tg duration niddm show significant correlation p conjugate dienes ldl tg concentration c conjugated dienes ldl ce ldl tg find significantly higher subject niddm ngt p conclusion niddm status metabolic control duration diabetes strong positive relation oxidative stress,Singh S,1997,Indian J Biochem Biophys,,9594432,Singh S; Melkani GC; Rani C; Gaur SP; Agrawal V; Agrawal CG,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D016022: Case-Control Studies; D002788: Cholesterol Esters; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D008077: Lipoproteins, LDL; D008875: Middle Aged; D018384: Oxidative Stress; D014280: Triglycerides",,,https://openalex.org/W2410897344,82,11,1,1146,209,8,en,en
false,effect acarbose treatment type ii diabetes mellitus double blind crossover placebo controlled trial,study evaluate efficacy acarbose improvement metabolic control patient fairly well control non insulin dependent diabetes mellitus niddm fifteen patient mean age duration diabetes se year respectively recruit complete study protocol study double blind crossover placebo controlled design consist two twelve week treatment acarbose placebo separate eight week washout period acarbose effective lower hour hour postprandial plasma glucose mg dl p mg dl p respectively fast plasma glucose slightly decrease without significant change mg dl p overall glycemic control tend improve study period indicate fall hba c level per cent p serum c peptide fasting postprandial well serum lipid affect acarbose almost half patient treat acarbose mild tolerable gastrointestinal adverse effect conclusion acarbose combine therapy oral hypoglycemic agent effective improvement glycemic control particularly postprandial hyperglycemia fairly well control niddm patient mild acceptable adverse effect,Soonthornpun S,1998,J Med Assoc Thai,,9623011,Soonthornpun S; Rattarasarn C; Thamprasit A; Leetanaporn K,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D020909: Acarbose; D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D014312: Trisaccharides",,,https://openalex.org/W2403369066,114,19,1,1475,257,9,en,en
false,begin insulin treatment obese patient even insulin plus glimepiride versus insulin alone,objective study test simple algorithm begin insulin obese patient type diabetes sulfonylurea failure compare suppertime insulin plus continued glimepiride insulin alone research design method multicenter ambulatory randomize double masked parallel comparison subject secondary failure sulfonylureas take glimepiride titrate mg b week subject fast plasma glucose fpg mg dl mmol treatment randomize placebo plus insulin pi glimepiride plus insulin gi week dosage insulin supper titrate seek fast capillary blood glucose fbg mg dl mmol equivalent fpg mg dl mmol outcome measure include fpg hba c insulin dosage weight serum insulin lipid adverse event result fpg hba c equivalent baseline vs mg dl vs mmol vs week fpg target achieve group vs mg dl vs mmol hba c value equal vs however gi control improve faster subject drop vs p lt less insulin need vs u p lt outcome alike respect subject severe hypoglycemia conclusion injection insulin supper safely restored glycemic control type diabetes control glimepiride alone control restore rapidly less injected insulin glimepiride continue,Riddle MC,1998,Diabetes Care,https://doi.org/10.2337/diacare.21.7.1052,9653594,Riddle MC; Schneider J,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001786: Blood Glucose; D002096: C-Peptide; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005215: Fasting; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D009765: Obesity; D010352: Patient Dropouts; D013453: Sulfonylurea Compounds; D016896: Treatment Outcome; D014280: Triglycerides",,,https://openalex.org/W1994999237,110,15,1,1646,322,13,en,en
false,acarbose niddm patient poor control conventional oral agent week placebo controlled study,determine efficacy acarbose compare placebo metabolic control niddm patient inadequately control maximal dos conventional oral agents three center double blind study chinese niddm patient persistent poor glycemic control despite maximal dos sulfonylurea metformin randomly assign receive additional treatment acarbose mg thrice daily placebo week week dietary reinforcement efficacy assess change hba c fast h postprandial plasma glucose insulin level fast lipid levels acarbose treatment associate significantly great reduction hba c vs placebo mean sem p h postprandial glucose mmol l vs placebo mmol l p body weight kg vs placebo kg p significant difference two group regard change fast plasma glucose lipid fasting postprandial insulin level flatulence common side effect acarbose vs placebo vs p one patient acarbose asymptomatic elevation serum transaminase normalize week acarbose withdrawal another patient acarbose develop severe hypoglycemia glycemic control subsequently maintain half baseline dosage sulfonylurea niddm patient inadequately control conventional oral agent acarbose moderate dos result beneficial effect glycemic control especially postprandial glycemia mean body weight additional use acarbose consider useful alternative patient reluctant accept insulin therapy,Lam KS,1998,Diabetes Care,https://doi.org/10.2337/diacare.21.7.1154,9653611,Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D020909: Acarbose; D000284: Administration, Oral; D001786: Blood Glucose; D002681: China; D002784: Cholesterol; D008076: Cholesterol, HDL; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004351: Drug Resistance; D005215: Fasting; D005260: Female; D005414: Flatulence; D005767: Gastrointestinal Diseases; D006442: Glycated Hemoglobin; D006723: Hong Kong; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D010349: Patient Compliance; D010919: Placebos; D019518: Postprandial Period; D013453: Sulfonylurea Compounds; D000637: Transaminases; D016896: Treatment Outcome; D014280: Triglycerides; D014312: Trisaccharides",,,https://openalex.org/W2115720674,108,16,1,1801,303,7,en,en
false,accelerated oral absorption gliclazide human subject soft gelatin capsule contain peg suspension gliclazide,whether rapid elevation serum gliclazide concentration human subject achieve acceleration dissolution gliclazide formulation examine soft gelatin capsule contain peg peg tween glycerin prepare formulation may accelerate dissolution gliclazide vitro dissolution gliclazide ph identical soft capsule conventional tablet diamicron diberin however ph dissolution soft capsule rapid compare tablet bioavailability parameter compare follow oral administration soft capsule diamicron healthy korean male subject parameter represent amount absorption e area serum gliclazide concentration vs time curve h auc peak serum concentration cmax statistically different formulation however time require reach peak tmax significantly short soft capsule diamicron result therefore indicate rapid elevation serum gliclazide concentration follow oral administration formulation achieve accelerate vitro dissolution gliclazide formulation acidic buffer thus rate gastrointestinal absorption gliclazide appear dependent vivo dissolution rate gastric fluid soft capsule contain peg suspension gliclazide appear appropriate formulation accelerate dissolution,Hong SS,1998,J Control Release,https://doi.org/10.1016/s0168-3659(97)00167-3,9685916,Hong SS; Lee SH; Lee YJ; Chung SJ; Lee MH; Shim CK,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D019540: Area Under Curve; D002214: Capsules; D016503: Drug Delivery Systems; D005780: Gelatin; D005907: Gliclazide; D005990: Glycerol; D006801: Humans; D006863: Hydrogen-Ion Concentration; D007004: Hypoglycemic Agents; D007408: Intestinal Absorption; D007723: Korea; D011092: Polyethylene Glycols; D011136: Polysorbates; D012995: Solubility; D013810: Therapeutic Equivalency",,,https://openalex.org/W1999710538,133,20,1,1602,270,10,en,en
false,isolated postchallenge hyperglycemia risk fatal cardiovascular disease old woman men rancho bernardo study,determine whether diabetes define isolated postchallenge hyperglycemia iph h postchallenge plasma glucose mmol l fast plasma glucose fpg mmol l increase risk fatal cardiovascular disease cvd old woman men prospective study follow men woman age year history diabetes myocardial infarction demonstrate fasting hyperglycemia e fpg mmol l undergo oral glucose tolerance test baseline baseline woman men previously undiagnosed diabetes iph next year woman iph significantly increase risk fatal cvd heart disease compare nondiabetic woman increase risk observe men iph association independent age hypertension central obesity cigarette smoking hdl cholesterol triglyceride multiply adjust hazard ratio ci cvd heart disease diabetes define iph alone common old adult double risk fatal cvd heart disease old woman prevalence iph increase age use fast glucose alone diabetes screen diagnosis may fail identify old adult high risk cvd reevaluate,Barrett-Connor E,1998,Diabetes Care,https://doi.org/10.2337/diacare.21.8.1236,9702426,Barrett-Connor E; Ferrara A,article,"D016428: Journal Article; D016448: Multicenter Study; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000367: Age Factors; D000368: Aged; D000369: Aged, 80 and over; D000428: Alcohol Drinking; D001786: Blood Glucose; D001824: Body Constitution; D015992: Body Mass Index; D002140: California; D002318: Cardiovascular Diseases; D002784: Cholesterol; D015331: Cohort Studies; D005060: Europe; D005215: Fasting; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006943: Hyperglycemia; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012307: Risk Factors; D012737: Sex Factors; D012907: Smoking; D014280: Triglycerides; D044465: White People",,,https://openalex.org/W1973855053,131,20,1,1398,259,5,en,en
true,placebo controlled randomized study glimepiride patient type diabetes mellitus diet therapy unsuccessful,multicenter randomize placebo controlled study glimepiride new oral sulfonylurea conduct patient type diabetes dietary treatment unsuccessful fast plasma glucose fpg mg dl week screening period patient randomize receive glimepiride n placebo n daily week dose titration period maintain individually determine optimal dose mg glimepiride placebo week glimepiride lower fpg mg dl hemoglobin c hba c hour postprandial glucose mg dl placebo glimepiride improve postprandial insulin c peptide response without produce clinically meaningful increase fast insulin c peptide level good glycemic control hba achieve patient take glimepiride versus take placebo overall incidence adverse event similar group clinically noteworthy abnormal laboratory value hypoglycemia blood glucose mg dl occur glimepiride safe effective treatment patient type diabetes diet therapy unsuccessful,Schade DS,1998,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1998.tb04471.x,9702849,Schade DS; Jovanovic L; Schneider J,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D000368: Aged; D001786: Blood Glucose; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D004035: Diet Therapy; D004311: Double-Blind Method; D005215: Fasting; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D019518: Postprandial Period; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2166418130,133,20,1,1217,219,8,en,en
false,troglitazone combination sulfonylurea restores glycemic control patient type diabetes,objective determine combination troglitazone peroxisome proliferator activated receptor activator sulfonylurea provide efficacy attainable either medication alone research design method patient inadequately control maximum dos sulfonylurea participate week randomized active controlled multicenter study patient randomize micronized glyburide mg q g troglitazone monotherapy mg q combine troglitazone glyburide q g g g efficacy measure include hba c fast serum glucose fsg insulin c peptide effect lipid safety also assess result patient g significantly low mean sem fsg mmol l mg dl compare control subject mmol l mg dl p lt significantly low mean hba c vs p lt significant dose related decrease also see g g among patient g achieve hba c achieve hba c achieve fsg mmol l mg dl fast insulin c peptide decrease treatment overall triglyceride free fatty acid decrease whereas hdl cholesterol increase ldl cholesterol increase slightly change apolipoprotein b adverse event similar across treatment hypoglycemia occur g patient compare lt g troglitazone monotherapy conclusion patient type diabetes inadequately control sulfonylurea effectively manage combination troglitazone sulfonylurea safe well tolerate represent new approach achieve glycemic target recommend american diabetes association,Horton ES,1998,Diabetes Care,https://doi.org/10.2337/diacare.21.9.1462,9727892,Horton ES; Whitehouse F; Ghazzi MN; Venable TC; Whitcomb RW,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001786: Blood Glucose; D001835: Body Weight; D002096: C-Peptide; D002839: Chromans; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008055: Lipids; D013453: Sulfonylurea Compounds; D013844: Thiazoles; D045162: Thiazolidinediones; D016896: Treatment Outcome; D000077288: Troglitazone",,,https://openalex.org/W2068531968,104,14,1,1902,349,16,en,en
false,metformin old drug treatment diabetes new drug protection endothelium,anti diabetic oral hypoglycaemic agent metformin first use clinically today first choice gold standard drug treatment type diabetes polycystic ovary disease particular importance treatment diabetes metformin affords protection diabetes induced vascular disease addition retrospective analysis suggest treatment metformin provide therapeutic benefit patient several form cancer despite almost year clinical use precise cellular mode action metformin remain controversial direct indirect role adenosine monophosphate amp activated protein kinase ampk fuel gauge cell infer many study evidence activation ampk may result mild inhibitory effect metformin mitochondrial complex turn would raise amp activate ampk discrepancy however concentration metformin use vitro study versus therapeutic level suggest caution apply extend inference derive cell based study therapeutic benefit see patient conceivably effect may least partially independent ampk mitochondrial respiration reflect direct effect either metformin minor yet unidentified putative metabolite metformin target protein signalling cascade review critically evaluate data study investigate pharmacokinetic property cellular clinical basis oral hypoglycaemic insulin sensitising vascular protective effect metformin,UK Prospective Diabetes Study Group,1998,BMJ,https://doi.org/10.1159/000381643,9732337,UK Prospective Diabetes Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000319: Adrenergic beta-Antagonists; D000419: Albuminuria; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001262: Atenolol; D001786: Blood Glucose; D002216: Captopril; D002561: Cerebrovascular Disorders; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D003930: Diabetic Retinopathy; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D007003: Hypoglycemia; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D010349: Patient Compliance; D016491: Peripheral Vascular Diseases; D011446: Prospective Studies; D011507: Proteinuria; D014792: Visual Acuity; D015430: Weight Gain",,,https://openalex.org/W1545732697,105,20,1,1703,284,8,en,en
false,repaglinide,repaglinide novel insulin secretagogue develop management type non insulin dependent diabetes mellitus stimulate release insulin pancreatic beta cell appear bind different receptor site sulphonylureas repaglinide lower fast postprandial blood glucose level animal healthy volunteer patient type diabetes mellitus repaglinide rapidly absorbed eliminate may allow relatively fast onset offset action excretion occur almost entirely non renal mechanism comparative clinical trial patient type diabetes mellitus repaglinide mg twice time daily meal provide similar glycaemic control glibenclamide glyburide mg day addition repaglinide exist metformin therapy result improved glycaemic control contrast glibenclamide use repaglinide allow patient miss meal without apparently increase risk hypoglycaemia,Balfour JA,1998,Drugs Aging,https://doi.org/10.2165/00002512-199813020-00008,9739505,Balfour JA; Faulds D,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,"D000818: Animals; D002219: Carbamates; D003921: Diabetes Mellitus, Experimental; D003924: Diabetes Mellitus, Type 2; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D007515: Islets of Langerhans; D010880: Piperidines; D016032: Randomized Controlled Trials as Topic; D013237: Stereoisomerism",,,https://openalex.org/W3187355937,11,1,1,1023,163,8,en,en
true,dietary advance glycation end product potential role cardiometabolic disease child,rise incidence obesity metabolic disease diabetes mellitus cardiovascular disease adolescent young adult grave concern recent study favor role lifestyle factor genetics perpetuation inflammation insulin resistance oxidative stress pathophysiologic process common disease furthermore importance dietary factor addition calorie physical activity process increasingly recognize advanced glycation end product age belong category dietary oxidant implicate pathogenesis inflammation oxidative stress insulin resistance cell failure endothelial dysfunction paper review study age focus role cardiometabolic disease child medline search perform use key word childhood obesity metabolic syndrome advance glycation end product article publish english reference review study perform adult study also demonstrate role age obesity associate cardiometabolic comorbidities young population available evidence suggest involvement age pathogenesis adiposity cell failure child potential area research investigate underlying mechanism propose,,1998,Lancet,https://doi.org/10.1159/000444053,9742976,,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D001786: Blood Glucose; D002747: Chlorpropamide; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D005260: Female; D005913: Glipizide; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012307: Risk Factors; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2302447233,103,14,1,1445,232,9,en,en
false,effect intensive blood glucose control metformin complication overweight patient type diabetes ukpds uk prospective diabetes study ukpds group,patient type diabetes intensive blood glucose control insulin sulphonylurea therapy decrease progression microvascular disease may also reduce risk heart attack study investigate whether intensive glucose control metformin specific advantage disadvantage patient recruit ukpds centre overweight ideal bodyweight patient newly diagnose type diabetes mean age year raise fast plasma glucose fpg mmol l without hyperglycaemic symptom month initial diet include randomised control trial median duration year conventional policy primarily diet alone n versus intensive blood glucose control policy metformin aim fpg mmol l n secondary analysis compare patient allocate metformin overweight patient allocate intensive blood glucose control chlorpropamide n glibenclamide n insulin n primary outcome measure aggregate diabetes related clinical endpoint diabetes related death cause mortality supplementary randomise controlled trial non overweight overweight patient mean age year already maximum sulphonylurea therapy raise fpg mmol l allocate continue sulphonylurea therapy alone n addition metformin n median glycated haemoglobin hba c metformin group compare conventional group patient allocate metformin compare conventional group risk reduction ci p diabetes related endpoint diabetes related death p cause mortality p among patient allocate intensive blood glucose control metformin show great effect chlorpropamide glibenclamide insulin diabetes related endpoint p cause mortality p stroke p early addition metformin sulphonylurea treated patient associate increase risk diabetes related death increase risk ci p compare continued sulphonylurea alone combined analysis main supplementary study show metformin allocated patient diabetes related endpoint risk reduction p epidemiological assessment possible association death diabetes related cause concurrent therapy diabetes patient show increase risk diabetes related death patient treat combination sulphonylurea metformin risk reduction p since intensive glucose control metformin appear decrease risk diabetes related endpoint overweight diabetic patient associate less weight gain hypoglycaemic attack insulin sulphonylureas may first line pharmacological therapy choice patient,,1998,Lancet,,9742977,,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D002747: Chlorpropamide; D003920: Diabetes Mellitus; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D009765: Obesity; D011446: Prospective Studies; D012307: Risk Factors",,,https://openalex.org/W2271771390,174,30,2,3103,520,11,en,en
false,pitfall treatment oral antidiabetic agent,treatment type diabetes niddm possess three group oral hypoglycaemic drug sulfonyl urea derivative biguanides metformin alpha glucosidase acarbose inhibitor oral treatment diabetes favourable impact patient metabolic deviation involve also certain danger pitfall side effects oral antidiabetic reduce minimum respect consequentially contraindication administration different preparation knowledge mechanism action individual selection suitable antidiabetic every patient,Perusicová J,1998,Vnitr Lek,,9750481,Perusicová J,article,D004740: English Abstract; D016428: Journal Article; D016454: Review,"D020909: Acarbose; D000284: Administration, Oral; D001645: Biguanides; D003924: Diabetes Mellitus, Type 2; D006801: Humans; D007004: Hypoglycemic Agents; D013453: Sulfonylurea Compounds; D014312: Trisaccharides",,,https://openalex.org/W2417992861,54,10,1,600,94,3,en,en
false,issue surround tight glycemic control people type diabetes mellitus,review prospective evidence surround issue tight glycemic control people type diabetes mellitus resultant long term complications conference proceeding medline search february identify pertinent english language publication type diabetes human key search term include insulin resistance diabetes mellitus non insulin dependent macrovascular complication microvascular complication intensive glycemic control selection prospective epidemiologic clinical study limit focus management type diabetes article pertinent information relevant scope article reviewed pathophysiology type type diabetes differ however share chronic complication significantly affect morbidity mortality people type diabetes absolute deficiency insulin whereas people type diabetes vary degree insulin resistance inadequate compensatory insulin secretory response diabetes control complication trial dcct clearly indicate intense control blood glucose type diabetes prevents slow progression microvascular e retinopathy nephropathy neuropathic complication kumamoto study show similar result nonobese patient type diabetes intense insulin therapy population proven advantageous thus support common pathophysiologic process microvascular neuropathic complication trend see toward macrovascular atherosclerotic disease complication intensive insulin arm dcct conversely trend see toward increase macrovascular complication va cooperative study people type diabetes use intensive insulin therapy may suggest discordance pathophysiology macrovascular disease type type diabetes additionally remain uncertain whether tight glycemic control prevent onset slow progression macrovascular disease two study university group diabetes program veteran affair cooperative study glycemic control complication type diabetes date examine pharmacotherapy option patient type diabetes resultant macrovascular complication yet determine whether therapeutic intervention decrease morbidity mortality macrovascular disease population type diabetes limited prospective evidence support tight glycemic control help prevent slow progression microvascular neuropathic complication uncertain whether tight glycemic control decrease macrovascular complication pharmacotherapeutic agent best option however therapy improve glucose control combination aggressive risk factor management initiate enforce patient type diabetes effort reduce long term complication,Cerveny JD,1998,Ann Pharmacother,https://doi.org/10.1345/aph.17375,9762378,Cerveny JD; Leder RD; Weart CW,article,D016428: Journal Article; D016454: Review,"D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D006801: Humans; D007333: Insulin Resistance; D016239: MEDLINE; D016032: Randomized Controlled Trials as Topic",,,https://openalex.org/W2126834915,81,12,1,3076,459,15,en,en
false,new therapy type diabetes,progress knowledge relate non insulin dependent diabetes mellitus niddm associate new therapeutic development different respective target allow classify drug stimulate insulin secretion glimepiride repaglinide glucagon like peptide medication reduce insulin resistance thiazolidinediones insulinmimetic agent vanadium alpha glucosidase inhibitor available france since constitute another therapeutic approach reduce postprandial hyperglycemia delay digestion complex carbohydrate new medication safer sometimes effective single daily administration represent alternative classic oral antidiabetic agent allow therapeutic combination global management niddm,Neyrolles N,1998,Ann Endocrinol (Paris),,9789590,Neyrolles N; Blicklé JF; Brogard JM,article,D016428: Journal Article; D016454: Review,"D003924: Diabetes Mellitus, Type 2; D004791: Enzyme Inhibitors; D065089: Glycoside Hydrolase Inhibitors; D006801: Humans; D007328: Insulin; D007333: Insulin Resistance; D000078790: Insulin Secretion; D012636: Secretory Rate; D013329: Structure-Activity Relationship; D014639: Vanadium",,,https://openalex.org/W2462748230,35,9,1,797,116,4,en,en
false,effect glibenclamide blood pressure cardiovascular responsiveness non insulin dependent diabetes mellitus,objective compare effect chronic glibenclamide therapy placebo blood pressure cardiovascular responsiveness patient non insulin dependent diabetes design method fourteen patient non insulin dependent diabetes mellitus seven receive angiotensin convert enzyme inhibitor therapy receive glibenclamide placebo month double blind randomize crossover study end treatment period patient attend study forearm vascular responsiveness intra brachial arterial infusion angiotensin ii acetylcholine sodium nitroprusside noradrenaline response blood pressure intravenous infusion noradrenaline angiotensin ii h ambulatory blood pressure monitoring result administration glibenclamide produce significantly well glycaemic control placebo fast blood glucose level versus mmol l p plasma insulin level significantly high glibenclamide treatment placebo versus mu l p body weight end glibenclamide treatment placebo phase similar versus kg p night time systolic blood pressure significantly high glibenclamide treatment placebo versus mmhg p due small day night difference systolic blood pressure glibenclamide treatment appear occur mainly patient receive angiotensin convert enzyme inhibitor response diastolic blood pressure intravenous infusion angiotensin ii forearm vascular response intra brachial arterial infusion angiotensin ii significantly great glibenclamide treatment placebo p however enhancement forearm vascular response glibenclamide treatment appear restrict patient receive angiotensin convert enzyme inhibitor response blood pressure intravenous infusion noradrenaline forearm vascular response infusion noradrenaline acetylcholine nitroprusside differ glibenclamide treatment placebo neither basal forearm vascular resistance conclusion glibenclamide therapy associate great response blood pressure forearm vascular response infusion angiotensin high nocturnal blood pressure effect appear influence concomitant angiotensin convert enzyme inhibition j hypertens lippincott raven publisher,Williams S,1998,J Hypertens,https://doi.org/10.1097/00004872-199816050-00019,9797183,Williams S; Abbott D; Morfis L; Manwaring P; Diamond T; Howes LG,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000109: Acetylcholine; D000328: Adult; D000368: Aged; D000804: Angiotensin II; D001794: Blood Pressure; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005260: Female; D005542: Forearm; D005905: Glyburide; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D009599: Nitroprusside; D009638: Norepinephrine; D012039: Regional Blood Flow; D014661: Vasoconstriction; D014662: Vasoconstrictor Agents",,,https://openalex.org/W2064750857,119,14,1,2662,399,12,en,en
true,randomized placebo controlled trial repaglinide treatment type diabetes,objective study assess efficacy safety repaglinide compare placebo treatment patient type diabetes phase ii multicenter double blind placebo controlled randomize dose adjustment maintenance trial screen week washout period patient randomize receive either repaglinide n placebo n patient underwent week dose adjustment follow week dose maintenance fasting stimulate glycosylated hemoglobin hba c plasma glucose insulin c peptide measure predetermined interval adverse event hypoglycemic episode recorded baseline last visit mean hba c decrease patient treat repaglinide increase patient receive placebo statistically significant difference p treatment group last visit mean fast plasma glucose postprandial glucose increase patient receive placebo decrease patient treat repaglinide statistically significant p difference group last visit concentration fasting postprandial insulin c peptide low last visit compare baseline patient treat placebo high patient treat repaglinide difference group statistically significant p overall repaglinide well tolerated study demonstrate repaglinide safe efficacious lower blood glucose concentration addition overall improvement glycemic control note repaglinide sulfonylurea treated patient oral hypoglycemic agent naive patient repaglinide potent glucose lowering effect postprandial period,Goldberg RB,1998,Diabetes Care,https://doi.org/10.2337/diacare.21.11.1897,9802740,Goldberg RB; Einhorn D; Lucas CP; Rendell MS; Damsbo P; Huang WC; Strange P; Brodows RG,article,"D016430: Clinical Trial; D017427: Clinical Trial, Phase II; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D002219: Carbamates; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D010880: Piperidines",,,https://openalex.org/W2077971957,89,14,1,1856,300,9,en,en
false,influence glucagon like peptide fast glycemia type diabetic patient treat insulin sulfonylurea secondary failure,glucagon like peptide glp glucose dependent insulinotropic glucagonostatic action type diabetic patient diet oral agent know however whether secondary sulfonylurea failure glp still effective therefore type diabetic patient woman men age year bmi kg hba c year start insulin treatment examine fasting state discontinue nph insulin evening two study day glp pmol x kg x min placebo nacl human serum albumin infuse h plasma glucose glucose oxidase insulin imx c peptide enzyme linked immunosorbent assay measure statistical analysis perform use repeated measure analysis variance fasting plasma glucose mmol l reduce glp mmol l placebo mmol l p glp transiently increase insulin pmol l min p c peptide nmol l min p effect placebo glucagon free fatty acid lower transiently normalization plasma glucose insulin c peptide concentration become low ongoing administration exogenous glp hypoglycemia occurred conclude exogenous glp effectively lower plasma glucose concentration advanced type diabetes long sulfonylurea secondary failure finding may broaden applicability glp derived drug new treatment nearly type diabetic patient,Nauck MA,1998,Diabetes Care,https://doi.org/10.2337/diacare.21.11.1925,9802745,Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001786: Blood Glucose; D002096: C-Peptide; D002153: Calorimetry, Indirect; D002784: Cholesterol; D003924: Diabetes Mellitus, Type 2; D004797: Enzyme-Linked Immunosorbent Assay; D005215: Fasting; D005230: Fatty Acids, Nonesterified; D005260: Female; D005934: Glucagon; D052216: Glucagon-Like Peptide 1; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged; D010446: Peptide Fragments; D019518: Postprandial Period; D011384: Proinsulin; D011498: Protein Precursors; D013453: Sulfonylurea Compounds; D014280: Triglycerides",,,https://openalex.org/W2025162869,143,21,1,1680,299,8,en,en
false,clinical study glibenclamide combination kelening treatment non insulin dependent diabetes mellitus,asses efficacy combination therapy glibenclamide kelening treat non insulin dependent diabetes mellitus niddm sixty five patient niddm randomly divide two group one group treat glibenclamide kelening glibenclamide alone treatment week level fast blood glucose fbg postprandial blood glucose pbg hbaic reduce significantly glibenclamide kelening group group degree drop level fbg almost level pbg hbaic glibenclamide kelening group reduce significantly glibenclamide group incidence hyperinsulinemia drop considerably glibenclamide combination kelening treatment niddm effective less toxic combination may reduce dosage glibenclamide niddm,Zhou P,1997,Zhongguo Zhong Xi Yi Jie He Za Zhi,,9812648,Zhou P,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D004338: Drug Combinations; D004365: Drugs, Chinese Herbal; D005260: Female; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2411309176,116,17,1,923,150,3,en,en
false,reduction oxidative stress oral n acetyl l cysteine treatment decrease plasma soluble vascular cell adhesion molecule concentration non obese non dyslipidaemic normotensive patient non insulin dependent diabetes,assess vivo effect antioxidant vascular cell adhesion molecule vcam expression circulate soluble vcam intraerythrocytic reduce glutathione gsh gsh disulphide gssg concentration evaluate non insulin dependent diabetic patient without complication men woman year old month either oral n acetyl l cysteine mg day placebo treatment give randomized cross double blind fashion ten healthy subject men woman year old serve control subject baseline plasma vcam concentration high p non insulin dependent diabetic patient ng ml control subject ng ml intraerythrocytic gssg content high non insulin dependent diabetic patient mol g hb control subject mol g hb p whereas intraerythrocytic gsh concentration low p non insulin dependent diabetic patient mol g hb control subject mol g hb mean gsh gssg ratio also low p first second group circulate vcam intraerythrocytic gsh concentration negatively correlate non insulin diabetic patient r p treatment n acetyl l cysteine decreased plasma vcam p intraerythrocytic gssg p increase gsh concentration p gsh gssg ratio p non insulin dependent diabetic patient data indicate vascular endothelium activate non insulin dependent diabetes antioxidant treatment counterbalance endothelial activation thus antioxidant agent might protect oxidant related upregulation endothelial adhesion molecule slow progression vascular damage non insulin dependent diabetes diabetologia,De Mattia G,1998,Diabetologia,https://doi.org/10.1007/s001250051082,9833950,De Mattia G; Bravi MC; Laurenti O; Cassone-Faldetta M; Proietti A; De Luca O; Armiento A; Ferri C,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000111: Acetylcysteine; D000284: Administration, Oral; D000328: Adult; D001786: Blood Glucose; D001794: Blood Pressure; D002784: Cholesterol; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004912: Erythrocytes; D005260: Female; D016166: Free Radical Scavengers; D019803: Glutathione Disulfide; D006801: Humans; D007328: Insulin; D008297: Male; D008875: Middle Aged; D018384: Oxidative Stress; D012016: Reference Values; D014280: Triglycerides; D019010: Vascular Cell Adhesion Molecule-1",,,https://openalex.org/W2016207537,233,27,1,1968,358,11,en,en
false,high fat versus high carbohydrate enteral formula effect blood glucose c peptide ketone patient type diabetes treat insulin sulfonylurea,recently two commercial enteral formula diabetic patient make available spain high complex carbohydrate low fat formulation hcf low carbohydrate formulation rcf study compare effect two enteral nutritional formula patient non insulin dependent diabetes mellitus type diabetes treat sulfonylurea insulin fifty two type diabetes patient randomly assign receive one two enteral formula test enteral formula breakfast cc consume approximately h routine medication insulin oral agent take venous blood sample obtain fasting medication min start meal glycemic response patient hcf significantly great rcf low sulfonyl type diabetes treat group incremental glucose response within acceptable level except insulin treatment type diabetes patient give hcf glucose insulin c peptide response high hcf rcf group two factor analysis variance mean increment blood glucose c peptide basal level min show type enteral nutrition main factor p p respectively rcf formula supply energy fat carbohydrate may ketogenic diet find ketone body high rcf hcf ingestion without statistical significance conclude partial replacement complex digestible carbohydrate monounsaturated fatty acid enteral formula supplementation oral diet may improve glycemic control patient type diabetes long term effect enteral diet high monounsaturated fatty acid need evaluation patient type diabetes,Sanz-París A,1998,Nutrition,https://doi.org/10.1016/s0899-9007(98)00124-5,9834926,Sanz-París A; Calvo L; Guallard A; Salazar I; Albero R,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000704: Analysis of Variance; D001786: Blood Glucose; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D004040: Dietary Carbohydrates; D004041: Dietary Fats; D002149: Energy Intake; D004750: Enteral Nutrition; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D007659: Ketones; D008297: Male; D008875: Middle Aged; D018709: Statistics, Nonparametric; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2144095888,169,26,1,1899,329,13,en,en
false,previous episode hypoglycemic coma associate permanent cognitive brain dysfunction iddm patient intensive insulin treatment,intensive insulin treatment iddm associate increased frequency hypoglycemic coma extent possible cerebral sequela recovery still unknown study impact previous hypoglycemic coma neurophysiological measure cognitive brain function patient adult onset iddm receive intensive insulin treatment study iddm patient age year mean sd history gt median range comatose hypoglycemic event compare iddm patient age year history hypoglycemic event use p event related potential psychometric test mini mental state exam trailmaking test part finding patient compare match healthy control subject difference observe p latency psychometric test patient without history hypoglycemic coma p latency vs trailmaking test vs mini mental state exam vs n diabetic patient however p latency delay compare healthy control subject vs p lt correlate diabetes duration total hypoglycemic episode score mini mental state exam vs p trailmaking test vs p different patient control subject conclusion previous episode hypoglycemic coma associate permanent impairment cognitive brain function patient adult onset iddm receive intensive insulin treatment compare patient without episode cognitive brain function however subclinically impair relation duration diabetes,Kramer L,1998,Diabetes,https://doi.org/10.2337/diabetes.47.12.1909,9836523,Kramer L; Fasching P; Madl C; Schneider B; Damjancic P; Waldhäusl W; Irsigler K; Grimm G,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000419: Albuminuria; D001921: Brain; D003072: Cognition Disorders; D003430: Cross-Sectional Studies; D003627: Data Interpretation, Statistical; D003922: Diabetes Mellitus, Type 1; D003929: Diabetic Neuropathies; D003930: Diabetic Retinopathy; D004569: Electroencephalography; D005071: Evoked Potentials; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D007331: Insulin Coma; D008297: Male; D008875: Middle Aged; D011594: Psychometrics",,,https://openalex.org/W1989244392,149,21,1,1792,325,10,en,en
false,impact nocturnal hypoglycemia hypoglycemic cognitive dysfunction type diabetes,test hypothesis glycemic threshold cognitive dysfunction hypoglycemia like autonomic symptomatic response shift lower plasma glucose concentration recent antecedent hypoglycemia patient type diabetes mellitus dm patient study two occasion cognitive function assess morning hyperinsulinemic step hypoglycemic clamp mg dl step random sequence nocturnal hypoglycemia mg dl one occasion nocturnal euglycemia mg dl compare nondiabetic control subject n patient dm absent glucagon p reduced epinephrine p norepinephrine p neurogenic symptom p response hypoglycemia epinephrine p neurogenic symptom p response reduce far nocturnal hypoglycemia nocturnal hypoglycemia contrast nocturnal euglycemia less deterioration cognitive function overall p hypoglycemia base analysis sum standardized score z scores relative preservation measure pattern recognition memory delay non match sample task p attention stroop arrow word task p measure information processing pace serial addition task declarative memory delay paragraph recall task nocturnal hypoglycemia thus glycemic threshold hypoglycemic cognitive dysfunction like autonomic symptomatic response hypoglycemia shift lower plasma glucose concentration recent antecedent hypoglycemia patient dm,Fanelli CG,1998,Diabetes,https://doi.org/10.2337/diabetes.47.12.1920,9836525,Fanelli CG; Paramore DS; Hershey T; Terkamp C; Ovalle F; Craft S; Cryer PE,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000704: Analysis of Variance; D001786: Blood Glucose; D002940: Circadian Rhythm; D003071: Cognition; D003072: Cognition Disorders; D003922: Diabetes Mellitus, Type 1; D004837: Epinephrine; D005260: Female; D005934: Glucagon; D005947: Glucose; D015309: Glucose Clamp Technique; D006801: Humans; D007003: Hypoglycemia; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D009483: Neuropsychological Tests; D009638: Norepinephrine; D010191: Pancreatic Polypeptide",,,https://openalex.org/W1991670137,90,13,1,1783,318,6,en,en
false,restrict home glucose monitoring strip patient take oral antidiabetic agent,journal article restrict home glucose monitoring strip patient take oral antidiabetic agent get access joseph p rindone pharm joseph p rindone pharm clinical pharmacist veteran affair medical center prescott az search work author oxford academic google scholar american journal health system pharmacy volume issue december page http doi org ajhp publish december,Rindone JP,1998,Am J Health Syst Pharm,https://doi.org/10.1093/ajhp/55.23.2509,9853636,Rindone JP,article,D016428: Journal Article,"D000284: Administration, Oral; D000328: Adult; D001130: Arizona; D001786: Blood Glucose; D015190: Blood Glucose Self-Monitoring; D003404: Creatinine; D003924: Diabetes Mellitus, Type 2; D011307: Drug Prescriptions; D004363: Drug Utilization; D005260: Female; D005905: Glyburide; D006441: Hemoglobin A; D006787: Hospitals, Veterans; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2474019865,86,10,1,487,80,3,en,en
false,insulin treatment elderly type diabetic patient effect retinopathy,insulin treatment reportedly associate transient progression retinopathy possibly development macular oedema middle aged type diabetic patient purpose study investigate effect insulin treatment eye grounds elderly year old type diabetic patient secondary failure oral antidiabetic drug therapy eye examination perform patient randomize insulin n sulphonylurea n treatment investigated one year insulin treatment reduce hba c p one year sulphonylurea treated group hba c change vs start patient retinopathy one year progression note patient insulin sulphonylurea treated insulin treated group patient progression high initial fast blood glucose level patient group vs mmol l p initial hba c level differ group vs n reduction hba c level treatment vs n thus diabetic retinopathy study common among elderly type diabetic patient progression retinopathy may fact associate insulin treatment improvement metabolic control,Tovi J,1998,Diabetes Metab,,9881243,Tovi J; Ingemansson SO; Engfeldt P,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D001786: Blood Glucose; D003924: Diabetes Mellitus, Type 2; D003930: Diabetic Retinopathy; D005215: Fasting; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D012307: Risk Factors; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2402199846,78,13,1,1371,258,11,en,en
false,effect regular insulin insulin lispro glucose metabolism oral glucose load patient type diabetes mellitus,seven obese type diabetic patient study two h period ingestion glucose load determine effect preprandial subcutaneous injection insulin lispro min meal regular insulin min meal glucose metabolism glucose production utilisation measure use dual isotope method lispro mean postprandial increase plasma glucose low increase insulin concentration high regular insulin p suppression endogenous glucose production similar type insulin thus preprandial injection lispro reduce postprandial glucose increment type diabetic patient compare regular insulin effect best explain increase postprandial bioavailability lispro,Paquot N,1998,Diabetes Metab,,9932219,Paquot N; Roulin D; Schneiter P; Ruiz J; Lefebvre P; Pahud P; Tappy L,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000368: Aged; D003924: Diabetes Mellitus, Type 2; D005260: Female; D005947: Glucose; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D061268: Insulin Lispro; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2225703314,136,23,1,832,142,6,en,en
false,efficacy combined treatment niddm patient secondary failure sulphonylureas predictable,treatment niddm patient secondary failure sulphonylurea common problem perform crossover study niddm patient secondary failure glibenclamide compare addition sulphonylurea either low dose bedtime nph insulin oral metformin analyze treatment efficacy relation patient disease characteristic combined therapy clearly improve glycaemic control hba c similarly reduce addition either bedtime nph insulin v p metformin v p also fast plasma glucose fpg post prandial plasma glucose pppg significantly decrease p treatment bed time nph insulin effective fpg reduction metformin vs p contrast metformin addition effective pppg reduction bedtime nph insulin addition vs p serum cholesterol marginally significantly decrease metformin v mm p nph insulin body weight increase significantly great insulin addition metformin kg v p patient prefer addition metformin rather nph insulin none measured clinical metabolic variable treatment fpg pppg hba c post glucagon c peptide level insulin sensitivity patient age bmi diabetes duration significantly correlate efficacy two combine treatment study conclusion niddm patient secondary failure sulphonylureas addition either low dose bedtime nph insulin metformin similarly effective improve glycaemic control metformin well accept patient provide modest advantage term body weight cholesterol level common clinical metabolic variable useful predict efficacy two combine treatment,Trischitta V,1998,J Endocrinol Invest,https://doi.org/10.1007/bf03348039,9972673,Trischitta V; Italia S; Raimondo M; Guardabasso V; Licciardello C; Runello F; Mazzarino S; Sangiorgi L; Anello M; Vigneri R,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001786: Blood Glucose; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004351: Drug Resistance; D004359: Drug Therapy, Combination; D005215: Fasting; D005260: Female; D005502: Food; D005905: Glyburide; D006442: Glycated Hemoglobin; D006801: Humans; D007004: Hypoglycemic Agents; D007328: Insulin; D008297: Male; D008687: Metformin; D008875: Middle Aged; D013453: Sulfonylurea Compounds",,,https://openalex.org/W2062772048,110,17,2,2036,353,15,en,en
true,drug induced hypoglycemic coma diabetic patient,hypoglycemic coma continuous threat diabetic patient treat insulin oral hypoglycemic agent may associate substantial morbidity mortality retrospectively review clinical experience drug induced hypoglycemic coma year period study consist patient include female male median age year ninety two patient suffer type diabetes mellitus patient type diabetes mellitus median low blood glucose level mmol l mg dl drug induced hypoglycemic coma occur patient hospital patient develop hospitalization drug induced hypoglycemic coma occur patient undergo treatment insulin glyburide combine therapy insulin glyburide insulin metformin glyburide metformin ninety three patient least following risk factor age old year renal dysfunction decrease intake energy infection fourteen patient concomitantly receive drug potentiate hypoglycemia forty patient respond treatment within first hour patient protract hypoglycemia hour duration morbidity include physical injury patient myocardial ischemia patient stroke patient death occur patients hypoglycemic coma serious uncommon problem among elderly patient diabetes mellitus treat insulin oral hypoglycemic drug risk factor contribute substantially morbidity mortality patient drug induced hypoglycemic coma enhance therapeutic monitoring may warrant hypoglycemic drug administer elderly patient predisposing factor potentiate drug hypoglycemia,Ben-Ami H,1999,Arch Intern Med,https://doi.org/10.1001/archinte.159.3.281,9989540,Ben-Ami H; Nagachandran P; Mendelson A; Edoute Y,article,D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D000367: Age Factors; D000368: Aged; D000369: Aged, 80 and over; D001786: Blood Glucose; D003128: Coma; D003920: Diabetes Mellitus; D003922: Diabetes Mellitus, Type 1; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006801: Humans; D007004: Hypoglycemic Agents; D008297: Male; D008875: Middle Aged; D012189: Retrospective Studies",,,https://openalex.org/W2045187622,55,7,1,1871,294,13,en,en
